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 Chapter 1      
 General introduction and outline of the thesis 
 
 
 
 
 
 
 
 
 
 
 
 
 Introduction Invasive coronary angiography is still considered a cornerstone in the diagnosis and treatment of coronary artery disease, despite its inherent limitations. Whereas visual estimates of coronary artery stenosis are highly variable even among experts, quantitative coronary angiography (QCA) has already been proven an objective and reproducible way to quantify the extent of coronary stenoses located in single-vessel segments. Angiographic measurements can be used on-line in order to help interventional cardiologists size and deploy intracoronary devices, whereas off-line they can help us evaluate the efficacy of coronary interventions as well as the progression of coronary atherosclerosis.   Two-dimensional (2-D) single-vessel analysis has long been the conventional methodology to analyze target vessel segments assuming smooth vessel tapering between adjacent bifurcations. However, this methodology fails in the analysis of bifurcation lesions, because of the relatively acute vessel tapering from the proximal main vessel (PMV) to the distal main vessel (DMV) and the side-branch (SB). By not acknowledging this fractal geometry, single-vessel analysis may result in the underestimation of proximal vessel size and stenosis severity; conversely, lesions in the distal vessel segments may be overestimated. These shortcomings call for the development of dedicated bifurcation QCA algorithms, reporting diameter derived values separately for PMV, DMV and the SB.   Beyond the diameter derived measures, another important piece of QCA derived information is the angulation between the main vessel and the SB; however, definitions and measurement methods are still at variance. The European Bifurcation Club has adopted a definition, according to which proximal and distal bifurcation angle (BA) are delineated between the PMV and the SB, and between the DMV and the SB respectively. Regarding BA quantification, until recently a binary approach was adopted; bifurcations used to be divided in T-shaped (BA≥70°) and Y -shaped ones (BA<70°) according to visual assessment or calculations using digital calipers. Therefore, automated algorithms for BA calculation have been implemented in dedicated bifurcation QCA software. Bifurcation angle has gained attention due to growing evidence that it can affect immediate procedural success and long-term outcome. 
16
 Notwithstanding the development of dedicated algorithms, optimal visualization of a bifurcation lesion, and especially the SB ostium, is equally important and increasingly challenging. However, conventional angiographic analysis is limited by the 2-D representation of 3-D coronary anatomy; resorting to operator expertise does not always help acquire the optimal projections. This difficulty is even more pronounced in the case of bifurcation lesions; vessel overlap and tortuosity interfere with angiographic analysis and can mask obstructive coronary lesions. Furthermore, out-of-plane magnification and foreshortening, often not fully appreciated, result in inaccurate estimates for vessel size and lesion length and thereby in erroneous stent sizing and deployment. Owing to flat-panel detectors and increased computational power of contemporary workstations, a spatially accurate 3-D reconstruction of the vessel lumen can be made available in real time for single-vessel and bifurcation lesions, when combining two orthogonal 2-D angiographic projections.   Single-vessel QCA algorithms were validated in vitro and in vivo versus phantom objects of known dimensions; a similar validation against a gold standard was lacking for 2-D and 3-D dedicated bifurcation QCA algorithms. The complex fractal nature of the coronary bifurcation along with the varying distribution of disease and angulation parameters posed a challenge equally for a representative design of a suitable bifurcation phantom as well as for the performance of QCA algorithms tested. Ultimately they will have to stand the test of reproducibility, precision and relevance, when used both in everyday clinical practice and in the context of large registries and randomized trials.  
The SYNTAX score is a lesion-based angiographic scoring system originally devised to quantify the complexity of coronary artery disease and thereby facilitate consensus in the study of a diagnostic angiogram between surgeons and interventional cardiologists. In the randomized SYNTAX trial, it proved effective in predicting clinical outcomes after elective percutaneous coronary intervention (PCI) procedures in patients with three-vessel and/or left main coronary artery disease. The score’s predictive ability for a number of clinical outcomes has subsequently been assessed in patient cohorts with a varying extent of coronary artery disease undergoing both elective and emergent PCI procedures, including but not limited to studies presented in this thesis. 
17
 Several of these studies have suggested that, being solely based on angiographic 
variables, the SYNTAX score cannot account for the variability related to clinical factors which are widely acknowledged to impact on long-term outcomes. Hence, integration of the patients’ age, left ventricular ejection fraction and creatinine clearance with the 
SYNTAX score, in the Clinical SYNTAX score, has been shown to improve the predictive ability for adverse clinical outcomes after PCI. However, information regarding the very long-term performance of either SYNTAX score or Clinical SYNTAX score in an all-comers population is lacking.  Incomplete revascularization has been shown to be a surrogate marker of a greater burden and complexity of coronary disease and clinical co-morbidity, in both coronary artery bypass graft (CABG) surgery and PCI treated patients. Although the baseline 
SYNTAX score, calculated prior to surgical revascularization, has been shown not to have any effect on the short- to long-term prognosis after CABG, it was hypothesized that a suitably developed (post)-CABG SYNTAX score that takes into account native coronary disease anatomy, including features such as calcification, bifurcation disease and the effects of surgical revascularization on the vessel-segment weighting, may have potential clinical and research applications. Naturally, validation of this new scoring methodology is required.  
Outline of the thesis In Part 2 of this thesis, the development and validation of dedicated bifurcation QCA software is discussed. The development of a series of precision-manufactured plexiglas bifurcation phantoms, specifically designed for the validation of bifurcation QCA algorithms is presented (Chapter 2). Several dedicated 2-D QCA algorithms for bifurcation segmental analysis are validated in vitro (Chapters 3 and 4).  Also, a novel dedicated 3-D QCA methodology for bifurcation lesions is described (Chapter 5), which was further developed and validated against the same precision-manufactured plexiglas bifurcation phantoms (Chapter 6). Finally, a number of bifurcation phantom images were used in order to investigate the adequacy of visual assessment in bifurcation lesions taking into account current bifurcation QCA software standards; the results of a survey among experts in the field of bifurcation PCI are reported (Chapter 7).  
18
 In Part 3 the use of bifurcation QCA in clinical studies is discussed. The long-term outcomes after the V stenting technique in de novo bifurcation lesions using drug-eluting stents are reported in patients from the RESEARCH and T-SEARCH registries (Chapter 8). The long-term clinical outcomes and independent predictors of major cardiac events in unprotected left main coronary artery disease treated by PCI with drug-eluting stents are investigated in patients from the RESEARCH and T-SEARCH registries; next to left main BA parameters, the prognostic value of SYNTAX score is explored as well (Chapter 9). The 3-D BA parameters of the left main coronary artery, the effect of PCI on this angulation, and the impact of 3-D BA on 1-year clinical outcomes are explored in patients randomized to left main PCI within the SYNTAX trial (Chapter 
10). The impact of 3-D BA parameters on 5-year clinical outcomes is further investigated in this same cohort of patients randomized to left main PCI within the 
SYNTAX trial (Chapter 11). Furthermore, the acute procedural and six-month clinical outcomes after left main PCI with a dedicated bifurcation stent are reported in patients included in the TRYTON left main multicentre registry (Chapter 12).  In Part 4 several clinical applications of the SYNTAX score and derivative scores are discussed. Initially, the reproducibility of the SYNTAX score is reassessed in the angiograms of 100 randomly selected patients enrolled in the SYNTAX trial (Chapter 
13). The predictive value of the SYNTAX score regarding 1-year major adverse cardiac events is evaluated in the all-comers population of the LEADERS trial (Chapter 14). In addition, the ability of SYNTAX score and Clinical SYNTAX score to predict very long-term outcomes in an all-comers population receiving drug-eluting stents is investigated 
in the SIRTAX trial population (Chapter 15). The rationale, development and feasibility of the newly developed CABG SYNTAX score are discussed (Chapter 16), whereas the 5-year outcomes from the CABG arm of the SYNTAX-LE MANS left main angiographic substudy are also reported stratified according to the CABG SYNTAX score (Chapter 
17).   
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Novel Bifurcation Phantoms for Validation of
Quantitative Coronary Angiography Algorithms
Chrysaﬁos Girasis,1 MD, Johan C.H. Schuurbiers,2 BSc, Yoshinobu Onuma,1 MD,
Patrick W. Serruys,1 MD, PhD, and Jolanda J. Wentzel,2* PhD
Background: Validation is lacking for two- and three-dimensional (2D and 3D) bifurca-
tion quantitative coronary angiography (QCA) algorithms. Methods: Six plexiglas phan-
toms were designed, each of them mimicking a coronary vessel with three successive
bifurcations lesions, wherein at least one vessel segment had a percent diameter ste-
nosis (DS) of 60%. The ﬁve most frequently occurring Medina classes (1,1,1), (1,1,0),
(0,1,0), (0,1,1), and (1,0,0) were used in the design. Diameters of the daughter vessels in
every bifurcation were dictated by the scaling law of Finet. Lesions were cosinus-
shaped in longitudinal view and circular-shaped in cross-sectional view. At the level of
the carina, lesions were becoming eccentric, favoring ‘‘plaque’’ at the outer bifurcation
walls. Adjacent bifurcation lesions were kept distant by nontapering, stenosis-free seg-
ments of 10 mm length. The direction of the side branch relative to the main vessel
was based on relevant literature. The phantoms were precision manufactured using
computer-aided design and machining techniques. Because of the high drilling accu-
racy (within 10 lm), the 3D luminal surface description of the phantom could be used
to determine the true lumen dimensions and bifurcation angle (BA) values of the ﬁnal
geometry. Results: Our series of bifurcation phantoms comprised 33 narrowed and 21
stenosis-free vessel segments with a mean true minimal lumen diameter (MLD) value
of 0.98 6 0.40 mm (range, 0.53–1.96 mm) and 2.29 6 0.74 mm (range, 1.40–4.00 mm),
respectively. Overall, the mean true values for MLD, reference diameter, and DS were
1.49 6 0.85 mm, 2.70 6 0.71 mm, and 40.9% 6 34.2%. The mean true values for
the proximal and the distal BA were 123.6 6 19.0 and 69.6 6 19.9, respectively.
Conclusions: Six plexiglas phantoms containing a total of 18 bifurcations lesions with
variable anatomy and Medina class were designed and precision manufactured to
facilitate the validation of bifurcation QCA algorithms. VC 2010 Wiley-Liss, Inc.
Key words: coronary angiography; quantitative coronary angiography; phantom;
software validation; in vitro
INTRODUCTION
Current quantitative coronary angiography (QCA)
algorithms, despite marked variability in performance
[1,2], can provide us with reliable geometric measure-
ments of single-vessel coronary lesions. These meas-
urements serve either as online sizing tools [3] and
help interventional cardiologists in tailoring therapy
to the anatomy of a given patient, or, when measured
ofﬂine, as surrogate endpoints to evaluate the efﬁcacy
of intracoronary devices [4,5] and the progression of
atherosclerosis [6]. To establish their accuracy and
precision, these algorithms were validated in vitro
and in vivo versus phantom objects of known dimen-
sions [1,2,7–10].
1Interventional Cardiology, Department of Cardiology, Erasmus
MC, Rotterdam, The Netherlands
2Biomedical Engineering, Department of Cardiology, Erasmus
MC, Rotterdam, The Netherlands
*Correspondence to: Dr. J.J. Wentzel, Biomechanics Laboratory,
Biomedical Engineering, EE2322, Erasmus MC, P.O. Box 2040,
3000 CA Rotterdam, The Netherlands.
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A similar validation is still lacking for two- and
three-dimensional (2D and 3D) bifurcation QCA algo-
rithms [11]. The complex fractal nature of the coronary
bifurcation along with the varying distribution of dis-
ease and angulation parameters between the parent and
the daughter vessels poses a challenge for a representa-
tive design of such a bifurcation phantom; therefore,
detailed analysis and literature review of reported
dimensions in the bifurcation region are required. This
is exactly what has been advocated by the European
Bifurcation Club to reconcile the diverse methodolo-
gies and to create a standard QCA approach for the
evaluation of bifurcation lesions [11–13].
This report presents the development of a series of
custom made, precision manufactured plexiglas bifur-
cation phantoms, based on data from relevant literature
and speciﬁcally designed for the validation of bifurca-
tion QCA algorithms.
MATERIALS AND METHODS
Six plexiglas phantoms were designed, each of them
mimicking a coronary vessel with three successive
bifurcations; every individual bifurcation had a lesion,
wherein at least one vessel segment had a percent di-
ameter stenosis (DS) of 60%. The Medina class [14]
of the bifurcation lesions was deﬁned by the distribu-
tion of degree of stenosis in the three vessel segments
comprising the bifurcation. The anatomy of the lesion
was deﬁned by the vessel segment reference diameter,
the minimal lumen diameter (MLD), the lesion length,
and the angulation parameters. The selection of indi-
vidual bifurcation lesion characteristics attributed to
this dataset of 18 phantom bifurcations was derived
from relevant literature.
Phantom Design
Medina class. The selection of the Medina classes
used in the phantoms’ design was based on studies
done by Enrico et al. [15], Collins et al. [16], Van
Mieghem et al. [17], and the British Bifurcation Coro-
nary Study (BBC ONE) [18]. The study size-adjusted
mean frequency of occurrence of the 7 Medina classes
in the summed patient population of these studies (n ¼
1,139) is reported in Table I. The ﬁve most frequently
registered Medina classes, (1,1,1), (1,1,0), (0,1,0),
(0,1,1), and (1,0,0) were used in the phantom bifurca-
tions (Fig. 1).
Vessel segment reference diameter. In every phan-
tom, the stenosis-free diameter of the proximal main
vessel (PMV) of the ﬁrst bifurcation was 4 mm,
reﬂecting the usual mean reference diameter of the left
main coronary artery (LMCA) [19,20]. As the bifurca-
tion is perceived to be an object of fractal geometry,
the stenosis-free diameters of the distal main vessel
(DMV) and the side branch (SB) were derived from
the study by Finet et al. [21], investigating the ratio
between PMV, DMV, and SB in 173 coronary bifurca-
tions using QCA. For every PMV diameter of the 18
phantom bifurcations, the corresponding DMV diame-
ter was determined from a table by Finet, showing ﬁve
decreasing PMV diameter ranges and the correspond-
ing mean DMV diameters. The SB diameter was then
calculated by the scaling law of Finet, wherein PMV
¼ 0.678 * (DMV þ SB). Consequently, in every phan-
tom, the PMV, DMV, and SB stenosis-free diameters
were 4.00, 3.30, and 2.60 mm for the ﬁrst, 3.30, 2.50,
and 2.40 mm for the second, and 2.50, 2.30, and 1.40
mm for the third bifurcation, respectively (Fig. 1).
Stenosis-free segments outside the lesion boundaries
in the PMV, DMV, and SB were not allowed to taper;
they were of adequate length (10 mm) to serve as
reference segments for the calculation of DS. Because
the reference diameter function in the current 2D QCA
bifurcation software is at variance [11,22], and not
wanting to introduce bias favoring either deﬁnition, we
opted for this procedure to deﬁne the reference diame-
ter and thus the DS values for the lesions in the respec-
tive vessel segments, very similar to the procedure
adopted by Oviedo et al. [20].
MLD. The vessel segments that were affected by
the bifurcation lesions were chosen to have DS values
of either 40, 60, or 80%; the MLD values were
derived, given the respective reference diameter. In the
remaining, stenosis-free, vessel segments the MLD
equaled the reference diameter.
The location of the MLD with respect to the bifurca-
tion was investigated by Sano et al. [23] in an intravas-
cular ultrasound (IVUS) study; of 115 LMCA lesions,
TABLE I. Medina Class Frequency of Occurrence
(1,0,0) (1,1,0) (1,0,1) (0,0,1) (0,1,0) (0,1,1) (1,1,1)
Enrico et al., n (%) (15) 26 (13.3) 79 (40.3) 1 (0.5) 11 (5.6) 45 (23.0) 0 (0.0) 34 (17.3)
Collins et al., n (%) (16) 38 (9.5) 28 (7.0) n/a 5 (1.2) 52 (13.0) 33 (8.3) 243 (60.9)
van Mieghem et al.*, n (%) (17) 10 (21.7) 8 (17.4) 8 (17.4) 5 (10.9) 8 (17.4) 2 (4.3) 5 (10.9)
BBC-ONE trial, n (%) (18) 24 (4.8) 45 (9.0) 45 (9.0) 3 (0.6) 15 (3.0) 67 (13.5) 299 (60.0)
Cumulative, study size-adjusted, frequency of occurrence 98 (8.6) 160 (14.0) 54 (4.7) 24 (2.1) 120 (10.5) 102 (9.0) 581 (51.0)
n/a, nonavailable.
*Angiographic adjudication.
26
the MLD was positioned within 3 mm of the bifurca-
tion in 65 cases. A criterion of 5 mm distance from the
SB ostium or the bifurcation has been used as well
[24,25]. In the phantom design, the bifurcation point
was deﬁned as the center of the largest inscribed
sphere within the reference diameter contours. Taking
this deﬁnition and literature data into account, we
opted for an MLD position within 3–6 mm from the
bifurcation point. The MLD position and the proximal
and distal ends of the lesion were joined using spline
interpolation.
Lesion length and shape. The length of the bifurca-
tion lesions was based on randomized trials by
Colombo et al. [26,27] and Steigen et al. [28] and large
prospective registries by Di Mario et al. [29] and Col-
lins et al. [16]. The mean lesion length in the bifurca-
tion region in these studies varied from 10.8  4.8 to
18.0  8.3 for the main vessel and from 5.1  4.4 to
9.2  4.8 mm for the SB. Di Mario et al. [29] found
mean PMV and DMV lesion lengths of 8.1  5.4 and
10.1  7.7, respectively.
From these data, main vessel and SB lesion length in
the phantom bifurcations were chosen to vary from 9 to
15 mm and from 6 to 8 mm, respectively; lesion con-
ﬁned to either PMV or DMV had a length from 8 to 10
mm. Lesions were cosinus-shaped in longitudinal view,
ensuring a smooth tapering length function; ‘‘plaque’’
was circular-shaped in cross-sectional view for design
simplicity and due to manufacturing constraints. How-
ever, at the level of the carina, lesions were becoming
eccentric, favoring ‘‘plaque’’ at the outer bifurcation
walls [20,30]. Adjacent bifurcation lesions in the main
Fig. 1. Overview of the speciﬁcations of the six different
bifurcation phantoms. Upper panel: schematic representation
of ﬁve different Medina classes employed in the design. Mid-
dle panel: left side: two bifurcation geometries involving sites
with 40% percent diameter stenosis (DS). Right side: sche-
matic representation of the minimal lumen diameter (MLD)
position and lesion length in the proximal main vessel (PMV),
the distal main vessel (DMV), and the side branch (SB). Bot-
tom panel: left side: stenosis-free diameters of the PMV, DMV,
and SB and segment lengths of the bifurcation phantoms.
Right side: schematic representation of all phantoms. Medina
class (including DS values) and SB direction with respect to
the DMV are reported for each bifurcation.
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phantom vessel were kept distant by nontapering, steno-
sis-free segments of 10 mm length.
Angulation parameters. In the phantoms design,
we had to arbitrarily deﬁne the SB direction with
respect to the DMV of each bifurcation as the angle
between straight lines extending from the bifurcation
point through the center of 15 mm long segments into
the DMV and SB segments, respectively. Values for
this angle were derived from studies, where bifurcation
angle (BA) calculations followed the European Bifur-
cation Club deﬁnitions [13]. Bifurcation QCA studies
on LMCA cohorts [31,32] were combined with studies
where the LMCA bifurcation was excluded [29],
reporting mean distal BA values from 95.6  23.6 to
58.1  19.3; in a multidetector computed tomogra-
phy (MDCT) study by Pﬂederer et al. [33] distal BA
values varied from 80  27 to 46  19. From
these data, we chose values of 40 (n ¼ 6), 70 (n ¼
9), and 90 (n ¼ 3) to be representative for the SB
direction relative to the DMV (Fig. 1).
Because the available bifurcation QCA algorithms
for BA deﬁnition are at variance, the true distal BA
value of the ﬁnal design was determined by deﬁning
branch vectors for the DMV and SB as described by
Thomas et al. [34]; the BA was then deﬁned as the
angle between the projections of the branch vectors
onto the bifurcation plane. Similar calculations were
carried out for the proximal BA, delineated between
the PMV and the SB.
Phantom Manufacturing
Taking into account the aforementioned, literature-
based, speciﬁcations, the phantoms were designed
using a computer-aided design program (Pro-engineer
wildﬁre v4). In this way, a digital 3D model of the
luminal surface of the three bifurcations for each phan-
tom was created. All bifurcations of the phantom were
in the same plane, which allowed splitting the 3D
model into two identical longitudinal halves (Fig. 2).
The geometric description of both half-luminal models
were used to instruct a computer numerically con-
trolled (CNC) milling machine (Fehlmann Picomax 60
HSC) to mill these models into 2 Perspex (Plexiglas)
blocks of 110  40  10 mm after carefully ﬂattening
the surfaces to get an optimal contact between both
halves of the phantom. Finally, a very thin layer of oil
was applied to the surface of both halves to seal the
transition layer. The two halves were put together with
nylon bolds. After assembling the phantom, it was
rinsed with a detergent solution to remove any redun-
dant oil from the luminal surface. The phantom was
ﬁlled with a contrast agent and closed at all SBs with
nylon plugs (Fig. 2).
Owing to the high accuracy of the machining process
(within 10 lm), the 3D luminal surface description of
the phantom, as exported from Pro-engineer in Surface
Tesselation Language (STL) ﬁle format (Fig. 2), was
used to determine the true lumen dimensions. Because
the design process using spline interpolation allowed
some freedom in lesion deﬁnition, the ﬁnal anatomy of
the bifurcation region, including the lesion shape, the
MLD, and the BA values, was slightly deviated from the
deﬁned values. The true MLD and BA were determined
from the 3D luminal surface description using VMTK
(Vascular Modeling Toolkit v0.7). These values can be
used as the golden standard for further validation studies.
RESULTS
The true MLD and DS values of the PMV, DMV,
and SB and the true BA values in every phantom bifur-
cation are shown in Table II.
Our series of bifurcation phantoms comprised 33
narrowed and 21 stenosis-free vessel segments with a
mean MLD value of 0.98  0.40 mm (range, 0.53–
1.96 mm) and 2.29  0.74 mm (range, 1.40–4.00 mm),
respectively. Overall, the mean values for MLD,
Fig. 2. Bifurcation phantom 1. A: Both half phantom parts of
phantom. B: The assembled phantom ﬁlled with a colored liq-
uid to visualize the lumen. C: Left side: a close-up of the ﬁrst
bifurcation. Right side: the resulting angiographic image.
D: Left side: the surface rendered image of the ﬁrst bifurca-
tion. Right side: a close-up of the bifurcation area indicated
by the square showing the tetrahedral surface elements.
28
reference diameter, and DS were 1.49  0.85 mm,
2.70  0.71 mm, and 40.9%  34.2%. The mean true
values for the proximal and the distal BA were 123.6
 19.0 and 69.6  19.9, respectively.
DISCUSSION
Bifurcation lesions constitute a distinct lesion subset
requiring dedicated classiﬁcation, analysis, and treat-
ment [12,13]. The multitude of studies already per-
formed and still ongoing, evaluating different techni-
ques and devices for bifurcation lesions, highlights the
fact that consensus has not yet been reached regarding
the optimum way to treat [13]. This has to some
degree to do with the fact that angiography, the current
golden standard to quantify outcome measures, is not
yet standardized, especially when it comes to the
ostium of the SB [11–13]. The obvious remedy for that
was to take a step back and validate the available
bifurcation QCA software packages to an object of
known dimensions.
For the validation of single-vessel QCA software
packages, three different series of phantoms had been
developed, sharing some common features. Our group
had produced a series of radiolucent plexiglas or poly-
amide cylinders with precision-drilled eccentric circular
lumens with a diameter of 0.5–1.9 mm; these were
ﬁlmed both in vitro and in vivo after inserting them in
swine coronary arteries [8]. Hausleiter et al. [2] for the
purpose of comparative in vitro validation of 8 QCA
systems created nine stenotic and nine nonstenotic glas
tubes, their inner diameter measuring 0.57–1.49 mm
and 0.54–4.9 mm, respectively; after imaging, these
tubes had to be cut into pieces to measure their true
inner diameter. Finally, van Herck et al. [9] and Tui-
nenburg et al. [10] used in their studies the Medis
QCA phantom (Medis medical imaging systems B.V.,
Leiden, The Netherlands), a plexiglas phantom consist-
ing of 12 nonstenotic circular tubes with varying diam-
eters from 0.51–5.00 mm. Obviously, these single-ves-
sel phantoms were not suitable for validating bifurca-
tion QCA algorithms owing to the complexity of the
TABLE II. Phantom Dimensions
Phantom
Bifurcation B1 B2 B3
Parameter PMV DMV SB PMV DMV SB PMV DMV SB
P1 MLD (mm) 1.56 0.66 1.03 0.64 0.99 2.40 2.50 0.53 1.40
DS (%) 60.9 80.0 60.3 80.5 60.6 0 0 76.9 0
Medina 1,1,1 1,1,0 0,1,0
DBA () 84.2 97.3 40.3
PBA () 123.2 97.3 140.0
P2 MLD (mm) 1.59 0.66 2.60 0.66 0.99 0.96 1.01 2.30 1.40
DS (%) 60.3 80.0 0 79.9 60.3 60.1 59.4 0 0
Medina 1,1,0 1,1,1 1,0,0
DBA () 81.1 102.9 40.3
PBA () 124.6 104.4 139.8
P3 MLD (mm) 1.58 0.65 1.04 1.96 0.55 2.40 0.99 2.30 1.40
DS (%) 60.6 80.2 60.0 40.7 78.1 0 60.3 0 0
Medina 1,1,1 0,1,0 1,0,0
DBA () 47.4 82.7 67.8
PBA () 146.0 120.6 111.4
P4 MLD (mm) 1.58 0.65 2.40 0.65 1.48 2.40 2.5 0.92 1.40
DS (%) 60.6 80.2 0 80.2 40.6 0 0 59.9 0
Medina 1,1,0 1,0,0 0,1,0
DBA () 53.7 82.4 68.1
PBA () 151.2 121.0 111.7
P5 MLD (mm) 4.00 1.32 0.55 1.32 2.50 2.40 0.55 0.55 1.40
DS (%) 0 60.1 78.7 60.0 0 0 78.0 76.1 0
Medina 0,1,1 1,0,0 1,1,0
DBA () 70.6 89.6 54.9
PBA () 111.3 90.4 159.2
P6 MLD (mm) 4.00 1.32 0.55 1.32 0.55 2.40 0.99 2.30 1.40
DS (%) 0 60.1 78.7 60.1 78.1 0 60.3 0 0
Medina 0,1,1 1,1,0 1,1,0
DBA () 39.5 82.2 67.8
PBA () 141.1 120.8 111.4
B1–B3, bifurcation 1–bifurcation 3; P1–P6, phantom 1–phantom 6; DMV, distal main vessel; DS, percent diameter stenosis; DBA, distal bifurcation
angle; PBA, proximal bifurcation angle; MLD, minimal lumen diameter; medina, medina class; PMV, proximal main vessel; SB, side branch.
Distal BA, angle between DMV and SB; proximal BA, angle between PMV and SB.
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bifurcation region; thus, a dedicated bifurcation phan-
tom had to be designed for this purpose.
We considered several techniques to create a bifur-
cation phantom. Stereolithography had too low a reso-
lution and poor sealing properties, whereas casts
derived from diseased human or animal coronaries are
complicated to create and it would be difﬁcult to get a
complete range of stenosis and BA values. Moreover,
it would be necessary to validate the internal dimen-
sions of these casts with another imaging modality
with its inherent variability, and the material properties
should match the typical characteristics of the imaging
modality. Finally, casts made of gels are fragile and
degrade over time and also need another imaging tech-
nique for validation.
We chose the above described computer-aided
approach for its relative design and machining simplic-
ity and for excluding the need of an additional valida-
tion of the internal dimensions of the phantom.
For the construction of the bifurcation phantoms, we
selected plexiglas for its extremely high radiolucency,
essentially having the same X-ray absorption coefﬁ-
cient as water, and its suitability for precision milling.
Moreover, its transparency allowed visual inspection of
the phantoms’ lumen (air bubble-free ﬁlling) and the
sealing quality of both halves.
MLD
A number of narrowed and stenosis-free vessel seg-
ments with varying MLD was created in order to repre-
sent the array of values encountered before interven-
tional treatment [1,16,26–29]. A well appreciated ﬂaw
of the previously developed QCA systems was the
over- and underestimation of small and large true
MLD values, respectively, due to the limitations of the
X-ray imaging systems [1–3,7–10]. Reiber et al. [35]
provided us with cut-off values for MLD (0.66 mm),
beneath which the true MLD values are signiﬁcantly
overestimated. Our selection of narrowed vessel seg-
ments in the bifurcation phantoms will allow us to
investigate this phenomenon in the newly developed
QCA systems.
Lesion Shape
A van der Giessen et al. [30], in a recent MDCT-
based study, explored the spatial distribution of plaque
in LMCA and non-LMCA bifurcation lesions relative
to the expected wall shear–stress patterns, as can be
derived from a general distribution in a bifurcation
region. In that study, cross-sections 1 mm distal to the
carina were studied. Plaque growth had indeed a predi-
lection for the walls opposite the carina; however, it
was reported to involve the carina in 31% of the stud-
ied cross-sections. In those cases, the plaque was
always present in either of the adjacent quartiles of the
vessel’s circumference as well as in the outer bifurca-
tion wall, thereby implying a circumferential growth of
plaque from the low wall shear stress locations into the
high wall shear stress ﬂow-divider in the event of
advanced atherosclerosis and excessive plaque burden.
On the other hand, Oviedo et al. [20], in a very recent
IVUS-based study on 140 patients with distal LMCA
bifurcation lesions, reported that the carina was always
spared of plaque growth, whereas plaque burden
40%, almost always being present in the PMV
(LMCA in this situation), expanded into the DMV (left
anterior descending) and the SB (left circumﬂex) in
90% and 66.4% of the cases, respectively. These ﬁnd-
ings were reported to be independent from BA, lesion
severity, LMCA length, or remodeling. However, judg-
ing from the Medina class distribution in the bifurca-
tion lesions of that cohort [20] by qualitative angio-
graphic evaluation and comparing with studies such as
the BBC-ONE [18], disease in the bifurcation region
was apparently not excessive.
The phantom design was expected to be representa-
tive of usual lesion patterns, yet challenging the QCA
software to be validated by presenting a number of
lesions with excessive narrowing. Although the carina
was kept free of disease, in the tightest stenoses
designed, there was some disease implemented down-
stream the carina, however, with an eccentric lesion
formation, favoring plaque presence on the opposite
wall. The lesion shape was selected to be cosinus-
shaped and of sufﬁcient length to allow smooth taper-
ing, contrary to the abrupt onset and termination of
plaque in earlier phantoms [1].
Medina Class
The ﬁve most common Medina classes as derived
from literature were used in the phantom design; the
(1,1,0) and (0,1,0) classes could almost interchangeably
be used for the ones not included, namely (1,0,1) and
(0,0,1). It is just a matter of deﬁnition which branch is
called the DMV and which is called the SB; analysis
per se would not differ. Introducing DS values of at
least 60% in the ‘‘diseased’’ vessel segments, we cre-
ated a quantitative Medina classiﬁcation, which by def-
inition expresses more severe disease than a classiﬁca-
tion based on visual stenosis evaluation, as was the
case in most clinical studies (Table I); it is well known
that QCA results underestimate the severity of a lesion,
compared to the angiographer’s perception [36]. How-
ever, to introduce examples with lower degree of ste-
nosis, we also included the 40% DS in our bifurcations
(Fig. 1).
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Angulation Parameters
BA measures have been linked both to procedural
complexity and outcome measures after bifurcation
stenting [13,37]. For design purpose, we deﬁned the
direction of the SB with respect to the DMV, based on
straight centerlines of an arbitrary length of 15 mm.
Despite the diversity in BA deﬁnition and calculations
in relevant literature [29,31–33], we used the reported
range of angles for the SB direction. To determine the
true BA values from the 3D luminal surface, we
reverted to the algorithm used by Thomas et al. [34];
this algorithm takes local vessel curvature into account
and is based on the 3D vessel centerlines.
Limitations
The phantom design naturally has the inherent limi-
tations of any artiﬁcial construction trying to mimic
real life. The smooth walls of the phantoms do not
resemble the jagged irregular appearance of the coro-
nary vessel walls, especially after balloon dilation [1],
nor can they reﬂect the bias of heart movement, being
static objects. The bifurcations were constructed in a
single plane, thereby permitting the placement in iso-
center, lying horizontally on the ﬂat surface of the
angiographic table. Unfortunately, designing a phantom
3D bifurcation out of one plane is not permitted using
the CNC method. However, in clinical practice, the
optimal degree of angulation and rotation of the angio-
graphic C-arm is selected in order to orient the X-ray
beams perpendicular to the plane of a given bifurca-
tion; thus, this limitation in design would hardly effect
the applicability of our phantoms.
CONCLUSIONS
For the purpose of validating the 2D and 3D bifurca-
tion QCA algorithms and thus standardizing the angio-
graphic analysis of coronary bifurcation lesions, six
plexiglas phantoms were designed and precision manu-
factured. Each phantom mimicked a coronary vessel
with three successive bifurcations lesions with variable
anatomy and Medina class. The selection of individual
bifurcation lesion characteristics attributed to this data-
set of 18 phantom bifurcations was derived from the
relevant literature.
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Two-Dimensional Quantitative Coronary Angiographic
Models for Bifurcation Segmental Analysis: In Vitro
Validation of CAAS Against Precision Manufactured
Plexiglas Phantoms
Chrysaﬁos Girasis,1 MD, Johan C.H. Schuurbiers,2 BSc, Yoshinobu Onuma,1 MD,
Jean-Paul Aben,3 BSc, Bas Weijers,3 BSc, Eric Boersma,4 MSc, PhD,
Jolanda J. Wentzel,2 PhD, and Patrick W. Serruys,1* MD, PhD
Background: Quantitative coronary angiography (QCA) analysis for bifurcation lesions
needs to be standardized. Objectives: In vitro validation of two models for bifurcation QCA
segmental analysis. Methods: In the latest edition of the Cardiovascular angiography anal-
ysis system (CAAS 5v8, Pie Medical Imaging, Maastricht, The Netherlands) a 6-segment
model for two-dimensional coronary bifurcation analysis was implemented next to the
currently available 11-segment model. Both models were validated against 6 precision
manufactured plexiglas phantoms, each of themmimicking a vessel with three successive
bifurcation lesions with variable anatomy and Medina class. The phantoms were ﬁlled
with 100% contrast agent and imaged with a biplane gantry. Images acquired in antero-
posterior (AP) direction by either C-arm and at 30 right and left anterior oblique angula-
tion were analyzed by two independent analysts, blinded to the actual dimensions. Manual
correction of the contours was not allowed. Measurements for minimal lumen diameter
(MLD), reference vessel diameter (RVD), percent diameter stenosis (DS) and bifurcation
angle (BA) were compared with the true phantom dimensions. Results: In AP views the ac-
curacy and precision (mean difference 6 SD) of 11- and 6-segment model for MLD, RVD,
and DS were 0.065 6 0.128 mm vs. 0.058 6 0.142 mm, 20.021 6 0.032 mm vs. 20.022 6
0.030 mm, and 22.45% 6 5.07% vs. 22.28% 6 5.29%, respectively. Phantom MLD values
0.7 mm were systematically overestimated; if excluded, MLD accuracy and precision
became 0.015 6 0.106 mm and 0.004 6 0.125 mm for the 11- and 6-segment model,
respectively. Accuracy and precision for BA were22.2 6 3.3. Interobserver variability for
MLD, RVD, DS, and BA for either model was 0.049 mm, 0.056 mm, 2.77%, and 1.6,
respectively. Agreement between models for MLD, RVD, and DS was 60.079 mm, 60.011
mm, and 62.07%. Accuracy and precision for diameter-derived parameters were slightly
decreased in angulated projections; precision for BA measurements dropped to 6.1.
Conclusions: The results of both models are highly reproducible and for phantom MLD
values >0.7mm in excellent agreement with the true dimensions. VC 2011 Wiley-Liss, Inc.
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INTRODUCTION
Single-vessel analysis has been the conventional meth-
odology for quantitative coronary angiography (QCA) of
coronary lesions [1–4]. However, in the analysis of bifur-
cation lesions, the validity of single-vessel QCA has been
brought into dispute, as it fails to predict the functional
signiﬁcance of ostial side-branch (SB) stenosis [5]. Dedi-
cated two-dimensional (2D) bifurcation software algo-
rithms have been developed recently to make up for the
shortcomings of 2D single-vessel QCA [6–8]. However
deﬁnitions of angiographic measures, such as the refer-
ence vessel diameter (RVD), are at variance, having not
yet been validated versus a golden standard [8] and thus
resulting in different measures for the percent diameter
stenosis (DS); moreover breaking up the reported values
over an increasing number of segments could render the
results too complicated for clinical use.
To meet these unanswered needs, a new simpliﬁed
model for 2D bifurcation segmental analysis has been
developed and integrated together with the current 11-
segment bifurcation model, into the latest version of
the Cardiovascular Angiography Analysis System
(CAAS 5v8, Pie Medical Imaging, Maastricht, The
Netherlands). This report presents the results of the
validation of both models by means of a series of cus-
tom-made, precision manufactured, plexiglas phantoms,
for measurements of minimal lumen diameter (MLD),
RVD, DS, and bifurcation angles.
MATERIALS AND METHODS
Phantoms
Six plexiglas phantoms, each of them mimicking a
vessel with three successive bifurcations, were designed
in 3D and manufactured with a tolerance <10 lm [9].
Every individual bifurcation had a lesion, wherein at
least one vessel segment had a DS of 60%, the MLD
being located within 3–6 mm from the point of bifurca-
tion; the range of diameters, lesion length, angulation,
and Medina class [10] used in the design of these 18
bifurcations reﬂected the anatomic variation and the
fractal nature of bifurcations [11] in the human coronary
tree as derived from relevant literature.
Acquisition and Calibration
The digital angiograms were acquired on a biplane
angiographic system (Axiom ArtisTM, Siemens, For-
chheim, Germany). All phantoms were ﬁlled with
100% Iodixanol 320 (VisipaqueTM, GE Healthcare,
Cork, Ireland) and imaged at 30 frames per second, in
a 20-cm ﬁeld, with the center of the phantom placed
precisely at the isocenter. For validation purposes,
images acquired in antero-posterior (AP) direction by
either C-arm were analyzed. Images acquired at 30
angulation, once in right- and once in left-anterior
oblique (RAO-LAO) projection, were analyzed as well,
to investigate the impact of gantry angulation on the
accuracy and precision of the measurements.
Calibration was performed on a 10-mm grid board
acquired in AP direction by either C-arm; the recording
geometry of the X-ray system obtained from the
DICOM (Digital Imaging and Communications In
Medicine) header and the phantom thickness were
taken into account to determine the true pixel size in
the phantom plane, separately for each C-arm.
Radiographic system settings, phantom arrangement,
table height, and source to image intensiﬁer distance
were kept constant throughout each phantom-cm grid
acquisition and were identical for all phantoms.
Quantitative Angiographic Analysis
The measurements were carried out with CAAS 5v8 2-
D bifurcation software. Next to the current 11-segment
model (the 10-segment model described by Ramcharitar
et al [7] modiﬁed by the addition of an 11th segment
reﬂecting the ostium of the distal main vessel) a new,
simpliﬁed model was implemented, wherein the analyzed
bifurcation is split into 6 segments, equally allocated to
proximal main vessel (PMV), distal main vessel (DMV),
and SB, separated by the point of bifurcation (Fig. 1).
Standard operator procedure for angiographic analy-
sis consisted in the following steps: (1) The middle
frame out of the total frame count of a given acquisi-
tion was consistently analyzed to avoid frame selection
bias. (2) The pixel size was manually entered. (3) The
bifurcation segmentation was initialized by placing one
proximal and two distal delimiter points at the largest
possible distance from the bifurcation to be analyzed,
however not touching the adjacent bifurcation lesions
or the phantom borders. (4) Contours were detected
and MLD was determined with an already described
methodology [7]. (5) Single point local reference
obstruction analysis was applied to each vessel seg-
ment; diameters within 1.5-mm proximal and distal of
each reference position were averaged to derive the
corresponding RVD. The reference positions were
automatically placed at a distance 5% of the vessel
segment length away from the delimiter points. (6)
Given the values of MLD and RVD, DS was automati-
cally calculated. (7) Proximal and distal bifurcation
angles were calculated according to the described
methodology [7]; angle calculations are model inde-
pendent. All aforementioned parameters for both mod-
els could be derived from the standard report capture
(Fig. 1).
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Validation Methodology
QCA was performed off-line by two experienced ana-
lysts (CG and YO), independent from each other, and
blinded to the phantom dimensions. During the study,
manual contour correction was not allowed; however, in
a few cases the contour detection was adjusted by using
the restriction option, an algorithm designed for exclud-
ing gross image artifacts without manually redeﬁning
the detected contours [12]. The extent of restriction
applied by either analyst was meticulously reported.
MLD, RVD, and DS were reported for Segments 2,
3, and 5 (Fig. 1) of either 11- or 6-segment model,
reﬂecting the segments, where in clinical practice the
stent would be placed in the PMV, DMV, and SB,
respectively; values were pooled together according to
parameter. The proximal and distal BA values calcu-
lated by CAAS 5v8 were pooled together and com-
pared to the phantom BA values.
Separate analysis of MLD, RVD, and DS was per-
formed for phantom vessel segments with relatively
larger (>0.70 mm) true MLD values. Moreover, results
were stratiﬁed across distal bifurcation angles, to check
for inﬂuence upon the performance of the QCA algo-
rithm; accuracy and precision for MLD, RVD, DS, and
BA measurements in bifurcations with narrow angle
(40) between SB and DMV direction [9] were com-
pared with respective measures in wide-angled bifurca-
tions (70 and 90).
Statistics
Statistical analysis was performed using SPSS 16.0
for Windows (SPSS, Chicago, IL). Continuous varia-
bles are presented as mean  1 standard deviation and
compared with the independent- or paired-samples t
test, as appropriate. Categorical variables are presented
as counts and/or percentages. Measurements for any
parameter or model derived from the two sets of
images acquired in AP view were expected to be corre-
lated (measurements of the same quantity); they were
indeed preemptively checked for correlation using the
Pearson coefﬁcient, compared with a paired t test and
then averaged, being henceforth treated as single val-
ues. The same procedure was followed for the two sets
of images acquired in angulated projections.
The ﬁrst analyst carried out two full rounds of meas-
urements, with a time interval of 2 weeks, to determine
intra-observer variability; the ﬁrst round of measure-
ments was compared both with the measurements of
the second analyst to determine interobserver variabili-
ty and with the corresponding phantom values for the
purpose of the software validation. To determine the
intra- and interobserver variability, we performed
Bland-Altman analysis [13], wherein paired values dif-
ferences were plotted against their respective average
values. The mean of the paired differences and its
standard deviation were calculated; the repeatability
coefﬁcient and the 95% limits of agreement were
Fig. 1. Standard report of CAAS 5v8 (compilation). A. Analyzed frame highlighting the
obstruction analysis (plaque in yellow) with diameter graphs and numerical results for diame-
ter-derived parameters for 11-segment model. B. Upper panel: Diameter graphs for main ves-
sel and side-branch for the 11- (left) and 6-segment (right) model. Middle panel: Model sche-
matics. Lower panel: Bifurcation angle values. [Color ﬁgure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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determined. Assessment of agreement between the two
bifurcation models was also performed using Bland-
Altman analysis.
A paired t test was used to compare the QCA meas-
urements by either model with the corresponding phan-
tom values. The individual signed differences were
averaged; the mean of these signed differences (bias) is
a measure of accuracy; the standard deviation is a mea-
sure of precision. As the phantom values were known,
we chose to plot these instead of the average values on
the x-axis against the signed differences and computed
the corresponding 95% limits of agreement [13]. When
appropriate, signed differences were plotted on the y-
axis of the plots as the percentage of the corresponding
true values [14]. The same statistical approach was fol-
lowed in the analysis of the vessel segments with
larger true MLD values.
All statistical tests were two-sided and a P value
<0.05 was considered statistically signiﬁcant.
RESULTS
Analysis (Validation) in AP Views
Measurements for any parameter or model did not
differ signiﬁcantly between images acquired with the
frontal and lateral C-arm (P  0.58 for every parame-
ter); values for MLD, RVD, DS, and BA were very
strongly correlated between C-arms (Pearson coefﬁ-
cient consistently 0.99, P < 0.001).
The extent to which restriction was applied during
the analysis is reported in Table I. The only case where
restriction was consistently applied was the ﬁrst bifur-
cation of the sixth phantom. Initial contour detection of
the shallow angled side branch identiﬁed a much larger
region of interest; once this was restricted, contours
were adequately traced.
Accuracy and precision for MLD, RVD, DS and BA
are reported in Tables II and III. MLD and DS for
both models differed signiﬁcantly from the phantom
values (P < 0.01 for every parameter); however, if
TABLE I. Extent of Restriction Applied During the Analysis (AP Views)
1st analyst–1st round 1st analyst–2nd round 2nd analyst
Bifurcations Rate Bifurcations Rate Bifurcations Rate
Frontal C-arm P1B3, P6B1 2/18 P1B3, P6B1 2/18 P6B1 1/18
Lateral C-arm P5B3, P6B1 2/18 P6B1 1/18 P6B1 1/18
AP ¼ antero-posterior, B1-B3 ¼ Bifurcation 1-Bifurcation 3, P1-P6 ¼ Phantom 1-Phantom 6.
TABLE II. Validation of 11-Segment Model vs. Phantom Dimensions (AP Views)
BSM11 Phantom Accuracy Precision Limits of agreement P-value* BSM11 vs. phantom
MLD-all (mm) 1.55  0.75 1.49  0.85 0.065 0.128 0.250 <0.001
MLD-large MLD (mm) 1.81  0.70 1.80  0.77 0.015 0.106 0.208 0.39
RVD-all (mm) 2.68  0.70 2.70  0.71 0.021 0.032 0.062 <0.001
RVD-large MLD (mm) 2.62  0.77 2.64  0.78 0.018 0.030 0.058 <0.001
DS-all (%) 38.50  29.75 40.94  34.15 2.45 5.07 9.94 <0.01
DS-large MLD (%) 27.08  26.13 27.63  29.72 0.55 4.30 8.43 0.43
BA () 94.4  33.1 96.6  33.4 2.2 3.3 6.4 <0.001
AP ¼ antero-posterior, BA ¼ bifurcation angle, BSM11 ¼ bifurcation 11-segment model, DS ¼ percent diameter stenosis, MLD ¼ minimal lumen
diameter, RVD ¼ reference vessel diameter.
*P signiﬁcant <0.05.
TABLE III. Validation of 6-Segment Model vs. Phantom Dimensions (AP Views)
BSM6 Phantom Accuracy Precision Limits of agreement P-value* BSM6 vs. phantom
MLD-all (mm) 1.55  0.73 1.49  0.85 0.058 0.142 0.279 <0.01
MLD-large MLD (mm) 1.80  0.68 1.80  0.77 0.004 0.125 0.244 0.83
RVD-all (mm) 2.68  0.70 2.70  0.71 0.022 0.030 0.060 <0.001
RVD-large MLD (mm) 2.610.77 2.640.78 0.021 0.028 0.054 <0.001
DS-all (%) 38.66  29.55 40.94  34.15 2.28 5.29 10.37 <0.01
DS-large MLD (%) 27.31  25.92 27.63  29.72 0.32 4.55 8.91 0.66
BA () 94.4  33.1 96.6  33.4 2.2 3.3 6.4 <0.001
AP ¼ antero-posterior, BA ¼ bifurcation angle, BSM6 ¼ bifurcation 6-segment model, DS ¼ percent diameter stenosis, MLD ¼ minimal lumen
diameter, RVD ¼ reference vessel diameter.
*P signiﬁcant <0.05.
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vessel segments with larger true MLD were only con-
sidered, no statistical difference was observed anymore.
MLD in vessel segments with smaller true minimal
lumen diameter was systematically overestimated,
whereas DS was systematically underestimated; oppo-
site phenomena were apparent in vessel segments with
larger true MLD, however to a lesser extent (Figs. 2
and 3). BA measurements underestimated on average
the true phantom values (DBA ¼ 2.2). There was
no signiﬁcant difference in accuracy and precision for
MLD, RVD, DS, or BA between wide- and narrow-
angled bifurcations (Table IV).
Intra- and interobserver variability. Bias, standard
deviation and repeatability coefﬁcient for either model
are reported in Table V. Bias both for intra- and inter-
observer comparisons was equal or very close to zero
for every parameter.
Intermodel agreement. Direct assessment of agree-
ment between the two models is presented in Table VI.
Limits of agreement for MLD, RVD, and DS between
models were 0.079, 0.011, and 2.07%, respec-
tively.
Analysis in Angulated Views
Values for MLD, RVD, DS, and BA were very
strongly correlated (Pearson coefﬁcient consistently
0.99, P < 0.001) and did not differ signiﬁcantly
between angulated views (P  0.16 for every compari-
son). Accuracy and precision of measurements in angu-
lated views are reported in Table VII. Interobserver
variability for MLD, RVD, DS, and BA was
0.042mm, 0.072mm, 2.87%, and 2.2 for either
model (not shown). Restriction was applied only once
by either analyst in the angulated projections.
DISCUSSION
The main ﬁndings of this study are: (1) The new 2D
QCA bifurcation software is highly accurate and
Fig. 2. Bland-Altman plots comparing 11-segment model results (54 vessel segments) to the
phantom values for minimal lumen diameter (MLD), reference vessel diameter (RVD), percent
diameter stenosis (DS) and bifurcation angle (BA); analysis in antero-posterior views. Solid
lines represent the mean difference (bias), dotted lines represent the 95% limits of agreement
(bias 6 1.96 SD). Deg 5 degrees.
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precise in terms of RVD and accurate and precise in
terms of MLD and DS, when compared in vitro with a
series of custom-made, precision manufactured plexi-
glas phantoms. Optimal accuracy and a higher level of
precision for MLD and DS are achieved, if vessel seg-
ments with smaller true MLD (0.70 mm) are
excluded from the analysis. The performance of the
QCA algorithm does not vary signiﬁcantly across distal
BA values. (2) Accuracy and precision for MLD, RVD
and DS in angulated projections are slightly decreased,
however comparable to the respective measures in AP
views. (3) Repeatability for all diameter-derived pa-
rameters and for both models is very high. (4) Agree-
ment between the 11- and the 6-segment model is high
Fig. 3. Bland-Altman plots comparing 11-segment model results to the phantom values for min-
imal lumen diameter (MLD); analysis in antero-posterior views. Absolute (upper panel) and rela-
tive (lower panel) differences are plotted on the Y-axis for the entire dataset (left column), for true
MLD values >0.7 mm (middle column) and for true MLD values <0.7 mm. Solid lines represent the
mean difference (bias), dotted lines represent the 95% limits of agreement (bias6 1.96 SD).
TABLE IV. Accuracy and Precision Across Distal BA Values (AP Views)
Small distal BA Large distal BA
P-value*Mean  SD Accuracy Precision Mean  SD Accuracy Precision
BSM11
MLD (mm) 1.49  0.82 0.068 0.129 1.58  0.72 0.064 0.129 0.91 (0.64)
RVD (mm) 2.67  0.83 0.016 0.027 2.69  0.64 0.023 0.034 0.41 (0.43)
DS (%) 40.32  31.21 2.51 5.19 37.59  29.39 2.42 5.09 0.95 (0.72)
BA () 94.3  52.7 1.8 3.3 94.5  18.4 2.4 3.3 0.60 (0.95)
BSM6
MLD (mm) 1.47  0.77 0.049 0.166 1.58  0.71 0.062 0.131 0.77 (0.71)
RVD (mm) 2.67  0.83 0.018 0.024 2.68  0.64 0.024 0.033 0.49 (0.52)
DS (%) 40.74  30.68 2.08 5.81 37.62  29.35 2.38 5.10 0.85 (0.73)
BA () 94.3  52.7 1.8 3.3 94.5  18.4 2.4 3.3 0.60 (0.95)
AP ¼ antero-posterior, BA ¼ bifurcation angle, BSM ¼ bifurcation segment model, DS ¼ percent diameter stenosis, MLD ¼ minimal lumen diame-
ter, RVD ¼ reference vessel diameter, SD ¼ standard deviation.
*P signiﬁcant < 0.05, values relate to the comparison between accuracy measures for the small and the large BA; numbers in parentheses are
derived for the respective comparison between accuracy measures relative to the true values.
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for all parameters. (5) BA measurements underestimate
the phantom values, whereas their repeatability is quite
high. Precision of BA measurements is diminished in
angulated views.
Since the early days of QCA analysis, there have
been serial validation studies [2,15–22], either in vitro
or in vivo, reporting on the accuracy and precision of
various software algorithms compared against a phan-
tom of known dimensions. The series of phantoms that
were used for this study were speciﬁcally designed for
the purpose of validation of 2D and 3D bifurcation
QCA algorithms. Contrast concentration of 100%
[17,19], calibration of images at isocenter [15,17,19,23]
and consistent frame selection [24,25] have been
employed, to acquire high quality images and high va-
lidity measurements.
Minimal Lumen Diameter
MLD is the only absolute angiographic measure-
ment, that can serve as a marker of progression-regres-
sion of atherosclerosis and directly relates to the physi-
ological signiﬁcance of the lesion [26]. Previous phan-
tom validation studies for the former editions of the
CAAS software showed varying degrees of accuracy
and precision in the analysis of single-vessel lesions:
0.03  0.09 mm by Reiber et al. in vitro [2] and
0.07  0.21 mm by Haase et al. in vivo [15] for
CAAS I, 0.00  0.11 mm in vitro and 0.01  0.18
mm in vivo by Haase et al. [18] for CAAS II (obstruc-
tion diameter using a slightly different deﬁnition) and
recently 0.19  0.06 mm in vitro by van Herck et al.
[21] for CAAS II; intra- and interobserver repeatability
of obstruction diameter for either edition has been
close to 0.2 mm [12].
Keane et al. [19] and Hausleiter et al. [20] explored
the boundaries of the then available systems through
comparative validation studies. For an array of stenotic
tubes with a mean diameter of 1.12 mm (range 0.5–1.9
mm), Keane et al found varying values for accuracy
(0.01/0.23 mm) and precision (0.07–0.28 mm) for
in-vitro measurements, no system being both very
TABLE V. Intra- and Interobserver Repeatability for 11-Segment and 6-Segment Model (AP Views)
INTRA-BSM11 INTRA-BSM6 INTER-BSM11 INTER-BSM6
Bias SD Repeat Bias SD Repeat Bias SD Repeat Bias SD Repeat
MLD (mm) 0.00 0.024 0.046 0.001 0.024 0.048 0.005 0.025 0.049 0.004 0.025 0.048
RVD (mm) 0.009 0.028 0.054 0.008 0.028 0.055 0.005 0.028 0.055 0.004 0.029 0.056
DS (%) 0.21 1.29 2.53 0.15 1.26 2.47 0.44 1.40 2.75 0.38 1.41 2.77
BA () 0.2 0.8 1.5 0.2 0.8 1.5 0.0 0.8 1.6 0.0 0.8 1.6
AP ¼ antero-posterior, BA ¼ bifurcation angle, BSM6 ¼ bifurcation 6-segment model, BSM11 ¼ bifurcation 11-segment model, DS ¼ percent
diameter stenosis, MLD ¼ minimal lumen diameter, RVD ¼ reference vessel diameter, repeat ¼ repeatability coefﬁcient, SD ¼ standard deviation.
TABLE VI. Agreement Between 11- and 6-Segment Model (AP Views)
BSM11 BSM6 Bias SD LA
MLD (mm) 1.55  0.75 1.55  0.73 0.008 0.040 0.079
RVD (mm) 2.68  0.70 2.68  0.70 0.002 0.006 0.011
DS (%) 38.50  29.75 38.66  29.55 0.16 1.05 2.07
AP ¼ antero-posterior, BSM6 ¼ bifurcation 6-segment model, BSM11 ¼ bifurcation 11-segment model, DS ¼ percent diameter stenosis, LA ¼
limits of agreement, MLD ¼ minimal lumen diameter, RVD ¼ reference vessel diameter, SD ¼ standard deviation.
TABLE VII. Accuracy and Precision in Angulated Views
BSM11 BSM6
Accuracy Precision AP vs. RL; P-value* Accuracy Precision AP vs. RL; P-value*
MLD-all (mm) 0.097 0.141 <0.01 0.082 0.170 0.01
MLD-large MLD (mm) 0.044 0.122 <0.01 0.025 0.159 0.07
RVD-all (mm) 0.009 0.041 0.08 0.011 0.041 0.09
RVD-large MLD (mm) 0.010 0.038 0.23 0.012 0.037 0.23
DS-all (%) 3.75 5.31 <0.01 3.34 5.87 0.03
DS-large MLD (%) 1.90 4.66 0.02 1.38 5.37 0.09
BA () 2.7 6.1 0.54 2.7 6.1 0.54
AP ¼ antero-posterior, BA ¼ bifurcation angle, BSM ¼ bifurcation segment model, DS ¼ percent diameter stenosis, MLD ¼ minimal lumen
diameter, RL ¼ right-left angulation, RVD ¼ reference vessel diameter.
*P signiﬁcant <0.05, values relate to the comparison between accuracy measures for AP vs. RL.
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accurate and precise. Hausleiter et al. found in a series
of stenotic and nonstenotic phantoms a wider range for
accuracy (0.040/0.039 mm) and precision (0.087–
0.184); inclusion of stenotic tubes with MLD in the
submillimeter range, limited the performance of the
tested systems. In this respect, Tuinenburg et al. in a
recent study, chose to exclude phantoms with an MLD
<0.60 mm, because they were expected to be overesti-
mated [22].
Our study yielded an accuracy of 0.065/0.058 mm
and a precision of 0.128/0.142 mm for 11- and 6-seg-
ment model, respectively, intra- and interobserver
repeatability being very high (<0.05 mm). To explore
the possible impact of small phantom MLD values on
the accuracy and precision of our study [20–22], we
ran a separate analysis excluding 14 stenotic (DS 
60%) vessel segments with a true MLD  0.7mm.
Indeed analysis of the remaining vessel segments
(MLD range 0.922–4.00 mm) resulted in optimal accu-
racy (0.015/0.004 mm) and higher precision (0.106/
0.125 mm) for 11- and 6-segment model respectively
being well in the range of recently suggested require-
ments [22]. It should be emphasized that this level of
accuracy and precision is achieved by a bifurcation
QCA algorithm despite the increased level of complex-
ity, when compared to single-vessel QCA; in a single
analytical process, measurements for all three bifurca-
tion vessel segments are provided.
It is well known that small objects are overestimated
due to the limitations related to the X-ray systems.
Accurate assessment of small diameters suffers signiﬁ-
cantly due to the blurring effect caused by the size of
the focal spot from the X-ray system [12,18]. Work is
in progress to design an improved contour detection
algorithm, which reduces the inﬂuence of the X-ray
system limited focal spot size yielding more accurate
assessment of small diameters.
Reference Vessel Diameter
Lansky et al. [8] argues that the user-deﬁned method
is prone to bias, requiring user-selection and not
accounting for tapering over long vessel segments, or
even the step-down phenomenon, if applied on either
side of the bifurcation. Thus an iterative regression
function, as already implemented in single-vessel anal-
ysis [27], would be preferred.
In our study, the RVD function was determined sep-
arately for each vessel segment of the bifurcation by
means of single point local reference obstruction analy-
sis. We followed a standardized approach of analyzing
segments between successive bifurcations, which are
not expected to taper if assumed healthy [28,29],
assumption inherent in the RVD derivation. This argu-
ment holds even more in the situation of a multi-seg-
mental model, wherein segments between bifurcations
are subdivided into smaller ones limiting the tapering
effect. Thus the reference of a given vessel segment
gets extrapolated from the diameter outside the
obstruction boundaries. To minimize the user-selection
bias, diameter averaging over a 3-mm long segment
(1.5mm from the reference position) is applied.
Moreover, in the 11-segment model, the RVD function
within the polygon of conﬂuence is still determined by
the current curvature interpolation technique (Fig. 1)
[7]; on the other hand, in the 6-seg model, RVD for
each vessel segment is called by one straight line up
until the point of bifurcation. Agreement between the
models for RVD was almost optimal despite this dif-
ference in methodology; accuracy 0.022 mm and pre-
cision 0.032 mm compared to the phantom values
rendered either approach valid.
Percent Diameter Stenosis
DS has been less reliable in the evaluation of percu-
taneous interventions [30] or the functional signiﬁcance
of ostial SB stenosis [5]; the application of single-ves-
sel analysis at bifurcation sites is rather cumbersome as
well [6]. Increasingly accurate, precise and repeatable
MLD and RVD measurements in our study resulted in
robust DS measurements, mainly in the vessel seg-
ments with larger (>0.7 mm) true MLD.
Bifurcation Angles
Recent publications from our group [31] and others
[32] reinforce the suggested prognostic role [33] of
bifurcation angulation parameters. CAAS is the sole
2D QCA software implementing automated algorithms
for the calculation of BA [7]. The BA could be deter-
mined with an accuracy of 2.2 and a precision of
3.3; values were remarkably repeatable thus consist-
ent. It has to be understood that the phantom BA val-
ues were determined in a 3D space with a 3D deﬁni-
tion [9] in contrast to the 2D deﬁnition used in the
CAAS software; this fact probably accounts for the
diminished agreement.
11- vs. 6-Segment Model
Segmentation of a bifurcation lesion results in the
accurate localization of MLD, RVD and DS pre-, post
PCI and at follow-up angiography. This way we can
increase our understanding of the mechanisms that lead
to post-intervention failure or success, especially at the
SB ostium [8]. On the other hand simplicity is a
requirement for on-line QCA; intuitive interpretation of
a simpliﬁed, still all-inclusive report facilitates accurate
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sizing of intracoronary devices and proper decision
making.
Agreement between the two models was excellent,
either of them being highly repeatable. In this respect
the two models are not mutually exclusive, but could
be used interchangeably according to research or clini-
cal purpose.
Impact of Gantry Angulation on the System
Performance
Similar to prior validation studies, primary analysis
was performed in AP views, in order to minimize
errors resulting from overlap and foreshortening [22].
In our study, angulated projections were also analyzed,
in order to simulate a clinical scenario of suboptimal
cineangiography. Because of the eccentric shape of the
phantom bifurcation lesions analyzed, it was expected
that measurements for diameter-derived parameters
would be slightly less accurate and precise compared
to the AP views. However, results were within the
range of current standards for single-vessel QCA, espe-
cially when vessel segments with smaller true MLD
were excluded. The decreased precision of the 2D BA
measurements is caused by the x-ray translation effect
of a 3D object into a 2D presentation. The BA is more
sensitive to such spatial deformation compared to di-
ameter-derived parameters, which are primarily
effected by foreshortening.
Limitations
Our measurements were performed in vitro, probably
not giving an accurate account of the system perform-
ance, when it comes to in vivo imaging. The phantoms
are static objects not taking into account the movement
of the coronary arteries and the inherent decrease in
image quality. However, in vivo validation of a bifur-
cation QCA algorithm would require measurements by
another imaging modality to be used as the golden
standard despite their inherent variability; insertion of
bifurcation phantoms in animal coronaries would be
technically demanding and unsafe. Recent experience
from comparative in vitro and in vivo validation stud-
ies allows us to extrapolate the in vivo performance of
angiographic analysis software given its in vitro accu-
racy and precision; modern digital angiography systems
make this extrapolation even more predictable.
Minimal user-interaction and editing of the lumen
contours is a requirement for QCA studies [8], even
more so for the purpose of validation. We were com-
pelled to apply restriction in a limited number of
images, where the contour of either the DMV or the
SB did not follow the intuitive path-line. However, the
restriction option is not a manual contour correction,
but instead offers users the possibility of excluding
parts of the image from the contour detection by
restricting the area of interest. Moreover, in our study,
selection of the restricted images was blinded, being
consistently applied in only one case.
CONCLUSIONS
The latest edition of CAAS 2D QCA bifurcation
software, implementing an 11-segment and a 6-seg-
ment model, was validated against a series of custom
made, precision manufactured plexiglas phantoms. The
software is highly accurate and precise in terms of
RVD and accurate and precise in terms of MLD and
DS; optimal accuracy and a higher level of precision
for MLD and DS were achieved, if vessel segments
with larger true MLD (0.70 mm) were only consid-
ered. Accuracy and precision for MLD, RVD, and DS
in angulated projections are comparable to the respec-
tive measures in AP views. BA measurements underes-
timate the phantom values, whereas their repeatability
is quite high; however precision is diminished in angu-
lated views. Both models are highly repeatable, and in
excellent agreement with each other, hence they can be
used interchangeably according to research or clinical
purpose.
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Abstract
Aims: To validate a new two dimensional (2-D) bifurcation quantitative coronary angiography (QCA) 
software.
Methods and results: In the latest edition of the Cardiovascular Angiography Analysis System (CAAS 5.9; 
Pie Medical Imaging, Maastricht, The Netherlands) video-densitometric information is dynamically inte-
grated into the edge-detection algorithm of 11- and 6-segment models to reduce overestimation of small 
diameters. Furthermore, automatic reference obstruction analysis was optimised. Values of the minimal 
lumen diameter (MLD), reference vessel diameter (RVD), percent diameter stenosis (DS) and bifurcation 
angle (BA) for the different bifurcation segment models were validated against precision manufactured plexi-
glass phantoms. In anteroposterior views, accuracy and precision (mean difference±SD) of 11- and 6-seg-
ment models for MLD were 0.013±0.082 mm vs. 0.003±0.100 mm, for RVD –0.030±0.047 mm vs. 
–0.029±0.045 mm and for DS –0.48±3.66% vs. –0.11±3.97%. In smaller vessel segments (true MLD 
<0.7 mm), MLD overestimation was reduced. Inter-observer variability for MLD, RVD and DS for either 
model was ≤0.052 mm, ≤0.043 mm and ≤2.24%, respectively. Agreement between models for MLD, RVD 
and DS was ±0.076 mm, ±0.021 mm and ±2.53%, respectively. Accuracy and precision for BA were 
–2.6±3.5°, and variability was ≤1.2°. Accuracy and precision for diameter-derived parameters were slightly 
decreased in projections with 30° rotation; BA precision dropped to 6.2°.
Conclusions: MLD quantification is improved for true MLD <0.7 mm, resulting in highly accurate and 
precise diameter measurements over the entire range of phantom diameters. Automatic reference obstruction 
analysis provides highly accurate, precise and reproducible RVD and DS measurements.
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 Introduction
The fundamental issue in the quantitative coronary angiography 
(QCA) analysis of bifurcation lesions is the calculation of the refer-
ence vessel diameter (RVD)1,2. It has been convincingly demonstrated 
that due to the step-down phenomenon, this should be calculated 
separately for the proximal main vessel (PMV), the distal main vessel 
(DMV) and the side branch (SB)3-5. Even so, there are two possible 
approaches to define the RVD values, either based on a user-defined 
reference position located outside the obstruction or by using an auto-
matic regression function. The validity of the former approach for 
2-D bifurcation QCA has been tested and verified during the valida-
tion process for the Cardiovascular Angiography Analysis System 
(CAAS; Pie Medical Imaging, Maastricht, The Netherlands)6. How-
ever, in true coronary cases interpolation via an automatic regression 
function can be of value in excessively long and/or tapered vessels2.
Angiographic imaging of small objects is historically known to be 
affected by blurring due to the limitations of the X-ray systems and 
noise7-11. Notwithstanding the introduction of flat panel detectors and 
increased software sophistication, these phenomena are still present, 
as evidenced by the overestimation of lumen diameters <0.70 mm in 
the validation of CAAS 5.86 and other similar reports12,13.
CAAS 5.9 2-D bifurcation QCA software implements both an 
optimised automatic reference analysis and a new small lumen 
detection algorithm; thus it would be expected to offer increased 
accuracy and precision over the entire range of lumen diameters 
anticipated in clinical practice. In this report we present the results 
of the in vitro validation of this software package based on a series 
of precision manufactured bifurcation phantoms.
Materials and methods
PHANTOMS
Six plexiglass phantoms, each of them mimicking a vessel with 
three successive bifurcations, were designed in 3-D and manufac-
tured with a tolerance <10 μm14 (Figure 1). Every individual bifur-
cation had a lesion, wherein at least one vessel segment had 
a percent diameter stenosis (DS) of ≥60%, the minimum lumen 
diameter (MLD) being located within 3-6 mm from the point of 
bifurcation; the range of diameters (0.53-4.00 mm), lesion length, 
bifurcation angles and Medina class15 used in the design of these 18 
bifurcations reflected the anatomic variation and the fractal nature 
of bifurcations3-5 in the human coronary tree.
ACQUISITION AND CALIBRATION
The digital angiograms were acquired on a biplane angiographic 
system (Axiom Artis™; Siemens, Forchheim, Germany). All phan-
toms were filled with 100% Iodixanol 320 (Visipaque™; GE 
Healthcare, Cork, Ireland) and imaged at 30 frames per second, in 
a 20 cm field of view, with the centre of the phantom placed pre-
cisely at the isocentre. For validation purposes, images acquired in 
anteroposterior (AP) direction by either C-arm were analysed. 
Images acquired at 30° rotation, once in right and once in left ante-
rior oblique (RAO-LAO) projection, were also analysed, in order to 
investigate the impact of gantry angulation on the accuracy and pre-
cision of the measurements.
Calibration was performed on a 10 mm grid board and the record-
ing geometry of the x-ray system obtained from the Digital Imaging 
and Communications in Medicine (DICOM) (National Electrical 
Manufacturers’ Association, DICOM, Rosslyn, VA, USA) header 
and the phantom thickness were taken into account to determine the 
true pixel size in the phantom plane, separately for each C-arm.
Radiographic system settings, phantom position, table height and 
source to image intensifier distance were kept constant throughout 
each phantom and centimetre grid acquisition and were identical 
for all phantoms.
QUANTITATIVE ANGIOGRAPHIC ANALYSIS
Standard operator procedure for angiographic analysis consisted of 
the following steps:
Figure 1. Precision manufactured bifurcation phantoms. Angiographic images were acquired after filling the phantoms with contrast and were 
then used in the software validation; P1: phantom 1
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1) The middle frame out of the total frame count of a given acquisi-
tion was consistently analysed to avoid frame selection bias; 2) The 
pixel size was manually entered; 3) The bifurcation segmentation 
was initialised by placing one proximal and two distal delimiter 
points at the largest possible distance from the bifurcation to be 
analysed, however not touching the adjacent bifurcation lesions or 
the phantom borders; 4) Contours were detected using the new 
lumen detection algorithm and MLD was determined with an 
already described methodology16; 5) On the same contours, both 
single point bifurcation local reference obstruction (BLRO) analy-
sis6 and automatic reference obstruction (BARO) analysis were 
applied for the RVD calculation (Figure 2); 6) Given the values of 
MLD and RVD, the DS was automatically calculated; 7) Proximal 
and distal bifurcation angles were calculated according to the 
described methodology16; angle calculations are independent of the 
bifurcation segment model used.
The new lumen detection algorithm is based on the method 
described by Ramcharitar16. In addition to that, it dynamically inte-
grates video-densitometric information from the image into the seg-
mentation algorithms thereby reducing the overestimation of the 
small diameters. The BARO algorithm has originally been described 
by Ramcharitar et al16. In order to improve the stability of the RVD 
function, this algorithm was slightly modified in the new version. 
In the original BARO algorithm16, RVD outside the bifurcation 
region was only based on the obstruction-free parts of PMV, DMV 
or SB, respectively; in the CAAS 5.9, the automatic RVD function 
also takes into account characteristics of the bifurcation region 
itself. However, the BLRO algorithm was left unchanged as 
described in the validation paper for CAAS 5.8. Briefly, reference 
positions were automatically placed at a distance 5% of the vessel 
segment length inside the delimiter points; diameters within 1.5 mm 
proximal and distal of each reference position were averaged to 
derive the corresponding RVD. It follows, that, as illustrated in 
Figure 2, the validity of the RVD/DS measurements derived in 
BLRO is dependent on the definition of the reference points. On the 
contrary, BARO is not affected from variable positioning of the 
delimiter points, by fitting a reference diameter curve based on the 
“healthy” diameters within a given bifurcation branch.
VALIDATION METHODOLOGY
QCA was performed off-line by two experienced analysts (CG, 
YO), independent from each other. During the study, manual con-
tour correction was not allowed. However, in a few cases the con-
tour detection was adjusted by using the restriction option, therein 
excluding gross image artefacts without manually redefining the 
detected contours17.
MLD, RVD and DS were reported for segments 2, 3 and 5 of either 
the 11- or 6-segment model (Figure 3), reflecting the vessel seg-
ments, where in clinical practice the stent would be placed in the 
PMV, DMV and SB, respectively. Segment values were pooled 
together and analysed. The proximal and distal BA values were also 
pooled together and compared to the phantom BA values.
Figure 2. Differences between automatic (BARO) and local reference obstruction (BLRO) analysis of bifurcation lesions. The first bifurcation 
of the second phantom was analysed twice with each method focusing on the DMV lesion (MLD=0.69 mm); the position of the distal delimiter 
point (indicated by the yellow arrow) shifted between analyses. A. Delimiter point is placed within the DMV. RVD is apparently equal between 
methods, resulting in identical DS measurements. B. Delimiter point is placed distal to the DMV, within the adjacent bifurcation lesion. Taking 
a severely stenosed lumen as reference for the preceding DMV segment, BLRO results in the recalibration of the reference curve (horizontal 
red line) and therefore in gross DS underestimation. On the contrary, in BARO, the reference curve (black line) is based on the healthy 
diameter values within DMV; thereby DS is almost identical to the previous analysis. DMV: distal main vessel; DS: percent diameter stenosis; 
MLD: minimal lumen diameter; RVD: reference vessel diameter: P: proximal main vessel; M: DMV; S: side branch
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Separate analysis of MLD, RVD and DS was performed for 
phantom vessel segments with relatively larger (>0.70 mm) true 
MLD values. Moreover, results were separately analysed for BARO 
and BLRO algorithms and compared.
STATISTICS
Statistical analysis was performed using SPSS 16.0 for Windows 
(SPSS Inc, Chicago, IL, USA). Continuous variables are presented 
as mean ±1 standard deviation and compared with the independent 
or paired samples t-test, as appropriate. Categorical variables are 
presented as counts and/or percentages. Measurements for any 
parameter or model derived from the two sets of images acquired in 
AP view were expected to be correlated (measurements of the same 
quantity). They were indeed pre-emptively checked for correlation 
using the Pearson coefficient, compared with a paired t-test and 
then averaged, being henceforth treated as single values. The same 
procedure was followed for the two sets of images acquired in 
rotated projections.
The first analyst carried out two full rounds of measurements, 
with a time interval of two weeks, in order to determine intra-
observer variability. The first round of measurements was com-
pared both with the measurements of the second analyst to 
determine inter-observer variability and with the corresponding 
phantom values for the purpose of validating the software against 
the ground truth; Bland-Altman analysis was performed for all 
comparisons18. Regarding intra- and inter-observer comparisons, 
the mean difference (bias) and its standard deviation were calcu-
lated; the repeatability coefficient (equal to 1.96 * standard devia-
tion of the bias) was determined as the measure of variability. 
Assessment of agreement between the two bifurcation models was 
also performed using the Bland-Altman analysis.
A paired t-test was used to compare the QCA measurements by 
either model with the corresponding phantom values. The individ-
ual signed differences were averaged; the mean of these signed dif-
ferences is a measure of accuracy; the standard deviation is 
a measure of precision. Measures of accuracy were compared 
between models and/or methods of obstruction analysis with the 
paired t-test; measures of precision/variability were compared with 
the F-test12. As the true values were known, we chose to plot these 
instead of the average values on the X-axis of the Bland-Altman 
plot against the signed differences and computed the corresponding 
95% limits of agreement18. When appropriate, signed differences 
were plotted on the Y-axis of the plots as the percentage of the cor-
responding true values19.
All statistical tests were two-sided and a p-value <0.05 was con-
sidered statistically significant.
Results
ANALYSIS (VALIDATION) IN AP VIEWS
The extent to which the restriction option was applied during the 
contour detection is reported in Table 1. The first analyst was con-
sistent in his choice between the two rounds of measurements; the 
Figure 3. Bifurcation segment models; difference in minimal lumen diameter (MLD) traced in the side branch (SB). Left: Analysed frame of a 
phantom bifurcation; MLD position in the 11-segment model is highlighted in yellow; in red for the 6-segment model. Right: diameter graphs 
and model schematics for the 11-segment (upper panel) and 6-segment models (lower panel). In the former, segments 2 (PMV) and 5  (SB) are 
separated by segment 7 corresponding to the polygon of confluence; proximal and distal borders thereof are highlighted in yellow on both 
graph and schematic. Whereas MLD value is common between models for the PMV, difference in bifurcation model definitions results in 
different MLD values for segment 5. PMV: proximal main vessel
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second analyst did in fact not apply the restriction mode but rather 
indicated the pathlines from the PMV into the DMV and SB, 
respectively by successive left mouse clicks.
Accuracy and precision for MLD, RVD and DS values are 
presented in Table 2 and Table 3. MLD values for all 54 phantom 
vessel segments evaluated had an accuracy and precision of 
0.013±0.082 mm and 0.003±0.100 mm for the 11- and 6-segment 
model respectively, this not being significantly different from 
phantom values (p-value 0.23 and 0.81). MLD was still overesti-
mated in vessel segments with smaller true MLD (<0.7 mm), 
however to a modest degree (Figure 4). Because of the difference 
in calibre between the smaller and larger vessel segments, accu-
racy and precision were also expressed in percentage values in 
order to facilitate a comparison of respective indices. Thus, per-
centage accuracy and precision for the 11- and 6-segment models 
was 10.8±4.2% and 10.6±4.2% in smaller segments and 1.1±5.5% 
and 0.5±5.6% in larger segments, respectively (compare graphs in 
Figure 4).
Values for RVD and DS did not significantly differ between 
BARO and BLRO analysis, the latter being slightly but not signifi-
cantly more precise compared to BARO (Table 2 and Table 3). 
Finally, DS values did not differ significantly compared to phantom 
values either for the 11-segment (-0.48±3.66%, p=0.34 for BARO 
and –0.60±3.21%, p=0.17 for BLRO) or for the 6-segment model 
(–0.11±3.97%, p=0.84 for BARO and –0.26±3.52%, p=0.59 for 
BLRO).
Table 1. Extent of restriction applied during the analysis (AP views).
1st analyst-1st round 1st analyst-2nd round 2nd analyst
Bifurcations Rate Bifurcations Rate Bifurcations Rate
Frontal
C-arm
P1B3
P6B1 2/18
P1B3
P6B1 2/18 (P6B1)* 0/18
Lateral
C-arm P6B1 1/18 P6B1 1/18 (P6B1)* 0/18
AP: anteroposterior; B1-B3: Bifurcation 1-Bifurcation 3; P1-P6: Phantom 1-Phantom 6; *: manual pathline
Table 2. Validation of 11-segment model vs. phantom dimensions (AP views).
BARO BLRO
Accuracy Precision
p-value 
BSM11 vs. 
phantom
Accuracy Precision
p-value 
BSM11 vs. 
phantom
p-value* 
BARO vs. 
BLRO
MLD-all, mm 0.013 0.082 0.23 0.013 0.082 0.23 N/A
MLD-large MLD, mm –0.005 0.087 0.73 –0.005 0.087 0.73 N/A
MLD-small MLD, mm 0.066 0.029 <0.001 0.066 0.029 <0.001 N/A
RVD-all, mm –0.030 0.047 <0.001 –0.025 0.041 <0.001 0.49 (0.16)
DS-all, % –0.48 3.66 0.34 –0.60 3.21 0.17 0.53 (0.17)
AP: anteroposterior; BARO: bifurcation automatic reference obstruction analysis; BLRO: bifurcation local reference obstruction analysis; BSM11: 
bifurcation 11-segment model; DS: percent diameter stenosis; MLD: minimal lumen diameter; RVD: reference vessel diameter; N/A: non-applicable; 
p-significant <0.05 *values relate to the comparison between accuracy measures; values in parentheses relate to the comparison between precision 
measures.
Table 3. Validation of 6-segment model vs. phantom dimensions (AP views).
BARO BLRO
Accuracy Precision
p-value 
BSM6 vs. 
phantom
Accuracy Precision
p-value 
BSM6 vs. 
phantom
p-value* 
BARO vs. 
BLRO
MLD-all, mm 0.003 0.100 0.81 0.003 0.100 0.81 N/A
MLD-large MLD, mm –0.018 0.107 0.29 –0.018 0.107 0.29 N/A
MLD-small MLD, mm 0.064 0.029 <0.001 0.064 0.029 <0.001 N/A
RVD-all, mm –0.029 0.045 <0.001 –0.025 0.037 <0.001 0.53 (0.08)
DS-all, % –0.11 3.97 0.84 –0.26 3.52 0.59 0.39 (0.19)
AP: anteroposterior; BARO: bifurcation automatic reference obstruction analysis; BLRO: bifurcation local reference obstruction analysis; BSM6: bifurcation 
6-segment model; DS: percent diameter stenosis; MLD: minimal lumen diameter; RVD: reference vessel diameter; N/A: non-applicable; p-significant <0.05 
*values relate to the comparison between accuracy measures; values in parentheses relate to the comparison between precision measures.
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INTRA- AND INTER-OBSERVER VARIABILITY  Bias, standard devi-
ation and repeatability coefficient for either model are reported in 
Table 4. Values for RVD derived with BARO were consistently more 
reproducible compared to BLRO (p<0.001 for all comparisons). DS 
values were also more reproducible with BARO compared to BLRO; 
p-value for comparisons in intra-observer analysis was 0.09 and 0.03 
for the 11- and 6-segment models, respectively, whereas in inter-
observer analysis it was 0.01 and 0.43, respectively.
INTER-MODEL AGREEMENT  Direct assessment of agreement 
between the two models is presented in Table 5. Limits of agree-
ment for MLD were ±0.076 mm, whereas for RVD and DS they 
were ±0.021 mm and ±2.53% in BARO, and ±0.035 mm and 
±2.98% in BLRO analysis, respectively. Accuracy and precision 
measures did not differ significantly between models except for 
BARO derived DS values, where bias differed by 0.37% (p=0.04).
ANALYSIS IN ROTATED VIEWS
Accuracy and precision of measurements in rotated views are 
reported in Table 6. Only MLD values differed significantly from 
the phantom values (p=0.02). Accuracy was increased for MLD and 
DS measurements with the 6-segment model, however precision 
was comparable between models. Inter-observer variability for 
MLD was ≤0.088 mm, for RVD was ≤0.043 mm (BARO) and 
Figure 4. Bland-Altman plots comparing the 11-segment model results to the phantom values for minimal lumen diameter (MLD); analysis in 
anteroposterior views. Absolute (upper panel) and relative (lower panel) differences are plotted on the Y-axis for the entire dataset (left 
column), for true MLD values >0.7 mm (middle column) and for true MLD values <0.7 mm (right column). Solid lines represent the mean 
difference; dotted lines represent the 95% limits of agreement (mean difference ±1.96 SD)
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Table 4. Intra- and inter-observer variability (AP views).
Intra-BSM11 Intra-BSM6 Inter-BSM11 Inter-BSM6
Bias SD Repeat Bias SD Repeat Bias SD Repeat Bias SD Repeat
MLD, mm –0.001 0.016 0.032 0.000 0.016 0.032 –0.004 0.019 0.037 0.001 0.026 0.052
BARO
RVD, mm 0.000 0.016 0.032 0.002 0.011 0.022 –0.002 0.022 0.043 0.002 0.020 0.040
DS, % 0.06 0.85 1.67 0.07 0.68 1.33 0.20 0.97 1.90 0.08 1.14 2.24
BLRO
RVD, mm 0.006 0.030 0.058 0.006 0.029 0.057 0.005 0.043 0.085 0.005 0.040 0.079
DS, % 0.20 1.02 2.01 0.18 0.89 1.74 0.41 1.38 2.71 0.20 1.17 2.29
AP: anteroposterior; BARO: bifurcation automatic reference obstruction analysis; BLRO: bifurcation local reference obstruction analysis; BSM: 
bifurcation segment model; DS: percent diameter stenosis; MLD: minimal lumen diameter; RVD: reference vessel diameter; repeat: repeatability 
coefficient; SD: standard deviation
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≤0.088 mm (BLRO), and for DS was ≤3.39% (BARO) and ≤4.22% 
(BLRO) for either model (not shown). Restriction was applied by 
the first analyst once (1/18) per rotated projection; for the same 
bifurcations pathlines were manually drawn by the second observer.
BIFURCATION ANGLE
In AP views, BA was significantly underestimated, with an accuracy and 
precision of –2.6±3.5°, (p<0.001). Intra- and inter-observer bias was 
zero, whereas variability was 1.0° and 1.2°, respectively. In rotated 
views, accuracy and precision became –3.1±6.2°, whereas inter-observer 
variability was 1.9°; precision and reproducibility were significantly 
decreased compared to the AP measurements (p<0.001 for both).
Discussion
The main findings of this study are: 1) The new lumen detection 
algorithm has improved the quantification of the MLD measure-
ments resulting in a highly accurate and precise performance across 
the entire range of diameter values anticipated in clinical practice; 
2) The new bifurcation automatic reference obstruction analysis 
algorithm has comparable accuracy and precision with local refer-
ence obstruction analysis, however is more reproducible for RVD 
and DS measurements; 3) There is high agreement between the 
bifurcation segment models for all parameters, the 11-segment 
model being slightly less accurate but more precise compared to the 
6-segment model regarding MLD values.
SMALL MLD VALUES
One can question whether analysis of diameters in the range 0.5-
0.7 mm is clinically meaningful, since these are prone to induce 
ischaemic changes and intra-luminal thrombosis20. However, the 
accuracy and precision of the measurements impact on the calcula-
tion of the post-procedure diameter gain and the late lumen loss, 
still seen as surrogate angiographic markers for the evaluation of 
intracoronary devices21. Several approaches have been reported to 
improve the accuracy of small diameters for single vessel analysis. 
Generally, these approaches can be divided into two categories: 
either correcting the system’s point spread function10,11, or incorpo-
rating an adaptive correction function for the weighting of the first 
and second derivatives of the brightness profile9,22.
In this report we presented the results of the in vitro validation of 
a new algorithm, wherein video-densitometric information is 
dynamically integrated in the lumen detection in order to reduce the 
Table 5. Agreement between 11- and 6-segment model (AP views).
BSM11-BSM6 BSM11 vs. BSM6
Bias SD 95% LA p-value bias p-value SD
MLD, mm 0.010 0.039 ±0.076 0.06 0.08
BARO
RVD, mm –0.001 0.011 ±0.021 0.48 0.38
DS, % –0.37 1.29 ±2.53 0.04 0.28
BLRO
RVD, mm 0.000 0.018 ±0.035 0.91 0.23
DS, % –0.34 1.52 ±2.98 0.10 0.25
AP: anteroposterior; BARO: bifurcation automatic reference obstruction analysis; BLRO: bifurcation local reference obstruction analysis; BSM: 
bifurcation segment model; DS: percent diameter stenosis; MLD: minimal lumen diameter; RVD: reference vessel diameter; LA: limits of agreement; 
SD: standard deviation
Table 6. Accuracy and precision in rotated views.
BSM11 BSM6
Accuracy Precision
BSM11 vs. 
phantom 
p-value
Accuracy Precision
BSM6 vs. 
phantom 
p-value
BSM11 vs. 
BSM6 
p-value*
MLD-all, mm 0.035 0.103 0.02 0.010 0.115 0.52 0.02 (0.21)
BARO
RVD-all, mm –0.004 0.041 0.49 –0.004 0.040 0.49 0.92 (0.43)
DS-all, % –0.74 4.52 0.24 0.13 4.40 0.84 0.02 (0.42)
BLRO
RVD-all, mm 0.001 0.049 0.91 0.000 0.046 0.94 0.88 (0.32)
DS-all, % –0.99 4.27 0.10 –0.14 4.02 0.80 0.03 (0.33)
BARO: bifurcation automatic reference obstruction analysis; BLRO: bifurcation local reference obstruction analysis; BSM: bifurcation segment model; 
DS: percent diameter stenosis; MLD: minimal lumen diameter; RVD: reference vessel diameter; p-significant <0.05 *values relate to the comparison 
between accuracy measures; values in parentheses relate to the comparison between precision measures
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overestimation of small diameters resulting from stand-alone edge 
detection. Thereby, this new approach benefits from the relative 
strengths of either technique (video-densitometry is better for small 
lumens whereas edge detection is better for larger lumens), by 
dynamically combining them as earlier suggested by Haase et al8. 
The algorithm takes into account that the image data produced by 
the angiographic system may influence the transfer function of the 
imaging chain while they are processed; for example, Siemens 
Axiom Artis™ (Siemens AG, Munich, Germany) angiographic sys-
tems might improve the image visibility by using edge enhance-
ment and dynamic density optimisation algorithms23. The perfor-
mance of the new algorithm for the range of phantom MLD below 
0.7 mm has improved as evidenced by the decreased percentage 
deviation from phantom values compared to the earlier software 
version (10% vs. 35%, respectively, Figure 3)6 and by the smaller 
difference in accuracy and precision between the overall values and 
the subgroup of vessel segments with larger MLD. Both statements 
hold for both 11- and 6-segment models suggesting an overall 
homogeneous performance of the software, without improvements 
in small lumen detection counteracting the software performance in 
the larger diameter range.
BARO VS. BLRO
Local reference analysis is based on the premise that straight vessel 
segments between adjacent bifurcations are not expected to taper, if 
assumed healthy6. Since the phantom vessel segments in our study 
had a constant calibre between bifurcations, BLRO derived RVD 
values at the site of the obstruction would not be expected to differ 
from the RVD at the respective reference positions, hence the excel-
lent accuracy and precision for BLRO. Furthermore, in order to 
stabilise these BLRO derived RVD values, diameters within 
1.5 mm proximal and distal to the reference positions are aver-
aged6. However, notwithstanding this averaging process, an auto-
matic regression function taking into account the whole length of 
the analysed straight vessel segment outside the obstruction bound-
aries would be expected to be more reproducible. Indeed, whereas 
BLRO derived RVD values were marginally but not significantly 
more accurate and precise compared to BARO, the latter method 
resulted in significantly higher (almost two-fold) reproducibility. 
This lower reproducibility in BLRO must have resulted from vari-
ability in placing the reference points coupled with contour irregu-
larities; had the contours been totally free of noise, selection bias 
would not have made any difference.
Naturally these effects are pronounced in real coronary cases, 
where one could expect increased variability for BLRO derived 
RVD values. Operators may choose different landmarks (bifurca-
tions) dependent on individual perception of what constitutes a true 
bifurcation (e.g., SB larger than 1.5 mm). Thus analysed segments 
may become exceedingly long and tapered, which is the case where 
automatic reference analysis is preferred2. Local reference analysis 
can still be beneficial in ectatic or diffusely diseased vessels, where 
a regression function could be severely mistaken, based on either 
too large or too small diameter values, respectively. Ultimately the 
point is that, independent of the bifurcation obstruction analysis 
methods (BARO or BLRO), the true reference of all vessel seg-
ments (PMV, DMV, SB) in any bifurcation lesion can be calculated 
simultaneously with a high accuracy and precision <0.05 mm; 
accurate sizing of balloons and intracoronary devices including 
dedicated bifurcation stents facilitates optimal deployment and 
final kissing ballooning resulting in optimal stent strut 
apposition24-26.
Improved lumen detection coupled with refined reference 
obstruction analysis resulted in highly accurate, precise and repro-
ducible DS measurements. In the context of bifurcation PCI, a pre-
cision of 3.2-3.7% (BLRO and BARO, respectively, in 11-segment 
model) for DS measurements at the SB ostium either pre-proce-
dure, after ballooning or after stenting could result in closer correla-
tion with fractional flow reserve values, and thus be included in the 
decision-making process27-29.
THE 11- VS. THE 6-SEGMENT MODEL
Whereas in the 11-segment model there is a provision for segment 7 
reflecting the central bifurcation region, also called the polygon of 
confluence (POC), in the 6-segment model there is no intervening 
segment; segments 2 (PMV), 3 (DMV) and 5 (SB) are separated by 
the point of bifurcation6,16. Thus in the 11-segment model there is a 
small chance that an obstruction located within the POC may go 
undetected, if we only take segments 2, 3 and 5 into consideration 
(Figure 2). However, in this way segments 2, 3 and 5 do not become 
“contaminated” by contours/diameters derived by interpolation 
opposite the SB ostium. This difference in bifurcation segment 
model makes MLD detection more accurate (p=0.06) for the 6-seg-
ment model, but more precise for the 11-segment model (p=0.08) 
(Table 5). Conclusions already made for the relative merits of 
BARO and BLRO analysis apply to both models. The 6-segment 
model BARO derived values are slightly more precise and repro-
ducible, probably because on average they are based on longer seg-
ments. However differences are too small to make a definite 
statement. Lastly, one could argue that in the analysis of true coro-
nary cases, the validity and reproducibility of the 11-segment model 
could be hampered by periprocedural changes in POC size. Indeed, 
in the original software design, POC definition was based on the 
luminal contours16, which were obviously different after PCI. A rel-
evant modification has already been integrated in CAAS 5.8, and 
therefore POC borders are now calculated on the reconstructed 
obstruction-free reference contours, thus making its size procedure 
independent. Naturally, the ultimate test for the two models would 
be the evaluation of their relative merits in the context of a large 
clinical registry of bifurcation PCI.
Bifurcation angle calculation algorithm did not change per se 
compared to the CAAS 5.8, thus accuracy and precision were not 
expected to vary significantly between versions. Indeed, accuracy 
and precision for the CAAS 5.9 2-D bifurcation QCA were –2.6° 
and 3.5° whereas they were –2.2° and 3.3°, respectively, for CAAS 
5.8. However, calculations had a higher intra- and inter-observer 
reproducibility in the new version (1.0° and 1.2°, respectively, 
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compared to 1.5° and 1.6° in the CAAS 5.8). Minor differences in 
BA values must have resulted from differences in contour drawing 
due to the new small lumen detection algorithm. In any case, 2-D 
QCA derived angle values are an approximation of a 3-D structure. 
The widest opening of a given bifurcation and the best view of the 
SB ostium usually coexist in one single good 2-D image, the AP 
view in the phantoms’ design. Declining accuracy and precision for 
BA calculations in the rotated views reflect this phenomenon.
Analysis in rotated views was not part of the validation study, 
however to a certain degree confirmed its findings. Accuracy and 
precision for MLD values was improved compared to the earlier 
version resulting in improved DS results. The 6-segment model was 
more accurate and precise compared to the 11-segment model. One 
would expect that a 3-D reconstruction combining these rotated 
views may have provided even better results compared to either the 
RAO or the LAO projection, eliminating the effect of overlap30.
Finally, it should be stressed that in vitro validation does not take 
into account the movement of the coronary arteries and the inherent 
decrease in image quality from beam scattering and periprocedural 
thrombus and dissection flaps. However, it is a useful means to 
objectify software performance and gain insight into the strengths 
and weaknesses of the software evaluated.
Conclusions
The new lumen detection algorithm integrated into the latest ver-
sion of the CAAS 2-D bifurcation QCA software improved MLD 
quantification for true MLD <0.7 mm resulting in highly accurate 
and precise diameter measurements over the entire range of diam-
eter values anticipated in clinical practice. Furthermore, the opti-
mised algorithm for automatic reference obstruction analysis 
provides highly accurate, precise and reproducible RVD and DS 
measurements, which may facilitate device sizing and periproce-
dural strategy in bifurcation PCI.
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Background
We developed a novel and dedicated three-dimensional (3-D) quan-
titative coronary analysis (QCA) software (Cardiovascular Angio-
graphy Analysis System, Pie Medical Imaging, Maastricht, The 
Netherlands) to overcome potential limitations associated with 
two-dimensional (2-D) quantitative coronary analysis of bifurca-
tion lesions (vessel overlap, foreshortening).
By combining two 2-D image data sets, the new CAAS 5, QCA 
3-D bifurcation software is able to perform a 3-D reconstruction of 
the bifurcation and determine lesion characteristics including bifur-
cation angle. This is achieved in the following steps: i) Contour 
detection on two angiographic projections of the involved vessel 
segments including the bifurcation segment identification of a com-
mon image point; ii) Creation of the 3-D model and definition of 
the Polygon of Confluence (POC); iii) Calculation of cross-sec-
tional area and diameter measurement; iv) Calculation of the refer-
ence area; v) Calculation of bifurcation angle.
This paper describes how the methodology is accomplished, in 
which the QCA 3-D bifurcation software performs a 3-D recon-
struction of the bifurcation and determines lesion characteristics 
including bifurcation angle, with improved accuracy by reducing 
overlapping. 
Introduction
In the percutaneous treatment of coronary artery disease, online 
two-dimensional (2-D) quantitative coronary angiography (QCA) 
is commonly used to determine lesion length and vessel size for 
stent implantation1. Two-dimensional QCA is accepted as the gold 
standard for reporting angiographic outcomes and has served as a 
surrogate endpoint for clinical events in large trials2. There are, 
however, several limitations with this 2-D technique. Depending on 
the angiographic view, vessel tortuosity, vessel overlap and fore-
shortening can result in inaccurate measurements3. This inaccuracy 
is important during percutaneous coronary intervention (PCI), 
because it may influence the selection of the correct size of the 
devices. In tortuous vessels this can lead to underestimation of the 
stent length required to cover the lesion4. To provide solutions for 
many of the inherent limitations associated with 2-D QCA, three-
dimensional (3-D) reconstruction software algorithms, that inte-
grate multiple single plane images, have been developed5,6. Briefly, 
the benefits of 3-D reconstruction include elimination of vessel 
foreshortening, out-of-plane magnification and calibration error7.
Recent advancements in the field of PCI (e.g., introduction of 
drug-eluting stents) have resulted in the treatment of more complex 
anatomies including bifurcation lesions8,9. Based on the assumption 
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of continuous tapering of the vessel, conventional QCA calculates 
the reference vessel diameter (RVD) by interpolation from the 
diameter of the non-diseased vessel sections. Because bifurcation 
lesions are associated with relatively acute tapering of the vessel 
(from the proximal main vessel to the distal vessel, “step-down”), 
analysis of bifurcation lesions may lead to (1) underestimation of 
the RVD and percent diameter stenosis (%DS) in the proximal ves-
sel and (2) overestimation of the RVD and %DS in the distal ves-
sel10. Several 2-D QCA software algorithms have attempted to 
address this issue by calculating the RVDs in the proximal main 
(PMV) and distal main vessel (DMV) and side branch (SB) sepa-
rately5,10. However, the inherent limitations in 2-D QCA call for 
dedicated 3-D QCA software, in order to provide more accurate 
measurements for the bifurcation lesions. This paper describes 
a novel methodology for true quantitative 3-D bifurcation analysis 
implemented in the new Cardiovascular Angiography Analysis 
System (CAAS) 5, 3-D software (Pie Medical Imaging, Maastricht, 
The Netherlands), wherein two 2-D images are combined into 
reconstructed 3-D images to determine lesion dimensions and char-
acteristics as well as bifurcation angle.
CAAS 5 QCA 3-D bifurcation methodology
The CAAS 5 3-D quantitative analysis of bifurcation vessels is 
accomplished in six steps:
1.  Contour detection on two angiographic projections of the 
involved vessel segments including the bifurcation segment.
2.  Identification of a common image point.
3.  Creation of the 3-D model and definition of the Polygon of Con-
fluence (POC).
4.  Calculation of the cross-sectional area and diameter measurement.
5.  Calculation of the reference area.
6.  Calculation of the bifurcation angle.
The average analysis time of all steps is around two seconds with 
use of a 2.33-GHz Dual Core Intel CPU.
CONTOUR DETECTION
In two 2-D image projections, being at least 30 degree apart, 
obtained either from a biplane or two monoplane acquisitions, the 
bifurcated vessel is detected. The bifurcation contour detection is 
performed using a semi-automated process that employs either a 
manually drawn initial pathline, or an automatic pathline initiated 
by mean of three user-defined points; one at the proximal side of the 
main vessel and two at both distal ends of the bifurcated branches. 
The automatic pathline is calculated by a wave propagation algo-
rithm11. The contours are detected by using the well established 
minimal cost algorithm12, wherein the bifurcated vessel is consid-
ered to be a single entity10. After the automatic contour detection is 
applied on the first 2-D image projection, automatically a region of 
interest in the second 2-D image projection is indicated in order to 
assist the user in selecting the correct vessel segment within the 
second projection.
IDENTIFICATION OF A COMMON IMAGE POINT
To obtain an accurate and robust 3-D reconstruction of the bifur-
cated vessel it is required to correct for the system distortion intro-
duced by the isocentre offset. This correction is performed by 
identifying a common image point (CIP) representing correspond-
ing anatomical landmarks between the selected projections. Using 
densitometry, the CAAS software automatically locates the CIP, by 
performing a correlation algorithm between the densitometric 
intensity obtained from the detected bifurcated vessel of the two 
images. The analyst can manually redefine the automatic CIP if 
necessary (Figure 1).
CREATION OF 3-D MODEL AND DEFINITION OF THE POLYGON 
OF CONFLUENCE (POC)
A 3-D model of the bifurcated vessel is constructed, based on the 
two 2-D angiographic segmented bifurcation and the geometric 
data of the acquisitions provided through the DICOM headers; 
Figure 1. Automatic selection of common imaging points (CIP, red crosses indicated with red arrows) in two different projections. The analysis 
can optimise the position of CIP manually if necessary.
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these are combined by means of the CIP merging point in order to 
correct for the distortion introduced by the isocentre offset. First the 
centre line of the main vessel, defined from the proximal edge of 
the PMV up to the distal edge of the DMV, is reconstructed in 3-D. 
Next the centre line of the side branch is reconstructed in 3-D, start-
ing at the origin of bifurcation as obtained in the 2-D projections up 
to the distal end of the SB. In both steps the 3-D centre line recon-
struction is performed by means of an adaptive 3-D epipolar geom-
etry algorithm. The first possible epipolar mismatch is detected, by 
comparing the angle between the direction of the vessel and the 
viewing direction of the system. Within regions where no epipolar 
mismatch is detected, the 3-D centre line reconstruction is based on 
epipolar geometry. Next, within regions with possible epipolar mis-
match, an iterative reduction of the cumulative difference of the 
2-D centre line and the 3-D back-projected centreline is performed. 
The 3-D centre line of the central bifurcation area can not be 
directly extracted from the 2-D information, since the information 
obtained from these 2-D images are hampered by foreshortening 
and missing information due to overlap in the main vessel and the 
side branch. Therefore the 3-D centre line within the estimated 
bifurcation area, defined as the union of both POC from the 2-D 
projections, is adjusted by fitting a 3-D parametric curve through 
the estimated bifurcation based on the 3-D centre line just outside 
the estimated bifurcation area. During the fitting process the loca-
tion of the detected bifurcation in each 2-D projection is taken into 
account to assure correct definition of the 3-D centre line. Based on 
the 3-D centre line combined with the contour information of each 
2-D projection, a 3-D model of the bifurcated vessel assuming an 
elliptical cross-section shape is constructed. In order to correctly 
reconstruct the central bifurcation area into 3-D, we have to take 
into account the fact that the contour information obtained from the 
2-D projections may contain vessel overlap, since the bifurcated 
vessel might be partly obscured in one or both of the image projec-
tions. To overcome this problem the 3-D cross-section shape is cre-
ated by using virtual vessel contours within each 2-D POC. These 
virtual vessel contours are derived in each 2-D projection from the 
edge information outside the POC. First the centre line covering the 
POC is redefined using a parametric interpolation technique known 
as Catmull-Rom splines13 and guided by control nodes extracted 
just outside the POC (Figure 2). Next, the virtual edge is positioned 
perpendicular to the new centre line at a distance defined by a linear 
radius function across the POC.
The central bifurcation area, described as the polygon of conflu-
ence (POC) is specifically defined for further analysis. In the previ-
ously reported method for 2-D bifurcation software, the point of 
bifurcation (POB) was defined as a centre of the circle touching the 
three contours while the POC was defined as the area delineated by 
the lines perpendicular to the centre line crossing this circle10. 
Extending the previous reported method to 3-D would suggest 
using a sphere as a mathematical object to define the POB and 
POC. However, the central bifurcation area in 3-D shows a “pea-
nut” shape; hence a new method is introduced for defining the POB 
and POC.
Figure 2. Two virtual vessel contours (i. from the proximal main 
branch [Dp] to the distal main branch [Ds1], ii. from the proximal 
main branch [Dp] to the side branch [Ds2]) are created by using 
a parametric interpolation technique of catmull-row splines.
The POC region in 3-D begins at the position where the 3-D cen-
tre line bifurcates (red line in Figure 3) and ends where the main 
and side branches stop coinciding with each other (green lines in 
Figure 3). In this new definition of the POC in current 3-D analysis, 
the location of the bifurcation carina is precisely adjusted with min-
imal overlap, based on the reconstructed 3-D model.
CALCULATION OF CROSS-SECTIONAL AREA AND DIAMETER 
VALUES
Cross-sectional areas are calculated on the assumption that the ves-
sel has an elliptical cross section based on the luminal diameters 
from the two different 2-D projections. Inside of the POC region, 
Figure 3. Upper panel: Definition of the polygon of confluence region 
for optimal 3-dimensional reconstruction. Lower panel: Adjustment of 
bifurcation carina with minimal overlap. In a 2-D projection (B), the 
carina looks more distal (green lines) to the actual position (black 
arrow) due to overlap. After 3-D reconstruction (C), the correct 
location of bifurcation carina is applied in the projection B.
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the cross-sectional area shows a so-called “peanut” shape. To define 
in the POC the “bifurcating” cross-sectional areas of the two daugh-
ter branches, the POC area is divided into two elliptical shapes 
along the two centre lines based on the virtual vessel contours.
Figure 4 shows in red (continuous line) one of the cross-sectional 
areas located in the POC region, the black dotted line indicates the 
projected diameters (2-D length) obtained in each angiographic 
view. The missing points in blue (A and B) are the two cross-points 
between the 2-D diameters obtained in each angiographic view and 
are based on the virtual vessel contours of the distal main vessel.
In the 3-D reconstruction, the elliptical cross-sectional area is the 
primary measured parameter. Next to this cross-sectional area, the 
equivalent luminal diameter, minimum luminal diameter and maxi-
mal luminal diameter curves are calculated based on circularity 
assumption (Figure 5). The minimum diameter represents the max-
imum circle that fits through the 3-D reconstruction while the maxi-
mum diameter represents the minimum circle that encloses the 3-D 
reconstruction; both are based on the virtual vessel contour when 
considering the POC.
CALCULATION OF REFERENCE AREA
For the reference cross-sectional area function, a reconstruction of 
the “healthy” part of the cross-sectional area function is made based 
on the 3-D reconstructed model for each of the branches connected at 
the POC. For this a 3-D equivalent as used in the CAAS single vessel 
software is used12. These results in a reference function for each of the 
three vessel branches connected at the POC. These three reference 
functions are used in the 2-D healthy bifurcation reconstruction algo-
rithm in order to create the 2-D healthy reconstructions as described 
by Ramcharitar et al10. Ramcharitar described a method to calculate 
the reference diameter within the POC using a curvature of a circle 
passing through the termination of reference vessel lines of the proxi-
mal and distal vessels at the entrance of POC where the centre of the 
circle is located outside the vessel, on the line perpendicular to the 
middle of the line connecting these termination points.
Figure 4. Upper panel shows area measurement inside a polygon of 
confluence. Since overlapping vessels create peanut-shaped area 
(lower panel), the points A and B are calculated from contours 
outside POC by polynominal interpolation to create a virtual 
ellipsoid area (dotted red line), which is used for area measurement. 
Lower panel: photograph of a peanut.
Figure 5. Measurement of diameters. The measured cross-sectional area is converted to a circle with similar cross-sectional area. 
The diameter of such circle is called an “equivalent diameter”.
Within the current method, the reference vessel lines up to the 
entrance of the POC in the 2-D projections, are based on the back-
projected 3-D reference area as described before. The “healthy” 
reconstructed 2-D measurements are then combined into 3-D meas-
urements using a similar approach as described for the cross-sec-
tional area calculation.
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CALCULATION OF BIFURCATION ANGLE
Two bifurcation angles are computed between the PMV and the SB 
(proximal angle), and between the DMV and the SB (distal angle); 
they are derived from the 3-D vector of the centre line in the PMV 
at the start of POC (directed from distal to proximal) and the 3-D 
vectors of centre line in the DMV and SB at distal ends of POC 
(directed from proximal to distal). The size of the vector, which can 
influence the angle, is half the size of the equivalent luminal diam-
eter at the start and end of the POC. This is based on the assumption 
that the curvature of the vessel is less than its radius. Bifurcation 
angles are calculated in 3-D space without overlap, and theoreti-
cally are more precise than 2-D QCA.
Discussion
Coronary bifurcation lesions are a challenging area in interven-
tional cardiology. The European Bifurcation Club has been estab-
lished to clarify some of this challenge.14-16 Contemporary studies 
using drug-eluting stents (vs. bare-metal stents) have shown a 
reduction of restenosis of the main vessel. Residual stenosis and 
restenosis at the ostium of the side branch, however, still remains a 
concern. In addition to the provisional one-stent and two-stent strat-
egy approach using the drug-eluting stents, dedicated bifurcation 
stents have been designed to specifically address this challenging 
issues17-23. To adequately determine the application and angio-
graphic outcome of such stents, characterisation of bifurcation 
lesion pre-procedure and assessment of luminal diameter post-pro-
cedure and at follow-up is mandatory by means of quantitative 
coronary angiography. Because two-dimensional QCA in bifurca-
tion lesion is limited by foreshortening and overlap, there has been 
recent interest in 3-D QCA for bifurcation lesions. Although there 
are multiple software programs dedicated for 3-dimensional quan-
titative coronary angiographic analysis, there are only two software 
packages dedicated for bifurcated 3-D QCA (Paieon and Pie Medi-
cal). So far, there is no direct comparison between these two QCA 
bifurcation software packages (Paieon vs. Pie), both of which 
reconstruct 3-D from two projections.
Over the years many techniques have been published describing 
methods for 3-D coronary reconstruction based on monoplane angi-
ography, biplane angiography and more recently, 3-D reconstruc-
tions from rotational angiography24-28. Three-dimensional coronary 
reconstruction was introduced in the mid 80’s and was mostly 
restricted by using angiography biplane systems. One of the limita-
tions was the need for a geometric calibration procedure to assess 
the 3-D system geometry29,30. In addition, 3-D reconstruction was 
inaccurate due to the distortion introduced by the conventional 
X-ray image intensifier systems31. With the introduction of the digi-
tal flat panel (DFP) technology this geometric distortion was elimi-
nated and the new storage capabilities with the introduction of the 
Digital Imaging in Communication in Medicine (DICOM) standard 
eliminated the need for 3-D system calibration. The DICOM stand-
ard provides the necessary X-ray system information needed to per-
form a 3-D reconstruction. Coronary 3-D reconstruction algorithms 
purely based on the 3-D system information, the so-called epipolar 
geometry reconstruction technique, provide only accurate recon-
structions in those cases, where the vessel is roughly perpendicular 
to the X-ray beam29. In the case where the vessel morphology is 
roughly parallel with the X-ray beam, the epipolar reconstruction 
technique fails due to multiple 3-D solutions. Another restriction of 
this technique is the erroneous assumption that the projected coro-
nary artery from the acquired views is spatially identical31,32. In 
practice this assumption is untenable, due to (relatively large) res-
piratory motions and cardiac contraction motions. Even when using 
a biplane system, there is a short time delay between the lateral and 
frontal C-arm detector, which is enough to generate inaccurate 3-D 
coronary reconstructions. The CAAS 5 3-D bifurcation software, 
incorporates an alternative new epipolar reconstruction technique 
for reconstructing a bifurcated vessel, combined with correcting for 
the system distortion introduced by the isocentre offset.
In single vessel analyses, 3-D QCA has been shown to be more 
accurate than 2-D QCA regarding measurement of lesion length. In 
a sub-study of the ABSORB cohort A trial by Bruining et al33, the 
length of bioresorbable scaffold made of polylactide (12 mm) was 
measured in multiple modality images (3-D QCA, 2-D QCA, IVUS 
and MSCT) using two metallic markers as landmarks, which are 
located in the both ends of the scaffold. The length of the 12 mm 
scaffold was measured as 9.89±0.93 mm, 12.24±0.55, 12.51±0.85 
and 11.89±0.20 mm with 2-D QCA, 3-D QCA, QCU and QMSCT-
CTA, respectively. Two-dimensional QCA apparently underesti-
mated the scaffold length, while 3-D QCA and QCU had similar 
results, very close to the actual length of 12 mm. In clinical settings, 
measuring the lesion length with 3-D QCA compared to 2-D QCA 
might be therefore more useful.
One of possible benefits of using 3-D QCA analysis is to predict 
outcomes of bifurcation treatment. The bifurcation angle has been 
shown to relate not only to the difficulty level of the procedure but is 
also associated with intermediate outcomes. Dzavik et al reported 
that a bifurcation angle over 50º was an independent predictor of 
MACE at one year after bifurcation crush stenting in 133 patients34. 
In 132 patients receiving Cypher stent in bifurcations excluding left 
main lesions, Adriaenssens et al reported that increasing bifurcation 
angles is an independent predictor of binary restenosis (HR 1.53 
[1.04–2.23] per 10 degree increase in angulation) after culotte stent-
ing35. Recently, in the sub-study of the Syntax study, Girasis et al 
reported that the bifurcation angles utilising 3-D QCA software have 
a slight but non-significant correlation with 1-year outcomes. When 
2-stent techniques were employed, the result was a trend towards 
higher event rates for patients with wider angled LM bifurcations.
In the CAAS 5 3-D bifurcation software, bifurcation angle meas-
urements are more accurate and robust due to the knowledge of the 
true 3-D vessels’ morphology obtained from the 3-D model. In 2-D 
QCA analysis, optimal assessment of bifurcation angles necessitates 
three planes that involve two branches (e.g., PMB+DMB, DMB+SB, 
PMB+SB), to avoid potential underestimation or overestimation of 
bifurcation angles. For example, one 2-D projection can be taken 
without any overlap / foreshortening for the distal main branch and 
side branch, however this projection may not necessarily be the opti-
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mal projection to separate the proximal main and side branch, or the 
proximal main and distal main branch. Three-dimensional QCA defi-
nitely addresses this issue by reconstructing a 3-D model and calculat-
ing the vectors of 3-vessels (e.g., the proximal main, distal main and 
side branch) in 3- dimensions without overlap. The system uses the 
3-D model in combination with the method of quantitative bifurcation 
lesion analysis as introduced in the previous paper to obtain bifurca-
tion lesion characteristics10. The basic concepts introduced in the pre-
vious paper are projected to the current 3-D methodology, resulting in 
a quantitative analysis of the 3-D bifurcation as a single entity.
To use this software in clinical practice, it is of importance during 
a procedure to take two separate images with the least overlap. 
However, in reality, such images are not frequently available. In 
a study aiming at measuring the bifurcation angle of the left main 
with 3-D QCA software36, the two separate images were available 
in only 50% of the angiographic acquisitions. The operator should 
bear in mind that two separate images are at least necessary to ena-
ble optimal assessment of bifurcated lesions with 3-D software.
The current methodology suffers from several limitations. Since 
3-D reconstruction consists of two projections, the issue of overlap-
ping vessels in tortuous bifurcation lesions may still be a problem. 
Taking into consideration the complexity of bifurcated lesions and 
the difficulty to take cineangiograms without overlap, one can spec-
ulate that reconstruction utilising more than two projections may 
yield optimal 3-D images, at the expense of the increasing com-
plexity of analytical software. Further developments towards using 
multiple projections are in progress. Furthermore, reproducibility 
and accuracy, and the potential clinical benefits of using 3-D QCA 
for bifurcation lesions should be the focus of future studies.
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Abstract
Aims: Validation of new three-dimensional (3-D) bifurcation quantitative coronary angiography (QCA) 
software.
Methods and results: Cardiovascular Angiography Analysis System (CAAS 5v10) allows 3-D angio-
graphic reconstructions based on two or more 2-D projection images. Measurements for minimal lumen 
diameter (MLD), reference vessel diameter (RVD), percent diameter stenosis (DS) and bifurcation angle 
(BA) were validated against precision manufactured phantom bifurcations. Length measurements were vali-
dated against angiographic measurement catheters inserted into a plexiglas bifurcation phantom. In 3-D 
reconstructions based on two 2-D images, acquired at variable rotation and angulation, accuracy and preci-
sion (mean difference ± SD) of the 11-segment model for MLD, RVD and DS were 0.013±0.131 mm, 
–0.052±0.039 mm and –1.08±5.13%, respectively; inter-observer variability was 0.141 mm, 0.058 mm and 
5.42%, respectively. Adding the antero-posterior (optimal) projection to these basic reconstructions resulted 
in reduced variability (0.101 mm, 0.041 mm and 3.93% for MLD, RVD and DS, p<0.01 for all) and showed 
a trend towards improved precision (0.109 mm, 0.031 mm and 4.26%, respectively, p>0.05 for all). In basic 
reconstructions, accuracy and precision for BA was –1.3±5.0°, whereas inter-observer variability was 7.5°; 
respective measures for length were 0.15±0.26 mm and 0.54 mm. Adding the antero-posterior projection 
resulted in decreased precision (0.47 mm, p<0.01) and increased variability (1.03 mm, p<0.01) for length 
measurements; precision (5.4°) and variability (7.9°) for BA did not change significantly (p>0.30).
 
Conclusions: Advances in the methodology of 3-D reconstruction and quantitative analysis for bifurcation 
lesions translated into highly accurate, precise and reproducible measures of diameter, length and BA.
KEYWORDS
• angiography
• coronary 
bifurcation
• quantitative 
coronary 
angiography
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Introduction
Percutaneous coronary interventions (PCIs) for the treatment of 
coronary bifurcation lesions require optimal angiographic analysis1; 
whereas visual assessment of lesion severity is still highly vari-
able even among experts in this field2, quantitative coronary 
angiography (QCA) analysis has seen improvements in perfor-
mance. Dedicated two-dimensional (2-D) bifurcation QCA 
software acknowledges the “step-down” in vessel calibre from 
the proximal main vessel into the distal main vessel and the side 
branch3 by determining reference vessel diameter (RVD) based 
on each of the three branches separately4,5. Thereby, higher pre-
cision in RVD and percent diameter stenosis (DS) values are 
attained, facilitating accurate balloon and stent sizing. In addi-
tion, reporting results over an increased number of bifurcation 
vessel segments facilitates accurate disease localisation and 
consistency in serial angiographic studies1. 
Nevertheless, the validity of 2-D QCA is dependent on the angio-
graphic view analysed and can be affected by foreshortening and 
variable magnification; tortuous and/or overlapping coronary struc-
tures could impose further limitations6. By eliminating these poten-
tial sources of error, 3-D QCA algorithms have been shown to 
provide accurate, precise and reproducible diameter, area and 
length measurements7-10 for single-vessel lesions in real time. 
Experience with 3-D bifurcation reconstructions has been reported 
comparing results with 2-D analysis11,12; however, accuracy and 
precision of 3-D bifurcation QCA measurements has not been 
established compared to a gold standard. 
Dedicated 3-D bifurcation QCA software incorporated in the latest 
version of Cardiovascular Angiography Analysis System (CAAS 
5v10; Pie Medical Imaging, Maastricht, The Netherlands) adopts algo-
rithms already validated in the 2-D software4,13 and applies them to the 
3-D reconstructions. Furthermore, the methodology has been revised 
compared to the previous version14, in order to allow reconstructions of 
more than two 2-D projections. In this report we present the theoretical 
provisions of this software and the results of in vitro validation for 
measures of diameter, length and bifurcation angle (BA).
Materials and methods
THEORETICAL PROVISIONS
A 3-D reconstruction requires at least two angiographic images sepa-
rated by a viewing angle ≥30°; up to four images acquired by a biplane, 
monoplane or a rotational angiographic system can be combined. 
Analy sis is initiated by demarcating the bifurcation to be analysed on 
the first selected angiographic image. Subsequently, automatic contour 
detection is performed via a validated algorithm featuring improved 
analysis for small vessel lumens13. The region of interest is automati-
cally indicated in the other selected image(s), thereby assisting the ana-
lyst in correctly placing the delimiter points around the bifurcation, 
which is then contoured with the same algorithm.
3-D RECONSTRUCTION
The acquisition geometry of the projection images provided through 
the DICOM (Digital Imaging and Communications in Medicine) head-
ers of the angiographic system is not sufficient to obtain an accurate 
3-D reconstruction due to the isocentre offset of the gantry. The isocen-
tre offset is the spatial difference between the centres of rotation (iso-
centres) of the frontal and lateral C-arms in a biplane gantry, attributable 
mainly to the imperfect alignment of both C-arms but also to gravity; 
even in a monoplane system active gantry rotation could result in a 
significant shift of its isocentre. In order to correct for this system dis-
tortion, a common image point (CIP) is determined by correlating the 
videodensitometric information obtained from the 2-D images. Subse-
quently, the 3-D centrelines for the bifurcation branches are recon-
structed by means of an adaptive 3-D epipolar geometry algorithm14. 
Respective 3-D cross-sections are constructed assuming an elliptical 
model, by using the luminal diameters of the corresponding 2-D cross-
sections and their spatial orientations to define the ellipse axes. In cases 
where >2 projections are used, already existing cross-sections are mod-
ified by integrating contour information from each additional 2-D 
image, while retaining an elliptical shape. In this fitting process, axes 
between adjacent cross-sections are kept aligned, in order to prevent 
the 3-D model from twisting along its centreline. For true 3-D quantita-
tive analysis the elliptical model is then converted into a 3-D triangular 
surface mesh by means of a marching cubes algorithm15.
3-D QUANTITATIVE ANALYSIS
Analogous to previous publications on bifurcation QCA analy-
sis14-16, the polygon of confluence (POC) is defined as the central 
bifurcation region which behaves differently from a single-vessel 
segment. Outside the POC, the cross-sectional area is defined per-
pendicular to the centre of the lumen; within the POC, the cross-
sectional area is defined by using the “minimum energy” 
cross-section, i.e., the smoothest possible surface that spans the 
lumen at each centre line position. This “minimisation” is per-
formed by using a level set algorithm17 and will result in curved 
cross-sections within the central bifurcation region (Figure 1). 
Automatic calculation of reference cross-sectional area adopts 
the methodology described for 2-D bifurcation QCA and applies it 
to the 3-D reconstructed model. Outside the POC, a 3-D equivalent 
of the algorithm used in single-vessel segments is employed13,18. 
Within the POC, the reference area is derived by applying an inter-
polation technique between the “healthy” reconstructed 3-D 
branches. Based on the respective cross-sectional areas, lumen 
diameter and RVD are defined as the equivalent diameters based on 
the assumption of circularity. Finally, proximal and distal BA val-
ues are derived according to the methodology already described14.
The CAAS 5v10 analysis software has no restriction regarding 
the number of bifurcations the 3-D model consists of: it is possible 
to reconstruct and analyse a vascular tree which consists of multiple 
bifurcations. We chose to focus on 3-D reconstructions of one bifur-
cation at a time, in order to mimic routine angiographic practice. 
Analysis regarding full-tree reconstructions of bifurcation phan-
toms is presented in an Online appendix. 
VALIDATION
DIAMETER AND BA
Six precision-manufactured plexiglas phantoms, each mimicking 
a vessel with three successive bifurcations lesions, were used for 
70
1453
 
the validation of minimal lumen diameter (MLD), RVD, DS and 
BA measurements. Their design has already been described in 
detail19. In total, 54 phantom vessel segments of reference diameter 
1.40-4.00 mm were evaluated; 33 of them had a stenosis within 
3-5 mm of the bifurcation (DS 40.6-80.5%; MLD 0.53-1.96 mm), 
whereas the rest were free of stenoses (MLD 1.40-4.00 mm). Prox-
imal and distal BA range was 90.4-159° and 39.5-102.9°, respec-
tively. Digital angiograms were acquired on a biplane angiographic 
system (Axiom ArtisTM; Siemens, Forchheim, Germany); all phan-
toms were filled with 100% Iodixanol 320 (VisipaqueTM; GE 
Healthcare, Cork, Ireland) and imaged at 30 frames per second in 
a 20 cm field of view. Multiple projections were acquired for vari-
able degrees of gantry rotation and angulation. For validation pur-
poses, five 2-D projections including the anteroposterior (AP) 
projection were employed in multiple combinations. Our recon-
struction protocol is shown in Figure 2. 
Figure 1. Definition of polygon of confluence (POC). A) Within POC (grey) the vessel is slowly widening, but at the same time the top and 
bottom are slowly collapsing towards a single point (figure-of-eight shape, in blue) after which we have two “normal”-shaped vessels. B) The 
start of the POC (in red) is defined as the position where plane cross-sections give way to curved ones; exactly the opposite marks the end of 
the POC. DMV: distal main vessel; PMV: proximal main vessel; SB: side branch
2-D projection
images
Basic 3-D recons
(2 images)
Basic 3-D recons
+AP image
RA030 RA030 RA030
RA030 LA030
LA030
RA030CRAN30
LA030CAUD30
RA030CRAN30
RA030CRAN30
RA030CRAN30LA030
LA030
LA030
RA030 RA030CRAN30
LA030CAUD30
LA030CAUD30
LA030CAUD30 RA030CRAN30 LA030CAUD30
LA030CAUD30
LA030 AP
AP
AP
AP
RA030
Figure 2. 3-D reconstruction protocol. For every phantom bifurcation, four 2-D projection images were combined into four separate 3-D 
reconstructions using two 2-D images at a time. Two potential combinations were a priori excluded, on the basis of providing limited 
information. The anteroposterior image (AP) was added to every one of these basic reconstructions, creating a second set of replicate 3-D 
QCA measurements. RAO/LAO: right/left anterior oblique (rotation); CRAN/CAUD: cranial/caudal angulation
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A standard operator procedure for angiographic analysis was fol-
lowed, wherein: 1) analysis was performed on the middle frame of 
every angiographic image acquisition; 2) delimiter points were placed 
at the furthest possible distance from the bifurcation to be analysed, but 
not touching the adjacent bifurcation lesions or the phantom borders; 3) 
manual contour correction was not allowed; however, contour detec-
tion could be adjusted by using the “restriction” option, thereby exclud-
ing gross image artefacts without manually redefining the detected 
contours18; 4) if the location of the automatically defined CIP differed 
between images, the user could manually reposition it to an easily iden-
tifiable landmark, preferably the centre of the bifurcation. 
Reconstruction resulted in a 3-D representation of the analysed bifur-
cation, displayed in the optimal projection, which was defined as the pro-
jection where mean foreshortening of the bifurcated vessels was 
minimised; quantitative analysis was reported according to the validated 
11- and 6-segment models (Figure 3)4,13. Segments 2, 3 and 5 of either 
model reflect the segments, where in clinical practice the stent would be 
placed in the proximal main vessel, distal main vessel and side branch, 
respectively. MLD, RVD and DS values for these segments were pooled 
together and compared to the phantom values. Angle calculations are 
independent of the bifurcation segment model used. Proximal and distal 
BA values were pooled together and compared to the phantom angles.
Figure 3. 3-D reconstruction and quantitative analysis (compilation). Phantom 2, bifurcation 2 was analysed in two projection images, one 
acquired at LAO30CAUD30 (A) and one at RAO30CRAN30 (not shown); the red cross indicates the common image point (CIP). B) 3-D 
reconstruction is shown in the optimal projection; P, M and S stand for PMV, DMV and SB. C) 11-segment model. Left: schematic; right: 
diameter graph with RVD curve for PMV into DMV. D) 6-segment model. Left: schematic; right: diameter graph with RVD curve for PMV 
into SB. RVD function is independent of segment model used. In both graphs, automatic reference analysis was applied. RAO/LAO: right/left 
anterior oblique (rotation); CRAN/CAUD: cranial/caudal angulation
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LENGTH
Due to the lack of reproducibly identifiable markers on the afore-
mentioned bifurcation phantoms, we used a different experimental 
set-up for the validation of length measurements (Figure 4). Two 5 
Fr Cook measurement catheters (Cook Medical, Bloomington, IN, 
USA) with a marker distance of 10 mm were inserted into a hollow 
plexiglas bifurcation phantom with an inner diameter of 4.3 mm. 
Measurement catheters were aligned in the proximal main vessel, 
one extending into the distal main vessel, the second one extending 
into the side branch. In order to distinguish between the two 
branches, a copper marker was mounted on the distal main vessel. 
The phantom was imaged on the same angiographic system at 30 
frames per second in a 25 cm field of view, and the same recon-
structions protocol was followed. Within each 3-D reconstruction, 
18 inter-marker segments of variable length (ranging from 20 mm 
up to 80 mm) were measured from leading edge to leading edge, all 
of these segments covering the central bifurcation region. 
All QCA analyses were performed off-line by two experienced 
analysts (CG, TM), independently from each other.
STATISTICS
Statistical analysis was performed using SPSS 17.0 for Windows 
(SPSS Inc., Chicago, IL, USA). Continuous variables are presented 
as mean ± 1 standard deviation and compared with the paired-samples 
Figure 4. Experimental set-up for validation of length measurements. 
Measurement catheters aligned in a plexiglas bifurcation phantom, 
one extending into the DMV, the second one extending into the side 
branch; DMV is identified by a copper marker on the catheter 
(arrow). Inter-marker segments of variable length are indicated on 
the DMV side, all of them covering the central bifurcation region. 
The same segments were defined and measured on the second 
catheter as well. DMV: distal main vessel
t-test; categorical variables are presented as counts. Replicate 
measurements reflecting multiple 3-D reconstructions of the same 
bifurcation were averaged separately for each analyst. The within-
segment deviation of these replicate measurements was reported as 
the measurement error20 and was integrated in the calculation of the 
final precision/variability estimates following Bland-Altman 
methodology21.
The first analyst carried out two full rounds of measurements with 
a time interval of two weeks, in order to determine intra-observer 
variability. The first round of measurements was compared both with 
the measurements of the second analyst to determine inter-observer 
variability and with the corresponding true values for the purpose of 
validating the software against the ground truth. Bland-Altman anal-
ysis was performed for all comparisons22. 
Regarding intra- and inter-observer comparisons, the mean dif-
ference (bias) and its standard deviation were calculated; the repeat-
ability coefficient (1.96×standard deviation) was determined as the 
measure of variability. For validation purposes, the signed differ-
ences between QCA measurements and the true values were aver-
aged: the mean of these signed differences is a measure of accuracy, 
and the standard deviation is a measure of precision. Measures of 
accuracy were compared with the paired t-test; measures of preci-
sion/variability were compared with the F-test. As the true values 
were known, we chose to plot these on the X-axis of the Bland-
Altman plot against the signed differences and computed the cor-
responding 95% limits of agreement22. 
All statistical tests were two-sided and a p-value <0.05 was con-
sidered statistically significant.
Results
MLD-RVD-DS
Accuracy and precision for 3-D reconstructions of individual phan-
tom bifurcations are shown in Table 1. MLD values for 3-D recon-
structions of two projections (basic reconstructions) had an 
accuracy and precision of 0.013±0.131 mm and -0.024±0.150 mm 
for the 11- and 6-segment models, respectively, not being signifi-
cantly different from phantom values (p-value 0.44 and 0.24). The 
reference size of phantom vessels was underestimated by an 
average 0.05 mm in both models, whereas DS estimates did not 
differ significantly from true values, precision being in the order 
of 5%. Adding the AP projection to the basic reconstructions 
resulted in improved precision for MLD, RVD and DS values for 
the 11-segment model (0.109 mm, 0.031 mm and 4.26%, respec-
tively) (Figure 5); however, improvement did not reach statisti-
cal significance for any parameter (p>0.05). 
VARIABILITY
Bias, standard deviation and repeatability coefficient for the basic 
reconstructions are reported in Table 2. Adding the AP projection to the 
basic reconstructions resulted in increased inter-observer reproducibil-
ity for the 11-segment model, the repeatability coefficient being 
0.101 mm for MLD, 0.041 mm for RVD and 3.93% for DS (p≤0.01 for 
every parameter). On the contrary, variability did not change signifi-
cantly for the 6-segment model (p>0.05 for every parameter). 
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Table 1. Validation of segment models vs. phantom dimensions (3-D reconstructions of individual bifurcations).
2 images (basic) 3 images p-value
Accuracy
Measurement
error
Precision Accuracy
Measurement
error
Precision
Basic vs.
phantom
3 images vs.
phantom
Basic vs.
3 images*
BSM11 MLD, mm 0.013 0.044 0.131 0.003 0.039 0.109 0.44 0.84 0.07 (0.09)
RVD, mm –0.052 0.023 0.039 –0.055 0.016 0.031 <0.001 <0.001 0.07 (0.06)
DS, % –1.08 1.68 5.13 –0.79 1.46 4.26 0.11 0.16 0.18 (0.09)
BA, ° –1.3 3.0 5.0 –1.9 3.1 5.4 0.09 0.02 0.15 (0.33)
BSM6 MLD, mm –0.024 0.041 0.150 –0.031 0.041 0.159 0.24 0.15 0.09 (0.34)
RVD, mm –0.051 0.024 0.039 –0.054 0.016 0.032 <0.001 <0.001 0.06 (0.08)
DS, % 0.22 1.52 4.85 0.37 1.62 5.04 0.73 0.58 0.41 (0.39)
BA, ° –1.3 3.0 5.0 –1.9 3.1 5.4 0.09 0.02 0.15 (0.33)
BA: bifurcation angle; BSM: bifurcation segment model; DS: percent diameter stenosis; MLD: minimal lumen diameter; RVD: reference vessel diameter. * values relate to the comparison between 
accuracy measures, values in parentheses relate to the comparison between precision measures.
Table 2. Intra- and inter-observer variability in basic 3-D reconstructions of individual bifurcations.
Intra-BSM11 Intra-BSM6 Inter-BSM11 Inter-BSM6
bias SD repeat bias SD repeat bias SD repeat bias SD repeat
MLD, mm 0.002 0.062 0.121 0 0.053 0.104 0.006 0.072 0.141 –0.002 0.058 0.114
RVD, mm 0 0.029 0.056 0 0.029 0.057 0.004 0.030 0.058 0.004 0.028 0.054
DS, % –0.08 2.36 4.64 –0.01 1.96 3.84 –0.18 2.76 5.42 0.10 2.08 4.07
BA, ° 0.0 4.0 7.8 0.0 4.0 7.8 0.1 3.8 7.5 0.1 3.8 7.5
BA: bifurcation angle; BSM: bifurcation segment model; DS: percent diameter stenosis; MLD: minimal lumen diameter; repeat: repeatability coefficient; RVD: reference vessel diameter; 
SD: standard deviation
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Figure 5. Bland-Altman plots comparing 11-segment model results to the phantom values. 3-D reconstructions combining two (upper panel) 
or three 2-D images (lower panel) were validated for measures of minimal lumen diameter (MLD), reference vessel diameter (RVD) and 
percent diameter stenosis (DS). Automatic reference obstruction analysis was always used. Solid lines represent the mean difference; dotted 
lines represent the 95% limits of agreement (±1.96 SD). BSM11: 11-segment model
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Figure 6. Bland-Altman plots for BA values and length measurements. 3-D reconstructions combining two (upper panel) or three 2-D images 
(lower panel) were employed. Solid lines represent the mean difference; dotted lines represent the 95% limits of agreement (±1.96 SD). 
Apparently wide limits of agreement for length measurements resulted from the relatively large variability between replicate measurements 
compared to the overall precision.
INTER-MODEL AGREEMENT
In basic reconstructions, the 11-segment model provided signifi-
cantly larger (p=0.02) and slightly more precise (p=0.16) MLD 
values compared to the 6-segment model; as expected, DS esti-
mates were significantly smaller (p=0.02) and also more precise 
(p=0.34). However, the 6-segment model had a higher inter-
observer reproducibility for DS and MLD (p-value 0.02 and 0.11, 
respectively). Adding the AP projection augmented the difference 
in precision in favour of the 11-segment model for MLD (p<0.01) 
and DS (p=0.11) values; there was also a trend towards higher 
reproducibility compared to the 6-segment model (p>0.05 for 
both MLD and DS). 
BA
Basic 3-D reconstructions underestimated BA by 1.3° (p=0.09) hav-
ing a precision of 5.0° (Table 2). Intra- and inter-observer bias was 
close to zero, whereas the repeatability coefficient was 7.8° and 7.5°, 
respectively. Adding the AP projection resulted in a larger underesti-
mation (–1.9°, p=0.02) and slightly reduced precision (5.4°, p=0.33) 
(Figure 6), whereas inter-observer variability was 7.9° (p=0.38). 
During the analysis the rates of applying restriction were uni-
formly low, namely 3.9% for reconstructions using either two or three 
images. The rates of CIP relocation were low for basic 3-D recon-
structions (11.1%), whereas they were higher for reconstructions of 
three projections (31.0%). The CIP had to be relocated most fre-
quently in reconstructions using angulated views.
LENGTH MEASUREMENTS
Compared to true inter-marker distances (46.67±19.40 mm), basic 
reconstructions showed an accuracy and precision of 0.15±0.26 mm 
and a measurement error of 0.23 mm; inter-observer bias was 
0.07 mm, whereas variability was 0.54 mm. Adding the AP projec-
tion resulted in an accuracy and precision of 0.04±0.47 mm (p<0.01 
for precision) and a measurement error of 0.50 mm; inter-observer 
variability was increased (1.03 mm, p<0.01). Relatively large vari-
ability between replicate measurements compared to the overall 
precision estimates resulted in apparently wide limits of agreement 
around the averaged length values (Figure 6). Nevertheless, both 
precision and measurement error were negligible when compared 
with true inter-marker distances. 
Discussion 
The main findings of this study are: 1) the new 3-D bifurcation 
QCA algorithm is highly accurate, precise and reproducible in 
terms of RVD; 2) in terms of MLD and DS, 3-D reconstructions 
using two 2-D projections are highly accurate and quite precise and 
reproducible; when adding a third projection, a higher level of pre-
cision and reproducibility is achieved; 3) BA measurements slightly 
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underestimate the true values, though precision and reproducibility 
are quite high and relatively unaffected by adding a third projec-
tion; 4) length measurements have excellent accuracy and precision 
and high reproducibility. 
A number of major randomised trials are under way in the field 
of bifurcation PCI. The EXCEL trial will evaluate the effectiveness 
of left main coronary artery revascularisation comparing PCI using 
second-generation drug-eluting stents to coronary artery bypass 
grafting. Bifurcation lesions are expected to represent the largest 
category of lesions treated23. On the other hand, TRYTON will 
evaluate the safety and effectiveness of a dedicated bifurcation stent 
in the treatment of de novo bifurcation lesions. Whereas workhorse 
angiographic analysis is going to be based on 2-D QCA, 3-D QCA 
is involved in the evaluation of a sizeable number of patients. 
Hence, validation of the software’s performance is imperative.
DIAMETER-DERIVED PARAMETERS
Earlier versions of 3-D reconstruction software were validated for 
measures of vessel diameter in the late 1990s; full coronary tree 
reconstruction, however, came at the cost of fair accuracy (3%-7% 
relative error in calculation) and increased time requirements (several 
hours down to 10 minutes)24,25. Next-generation algorithms focused 
on the reconstruction of single-vessel segments rather than entire 
coronary arteries, thereby enabling reliable results to be available in 
real time7-10,26.
Achieving similar results in the 3-D reconstruction of coronary 
bifurcations is not a trivial task. For any given bifurcation there is 
usually one single optimal projection1. It follows that in any other 
projection certain parts of the anatomy, usually the ostia of the 
daughter branches, are obscured due to overlap. The new algorithm 
can retrieve missing information even from a combination of sub-
optimal views14; however, a reconstruction including the optimal 
2-D projection would be expected to be even more robust.
In our study, the basic 3-D reconstructions did not include the AP 
view, which was the optimal 2-D view due to the phantoms’ orienta-
tion. Nevertheless, compared to analysis performed on the same 
phantom bifurcations using 2-D CAAS , 3-D software showed simi-
lar accuracy and precision: in images acquired at 30° rotation  respec-
tive 2-D measures were 0.035±0.10 mm for MLD, –0.004±0.041 mm 
for RVD and –0.74±4.52% for DS13. Moreover, since the same con-
tour detection algorithm was used, the extent of overestimation for 
small true MLD values (≤0.70 mm) was uniformly limited in both 
2-D and 3-D analysis. However, whereas full automatic calibration 
was readily available in 3-D QCA, for the purpose of 2-D validation 
the pixel size had to be derived off-line based on geometric calibra-
tion. Contrary to our phantoms, the course of coronary vessels does 
not usually lie on a single plane inside the human thorax. Hence, ves-
sel segments analysed on a 2-D angiographic image are subject to 
errors from variable magnification, since an automatically derived 
pixel size can be valid on only one plane10. Naturally the same phe-
nomenon applies to catheter calibration as well.
Adding the AP view to the basic 3-D reconstructions resulted in 
improved precision and reproducibility for all diameter-derived 
parameters in our study. One may argue that combining more than 
two 2-D images is rarely feasible at any stage during a procedure, at 
least not retrospectively, as there are simply not enough images 
available which are also suitable for a 3-D reconstruction27. 
However, when used on-line, this innovation can be clinically rel-
evant. Even if the optimal view is not among the images initially 
acquired, it can be suggested by a 3-D reconstruction based on two 
suboptimal views; time requirements (<10 sec for reconstruction of 
two images, <60 sec for three images) should not be an issue. 
However, limitations imposed by patient anatomy (vessel overlap) 
or proximity between the gantry and the patient/table may make it 
difficult to acquire the optimal view exactly as suggested10.
RVD-DS
Highly accurate, precise and reproducible RVD measurements 
were achieved by combining a validated algorithm for automatic 
RVD derivation in bifurcation lesions with genuine 3-D calcula-
tions. Thereby, instead of performing a tedious and arbitrary single-
vessel analysis for all three branches separately, RVD and DS 
values can be derived in the time of a single analysis, having at the 
same time all the advantages of the 3-D reconstruction. When 
applied on-line, 3-D QCA-derived information may potentially 
complement or even substitute invasive imaging modalities in stent 
sizing and deployment, thereby minimising adverse event rates.
Furthermore, 3-D QCA-derived MLD and DS values for bifurca-
tion lesions should be expected to have a better correlation with 
respective fractional flow reserve (FFR) values, when compared to 
2-D measures28,29. It is not implied that a single angiographic meas-
ure can fully reflect all anatomic and haemodynamic parameters 
that determine the functional significance of a lesion30; however, we 
believe that spatially accurate measurements will help improve 
periprocedural strategy in bifurcation PCI.
SEGMENT MODELS
Agreement between models in the new software looks diminished 
compared to 2-D validation; however, the difference in results for 
MLD and DS was largely driven by a small number of outliers in MLD 
detection, resulting from different segment definitions between mod-
els13. Cases where the MLD was located in the POC rather than seg-
ments 2, 3 or 5 resulted in overestimates for the 11-segment model. On 
the contrary, cases where a stenosis-free proximal main vessel impinged 
on a distal stenosis resulted in underestimates for the 6-segment model. 
Similar differences were already observed in 2-D analysis, only to be 
inflated in the process of 3-D reconstruction. The fact remains that the 
6-segment model offers a quick overview of results during a procedure, 
whereas the 11-segment model is more of a research tool providing 
more detailed information. Nevertheless, it appears that the algorithms 
are not mutually interchangeable when it comes to long-term angio-
graphic analysis: whichever algorithm is adopted for reporting results 
pre- and post-procedure would have to be used at follow-up as well.
BA
Angle calculations have recently gained attention due to growing 
evidence that wider distal BA values might lead to a worse outcome, 
especially with two-stent techniques27,31,32. To our knowledge, there 
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is a single validation study on 3-D derived BA reporting an under-
estimation of the phantom values by 2.6° and a standard error of the 
estimate equal to 0.7725. In our study, BA accuracy and precision 
were improved compared to the 2-D QCA software validation 
(–3.1±6.2° in rotated views), which was not unexpected. This dif-
ference might have been more pronounced if our phantom bifurca-
tions had lain in more than one plane. This could also explain the 
lack of improvement seen following the addition of the optimal 
view. Currently, there is a binary approach regarding BA size: sev-
eral cut-off values (50°, 70°) have been proposed; however, defini-
tions and measurement methods are still at variance. Pending more 
detailed data from 3-D QCA-based computations regarding the 
effect of BA on outcome, precision of 5.0° is considered high. 
LENGTH
One of the most acknowledged advantages of 3-D QCA is its accu-
racy in length derivation. Foreshortening in 2-D analysis may result 
in erroneous sizing and deployment of stents. This could translate 
either into incomplete lesion coverage and the need for additional 
stents or into excessive stent length, jailing of a side branch and 
increased restenosis rates33. This is why length measurements have 
the most comprehensive validation. Demarcated wires8, wire phan-
toms10, stent balloons9 or stented coronary segments, identified by 
radio-opaque markers34, and 3-D reconstructions based on fusion of 
angiography and intravascular ultrasound26 have all been used as a 
gold standard. In our study, length measurements were performed on 
demarcated catheter segments spanning the phantom bifurcation, 
thereby proving that they are consistent and impervious to bifurcation 
region definitions. Variability, albeit negligible, is assumed to corre-
late with the marker placement procedure, which was not automated 
but relied on the analysts’ visual perception. 
LIMITATIONS
In vitro validation has the obvious limitation of being based on 
static objects, acquired under ideal angiographic conditions. In our 
phantom bifurcations, lesions were circular-shaped in cross-sec-
tional view for design simplicity and due to manufacturing con-
straints19. On the contrary, more than 50% of coronary lesions are 
asymmetric, where 2-D analysis is known to be inaccurate35. Fur-
thermore, as opposed to straight phantom vessel segments, coro-
nary vessels usually have curved trajectories, which augment the 
effect of foreshortening in 2-D projection images10,11. Taking the 
calibration issues already mentioned into account, we have to 
assume that the incremental value of 3-D bifurcation QCA as com-
pared to 2-D analysis may have been underestimated.
Recently, minimal lumen area and percent area stenosis were 
shown to have a higher power for predicting reduced FFR values, 
when compared to the respective diameter-derived parameters29. In 
our study only diameter-derived measures were reported. However, 
due to the symmetric design of the phantom bifurcation lesions and 
because of the circularity assumption in diameters’ derivation from 
respective cross-sectional areas, our findings are transferable to 
area-derived parameters as well.
Conclusions
The new dedicated 3-D bifurcation QCA software allows angio-
graphic reconstructions of more than two 2-D projection images, 
and features novel 3-D quantitative analysis of bifurcation lesions. 
These advances translate into accurate, precise and reproducible 
measures of diameter, length and bifurcation angle. There is still 
work to be done regarding the in vivo validation of this software, in 
order to determine the clinical relevance of these data.
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ONLINE APPENDIX
Software validation for full-tree 3-D reconstructions of bifurcation 
phantoms
This appendix complements the main manuscript “Advanced three-
dimensional quantitative coronary angiographic assessment of bifurca-
tion lesions: methodology and phantom validation” and provides the 
results from additional analyses.
The new three-dimensional (3-D) bifurcation quantitative coronary 
angiography (QCA) algorithm has no restriction regarding the number 
of bifurcations the 3-D model consists of; it is possible to reconstruct 
and analyse a vascular tree which consists of multiple bifurcations. 
Methods
In order to investigate the accuracy, precision and reproducibility of this 
methodology, we performed full-tree 3-D reconstructions for the entire 
series of bifurcation phantoms1: images acquired at 30° rotation, in right 
and left anterior oblique (RAO-LAO) projection were combined. The 
operator procedure for angiographic analysis was amended accordingly, 
wherein: 1) for every given phantom, delimiter points were placed in the 
proximal main vessel of the proximal bifurcation, in the distal main ves-
sel of the distal bifurcation and in a side branch of any of the three bifur-
cations: by default we chose to begin with the side branch of the proximal 
bifurcation; 2) the remaining side branches were added to the phantom 
tree (one at a time), by indicating the junction point with the contoured 
main vessel and a distal delimiter; the first two steps were then repeated 
in the next image; 3) reconstruction was performed for the entire phan-
tom, and the common image point (CIP) was relocated as appropriate; 4) 
in the 3-D reconstructed phantoms one bifurcation was selected and ana-
lysed at a time (region of interest could be edited in order that analysis 
was not influenced by adjacent bifurcation lesions); 5) quantitative anal-
ysis was performed and reported for minimal lumen diameter (MLD), 
reference vessel diameter (RVD), percent diameter stenosis (DS) and 
bifurcation angles (BAs) as described in the main manuscript. Results 
were compared with the true phantom values and with separate 3-D 
reconstructions of individual bifurcations using the same combinations 
of images (30° RAO-LAO).
Results
MLD-RVD-DS
Accuracy and precision for full-tree and individual 3-D reconstruc-
tions are shown in Table 1. MLD values for full-tree reconstruc-
tions had an accuracy and precision of 0.012±0.135 mm and 
–0.021±0.155 mm for the 11- and 6-segment models, respectively, 
not being significantly different from phantom values (p-value 0.51 
and 0.33). The reference size of phantom vessels was underesti-
mated by an average 0.06 mm in both models, whereas DS esti-
mates did not significantly differ from true values, precision being 
in the order of 5%. Accuracy and precision did not differ signifi-
cantly between full-tree and individual reconstructions. 
Inter-observer variability for 11- and 6-segment models was 
0.146/0.155 mm for MLD, 0.038/0.039 mm for RVD and 
5.59/5.41% for DS values.
The 11-segment model was more accurate (p=0.05) and precise 
(p=0.16) for MLD, while the 6-segment model was more accurate 
(p=0.04) for DS values; difference in DS precision was not signifi-
cant (p=0.47).
BA
Full-tree 3-D reconstructions underestimated BA by 2.1° (p=0.01) 
having a precision of 4.7°; individual reconstructions had slightly 
increased accuracy (–0.9°, p=0.16) but equal precision. Inter-observer 
bias was 0.7°, whereas the repeatability coefficient was 8.8°. 
SUMMARY
The performance of the new 3-D bifurcation QCA software in full-
tree reconstructions of the bifurcation phantoms was comparable, 
but slightly inferior to the results attained from reconstructions per-
formed separately for each individual phantom bifurcation.
Reference
 1. Girasis C, Schuurbiers JC, Onuma Y, Serruys PW, Wentzel JJ. 
Novel bifurcation phantoms for validation of quantitative coronary 
angiography algorithms. Catheter Cardiovasc Interv. 2011;77:790-7.
Table 1. Validation of segment models vs. phantom dimensions (full-tree 3-D reconstructions of bifurcation phantoms).
Full-tree Individual p-value
Accuracy Precision Accuracy Precision
Full-tree vs.
phantom
Individual vs.
phantom
Full-tree vs.
individual*
BSM11 MLD, mm 0.012 0.135 0.001 0.118 0.51 0.97 0.30 (0.17)
RVD, mm –0.059 0.037 –0.056 0.040 <0.001 <0.001 0.29 (0.29)
DS, % –1.18 5.25 –0.71 4.75 0.10 0.28 0.25 (0.23)
BSM6 MLD, mm –0.021 0.155 –0.038 0.146 0.33 0.06 0.07 (0.33)
RVD, mm –0.058 0.037 –0.056 0.041 <0.001 <0.001 0.27 (0.23)
DS, % 0.04 5.20 0.67 4.80 0.96 0.31 0.12 (0.28)
BSM: bifurcation segment model; DS: percent diameter stenosis; MLD: minimal lumen diameter; RVD: reference vessel diameter. *values relate to the comparison between accuracy measures, 
values in parentheses relate to the comparison between precision measures.
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Validity and Variability in Visual Assessment of
Stenosis Severity in Phantom Bifurcation Lesions: A
Survey in Experts During the Fifth Meeting of the European
Bifurcation Club
Chrysaﬁos Girasis,1 MD, Yoshinobu Onuma,1 MD, Johan C.H. Schuurbiers,2 BSc,
Marie-angele Morel,3 BSc, Gerrit-Anne van Es,3 PhD, Robert-Jan van Geuns,1 MD, PhD,
Jolanda J. Wentzel,2 PhD, and Patrick W. Serruys,1* MD, PhD, on behalf of the
participants of the 5th meeting of the European Bifurcation Club
Objectives: To investigate the adequacy of visual estimate regarding the percent diam-
eter stenosis (DS) in bifurcation lesions. Background: Quantitative coronary angiogra-
phy (QCA) is more accurate and precise compared to visual estimate in assessing
stenosis severity in single-vessel lesions. Methods: Thirty-six experts in the ﬁeld of
bifurcation PCI visually assessed the DS in cine images of ﬁve precision manufactured
phantom bifurcation lesions, experts being blinded to the true values. Expert DS esti-
mates were compared with the true values and they were also used to deﬁne the
Medina class of each individual bifurcation. Results were pooled together both for
proximal main vessel (PMV), distal main vessel (DMV) and side-branch (SB) segments
and for vessel segments with similar DS values. Results: Individual performance was
highly variable among observers; pooled values and range of accuracy and precision
were 2.79% (26.67% to 17.33%) and 8.69% (4.31–16.25%), respectively. On average, DS
was underestimated in the PMV (21.08%, P 5 0.10) and overestimated in the DMV
(3.86% P < 0.01) and SB segments (5.58%, P < 0.01). Variability in visual estimates was
signiﬁcantly larger in lesions of medium severity compared to the clearly obstructive
ones (P < 0.01); the latter were consistently overestimated. Inter-observer agreement
was moderate (j 5 0.55) over the entire number of estimates. However, if the segments
with true DS 5 0% were excluded, agreement was diminished (j 5 0.27). Inter-observer
agreement in Medina class was rather low (j 5 0.21). True bifurcation lesions were
misclassiﬁed as non-true ones in 14/180 estimates. Conclusions: Visual assessment
by experts is more variable and less precise in the analysis of bifurcation lesions
compared to bifurcation QCA software. VC 2011 Wiley Periodicals, Inc.
Key words: angiography; QCA; bifurcation
INTRODUCTION
Visual assessment of coronary stenosis severity in
single-vessel lesions is known to have considerable
intra- and inter-observer variability [1–3]; quantitative
coronary angiography (QCA) is more accurate and pre-
cise in evaluating the percent diameter stenosis (DS),
both in everyday clinical practice [4–9] and in the con-
text of large randomized trials [10–12].
This inaccuracy in visual assessment would be
expected to be even more pronounced in bifurcation
lesions, where even experienced operators can be con-
fused by the difference in caliber between the proximal
and the distal branches. However, since the validity of
conventional single-vessel QCA derived DS measure-
ments is also questionable, especially at the ostium of
the side branch (SB) [13], visual assessment is still
employed in the design and screening process for
randomized trials evaluating bifurcation percutaneous
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coronary intervention (PCI) strategies and dedicated
bifurcation stents.
To improve the QCA-derived DS assessment in bifur-
cation regions, dedicated bifurcation QCA software pack-
ages were developed [14,15]. In order to validate their
performance, a series of plexiglas phantoms was precision
manufactured, each of them mimicking a vessel with
three successive bifurcation lesions [16]. The range of
diameters, lesion length, angulation, and Medina class
[17] used in the phantoms’ design reﬂected the anatomic
variation and the fractal nature of bifurcations in the
human coronary tree as derived from relevant literature.
These phantom images were used in order to investi-
gate the adequacy of visual assessment in bifurcation
lesions taking into account current bifurcation QCA soft-
ware standards. This survey was carried out among a
selected group of experts in the ﬁeld of bifurcation PCI
and the results are presented in this report.
MATERIALS AND METHODS
Material
During the ﬁfth annual meeting of the European
Bifurcation Club, held in Berlin, October 16–17, 2009,
the participants were asked to ﬁll out questionnaires,
visually assessing the DS in the vessel segments
comprising ﬁve bifurcation lesions out of the afore-
mentioned series of plexiglas phantoms.
True bifurcation lesions (involving both the main
vessel and the SB) were selected to be evaluated; one
lesion was selected out of every phantom (Fig. 1), with
the exception of phantom 4, which did not include a
true bifurcation lesion [16]. The true DS values in the
bifurcation lesions selected are reported in Table I.
Stop-frames of the phantom images acquired in
antero-posterior direction were projected onto a high re-
solution screen including zoomed/magniﬁed views of the
bifurcation lesions evaluated. Each stop-frame was pro-
jected for over a minute; upon request, a given lesion
was projected again on the screen to assist ﬁnal decision.
Thirty-six fully ﬁlled-in questionnaires were handed
in; the identity of most of the observers was stated,
Fig. 1. Phantom bifurcations visually assessed. From left to right, cine images of ﬁve preci-
sion manufactured bifurcation phantoms acquired in antero-posterior direction. Out of every
phantom a true bifurcation lesion (involving both the main vessel and the side-branch) was
selected. Lesion contours presented here for illustration purposes were not made available
to the observers during the survey. P1B1 reads phantom 1, bifurcation 1. P 5 proximal main
vessel, M 5 main vessel, S 5 side-branch.
TABLE I. Average Visual Estimate for Individual Phantom
Bifurcation Vessel Segments Over 36 Observers
Bifurcation
vessel
segments
True
DS (%)
Estimate
mean (%)
Estimate
bias (%)
Estimate
SD (%)
Estimate
CV
P1B1 PMV 60.88 56.25 4.63 10.78 0.19
P1B1 DMV 80.03 85.33 5.30 8.02 0.09
P1B1 SB 60.31 66.81 6.50 10.50 0.16
P2B2 PMV 79.97 83.94 3.97 7.02 0.08
P2B2 DMV 60.32 66.97 6.65 10.02 0.15
P2B2 SB 60.13 63.19 3.07 9.79 0.15
P3B1 PMV 60.60 53.17 7.43 10.19 0.19
P3B1 DMV 80.18 86.83 6.65 6.20 0.07
P3B1 SB 60.00 58.03 1.97 13.04 0.22
P5B1 PMV 0.00 1.33 1.33 4.02 N/A
P5B1 DMV 60.09 60.17 0.08 9.12 0.15
P5B1 SB 78.73 89.83 11.10 5.33 0.06
P6B1 PMV 0.00 1.36 1.36 4.69 N/A
P6B1 DMV 60.09 60.69 0.60 9.47 0.16
P6B1 SB 78.69 87.89 9.20 5.92 0.07
P1B1 reads phantom 1, bifurcation 1
CV ¼ coefﬁcient of variation, DMV ¼ distal main vessel, DS ¼ percent
diameter stenosis, PMV ¼ proximal main vessel, SD ¼ standard devia-
tion, SB ¼ side-branch, N/A ¼ non-applicable.
84
however individual performance is not disclosed in the
present report, since the objective of this query was
not to grade the participants.
Analysis Method
In order to unveil patterns in visual assessment, rates
of fair visual assessment, under- or over-estimation were
derived comparing individual estimates by the experts
with the true DS values. A difference of 10% in meas-
ured percent DS is described to be visually perceptible
and was used in our study in order to set realistic limits
of agreement [10]. Thus, estimates within 10% from
the true DS values were considered as fair visual assess-
ment. Estimates exceeding the lower or upper limits of
agreement were, respectively, considered to under- or
over-estimate the true stenosis severity. In the vessel
segments with true DS ¼ 0%, estimates between 0 and
10% were considered fair assessment; other than that
true DS could only be over-estimated.
Statistical measures were calculated at an observer
and a vessel segment level. Moreover, results were
pooled together for the proximal main vessel (PMV),
the distal main vessel (DMV) and the SB segments,
and for the entire number of vessel segments evaluated.
Finally, vessel segments with similar DS values were
pooled together and studied separately.
Considering the fact that stenosis severity in seg-
ments with true DS value of 0% could only be overes-
timated, comparisons between the pooled results of
PMV, DMV, and SB segments were performed with or
without these segments.
Following the Medina bifurcation lesion classiﬁca-
tion, an integer of 1 was attributed to the vessel seg-
ments, when DS50% and an integer of 0, when
DS<50%. Vessel segments were classiﬁed according
to both the true values and the visual assessment of the
observers; the respective Medina class for every lesion
evaluated was also derived. Agreement between the
actual and the derived Medina class was investigated
at the level of individual vessel segments and the entire
bifurcation lesions.
Statistics
Statistical analysis was performed using SPSS 16.0
for Windows (SPSS Inc, Chicago, IL). Continuous var-
iables are presented as mean  1 standard deviation
(SD); categorical variables are presented as counts and/
or percentages. Comparisons of continuous variables
among groups were performed with the paired or
unpaired t-test, as appropriate; for multiple compari-
sons, one-way analysis of variance (ANOVA) with
Bonferroni post-hoc analysis was employed. Compari-
sons of categorical variables among groups were per-
formed with the chi-square test.
In order to be able to compare DS estimates for vari-
ability, coefﬁcients of variation (CVs) were formed for
every single vessel segment dividing the estimate SD
by the estimate mean, thus providing a value independ-
ent measure of variability. CVs were pooled according
to the root mean square method [18]; their values were
squared for the purpose of comparison.
For every single observer, Bland–Altman analysis
[19] was performed to compare the DS estimate for all
15 vessel segments with the corresponding true values;
accuracy and precision of the estimate were calculated.
The individual signed differences with the true values
were averaged; the mean of these signed differences
(bias) is a measure of accuracy; SD is a measure of
precision. Bias was averaged over the entire number of
observers; the overall precision (SD) was calculated
with the root mean square method. The corresponding
95% limits of agreement were computed for every ob-
server and for an average visual estimate (average bias
with average precision).
Inter-observer agreement in visual assessment was
measured using the j statistic. The intra-class correla-
tion coefﬁcient was calculated in SPSS, as this is math-
ematically equal to the average of weighted j values
[20] for all possible pairwise comparisons between
multiple observers [21]. The qualitative classiﬁcation
of the j values used to interpret the degree of agree-
ment beyond the level of chance is shown in Table II.
All statistical tests were two-sided and a P value
<0.05 was considered statistically signiﬁcant.
RESULTS
The mean  1SD, the bias, and the CV of the visual
estimate for DS in every vessel segment are reported
in Table I.
Bland–Altman Analysis
Individual performance was highly variable among
the observers; range for accuracy and precision were
TABLE II. Quantitative Classiﬁcation of Kappa Values as a
Degree of Agreement Beyond the Level of Chance
Kappa value
Degree of agreement
beyond chance
0 None
0.0< j  0.2 Slight
0.2< j  0.4 Fair
0.4< j  0.6 Moderate
0.6< j 0.8 Substantial
0.8< j  1.0 Almost perfect
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6.67% to 17.33% and 4.31%–16.25%, respectively.
Pooled accuracy and precision were 2.79% and 8.69%;
95% limits of agreement of this pooled estimate with
the true DS values were 14.24% to 19.82% (Fig. 2).
However the distribution of accuracy and precision
measures among the observers was not always uni-
form; higher accuracy could coincide with diminished
precision and vice versa.
Accuracy and Precision in Subgroups
Visual assessment of stenosis severity in PMV seg-
ments underestimated the true DS values (1.08%, P
¼ 0.10); bias was larger when segments with true DS
¼ 0% were not considered (2.69%, P < 0.01). On
the contrary, in DMV and SB segments, DS was over-
estimated (bias 3.86% and 5.58%, respectively, P <
0.01 for both). There was no signiﬁcant difference in
variability of the DS estimates (P ¼ 0.68) between the
pooled PMV (true DS>0%), DMV, and SB vessel seg-
ments (Table III). Visual estimate in segments with
true DS 60% did not differ on average from the true
values (P ¼ 0.59), whereas segments with true DS
80% were consistently overestimated (7.25%, P <
0.01). However, there was a signiﬁcantly larger vari-
ability (P < 0.01) for the DS estimate in the former
compared to the latter (Table III).
Semiquantitative Visual Assessment of Stenosis
Severity in Vessel Segments
Rates of wrong assessment (either over- or under-
estimation) of stenosis severity were signiﬁcantly
higher in SB compared to PMV segments (50.6% vs.
33.9%, P < 0.01); this difference was no longer signif-
icant (P ¼ 0.63), when PMV segments with true DS ¼
0% were excluded. Within the wrong assessments, the
SB was more often over-estimated compared to the
PMV segments (78.0% vs. 37.7%, P < 0.01). Rates of
wrong assessment were higher in SB compared with
DMV segments (50.6% vs. 26.7%, P < 0.01); there
was also more frequent DS over-estimation in SB com-
pared with DMV (78.0% vs. 58.3%, P ¼ 0.02) (Fig. 3).
Rates of wrong assessment did not differ between
segments with true DS 60% compared to the ones
with true DS 80% (43.1% vs. 40.6%, P ¼ 0.63).
However, within these wrong assessments, DS was
almost always overestimated in the latter segments
(97.3%), but more frequently underestimated in the for-
mer (61.3%); difference in distribution of wrong assess-
ments was signiﬁcant (P < 0.01) (Fig. 4). Overall, in
20% of the cases, a lesion with true DS 80% was esti-
mated by the observers to have a stenosis >90%.
Inter-observer agreement following this visual
assessment classiﬁcation (fair, over- or underestima-
tion) was moderate (j ¼ 0.55) over the entire number
of estimates (Table IV). However, if the segments with
true DS ¼ 0% were excluded, agreement was dimin-
ished (j ¼ 0.27).
Medina Classiﬁcation
At the vessel segment level, there were 25/540 false
negative estimates (integer 0 instead of 1), all of them in
segments with true DS 60% with no difference in fre-
quency between PMV, DMV, and SB (P value¼0.58);
inter-observer agreement was high (j ¼ 0.74). However,
if the segments with true DS ¼ 0% were excluded,
inter-observer agreement was barely higher than the level
Fig. 2. Accuracy and precision of visual estimates for percent
diameter stenosis (DS) among experts. Error bars indicate the
95% limits of agreement for every individual observer, circle
marks the mean intra-observer bias. The error bar in red iden-
tiﬁes the most precise estimate among observers. Solid black
line indicates bias averaged over all observers; dotted black
lines indicate the respective 95% limits of agreement for this
average estimate. Solid and dotted blue lines indicate the re-
spective measures for CAAS 5.9 bifurcation QCA software for
the purpose of comparison. [Color ﬁgure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
TABLE III. Visual Estimate for Pooled Phantom Bifurcation
Vessel Segments
Vessel segments Pooled bias (%) Pooled SD (%) Pooled CV
PMV 1.08 7.84 N/A
PMV>0% 2.69 9.48 0.164
DMV 3.86 8.67 0.129
SB 5.58 9.38 0.146
True DS 60% 0.36 10.42 0.174
True DS 80% 7.25 6.56 0.076
True DS>0% 3.01 9.14 0.144
All segments 2.79 8.69 N/A
CV ¼ coefﬁcient of variation, DMV ¼ distal main vessel, DS ¼ percent
diameter stenosis, PMV ¼ proximal main vessel, SD ¼ standard devia-
tion, SB ¼ side-branch; N/A ¼ non-applicable
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of chance (j ¼ 0.08) (Table IV). In regard to the
derived Medina class, inter-observer agreement was
rather low (j ¼ 0.21). In total, errors in single vessel
segments resulted in the derivation of a false Medina
class in 22/180 estimates; in 14 (7.8%) of them the
derived Medina class corresponded to a non-true bifurca-
tion lesion.
DISCUSSION
The main ﬁndings of this study are: (1) Accuracy
and precision in visual assessment of the stenosis se-
verity in bifurcation lesions was highly variable among
experts in bifurcation PCI. On average, stenosis sever-
ity was underestimated in the PMV and overestimated
in the DMV and SB segments. (2) Variability of visual
estimate was signiﬁcantly larger in lesions of medium
severity compared to the clearly obstructive ones,
which on the other hand were consistently overesti-
mated. (3) Inter-observer agreement in derived Medina
class was rather poor; true bifurcation lesions were
misclassiﬁed as non-true ones in 14/180 estimates.
Visual Assessment vs. QCA
Already in the early 80s Serruys et al. [4] had
reported a discrepancy between visual and QCA
Fig. 4. Visual estimates for segments with true percent diam-
eter stenosis 60% (DS60) or 80% (DS80) pooled over the 36
observers. Fair estimates do not differ signiﬁcantly, however
for DS80 segments over-estimates are signiﬁcantly more and
under-estimates very limited. [Color ﬁgure can be viewed in
the online issue, which is available at wileyonlinelibrary.com.]
Fig. 3. Visual estimates for proximal main vessel (PMV), distal
main vessel (DMV), and side-branch (SB) segments pooled
over the 36 observers. Left side: All segments assessed; there
are signiﬁcantly less fair estimates but more over-estimates
(P-value not shown) for the SB. Right side: Segments with
true percent diameter stenosis 0% were removed; fair esti-
mates in the PMV segments are decreased, under-estimates
are increased. Wrong estimates in DMV segments are rather
limited and balanced. [Color ﬁgure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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estimates of DS values in single-vessel lesions, visual
estimate systematically overestimating severe QCA-
assessed stenoses by almost 10%; similar studies corro-
borated this ﬁnding [22,23]. On the other hand, the
large intra- and inter-observer variability of visual esti-
mate (SD up to 18%) has been a consistent ﬁnding
since the late 70s [1–3].
The extent of inaccuracy and variability in visual
assessment in our study possibly represents an additive
effect between these well known shortcomings of vis-
ual estimates and the particularities in bifurcation
lesion interpretation, especially when it comes to the
interpretation of the SB ostium [14,24]. The vessel seg-
ments distal to the bifurcation carina taper in size, their
reference diameter being dictated by laws of fractal ge-
ometry [25]. However, the intuitive way, in which
even experienced operators interpret stenosis severity
at or close to the ostium of distal bifurcation branches,
is by referring to the PMV segment, thus resulting in
overestimated DS values. Conversely, yet to a lesser
extent, lesions in the PMV may be underestimated
[26].
These phenomena are also reﬂected in the way sin-
gle-vessel QCA analysis has been applied in the bifur-
cation lesions. Manual extension of vessel contours
from the SB into the PMV and reference vessel size
interpolations across the carina often resulted in invalid
DS measurements that failed to predict the functional
signiﬁcance of ostial SB stenoses [13]. In order to
make up for these shortcomings, dedicated 2-D bifurca-
tion QCA algorithms have been developed; the Cardio-
vascular Angiography Analysis System (CAAS, Pie
Medical Imaging, Maastricht, The Netherlands) [15,27]
and QAngio XA (Medis medical imaging systems, Lei-
den, The Netherlands) [14,28] have been validated
against the entire series of plexiglas phantom bifurca-
tions already mentioned and rendered excellent accu-
racy and precision for DS measurements, 0.5  3.7%
for CAAS and 0.6  4.2% for QAngio XA respec-
tively (Girasis, 6th meeting of the European Bifurca-
tion Club, Budapest, 2010).
These algorithms outperform average visual assess-
ment among experts in our study almost by a factor of
three. Actually, only one out of 36 participants could
match the QCA software accuracy and precision; for
the rest higher accuracy could coincide with dimin-
ished precision and vice versa. Furthermore, average
bias was negative for the pooled PMV segments,
whereas positive for both DMV and SB segments.
Because these pooled accuracy measures derived over
the 36 participants could obscure patterns in visual
assessment, individual estimates were semi-quantita-
tively classiﬁed applying 10% limits of agreement
and a stratiﬁed analysis was performed. Indeed, there
was a consistent trend for underestimation of stenosis
severity in the PMV and overestimation in the SB;
wrong estimates in DMV segments were rather limited
and balanced.
Variability of Assessment for Varying Stenosis
Severity
There have been varying reports on the extent of
change in DS before and immediately after PCI and at
follow-up angiography [5,7,8]. Nonetheless, they all
seem to agree that in equivocal stenoses visual esti-
mates are highly variable showing a bimodal distribu-
tion [7,8], as opposed to the Gaussian distribution of
QCA derived DS values [29]; small true DS values are
underestimated, large true DS values are overestimated,
when visually assessed. Following this pattern, in our
study, variability of visual assessment compared to the
true DS values was signiﬁcantly larger in the vessel
segments with true DS 60%, that is where it matters
the most in clinical practice. Inter-observer agreement
was limited, especially when registering visual estimate
according to the 50% criterion (Medina classiﬁcation).
On the other hand, in clearly obstructive lesions (true
DS 80%), DS values were almost always overesti-
mated, estimates in excess of 90% not being rare.
However, such high degrees of luminal restriction are
unlikely to occur in human coronaries, being prone to
intraluminal thrombosis and obstruction [4].
Inter-Observer Agreement–Medina Classiﬁcation
The current consensus in bifurcation lesion classiﬁ-
cation is the one proposed by Medina. Lesions with
Medina class (1,1,1), (1,0,1) and (0,1,1), where both
the main vessel and the SB display signiﬁcant stenosis,
are designated as ‘‘true’’ bifurcation lesions, where a
two-stents strategy is still debatable. Whereas Medina
class derivation in upcoming randomized bifurcation
PCI trials, such as EXCEL, Tryton and EBC TWO
TABLE IV. Inter-Observer Agreement (in Kappa) Applying the
Fair-Over-Under or the MEDINA Classiﬁcation on Individual
Vessel Segments
Vessel segments Fair-over-under Medina
PMV 0.35 0.84
PMV>0% 0.39 0.06
DMV 0.06 0.01
SB 0.26 0.17
True DS 60% 0.13 0.05
True DS 80% 0.26 N/A
True DS>0% 0.27 0.08
All segments 0.55 0.74
DMV ¼ distal main vessel, DS ¼ percent diameter stenosis, N/A ¼
non-applicable, PMV ¼ proximal main vessel, QCA ¼ quantitative cor-
onary angiography, SB ¼ side-branch.
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will still be based on visual assessment, a more rigor-
ous approach would be suggested by the ﬁndings of
this study. Marked inter-observer variability in visual
assessment among experts participating in our study
resulted in relatively poor agreement in the derived
Medina classiﬁcation. Low levels of inter-observer
agreement have been reported before and were attrib-
uted either to variable operator experience [3,30], or to
a lesion location in the distal coronary segments having
smaller caliber and inadequate opaciﬁcation [1,3].
Employing a consensus decision among 3 observers
[6] or a 70% DS criterion for angiographic signiﬁcance
[3,30] is known to have improved visual assessment on
occasion. Lastly, one cannot rule out variability in clin-
ical expertise, even among experts in the ﬁeld; how-
ever the extent of variability reported in this selected
group of interventional cardiologists has apparent
implications for the recruitment strategy in major bifur-
cation studies and everyday clinical practice. If resort-
ing to the Core Laboratory to determine the eligibility
of a patient/lesion for a given trial is deemed cumber-
some, online bifurcation QCA could aid patient inclu-
sion and/or procedure strategy being accurate, repro-
ducible and time efﬁcient at the same time.
Limitations
The lesions evaluated in our study had all the advan-
tages and limitations of phantoms. Angiographic evalu-
ation was free of technical difﬁculties regarding acqui-
sition, opaciﬁcation, and orientation of SB ostium. Ves-
sel segments had sufﬁciently large caliber and did not
display diffuse/ectatic reference segments or post-
PTCA haziness [4]; in short an optimal clinical sce-
nario. However, this study provided us with measura-
ble indices and helps us understand how visual assess-
ment by experts relates to current bifurcation QCA
standards.
Lesions with true DS values of 0%, 60%, or 80%
were scored; admittedly a larger number of lesions
with 30–50% DS could have been included. The ra-
tionale behind the phantoms’ design has already been
detailed elsewhere [16]. In short, 0% was selected as
the lowest possible degree of stenosis (instead of a pos-
sible 25%) due to manufacturing constraints; addition-
ally, vessel segments with true DS of 40% were
included as well in that series of phantoms. However,
during this survey we purposely used only true bifurca-
tions lesions of the largest possible phantom vessel cal-
iber, in order to test our hypothesis on inter-observer
agreement on Medina class, thereby simulating the
enrolment phase of a bifurcation study. Due to this
selection process, lesions with 40% true DS were left
out. Nevertheless, visual assessment is most variable in
medium severity lesions; thus our ﬁndings in the
lesions with 60% true DS can quite safely be extrapo-
lated to this medium-low part (25–40%) of the lesion
severity spectrum.
CONCLUSIONS
In a survey among experts in the ﬁeld of bifurcation
PCI, accuracy and precision of visual estimates of DS
in phantom bifurcation lesions was highly variable
compared to current bifurcation QCA standards. Large
variability of visual estimate in equivocal stenoses and
low inter-observer agreement in derived Medina classi-
ﬁcation may justify the inclusion of online bifurcation
QCA in the decision making process.
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Abstract
Aims: To report long-term outcome data on the V technique using drug-eluting stents.
Methods and results: From April 2002 to December 2006, 31 consecutive patients were successfully
treated with V stenting of a de novo bifurcation lesion. The technique involves the deployment of two stents
in the two branches of a bifurcation, the proximal edges of the stents just touching one another. Patients
exclusively received either sirolimus- (10), paclitaxel- (20) or biolimus-eluting (one) stents. On average,
1.5±0.8 stents with a total length of 26.6±17.2 mm and 1.1±0.4 stents with a total length of 18.3±7.6 mm
were deployed in the distal main vessel and side branch respectively. Mean duration of follow-up was
853±553 days. Within 30 days, three patients died; two other patients had definite stent thrombosis
involving the V stents, both requiring re-PCI. Beyond 30 days and within one year, there was one death and
three cases of target vessel revascularisation, including one target lesion revascularisation. There were a
further three deaths (one cardiac) beyond one year. Eleven patients (35.5%) had angiographic follow-up,
exhibiting a binary restenosis rate of 9.1% at 203±33 days.
Conclusions: In this real-world cohort, late clinical events stand in accord with studies on competitive
techniques, but early outcome was less encouraging, probably due to the baseline risks.
KEYWORDS
Angioplasty, drug
eluting stent, stent
thrombosis
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Introduction
The optimal technique for treating bifurcation lesions with
percutaneous coronary intervention (PCI) has not been clearly
established. There is particularly little outcome data on V stenting in
the current drug-eluting stent (DES) era. The V stenting technique
scaffolds both distal limbs of a bifurcation lesion from the carina
onwards and is only suitable when the lesion spares the proximal
main vessel (PMV)1. In treating bifurcation lesions, optimal coverage
without any un-stented gaps is essential for optimal scaffolding and
drug delivery to mitigate the restenotic process2-4. Recently, various
groups have described the Simultaneous Kissing Stents (SKS)
technique – the simultaneous deployment of the distal main vessel
(DMV) and side branch (SB) stents so that the new apposing struts
from the two adjacent stents extended proximally from the carina5-7
for 8±5 mm5 or 8.9±2.5 mm6. Preliminary angiographic6 and
histologic7 results showed that a new carinal membrane developed
on these struts. While this technique can handle proximal disease
close to the carina, the PMV receiving the two stents is often over-
dilatated with its attendant risks5. A newer approach is to implant in
the PMV a conical self-expandable Axxess (Devax, Irvine, CA, USA)
stent with a “flared” distal part covering the outer rim of the
bifurcation and two stents distally with V technique to scaffold the
inner rim. To facilitate progress in this field, noting the possible
dreaded complication of late stent thrombosis8, we reviewed the
long-term outcome of V stenting using DES from April 20029 to
December 2006. 
Methods
Study population
On April 16, 2002, our institution began to use sirolimus-eluting
stents (SES, Cypher, Cordis Corporation, Warren, NJ, USA) as the
default strategy for every PCI, until Feb 16, 2003 when paclitaxel-
eluting stents (PES, Taxus, Boston Scientific, Natick, MA, USA)
became our default strategy. Data were recorded in the Rapamycin-
Eluting Stent Evaluated at Rotterdam Cardiology Hospital
(RESEARCH) registry10 and the Taxus Stent Evaluated AT
Rotterdam Cardiology Hospital (T-SEARCH) registry11. From April
2002 to December 2006, 656 procedures involving treatment of de
novo bifurcation lesions were performed in 638 patients. Out of this
cohort, and after reviewing the angiographic films, we identified
31 consecutive patients, who had one bifurcation lesion
successfully treated with V stenting; none of them had a second
procedure involving this technique. Written informed consent was
obtained from all patients prior to the procedure.
Procedure
V stenting is defined as the delivery and implantation of two stents in
the two branches of a bifurcation; one stent is deployed in the DMV
and the other one in the SB12. The stents can be deployed either
concurrently or in a successive mode13. The latter is presumably an
acceptable alternative, provided that the second stent is deployed
concurrently with a balloon inflated in the first stent, to protect this
from being crushed; systematic post-dilation with kissing balloons
should be performed. To differentiate from the SKS technique, we
defined V stenting as the proximal edges of the stents just touching
one another without any significant overlap, protruding into the PMV
by no more than 5 mm12 (Figure 1).
All procedures were performed according to current interventional
standards at the time. The use of predilation, post-procedure kissing
balloon inflation and the use of glycoprotein IIb/IIIa inhibitors was left
to the operators’ discretion. During the procedure, intravenous
heparin was administered, in order to maintain an activated clotting
time above 250 seconds. All patients were prescribed 80 mg of
aspirin lifelong and were pretreated with 300 mg clopidogrel followed
by 75 mg clopidogrel for at least six months.
Clinical definitions and follow-up
Angiographic success was defined as residual stenosis <30% by
visual estimation in the presence of Thrombolysis In Myocardial
Infarction (TIMI) grade 3 flow. Clinical success was defined as
angiographic success without the occurrence of death, myocardial
infarction or repeat revascularisation of the target lesion during the
hospital stay. Myocardial infarction was diagnosed by an increase in
creatine kinase-MB fraction of three times the upper limit of normal,
according to American Heart Association / American College of
Cardiology guidelines14. Target lesion revascularisation (TLR) and
target vessel revascularisation (TVR) were defined according to the
Academic Research Consortium (ARC) recommendations15; they
were adjudicated as clinically indicated, only if driven by symptoms/
objective signs of ischaemia and a percent diameter stenosis exceeding
50% on follow-up angiography. Clinical events were recorded in two
ways: firstly, as composite major adverse cardiac events (MACE),
including all-cause death, nonfatal myocardial infarction and TVR and
secondly, in the form of the ARC recommended device-oriented
composite, including cardiac death, myocardial infarction (not clearly
attributable to a non-target vessel) and TLR.
We applied ARC recommendations to adjudicate stent thrombosis.
Angiographically defined thrombosis with TIMI grade 0 or 1 flow or
the presence of a flow-limiting thrombus accompanied by acute
symptoms was considered as definite stent thrombosis.
Unexplained death was adjudicated as probable stent thrombosis if
occurring within 30 days, and as possible stent thrombosis if after
30 days15. Stent thrombosis was further categorised according to
the timing of the event into acute (within 24 hours), subacute
(24 hours-30 days), late (30 days-1 year) and very late (beyond one
year). We retrieved electrocardiographic (ECG) information on
patients with myocardial infarction for adjudication. 
Data sources for both registries included municipal civil registries
for survival status, information from health questionnaires, medical
records, and information from local physicians on repeat coronary
interventions (surgical or PCI), myocardial infarction and
medication usage 10, 11. 
Angiographic evaluation
The bifurcation lesions were adjudicated according to the Medina
classification16 after reviewing the pre-procedure images.
Quantitative coronary angiographic (QCA) analysis was performed
by means of dedicated bifurcation QCA software (CAAS 5.4,
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Maastricht, PIE Medical software, The Netherlands) (Figure 2); the
relevant methodology employing a ten-segment model for the
bifurcation lesion has already been described17. Angiographic
parameters, namely minimal lumen diameter (MLD), interpolated
reference vessel diameter (RVD) and percentage diameter stenosis
(DS), were independently determined both within the stent(s) and
within the segment(s). These parameters were measured pre-
procedure, post-procedure and, when available, at follow-up. In the
case of a chronic total occlusion (CTO), the MLD equals 0 mm,
%DS equals 100% and RVD cannot be determined. Late lumen
loss (LLL) was calculated as the difference in MLD between post-
procedure and follow-up. Angles between the PMV and SB
(proximal bifurcation angle) and between DMV and SB (distal
bifurcation angle) were automatically determined. Binary
angiographic restenosis was defined as DS ≥50% at follow-up. 
Statistical analysis
Categorical variables are presented as counts and percentages,
whereas continuous variables are expressed as mean ± standard
deviation. A comparison of angiographic variables both between pre
and post and between post and follow-up was performed with a
Wilcoxon signed rank test. A p- value of <0.05 was considered
significant. Statistical analysis was performed using commercially
available software (SPSS 12.0 for Windows, SPSS, Chicago, IL, USA).
Results
The baseline demographics and procedural characteristics in the
31 patients are reported in Tables 1 and 2. PCI was performed in
20 (64.5%) patients for an acute coronary syndrome (22.6% with ST
elevation myocardial infarction and 41.9% with unstable angina or
non-ST elevation myocardial infarction). Twenty-three patients
(74.2%) had multivessel disease and 12 of them (38.7%) had
interventions to at least one additional major epicardial vessel beyond
the target vessels. All patients received exclusively one type of DES;
Taxus and Cypher stents were implanted in 20 and 10 cases
respectively. There was a single patient who received exclusively
biolimus-eluting stents (BES, Biomatrix, Biosensors, Singapore); he
was recruited in a research study and had no clinical event during the
follow-up period. The average number of stents was 3.5±1.5 per
patient with a total stent length 64.1±32.6 mm. However, regarding
Figure 1. Illustration of V stenting technique. A. Typical 0,1,1 bifurcation lesion involving the left circumflex (LCX) and the obtuse marginal (OM)
branch (distal main vessel). B. Two sirolimus-eluting, Cypher, stents have been advanced into position. The 3.0 x 23 mm stent is in the OM, the
2.5 x 13 mm stent is in the LCX. Arrows point at the stents’ markers; the proximal markers barely touch each other, not protruding into the proximal
main vessel. C. Both stents are simultaneously deployed. D. Final result.
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the bifurcation lesion itself, 1.5±0.8 stents with a mean total length of
26.6±17.2 mm and 1.1±0.4 stents with a mean total length of
18.3±7.6 mm were deployed in the DMV and SB respectively. All
patients had Medina bifurcation lesion classification of 0,1,1 for the
lesion receiving V stenting. The left main bifurcation was the location
of the lesion in the majority of the cases (16 cases-51.6%); the lesion
involved the left anterior descending (LAD)/diagonal bifurcation in
eight cases, the left circumflex (LCX)/obtuse marginal bifurcation in
six cases and the distal right coronary artery (RCA) bifurcation in one
case. Stents were deployed simultaneously at all times, whereas post-
dilation with kissing balloons was performed in 10 cases (32.3%);
glycoprotein IIb/IIIa inhibition was employed in 13 cases (41.9%).
Thirty-day outcome
Within 30 days, three patients died (patients 1, 2 and 3 in Table 3).
The first death was regarded as non-cardiovascular, since the
patient succumbed to hospital acquired pneumonia after a stroke,
whereas patient 2 was adjudicated to have probable stent
thrombosis. Patient 3 could not be saved despite a rescue
procedure for cardiogenic shock after failed thrombolysis, and died
of heart failure. Two other patients had definite stent thrombosis and
required emergency PCI, one on day 0 and one on Day 5. The latter
(patient 4 in Table 3), a 78-year old man suffering a heart attack five
days after a prostate operation, had a cerebral haemorrhage on day
4 and therefore aspirin and clopidogrel were discontinued; the
stents occluded the very next day. Finally, another patient who had
the V stents placed at the left main bifurcation, and also had
intervention on a sub-totally occluded venous graft to his right
coronary artery, had a myocardial infarction on the same day; ECG
changes pointed to the treated graft as the culprit.
Figure 2. Quantitative coronary angiography of a bifurcation lesion
involving the left anterior descending (LAD) and the diagonal branch
(side branch). Automatic contour detection pre-procedure (A) and
post-procedure (B). Images include the corresponding diameter plots
for the main branch and the side branch (CAAS 5.4, Maastricht, PIE
Medical software, The Netherlands).
Table 1. Patient demographics and clinical characteristics (n = 31).
Age (years) 65.9±11.4
Male gender (%) 22 (70.9)
Diabetes mellitus (%) -all NIDDM 5 (16.1)
Hypertension (%) 10 (32.3)
Hypercholesterolaemia (%) 15 (48.4)
Current smoker (%) 6 (19.4)
Previous myocardial infarction (%) 12 (38.7)
Previous PCI (%) 4 (12.9)
Previous CABG (%) 2 (6.5)
Clinical presentation
Stable angina (%) 11 (35.5)
Unstable angina or non-ST elevation 
myocardial infarction (%) 13 (41.9)
ST elevation myocardial infarction (%) 7 (22.6)
Glycoprotein IIb/IIIa inhibitors 
periprocedural usage (%) 13 (41.9)
NIDDM: non insulin dependent diabetes mellitus; PCI: percutaneous
coronary intervention; CABG: coronary artery bypass graft surgery
Table 2. Baseline angiographic and procedural characteristics 
(n = 31).
Multivessel disease (%) 23 (74.2)
Multivessel intervention (%) 21 (67.7)
Angiographic success (%) 31 (100)
Clinical success (%) 25 (80.6) 
Target bifurcation lesion location
LMS (%) 16 (51.6)
LAD / diagonal (%) 8 (25.8)
LCX / obtuse marginal (%) 6 (19.4)
RCA bifurcation (%) 1 (3.2)
CTO within the target bifurcation lesion 5 (16.1)
In the distal main vessel 4 (12.9)
In the side branch 1 (3.2)
Mean number of stents per patient 3.5±1.5
Mean total length of stents (mm) 64.1±32.6
Mean number of stents in the main vessel 1.5±0.8
Mean total length of stents 
in the main vessel (mm) 26.6±17.2
Mean number of stents in the side branch 1.1±0.4
Mean total length of stents 
in the side branch (mm) 18.3±7.6
DES implanted
Patients receiving SES (%) 10 (32.3)
Patients receiving PES (%) 20 (64.5)
Patients receiving BES (%) 1 (3.2)
Post-dilation with kissing balloons (%) 10 (32.3)
LMS: left main stem; LAD: left anterior descending; LCX: left circumflex;
RCA: right coronary artery; CTO: chronic total occlusion; DES, SES, PES,
BES: drug-, sirolimus, paclitaxel and biolimus- eluting stents respectively
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Late clinical outcome
Survival status was available in every patient for ≥ 12 months after
the initial PCI. The mean duration to the last follow-up or to death
was 853±553 days. Beyond 30 days, and within a year, there was
one more death (Table 4). Patient number 4 in Table 3 died on day
42 while recovering from the cerebral haemorrhage; this sudden
death was adjudicated as possible stent thrombosis. Three patients
required a target vessel revascularisation, but in only two were the
bifurcation V stents the targets for re-intervention. One patient
underwent repeat coronary angiography and subsequently
reintervention on day 160 upon referral for unstable angina. He had
a mid-LAD in-stent restenosis of 70% and a borderline 50% (by
visual estimation) ostial LAD restenosis, involving the V stents
implanted at the LAD-LCX bifurcation. The former lesion was
deemed the culprit lesion and was re-stented with a DES, whereas
the latter was also treated with a DES deployed in the distal left main
into the proximal LAD, fenestrated to the LCX; the procedure was
completed with a kissing balloon inflation. However, QCA analysis
ascribed a 43.9% stenosis to the ostial LAD restenotic lesion; thus
this was not adjudicated as an ischaemia-driven revascularisation.
Another patient with LAD-LCX V stents, had a re-study on day
189 revealing ostial LCX in-stent restenosis, which was treated with
balloon dilatation. No patients had reinfarction beyond 30 days
(Table 4). There were a further three deaths on days 450, 1058,
1206; the causes of death were respectively sepsis, end-stage heart
failure and sepsis and none was adjudicated as having stent
thrombosis (Table 3). The patient who died of heart failure was
actually the single ischaemia-driven TLR case. The overall rates of
mortality and other clinical endpoints within 30 days and 1-year
(cumulative) are summarily reported in Table 4. 
Quantitative angiographic analysis
Analysis of the baseline procedure could be done for 30 out of the
31 patients (Table 5); we could not retrieve post-procedure images
for one case. Out of the 30 baseline procedures analysed, there
were five cases involving a CTO, therefore the preprocedure RVD
and the bifurcation angulation parameters could not be determined.
In 11 cases, there was minimal stent protrusion into the PMV
(2.23±0.72 mm), however never exceeding 5 mm or the respective
RVD of the PMV; in three cases the protrusion was actually less than
half the respective RVD. Angiographic follow-up (at a period of
203±33 days) was available for 11 patients (35.5%); data are
presented in Table 6. Out of this group, eight patients underwent
routine control coronary angiography and presented no binary
angiographic restenosis of the target bifurcation lesion; out of the
three patients who were referred for anginal symptoms (two with
stable angina and one with unstable angina), one patient had binary
in-stent restenosis. Thus, this cohort exhibited a restenosis rate of
9.1% (1/11). The LLL in the DMV and SB was 0.17±0.53 mm and
Table 3. All-cause death: patient characteristics and procedural details.
Patient Gender/Age Index PCI Treated V stents Stent GP IIb/IIIa Kissing Stent thrombosis Time to Time to Remarks
indication vessels location type Inhibitor use balloon by ARC TLR/TVR, Death,
inflation definitions days days
1 M/64 yrs Unstable LCX, LCX- PES Yes Yes No No 11 Stroke on day 4, died
angina intermediate intermediate of hospital acquired 
pneumonia
2 F/63 yrs Unstable LAD, LCX LAD-LCX PES Yes Yes Probable No 11 Pulmonary embolism,
angina hence anti-coagulated. 
Sudden death preceded
by generalised convulsion
3 M/78 yrs ST elevation LAD, LCX LAD-LCX SES No No No No 14 Index PCI was rescue
myocardial procedure for cardiogenic
infarction shock. Died of heart failure
4 M/78yrs ST elevation LAD, LAD- PES No No Definite LAD stent 42 Cerebral haemorrhage
myocardial diagonal diagonal thrombosis on day 4; cessation of
infarction Day 5 aspirin and clopidogrel on
the same day; LAD and
LM stented on re-PCI
with moderate result
Sudden death during recovery
5 F/80yrs Unstable LAD, LCX, LCX-OM SES No No No No 450 Sepsis after amputation
angina OM
6 M/74yrs Unstable LAD, LCX LAD-LCX SES No No No Ostial LCX 1058 Ischaemia-driven TLR, 
angina restenosis day 189. Succumbed to
Day 189 end-stage heart failure
7 M/66yrs Stable angina LAD, LCX LAD-LCX SES Yes No No No 1206 Sepsis due to pneumonia
PCI: Percutaneous coronary intervention; TLR: Target lesion revascularisation; TVR: Target vessel revascularisation; ARC: Academic Research Consortium; LCX:
Left circumflex; LAD: Left anterior descending; OM: Obtuse Marginal branch; LM: Left Main coronary artery; SES/PES: sirolimus-/paclitaxel-eluting stents 
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Table 4. Clinical outcome over the follow-up period.
Within 30 days At one year (cumulative)
All-cause mortality 3 (9.7%) 4 (12.9%)
Cardiac mortality 2 (6.5%) 3 (9.7%)
Non-cardiovascular mortality 1 (3.2%) 1 (3.2%)
Non-fatal myocardial infarction 2 (6.5%) 2 (6.5%) 
Target lesion revascularisation 
(ischaemia driven) 2 (6.5%) 3 (9.7%)
Target vessel revascularisation 
(ischaemia driven) 2 (6.5%) 5 (16.1%)
MACE-Mortality or non-fatal ST 
elevation myocardial infarction 
or target vessel revascularisation 6 (19.4%) 9 (29.0%)
Device oriented composite-cardiac 
mortality or target vessel related 
myocardial infarction or target lesion 
revascularisation 4 (12.9%) 5 (16.1%)
Stent thrombosis according to Academic 
Research Consortium definitions Acute Subacute Late 
Definite 1 (3.2%) 1 (3.2%) 0 (0%)
Probable 0 (0%) 1 (3.2%) 0 (0%)
Possible 0 (0%) 0 (0%) 1 (3.2%)
MACE: Major Adverse Cardiac Events
Table 5. Angiographic parameters for the baseline procedure (n=30).
Pre Post P-value
Proximal main vessel
MLD (mm) 1.73±0.55 2.45±0.46 <0.01
RVD (mm) 2.69±0.92 2.90±0.65 0.73
%DS 26.2±16.0 13.8±6.8 <0.01
Distal main vessel
In segment
MLD (mm) 0.96±0.59 2.13±0.43 <0.01
RVD (mm)* 2.10±0.47 2.69±0.46 <0.01
%DS 54.8±25.9 19.5±10.1 <0.01
In stent
MLD (mm) 0.96±0.59 2.39±0.37 <0.01
RVD (mm)* 2.10±0.47 2.70±0.45 <0.01
%DS 54.8±25.9 11.0±7.9 <0.01
Side branch
In segment
MLD (mm) 0.99±0.41 1.91±0.47 <0.01
RVD (mm)** 2.04±0.49 2.41±0.44 <0.01
%DS 50.3±19.1 21.6±10.5 <0.01
In stent
MLD (mm) 0.99±0.41 2.10±0.43 <0.01
RVD (mm)** 2.04±0.49 2.45±0.44 <0.01
%DS 50.3±19.1 14.4±6.0 <0.01
Distal bifurcation 
angle (degrees) 60.7±21.0 51.1±18.3 0.01
MLD: minimal lumen diameter; RVD: reference vessel diameter; DS:
diameter stenosis. * 26 patients (4 pre-procedure chronic total occlusions).
** 29 patients (1 pre-procedure chronic total occlusion).
Table 6. Angiographic parameters from the patients having
angiographic follow-up (n=11).
Post Follow-up P-value
Proximal main vessel
MLD (mm) 2.56±0.48 2.29±0.38 0.09
RVD (mm) 3.03±0.53 2.85±0.36 0.16
%DS 15.9±7.1 19.7±8.2 0.42
LLL (mm) 0.27±0.44
BAR 0
Distal main vessel
In segment
MLD (mm) 2.24±0.46 2.07±0.44 0.35
RVD (mm) 2.74±0.51 2.65±0.41 0.37
%DS 1.6±1.0 23.0±9.5 <0.01
LLL (mm) 0.17±0.53
BAR 0
In stent
MLD (mm) 2.39±0.41 2.08±0.45 0.04
RVD (mm) 2.74±0.54 2.66±0.42 0.45
%DS 12.1±8.4 22.0±10.3 0.03
LLL (mm) 0.31±0.43
BAR 0
Side branch
In segment
MLD (mm) 1.96±0.46 1.78±0.49 0.33
RVD (mm) 2.42±0.49 2.44±0.59 0.65
%DS 19.0±7.4 27.1±14.0 0.11
LLL (mm) 0.18±0.60
BAR 0
In stent
MLD (mm) 2.12±0.55 1.83±0.49 0.16
RVD (mm) 2.46±0.50 2.46±0.55 0.79
%DS 14.8±5.9 25.9±14.5 0.04
LLL (mm) 0.29±0.57
BAR 1 (9.1%)
Distal bifurcation 
angle (degrees)  45.6±13.2 50.9±17.7 0.29
MLD: minimal lumen diameter; RVD: reference vessel diameter; DS:
diameter stenosis; LLL: late lumen loss; BAR: binary angiographic
restenosis
0.18±0.60 mm in-segment and 0.31±0.43 mm and 0.29±0.57 mm
in-stent respectively. Sixteen cases exhibited a Y anatomical
configuration regarding the bifurcation treated, whereas nine were
T-shaped; the distal bifurcation angle was smaller than 70 degrees
in the former and larger in the latter. 
Discussion
This paper reports a real-world experience on V stenting technique
using DES. The paucity of outcome data after V stenting reflects that
this technique is rarely performed9; the current series of 31 patients
were collected over nearly five years. A percentage of 13.7% has
been reported18 regarding the frequency of the type 4 bifurcation
lesion according to the ICPS classification system, which is the
equivalent of the 0,1,1 lesion in the Medina classification. Even if
this is per definition, the ideal lesion configuration for the
implementation of V stenting, similar techniques such as
Simultaneous Kissing Stents claim a great share of those
procedures, accounting for the rarity of V stenting.
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Many techniques have been described to treat bifurcations,
reflecting the lack of a perfect solution. Although the proposed
strategy would be stenting the main branch with provisional stenting
of the side branch, this would not apply in this setting; a bifurcation
lesion involving a large side branch with a long stenosis certainly
calls for a two-stent strategy. With the Crush technique, bench
studies revealed that stent deployment even after kissing balloon
inflation is often suboptimal and associated with malapposition4,19,
findings corroborated by intravascular ultrasound studies20. Stent
under-expansion could predispose to higher restenosis rate and
thrombotic risk21,22. Less data has accumulated for Culotte stenting
in the current DES era, but this technique has attracted renewed
attention23,24.
Early outcome
The admittedly less than desirable early outcome (MACE rate of
19.4%) should be interpreted in the context of unstable clinical
presentation, extensive coronary disease and a multitude of
aggravating factors. This series bears the highest rate (64.5%) of
acute coronary syndrome as the clinical presentation compared to
other relevant studies in the DES era (13.3-62.0%)2,3,6,7,24,25; moreover
the rates of multivessel disease (74.2%), multivessel intervention
(67.7%), intervention on additional major epicardial vessels beyond
the target vessels (38.7%) and the rate of left main stem stenting
(51.6%) rank high among the corresponding studies. Out of the three
deaths occurring within 30 days, none was clearly attributable to the
PCI itself, even though two of them were adjudicated as cardiac. One
was due to cardiogenic shock, not reversed by a rescue procedure
after failed thrombolysis, and the other one had to be adjudicated as
probable stent thrombosis, recent pulmonary embolism
notwithstanding; an autopsy was not performed. 
As to the two definite stent thrombosis cases, both of them
presented with ST elevation myocardial infarction; neither of them
was treated with glycoprotein IIb/IIIa inhibitors at index procedure,
most probably due to old age; cessation of both antiplatelet agents
in the second case was undoubtedly the major contributor to the
stent thrombosis within 24 hours. Interestingly, in these two cases,
stent protrusion by QCA was either trivial on non-existent. The
remaining case of myocardial infarction was related to the
concomitant intervention on the sub-totally occluded saphenous
vein graft. Applying the ARC recommended device-oriented
composite, the event rate substantially drops (12.9%), not adjusting
however for the aforementioned circumstances.
Late outcome
Contrary to the early outcome, event rates at one year excluding the
first 30 days, are close to the corresponding values reported in the
vast majority of the relevant literature. As a matter of fact,
cumulative 1-year TVR and TLR rates (16.1% and 9.7%
respectively) compare favourably to DES studies employing Crush
(11.0% TVR and 9.7% TLR at nine months)25, Culotte (11.1% TVR
and 8.9% TLR at nine months)24, T stenting (TVR and TLR 27.3%
at nine months)24, SKS (TLR 4.0-13.9%)5,6 and mixed cohorts (TLR
4.3-9.5 at six months)2,3,9. Equally amenable are the angiographic
features (low LLL in both branches and low binary restenosis rate),
despite the increased average number of stents and total stent
length implanted. Of note, in the RESEARCH and T-SEARCH
registries10,11, the average stent length was 38.7±23.7 mm and
42.9±31.2 mm respectively. The Nordic Bifurcation Study stands
out due to its strikingly low rates of events (3.4% MACE and 1.0%
TLR at six months in the two stent arm); however, this is offset by
leaving the much higher angiographic restenosis (16.0%)
unattended26. Over an average of 853 days of follow-up, there was
only one case of possible late stent thrombosis.
Unlike the Crush or Culotte techniques, the V stenting technique
does not deform conventional tubular stents. It allows the operator
to preserve access to both branches throughout the procedure,
without the need to rewire. However, this has to be traded against
the possibility of using a smaller guiding catheter, since a guiding
catheter of at least 7 Fr for the Taxus stent or even 8 Fr for the
Cypher stent, is required for simultaneous stent deployment12.
Moreover, great precision is required for accurate positioning of the
stents, in order to avoid geographic miss or protrusion into the PMV.
When the PMV is also involved (i.e. Medina classification 1,1,1),
usage of dedicated devices such as the Devax stent to deal with the
proximal lesion in the main vessel combined with V stenting of the
bifurcation should provide full coverage of the lesion with minimal
overlapping of the stent struts. The recent multicentre Axxess Plus
trial27 on 139 patients receiving the Axxess (Devax) stent, reported
satisfactory outcome at 6-months with a TLR rate of 7.5% and
angiographic in-stent LLL of 0.09 mm. However, only 77.7% of
patients were regarded as having “true” bifurcation lesions involving
both the PMV and SB and only 41.9% had stenting of both DMV
and SB27. Future studies with V stenting, plus a proximal dedicated
device for more challenging bifurcation lesions, are eagerly awaited.
Limitations
An obvious limitation to this analysis is the small number of patients
involved. This precluded us from performing any kind of subgroup
analysis; we could not compare events in the DMV and the SB or
study the influence of variables, such as the type of DES, the clinical
indication, the number of stents and total stented length, the
location of the bifurcation lesion and last, but not least, the impact
of angulation on the short- and long-term outcome. Even more
limited was the rate of angiographic follow-up (35.5%), which was
not routinely acquired. Regrettably, IVUS images were not available;
in this setting they would have verified complete and accurate lesion
coverage and adequate stent struts apposition. Finally, this is a
retrospective, single-centre study, with no control arm. This does
not allow us to favour or discredit the technique at hand.
Conclusions
We provided long-term outcome data on an unselected cohort who
had V stenting of de novo bifurcation lesions with drug-eluting
stents. It is a technique dedicated to a distinct anatomic dataset.
Early outcome looks less than encouraging, but on closer scrutiny
could appear circumstantial and endpoint-dependent; late
outcome, on the other hand, stands in accord with competitive
techniques and merits further evaluation.
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Chapter 9      
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Aong-Term Clinical Results Following Stenting of
he Left Main Stem
nsights From RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam
ardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology
ospital) Registries
oshinobu Onuma, MD,* Chrysafios Girasis, MD,* Nicolo Piazza, MD,*
ector M. Garcia-Garcia, MD,* Neville Kukreja, MA,* Scot Garg, MD,*
annet Eindhoven, MSC,* Jin-Ming Cheng, MSC,* Marco Valgimigli, MD, PHD,†
on van Domburg, PHD,* Patrick W. Serruys, MD, PHD,* on behalf of Interventional
ardiologists at Thoraxcenter 2000–2005
otterdam, the Netherlands; and Ferrara, Italy
bjectives We investigated the long-term clinical outcomes and independent predictors of major
ardiac events in unprotected left main coronary artery disease (ULMCA) patients treated by percu-
aneous coronary intervention with drug-eluting stent (DES).
ackground There is limited information on long-term (3 years) outcomes after DES implantation
or ULMCA. Furthermore, bifurcation angle and SYNTAX (Synergy between Percutaneous Coronary
ntervention with Taxus and Cardiac Surgery) score are emerging as parameters for patient risk strat-
ﬁcation, and their prognostic implications have still to be elucidated.
ethods One hundred forty-eight patients with ULMCA treated with DES were analyzed and com-
ared with a historical cohort of 79 patients who received bare-metal stents for the treatment of
LMCA. Patient-oriented composite end point was deﬁned as the occurrence of all-cause death, any
yocardial infarction, or any revascularization.
esults The 4-year cumulative incidence of all-cause death, any myocardial infarction, any revascular-
zation, and patient-oriented composite were 35.6%, 3.8%, 25.2%, and 54.4%, respectively. These end
oints had relatively increased from 1 year to 4 years by ∆70%, ∆5%, ∆50%, and ∆68%, respectively.
hen compared with a historical cohort who received bare-metal stents for ULMCA treatment, landmark
nalysis performed after the ﬁrst 2 years of follow-up demonstrated that the DES cohort had signiﬁ-
antly higher patient-oriented composite end point over the last 2 years of follow-up (26% vs. 8%,
 0.02). EuroSCORE (European System for Cardiac Operative Risk Evaluation), cardiogenic shock,
nd SYNTAX score were identiﬁed as independent predictors for the 4-year patient-oriented com-
osite, whereas bifurcation angle was not.
onclusions Late increase in patient-oriented composite end points after DES implantation for ULMCA
arrants careful and long-term follow-up. SYNTAX score and EuroSCORE appear to have a signiﬁcant
rognostic value in long-term patient risk. (J Am Coll Cardiol Intv 2010;3:584–94) © 2010 by the
merican College of Cardiology Foundation107
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phe prevalence of left main disease in patients with coro-
ary artery atherosclerosis varies from 2.5% to 10% (1).
oronary artery bypass graft (CABG) remains the treat-
ent of choice in patients with unprotected left main
oronary artery disease (ULMCA) (2,3). Although percu-
aneous coronary intervention (PCI) using bare-metal stent
BMS) in patients having 2- or 3-vessel disease is associated
ith no significant difference in long-term mortality com-
ared with CABG, restenosis and need for repeat revascu-
arization remain major limitations of this mode of revas-
See page 642
ularization. These latter limitations have precluded the
idespread use of PCI, not only in multivessel disease, but
lso in LM disease (4). Reduction of restenosis with
rug-eluting stents (DES), however, has raised the possi-
ility of their use for multivessel treatment as well as LM
reatment. So far, several registries and randomized trials
ave investigated the short- and mid-term clinical outcomes
f PCI using DES for ULMCA treatment (5–14), but little
s known about its long-term safety and efficacy beyond 3
ears (15). In addition, the rate of potentially fatal conse-
uences of stent thrombosis or in-stent restenosis in this
atient subset has not fully been investigated (16,17).
Several clinical and angiographic parameters for risk
tratification after PCI are emerging. Recently, Euro-
CORE (European System for Cardiac Operative Risk
valuation), a typically surgical risk stratification score, has
een applied to the PCI population (18). As angiographic
nalysis, the angle between bifurcated branches has been
ecognized as a significant prognostic factor for immediate
rocedural outcomes as well as for intermediate-term out-
omes (19–21). In addition, a comprehensive, angiographic
coring system, the SYNTAX (Synergy between Percutaneous
oronary Intervention with Taxus and Cardiac Surgery) score
22,23) based on morphology and location of coronary artery
tenoses in the coronary tree has been proven to predict clinical
utcomes in high-risk patients (9,24,25).
The main aim of this study was to report the long-term
linical outcomes of patients receiving DES for unprotected
M lesions in a daily practice of a tertiary medical center. In
ddition, we assessed the prognostic value of recently
merging predictors of adverse outcomes for PCI treatment
f multivessel disease and ULMCA, such as EuroSCORE,
he bifurcation angle, and SYNTAX score.
ethods
tudy design and patient population. Between April 2002
nd December 31, 2005, 210 consecutive patients under-
ent PCI for LM stenting (7,8). Sixty-two patients with a
istory of CABG were not retained in this analysis. The
emaining 148 patients are the subject of the present108nvestigation. On April 16, 2002, our institution adopted
he use of sirolimus-eluting stents (Cypher, Cordis, War-
en, New Jersey) as the default strategy for all coronary
nterventions, as part of RESEARCH (Rapamycin-Eluting
tent Evaluated at Rotterdam Cardiology Hospital) registry
26). On February 16, 2003, sirolimus-eluting stents were
eplaced by paclitaxel-eluting stents (Taxus Express2, Bos-
on Scientific, Natick, Massachusetts) as the default stent, as
art of the T-SEARCH (Taxus-Stent Evaluated at Rotter-
am Cardiology Hospital) registry (27). For evaluation of
ong-term outcomes, this DES group was compared with a
istorical cohort who received BMS in the unprotected LM
runk before April 2002 (n  79).
In this study, the decision to intervene in the patients with
CI was based on a consensus
eached during a multidisciplinary
edical surgical conference (the
o-called heart-team conference)
nvolving surgeon, interventional-
st, and referring physician (28),
xcept for patients who presented
ith ST-segment elevation myo-
ardial infarction (STEMI), con-
idering the emergent character of
he clinical presentation. All pro-
edures were performed according
o standard clinical guidelines at
he time. All patients were pre-
reated with 300 mg of clopi-
ogrel. At least 1 month of clopi-
ogrel treatment (75 mg/day) was
ecommended for patients treated
ith BMS. Clopidogrel was pre-
cribed for at least 3 months for
atients with DES. Life-long as-
irin therapy was recommended
n all patients.
CA analysis. To assess the bi-
urcation angle between the left
nterior descending and left cir-
umflex arteries, 3-dimensional quantitative coronary angiog-
aphy (QCA) analyses were performed by 2 observers blinded
o the patient data and clinical outcomes. A validated program
as used to reconstruct 3-dimensional images from 2 different
rojections at least 30° apart from each other (CardiOp-B
ystem version 2.1.0.151, Paieon Medical Ltd., Park Afek,
srael) (29–31). Separate 3-dimensional angiographic images
ere constructed for systolic and diastolic phases. The bifur-
ation angle was defined as the angle between the left anterior
escending and left circumflex arteries (32). In cases where the
eparate projections were not available, 2-dimensional bifurca-
ion software (CAAS version 5.6, PieMedical, Maastricht, the
etherlands) was used to calculate bifurcation angle (33). In
rimary PCI cases where TIMI (Thrombolysis In Myocardial
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
LM  left main
MACCE  major adverse
cerebrovascular cardiac
event
MACE  major adverse
cardiac events
PCI  percutaneous
coronary intervention
QCA  quantitative coronary
angiography
STEMI  ST-segment
elevation myocardial
infarction
TVR  target vessel
revascularization
ULMCA  unprotected left
main coronary artery disease
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pnfarction) flow grade was 0 or 1 pre-procedure, the cinean-
iography following the first balloon angioplasty was analyzed
or the determination of the angle.
YNTAX score. Two analysts blinded to patient characteris-
ics and clinical outcomes reviewed the angiograms to
alculate the SYNTAX score (22,23). In case of disagree-
ent, the opinion of a third observer was obtained and the
nal decision was made by consensus. Each coronary lesion
roducing 50% luminal obstruction in vessels 1.5 mm
as separately scored and added to provide the overall
YNTAX score. The SYNTAX score was calculated using
edicated software that integrates the following: 1) the
umber of lesions with their specific weighting factors based
n the amount of myocardium distal to the lesion according
o the score of Leaman et al. (34); and 2) the morphologic
eatures of each single lesion (35,36). The reproducibility of
he SYNTAX score was recently reported (22).
linical follow-up. Survival data for all patients were ob-
ained from municipal civil registries on a yearly basis. A
uestionnaire was subsequently sent to all living patients
ith specific enquiries on rehospitalization and major ad-
erse cardiac events (MACE). As the principal regional
ardiac referral center, most repeat revascularization (either
ercutaneous or surgical) is normally performed at our
nstitution and recorded prospectively in our database. For
atients who suffered an adverse event at another center,
edical records or discharge letters from the other institu-
ions were systematically reviewed. General practitioners
nd referring physicians were contacted for additional in-
ormation if necessary. Causes of death were obtained from
edical records when they happened during hospitalization,
nd otherwise from the Central Bureau of Statistics, The
ague, the Netherlands (37,38). Causes of death were
lassified according to the International Classification of
iseases and Related Health Problems-10th Revision. For
he present analysis, death from ischemic heart disease (I-20
o I-25), sudden cardiac death (I-46), sudden death unde-
ned (R-96), or death from heart failure (I-50) were
onsidered to be cardiac. Death from cancer was defined as
ny death from malignant neoplasm (C-009 to C-97). All
he remaining deaths were classified as being due to other
auses, and no further distinction was made. In this study,
here was no mandatory angiographic follow-up.
nd point deﬁnitions. The primary end point was a patient-
riented composite defined as all-cause death or any myo-
ardial infarction (MI) or any revascularization (all surgical
nd percutaneous, target lesion, target vessel, and non–
arget vessel revascularization) according to the Academic
esearch Consortium definitions (39). The secondary end
oint was the device-oriented composite end point defined as
ardiac death,MI in the target vessel territory, or a target lesion
evascularization. In addition, each individual component end
oint was analyzed in a nonhierarchical way. Definite stenthrombosis was also considered as a separate secondary end
oint.
Myocardial infarction included periprocedural MI (diag-
osed by a rise in creatine kinase-myocardial band fraction
f 3 times the upper limit of normal), reinfarction (defined
s recurrence of symptoms together with ST-segment ele-
ation or new left bundle branch block and an increase in
ardiac enzymes following stable or decreasing values), or
pontaneous MI (diagnosed by any rise in creatine kinase-
yocardial band fraction above the upper limit of normal)
40). Target lesion revascularization was defined as a repeat
evascularization of in-stent or within 5 mm proximal or
istal to the stent implanted in the index procedure (41).
arget vessel revascularization (TVR) was defined as any
evascularization in the same epicardial vessel treated in the
ndex procedure. Definite stent thrombosis was defined as
IMI flow grade 0 or 1 or the presence of a flow-limiting
hrombus, accompanied by acute symptoms, irrespective of
hether there had been an intervening reintervention (42).
he timing of stent thrombosis was categorized as early
within 30 days after implantation), late (between 30 days
nd 1 year), or very late (more than 1 year) (39).
tatistical analysis. Continuous variables are presented as
ean  SD, whereas categorical variables are expressed as
ercentages. Comparisons among groups were performed by
he independent t test for continuous variables and Pearson
hi-square test for categorical variables. All statistical tests were
-tailed, and p value of 0.05 was considered as statistically
ignificant. The incidence of events over time was studied with
he use of the Kaplan-Meier method, whereas log-rank tests
ere applied to evaluate differences between the current cohort
nd the historical control. Patients lost to follow-up were
onsidered at risk until the date of last contact, at which point
hey were censored. Cox regression models were built to
lucidate independent predictors of clinical end points. Signif-
cant variables in univariate analysis (p  0.1) were selected to
ut in the multivariate model. The following pre-procedural
ariables were included in the initial univariate analysis: gender,
iabetes, current smoking habit, hypertension, hypercholester-
lemia, age, previous history of myocardial infarction or PCI,
YNTAX score, EuroSCORE, shock at entry, clinical pre-
entation, and bifurcation angle. Clinical presentation
STEMI, unstable angina or non-STEMI, and stable angina)
as coded as a categorical variable. Bifurcation angle was
artitioned according to tertiles (lowest tertile as a reference).
he results are presented as adjusted hazard ratios (HR) with
5% confidence intervals (CI). Statistical analysis was per-
ormed with SPSS version 16 for windows (SPSS Inc.,
hicago, Illinois).
esults
aseline and procedural characteristics. The baseline and
rocedural characteristics of the patients are shown in Table 1.109
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she mean age of the patients was 64.9 years old, 16.2% of
he patients had diabetes, and 33% had previous history of
I. Approximately one-quarter of patients presented with
TEMI, and 8% presented with severe hemodynamic com-
romise at entry. The average additive EuroSCORE and
YNTAX score was 4.26 and 39.4, respectively.
linical outcomes. Clinical follow-up was available in all
atients, with a median duration of follow-up of 1,473 days
interquartile range: 1,182 to 1,848 days) for patients alive at
Table 1. Baseline Characteristics
Curren
Demographics
Age, yrs
Men
Diabetes
Hypertension
Hypercholesterolemia
Family history of coronary artery disease
Current smoking
Previous PCI
Previous MI
Additive EuroSCORE
SYNTAX score
LVEF, %
Presentation
STEMI
Stable angina
Unstable angina/non-STEMI
Shock at entry
Pre-procedural quantitative angiographic analysis
Bifurcation angle in diastole, °
Bifurcation angle in systole, °
Minimal lumen diameter, mm
Reference vessel diameter, mm
Procedural characteristics
Number of implanted stents
Total stented length per patient
Average stent diameter
Clopidogrel duration in month
IVUS use
Stenting strategy
Provisional
Culotte
T-stenting
Crush stenting
Kissing technique
Post-procedural bifurcation angle
Bifurcation angle in diastole, °
Bifurcation angle in systole, °
Values are expressed as n (%) or mean SD.
BMS bare-metal stents; DES drug-eluting stents; EuroSCORE
ultrasound; LVEF left ventricular ejection fraction; MImyocardial
elevation myocardial infarction; SYNTAX Synergy Between Percutan110ollow-up. Hierarchical count of adverse events is shown in
able 2. Patient-oriented composite increases from 32.4%
t 1 year to 51.4% at 4 years (58%), which was mainly driven
y an increase in all-cause mortality from 19.6% at 1 year to
3.1% at 4 years, a relative increase of 68%. There was 1 case
f definite late stent thrombosis at 1 year, and there was 1 case
f definite very late stent thrombosis at 4 years.
Kaplan-Meier estimates of clinical end points are pre-
ented in Figures 1A to 1C. At 4 years, the cumulative
ort With DES
148)
Historical Cohort With BMS
(n  79) p Value
12.1 65.1 11.2 0.96
(73) 49 (62) 0.10
16.2) 15 (19) 0.59
41) 34 (43) 0.89
54) 34 (43) 0.13
32) 15 (19) 0.04
18) 14 (18) 1.00
22) 25 (32) 0.11
33) 24 (30) 0.77
3.54 4.37 3.57 0.82
22.9 36.8 24.6 0.96
13.6 41.8 16.9 0.48
24.3) 22 (27.8) 0.64
40.5) 30 (33.3) 0.78
35.1) 27 (34.2) 1.00
8.8) 6 (7.6) 1.00
25.5 89.5 25.3 0.29
26.6 81.42 23.8 0.42
0.32 1.08 0.27 0.92
2.49 3.31 0.36 0.69
0.37 2.85 0.47 0.0001
40.4 42.4 28.4 0.0001
0.37 3.52 0.47 0.0001
5.32 5.27 4.86 0.01
32) 34 (43) 0.15
77) 70 (89) 0.07
9) 1 (1)
10) 8 (10)
3) 0
1) 0
24.8 84.2 25.9 0.83
23.7 76.7 21.2 0.38
an System for Cardiac Operative Risk Evaluation; IVUS intravascular
on; PCI percutaneous coronary intervention; STEMI ST-segment
oronary Intervention with Taxus and Cardiac Surgery.t Coh
(n 
64.9
108
24 (
61 (
80 (
47 (
27 (
32 (
49 (
4.26
39.4
45.3
36 (
60 (
52 (
13 (
94.1
84.9
1.09
3.35
3.08
59.9
3.08
7.53
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(ncidence of all-cause death, MI, any revascularization, and
atient-oriented composite were 35.6% (95% CI: 27.3% to
3.8%), 3.8% (95% CI: 0.5% to 7.1%), 25.2% (95% CI:
6.9% to 33.6%), and 54.4% (95% CI: 45.8% to 63.1%),
espectively. Cardiac mortality, all-cause mortality, and any
evascularization rate relatively increased from 1 year to 4
ears by 68%, 82%, and 49%, respectively, whereas the
hanges in target lesion revascularization and MI was less
ncreased from 1 year to 4 years (5% and 28%, respec-
ively) (Figs. 1A and 1B). In summary, the device-oriented
nd patient-oriented composite increased from 1 year to 4
ears by 56% and 68%, respectively (Fig. 1C). If strati-
ed by the presentation with STEMI versus others (non-
TEMI, unstable angina, and stable angina), the patient-
riented composite was higher in STEMI patients (68.6%)
han the others (49%, p  0.001), also the device-oriented
omposite, all-cause death, and cardiac death were higher in
he STEMI patients than the others (53% vs. 30%, p 0001;
5% vs. 29%, p  0.001; 48% vs. 16%, p  0.001) (Fig. 2A).
ith stratification according to the tertiles of EuroSCORE
2, 2 and 5, 5), the patient-oriented composite was
igher in the high tertile (76.8%) than in the low (41.2%,
og-rank p  0.001) or intermediate tertiles (51.8%, log-rank
 0.001) (Fig. 2B). If stratified according to type of DES
Cypher and Taxus), the patient-oriented composite was
Table 2. Hierarchical Count of Patient-Oriented Composite After
DES Implantation Compared With the Historical Cohort With BMS
Current Cohort
With DES
(n  148)
Historical Cohort
With BMS
(n  79) p Value
1 yr
All-cause death 29 (19.6) 23 (29.1) 0.14
Any MI 2 (1.4) 1 (1.3) 1.00
Any revascularization 17 (11.5) 10 (12.7) 1.00
Patient-oriented composite 48 (32.4) 34 (43) 0.15
2 yrs
All-cause death 35 (23.6) 27 (34.2) 0.11
Any MI 3 (2.0) 1 (1.3) 1.00
Any revascularization 19 (12.8) 11 (13.9) 0.84
Patient-oriented composite 57 (38.5) 39 (49.4) 0.12
3 yrs
All-cause death 41 (27.7) 29 (36.7) 0.18
Any MI 3 (2.0) 1 (1.3) 1.00
Any revascularization 23 (15.5) 11 (13.9) 0.85
Patient-oriented composite 67 (45.3) 41 (51.9) 0.4
4 yrs
All-cause death 49 (33.1) 30 (38) 0.47
Any MI 3 (2.0) 1 (1.3) 1.00
Any revascularization 24 (16.2) 11 (13.9) 0.7
Patient-oriented composite 76 (51.4) 42 (53.2) 0.9
Event rates were calculated as number of events divided by total number of patients and
therefore differ from those in the figures, where event rates were calculated by Kaplan-Meier
methods. In this table, comparison was made with the chi-square or Fisher exact test.
Abbreviations as in Table 1.50
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Figure 1. Kaplan-Meier Estimates After Implantation of DES
(A) Kaplan-Meier estimates demonstrate all-cause mortality (black line) and
cardiac mortality (red line). (B) Kaplan-Meier estimates present the end points
of any myocardial infarction (red line), target lesion revascularization (blue
line), target vessel revascularization (green), and any revascularization includ-
ing target and non–target vessel revascularization (black line). (C) Kaplan-
Meier estimates show the composite end point (red line) of cardiac mortality,
myocardial infarction in the stented vessel territory, or target lesion revascular-
ization and the composite end point (black line) of all-cause mortality, any
myocardial infarction, or any revascularization. DES  drug-eluting stent.111
Figure 2. Kaplan-Meier Estimates After Implantation of DES With Stratification of Subgroups
(A) All-cause mortality and (B) patient-oriented composite end point (all-cause mortality, any myocardial infarction [MI]), or any revascularization) according to a
presentation of ST-segment elevation myocardial infarction or the others (stable angina, non–ST-segment elevation myocardial infarction, or unstable angina).
Patient-oriented composite end point stratiﬁed by (C) tertile division of EuroSCORE (European System for Cardiac Operative Risk Evaluation) with cutoff values of
2 and 5 and (D) tertiles of SYNTAX (Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score of the current cohort (cutoff
values of 27 and 44). (E) The patient-oriented composite end points were classiﬁed according to tertiles of bifurcation angle (BA) between the left anterior
descending and circumﬂex arteries (cutoff values of 67 and 91.7). Abbreviations as in Figure 1.112
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i3.8% in Cypher and 54.8% in paclitaxel-eluting stent (p 
.83), whereas the all-cause mortality was 30.8% versus 36.5%,
espectively (p  0.56).
omparison with historical cohort. Patient demographics in
he historical control (n  79) were similar to the current
ohort except for a lower frequency of family history of
oronary artery disease (32% vs. 19%, p 0.04), reflecting that
he changes in clinical practice, number of implanted stents,
tent length, stent diameter, and clopidogrel duration are
igher in the current cohort than in the historical control
roup.
Figure 3 shows the Kaplan-Meier estimates of all-cause
ortality and the patient-oriented composite end point of
he current cohort with DES and the historical control with
MS. At 1 year, the rate of all-cause death (current cohort
9.6% vs. historical cohort 29.1%) and patient-oriented
omposite (32.4% vs. 43.0%) was lower in the current
ohort than in the historical cohort (Figs. 3A and 3B). At 4
ears the events rate, however, became comparable between
he 2 groups (all-cause mortality: 38.0 vs. 35.6%, p  0.48;
atient-oriented composite: 54.4 vs. 53.2%, p  0.64) as a
esult from a late increase of events in the current cohort.
aplan-Meier estimate before 2 years yielded a numerically
igher patient-oriented composite end point in the histor-
cal cohort (log-rank p  0.1), whereas landmark analysis
Fig. 3B) after the second year demonstrated a significantly
igher event rate in the current cohort than the historical
ohort (log-rank p  0.02).
YNTAX score. In the current cohort, the SYNTAX score
anged from 7 to 104 with median of 33.0. If the SYNTAX
core is divided into tertiles, the cutoff values were 27.0 and
4.0. The Kaplan-Meier curves of device-oriented compos-
te stratified by these tertiles of SYNTAX score are presented
n Figure 2C. The 4-year event rates were 46.2%, 55.1%, and
9.6% in low, intermediate, and high tertile groups, respec-
ively. High tertile group demonstrated significantly higher
vent rates than intermediate tertile (log-rank p  0.03) and
ow tertile (log-rank p  0.005) groups did.
hree-dimensional QCA analysis. Three-dimensional QCA
nalysis was feasible in only 50.7% of patients due to the
navailability of 2 separate angiographic views of more than
0° that is a prerequisite for 3-dimensional QCA; in the
emaining patients, 2-dimensional QCA was performed.
he results are shown in Table 1. In the patient receiving
ES, the Kaplan-Meier curves of patient-oriented compos-
te were separated according to the tertiles of systolic
ifurcation angle (high 91.7, intermediate 91.7 and
67, low 67) as shown in Figure 2E. High tertile group
emonstrated higher patient-oriented composite at 4 years
66.3%) than the intermediate (51.0%) and the low (45.2%)
roups did (log-rank high vs. low: p  0.04; high vs.
ntermediate: p  0.09).
redictor of adverse events. Table 3 shows the results of the
nivariate and multivariate analyses to identify the predic-ors for all-cause mortality and for patient-oriented com-
osite. Bifurcation angle did not remain as a significant
redictor of either all-cause mortality or patient-oriented
nd point in the multivariate analysis.
At 1 year, multivariate analysis demonstrated that Euro-
CORE, age, shock at entry, and SYNTAX score were
ndependent predictors for all-cause mortality and patient-
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Figure 3. Kaplan-Meier Estimates of DES and BMS Cohorts
Kaplan-Meier estimates of the current cohort treated with drug-eluting
stent (red line) or historical cohort treated with bare-metal stent (black
line). All-cause mortality is demonstrated in (A), whereas (B) demonstrates
patient-oriented composite end point (all-cause mortality, any myocardial
infarction, or any revascularization) with a landmark analysis more than 2
years after implantation. Dotted lines  95% conﬁdence interval. BMS 
bare-metal stent(s); other abbreviations as in Figure 1.113
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ariented composite. At 4 years, in the final multivariate
odels, age, shock at entry, the SYNTAX score and
uroSCORE remained as independent predictors for all-
ause mortality, whereas EuroSCORE, shock at entry, and
YNTAX score were identified as independent predictors
or patient-oriented composite.
iscussion
he main findings of the current study are the following:
) At 4-year follow-up after DES implantation in
LMCA, patient-oriented composite end point was 51.4%
ith a 58% relative increase of events from 1 year to 4 years.
) A landmark analysis of the last 2 years of follow-up
ndicated a higher composite end point for the current
ohort with DES when compared with the historical cohort
ith BMS (25% vs. 8%, p  0.02). 3) EuroSCORE and
YNTAX score were independent predictors for both
ll-cause mortality and the patient-oriented composite end
oint up to 4 years, whereas pre-procedural bifurcation
ngle between the left circumflex and left anterior descend-
ng arteries was not.
According to the current guidelines of the European
ociety of Cardiology and the American Heart Association
nd American College of Cardiology guidelines (40,43), the
resence of a stenosis in the LMCA is a class IIB or III
ndication for PCI unless the patient is not eligible for
ABG in presence of extreme comorbidities and STEMI.
n the recent U.S. criteria for appropriateness of revas-
ularization, percutaneous treatment of LM disease is
Table 3. Univariate and Multivariate Analysis for Predictors of All-Cause M
in the Left Main Trunk
All-Cause Mortality
Univariate
Hazard Ratio (95% CI) p Value
Multivariate
Hazard Ratio (95%
1-year outcome
EuroSCORE 1.26 (1.17–1.36) 0.001 1.24 (1.11–1.39)
Presentation of STEMI* 6.77 (3.56–18.66) 0.001
Age 1.06 (1.02–1.09) 0.003 1.05 (1.01–1.10)
Shock at entry 8.56 (3.83–19.1) 0.001 4.21 (1.50–1.82)
SYNTAX score† 1.35 (1.17–1.56) 0.001 1.23 (1.06–1.42)
Hypercholesterolemia 0.33 (0.15–0.73) 0.006
Hypertension 0.41 (0.18–0.96) 0.04 0.34 (0.13–0.88)
4-year outcome
EuroSCORE 1.19 (1.12–1.26) 0.001 1.13 (1.03–1.24)
Presentation of STEMI* 4.38 (2.08–9.23) 0.001
Age 1.05 (1.03–1.08) 0.001 1.04 (1.01–1.08)
Shock at entry 8.26 (4.09–16.68) 0.001 5.46 (2.35–12.69
SYNTAX score† 1.27 (1.13–1.42) 0.001 1.15 (1.02–1.30)
High bifurcation angle‡
Univariate or multivariate hazard ratios were calculated by Cox regression models.
*Stable angina used as a reference. †Each 10-point increase of SYNTAX score. ‡Low tertile bifurcat
Abbreviations as in Table 1.114onsidered “inappropriate” (2). In European daily prac-
ice, however, 4.6% of patients treated in the catheter-
zation lab have LM stenosis, and 58% of those are
reated by percutaneous means (44).
Up to now, 2 randomized trials have been performed to
ompare CABG and PCI using DES in patients undergo-
ng treatment for LM disease. In the LE MANS (Left
ain Coronary Artery Stenting) study by Buszman et al. (10),
CI was associated with a lower 30-day risk of major
dverse cerebrovascular cardiac event (MACCE) (p 0.03)
nd had comparable 1-year mortality or MACCE to sur-
ery. In the more recent SYNTAX trial (9), which random-
zed 1,800 patients with 3-vessel or LM coronary artery
isease to either CABG or PCI, the use of PCI at 1 year was
ssociated with safety end points (death, cerebrovascular
ccident, and MI) but a higher rate of MACCE than
ABG, due to a significantly higher rate of revasculariza-
ion. However, in the subgroup of patients with LM disease
ith an average SYNTAX score of 28.1, PCI and CABG
ere associated with similar MACCE rates at 1 year (PCI
5.8% vs. CABG 13.6%). In the DES cohort of the present
tudy, the 1-year all-cause mortality and revascularization
ate of patients treated with DES (19.6% and 16.9%,
espectively) were higher than rates reported in the LM
ubgroup of the randomized cohort in the SYNTAX trial
4.2% and 12.0%, respectively). This is likely due to the
igh-risk nature of our all-comers registry (e.g., including
4% STEMI patients with a mean EuroSCORE of 4.26
nd an average SYNTAX score of 39.4).
y and Patient-Oriented Composite After DES Implantation
Patient-Oriented Composite
p Value
Univariate
Hazard Ratio (95% CI) p Value
Multivariate
Hazard Ratio (95% CI) p Value
0.001 1.19 (1.12–1.26) 0.001 1.13 (1.03–1.24) 0.009
4.38 (2.08–9.23) 0.001
0.03 1.05 (1.03–1.08) 0.001 1.04 (1.01–1.08) 0.009
0.006 8.26 (4.09–16.68) 0.001 5.46 (2.35–12.69) 0.001
0.006 1.27 (1.13–1.42) 0.001 1.15 (1.02–1.30) 0.03
0.43 (0.24–0.76) 0.004
0.03 0.45 (0.24–0.84) 0.01
0.009 1.16 (1.09–1.24) 0.001 1.09 (1.02–1.16) 0.02
3.42 (1.69–6.94) 0.001
0.009 1.04 (1.01–1.070) 0.004
0.001 4.61 (2.21–6.61) 0.001 2.74 (1.30–5.80) 0.008
0.03 1.22 (1.08–1.38) 0.001 1.12 (1.01–1.24) 0.4
1.99 (0.93–4.26) 0.075
le used as a reference.ortalit
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aIn this analysis, we selected a patient-oriented composite
nd point as a primary end point, because it represents the
ost critical clinical approach for a population undergoing
new form of treatment. The Academic Research Consor-
ium defined 2 methodological approaches to report clinical
ollow-up: 1) the device-oriented composite end point; and
) the patient-oriented composite end point. The device-
riented approach put the accent on the efficiency and
fficacy of a new device, therefore, focusing on the cardiac
eath, MI, and reintervention related to the device. The
atient-oriented end point is a follow-up, which specifically
onsiders the welfare of the patient, and includes all-cause
eath, any MI, and any revascularization.
In the current analysis, we entered only the pre-
rocedural parameters in the multivariate analysis and ex-
luded the procedural variables such as angulation after
tenting, technique of stenting, number of stent, length of
tent, and so forth, because they are factors reflecting the
reatment modalities rather than the anticipated prognosis
f the treatment. Parameters describing lesion characteris-
ics were also excluded because they were incorporated in
he SYNTAX score: for example, Medina classification,
hronic total occlusion, American College of Cardiology/
merican Heart Association lesion classification (45).
Long-term outcomes after PCI in the LM population are
imited. Park et al. (46) reported the 3-year safety composite
ate (death, Q-wave MI, or stroke) of 9.7% with TVR rate
f 12.6%. Vaquerizo et al. (12) demonstrated the device-
riented composite end point at 2 years of 12.6% after
CLMA stenting with paclitaxel-eluting stents in 291
atients from multicenter registry. In these registries, the
atients with acute MI or cardiogenic shock were excluded;
hereas in our registry, such patients were included and had
negative impact on clinical outcomes. Also, frequent use of
ntravascular ultrasound might contribute the relatively
ower mortality in the Korean registry than in our European
egistry (46). In one of largest “all-comer” DELFT (Drug-
luting Stent for Left Main) registries exclusively using
ES in ULMCA with 3-year complete follow-up, Meliga
t al. (15) demonstrated 3-year MACE rate (a composite of
ardiac mortality, MI, and TVR) of 26.5%, cardiac mortal-
ty of 9.2%, and TVR of 14.2%. If the same composite
efinition were applied to the present study, the 3-year
ACE rate in our study (26.0%) would be similar to the
ELFT registry (26.5%). Wood et al. (47) reported a
ong-term outcome of 100 patients with high surgical risk
fter PCI. All-cause mortality at 28 months was 21%;
vent-free survival was around 65% at 27 months (47).
In the current study, the baseline patient demographics
re comparable between the current and the historical
ohorts. Although the anatomical complexity reflected by
YNTAX score was comparable between the 2 cohorts (the
urrent cohort 39.4 vs. the historical control 36.8, p 0.96),
he cohort with DES was more aggressively treated than theistorical cohort with BMS, as indicated by a higher
ncidence of bifurcation stenting (48% vs. 57%, p  0.04),
y a larger number of stents implanted (2.85  0.47 vs.
.08  0.37), and by on average a longer stented length
42.4  28.4 mm vs. 59.9  40.4 mm).
The source of our concerns is the increase of the patient-
riented composite in the DES group between 2 and 4
ears, which was significantly higher than in the historical
ohort of BMS, and the long-term safety of DES in the
reatment of patients with ULMCA remains an unanswered
uestion. One possible explanation for unfavorable
ollow-up could be the occurrence of occult stent thrombo-
is. Occlusion of the LM trunk with thrombus is likely to be
ethal. Thus, patients can present with sudden and/or
ut-of-hospital death rather than with angiographically
roven stent thrombosis. The very late stent thrombosis
resenting with out-of-hospital death, however, can be
ndiagnosed and under-reported. The cause of death was
btained from the civil registry, and it is up to the general
ractitioners to classify the cause of mortality according to
nternational Classification of Diseases and Related Health
roblems-10th Revision unless the patient passed away in
he hospital. Therefore, no attempt was made to impute
eath to possible or probable stent thrombosis.
In the large multicenter registry (n  731) by Chieffo et
l. (17), the cumulative incidence of stent thrombosis at 29.5
onths after LM stenting was reported to be 0.95% for
efinite stent thrombosis and 2.7% for possible stent throm-
osis. In DELFT registry (15) (n  358) at 3-year
ollow-up, the incidence of definite, probable, and possible
tent thrombosis were 0.6%, 1.1%, and 4.4%. In ISAR-
EFT MAIN (Intracoronary Stenting and Angiographic
esults: Drug-Eluting Stents for Unprotected Coronary
eft Main Lesions) trial (48) (n  607), the 2-year rate of
efinite or probable stent thrombosis was about 0.5% to
.0%. In a series of high surgical risk patients, Wood et al. (47)
eported a 5% possible stent thrombosis presenting as
udden death. Taking into account the late increase in
ortality shown in our study, follow-up extending beyond 3
ears is warranted for patients receiving DES in the setting
f ULMCA.
The bifurcation angle has been shown to relate not only
o the difficulty level of the procedure but is also associated
ith intermediate outcomes. Dzavik et al. (19) reported that
bifurcation angle 50 was an independent predictor of
ACE at 1 year after bifurcation crush stenting in 133
atients. In 132 patients receiving Cypher stents in bifur-
ations excluding LM lesions, Adriaenssens et al. (49)
eported that increasing bifurcation angles is an indepen-
ent predictor of binary restenosis (HR: 1.53 [95% CI: 1.04
o 2.23] per 10° increase in angulation) after culotte stent-
ng. The worse outcomes in high-angulated bifurcation
esions might be the result of the adjacent presence of low
nd high shear stress found in bifurcation lesions. High115
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1hear stress possibly stimulates platelet activation and ag-
regation, and low shear stress might enhance deposition of
latelets. This mechanism can be potentially exaggerated in
igher bifurcation angles. Furthermore, when bifurcation
tenting is performed in high-angle lesions, the stent will
ikely not appose against the wall of bifurcation (50),
specially in the ostium of the left circumflex artery (20). In
he present study, however, we observed that the bifurcation
ngle between the left anterior descending and left circum-
ex arteries was not an independent predictor for adverse
vents, although there is a weak statistical association with
-year composite end points in the univariate analysis (HR:
.99 [95% CI: 0.93 to 4.26], p  0.07).
tudy limitations. This study has several limitations. This is
single center, observational study that included a modest
umber of patients. The results of this landmark analysis
reporting a higher event rate in patients treated with DES
ompared with BMS after 2 years) would need to be
onfirmed in a larger study. In addition, the low 1-year
ortality rate compelled us to include only 2 or 3 indepen-
ent variables in the Cox regression model, resulting in
verfitting of the model. Confounding factors, such as
rocedural variables, might have been overlooked. Although
aseline characteristics were similar in the historical BMS
nd current DES groups, some procedural variables were in
act different and as a result might have influenced
utcomes.
onclusions
ur study reports a late increase in adverse events up to 4
ears, which warrants careful follow-up of the patient
eceiving DES in the LM trunk. The SYNTAX score and
uroSCORE can be considered important components of
isk stratification.
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3-Dimensional Bifurcation Angle Analysis
in Patients With Left Main Disease
A Substudy of the SYNTAX Trial (SYNergy Between Percutaneous
Coronary Intervention With TAXus and Cardiac Surgery)
Chrysaﬁos Girasis, MD,* Patrick W. Serruys, MD, PHD,* Yoshinobu Onuma, MD,*
Antonio Colombo, MD,† David R. Holmes, JR, MD,‡ Ted E. Feldman, MD,§
Eric J. Bass, BA, Katrin Leadley, MD, Keith D. Dawkins, MD,
Marie-Claude Morice, MD¶
Rotterdam, the Netherlands; Milan, Italy; Rochester, Minnesota; Evanston, Illinois;
Natick, Massachusetts; and Massy, France
Objectives We explore the bifurcation angle (BA) parameters of the left main coronary artery (LM),
the effect of percutaneous coronary intervention (PCI) on this angulation, and the impact of BA on
clinical outcome.
Background The BA is emerging as a predictor of outcome after PCI of bifurcation lesions. Three-
dimensional (3D) quantitative coronary angiography (QCA) overcomes the shortcomings of 2-dimen-
sional analysis and provides reliable data.
Methods This is a substudy of the SYNTAX (SYNergy Between Percutaneous Coronary Intervention
With TAXus and Cardiac Surgery) trial. The cineangiograms of the 354 patients who underwent PCI
of their LM stem were analyzed with 3D QCA software (CardiOp-B, Paieon Medical, Ltd., Rosh
Ha’ayin, Israel). The proximal BA (between LM and left circumﬂex [LCX]) and the distal BA (between
left anterior descending and LCX) were computed in end-diastole and end-systole, both before and
after PCI. The cumulative major adverse cardiac and cardiovascular event (MACCE) rates throughout
the 12-month period after randomization were stratiﬁed across pre-PCI distal BA values and com-
pared accordingly.
Results Complete analysis was feasible in 266 (75.1%) patients. Proximal and distal BA had mean
pre-PCI end-diastolic values of 105.9  21.7° and 95.6  23.6°, respectively, and were inversely cor-
related (r  0.75, p  0.001). During systolic motion of the heart there was an enlargement of the
proximal angle and a reduction of the distal angle (ΔBA 8.2° and 8.5°, respectively, p  0.001 for
both). The PCI resulted in a mean decrease in the distal BA (ΔBA 4.5°, p  0.001). The MACCE rates
did not differ across distal BA values; freedom from MACCE at 12 months was 82.8%, 85.4%, and
81.1% (p  0.74) for diastolic values (ﬁrst through third tertile).
Conclusions Left main BA analysis with 3D QCA is feasible. Both proximal and distal angles are af-
fected by cardiac motion; PCI modiﬁes the distal angle. There is no clear difference in event rates
across pre-PCI distal BA values. (J Am Coll Cardiol Intv 2010;3:41–8) © 2010 by the American
College of Cardiology Foundation
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The optimal treatment of left main coronary artery (LM)
disease remains contentious (1,2), with much of the debate
focused on the treatment of its distal part (3,4). Despite
increasing data on LM interventions (5–8), the importance
of anatomical parameters such as the bifurcation angle (BA)
has not been fully appreciated (9).
A number of clinical (10–13) and bench (14,15) studies
identify the signiﬁcance of this angle in predicting the
immediate procedural success or the long-term outcome.
Limitations to previous studies include ambiguity in the
deﬁnition of the BA and the speciﬁc stenting techniques.
The most prominent limitation is that almost all relevant
clinical studies rely on 2-dimensional (2D) analysis. The
LM bifurcation is particularly difﬁcult to image, because of
foreshortening and vessel overlap (16); 3-dimensional (3D)
quantitative coronary angiography (QCA) overcomes these
shortcomings of 2D analysis and
might be beneﬁcial in this set-
ting (16–18).
The purpose of this study was
to test the feasibility of assess-
ment of the LM BA with a 3D
QCA algorithm, describe the
angulation parameters before
and after PCI and evaluate their
impact on the clinical outcome
of the patients.
Methods
Study population. This is a sub-
study of the SYNTAX (SYNergy
Between Percutaneous Coronary
Intervention With TAXus and
Cardiac Surgery) trial (19), which
was a prospective, randomized,
all-comers clinical trial with the
overall goal of assessing the op-
timum revascularization treatment for patients with de novo
3-vessel disease or LM disease (either isolated or in com-
bination with 1-, 2-, or 3-vessel disease). Patients (n 
1,800) suitable for either treatment option were randomized
to PCI with polymer-based, paclitaxel-eluting TAXUS
Express (Boston Scientiﬁc Corp., Natick, Massachusetts)
stents or coronary artery bypass graft surgery; they were also
stratiﬁed according to the presence or absence of LM
disease. For the purpose of this study, we reviewed the
cineangiograms of the 354 patients who underwent PCI
of the LM stem. Patients with both bifurcation and
nonbifurcation LM lesions were included in the study
population.
This study was performed in Cardialysis BV (Rotterdam,
the Netherlands) as an exploratory analysis and was not
subsidized by the ofﬁcial sponsor of the trial, Boston
Scientiﬁc Corporation. Prior permission was sought and
granted by the Steering Committee to access and analyze
this dataset.
Analysis method. Three-dimensional reconstruction was
performed ofﬂine by 2 experienced operators (C.G. and
Y.O.), blinded to individual patient data and clinical out-
come, with a validated (20) program for 3D QCA
(CardiOp-B system version 2.1.0.151, Paieon Medical,
Ltd., Rosh Ha’ayin, Israel); the sequence of a single 3D
reconstruction has already been amply described elsewhere
(21–23). The software algorithm rendered an image as well
as quantitative information including BA values; these were
derived from images without any guidewires in place, which
could modify the angle.
Two angles are presented in accordance with the European
Bifurcation Club consensus document (9). Proximal Angle A
is deﬁned as the angle between the proximal main vessel and
the side branch (SB), whereas distal Angle B is delineated
between the distal main vessel and the SB (Fig. 1). By
convention the left anterior descending coronary artery
(LAD) was designated as the distal main vessel, and the left
circumﬂex (LCX) as the SB. The LM bifurcation was
designated as Y-shaped for distal BA values 70°.
Study design. Three-dimensional reconstructions were per-
formed before and after PCI. To assess the effect of the
systolic-diastolic motion on the LM bifurcation angulation,
separate 3D images were reconstructed for the end-diastolic
and -systolic frames, both before and after the procedure.
Systolic-diastolic variation of BA equals the difference of
the respective end-diastolic and -systolic values.
Analysis was deemed complete, only if all 4 of the 3D
images that were required were successfully reconstructed;
outcome of each individual case study was categorized as
partially analyzable or nonanalyzable, in cases where 4 or
no images at all, respectively, were obtained.
The primary clinical end point of the trial was a compos-
ite of major adverse cardiac and cardiovascular events
(MACCE) (death from any cause, stroke, myocardial in-
farction, or repeat revascularization) throughout the 12-
month period after randomization.
Statistical analysis. Statistical analysis was performed with
SPSS version 16.0 forWindows (SPSS, Inc., Chicago, Illinois)
and SAS version 9.2 (SAS Institute, Inc., Cary, North Caro-
lina). Continuous variables are expressed as mean 1 SD and
compared between groups by unpaired Student t test; paired
t test was employed for within-group comparisons. Categorical
variables are expressed as counts and/or percentages. Correla-
tions between continuous variables were performed with the
Pearson coefﬁcient. Cumulative survival free of adverse events
was calculated according to the Kaplan-Meier method and
compared across the median and the tertile values of pre-PCI
distal BA with the log-rank test. All statistical tests were
2-sided, and a p value 0.05 was considered statistically
signiﬁcant.
Abbreviations
and Acronyms
BA  bifurcation angle
LAD  left anterior
descending coronary artery
LCX  left circumﬂex
coronary artery
LM  left main coronary
artery
MACCE  major adverse
cardiac and cardiovascular
events
PCI  percutaneous
coronary intervention
QCA  quantitative coronary
angiography
SB  side branch
TLR  target lesion
revascularization
3D  3-dimensional
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Results
Complete 3D QCA analysis was feasible in 266 (75.1%)
patients. The baseline demographic data and clinical char-
acteristics of these patients are reported in Table 1. Total
SYNTAX score (24) measured 29.9  13.2. Stents were
placed across the LM bifurcation in 185 cases; 1 stent was
used in 75 cases, whereas 2 stents were used in 110 cases.
Only 8.8% of all patients had isolated LM disease without
additional diseased vessels.
Feasibility of analysis with 3D QCA. Beyond the 266 cases
completely analyzed, another 88 could be analyzed either partly
or not at all (48 and 40 cases, respectively). Less than complete
analysis was attributable to 3 main reasons: 1) inadequate
cineangiography and difﬁcult anatomy in 42 cases; these cases
displayed overlap and/or tortuosity of the branch vessels,
particularly in their proximal segments; appropriate demarca-
tion of the bifurcation was also compromised by a very short
LM stem or a very small LCX (1.5 mm); 2) failure to record
2 separate angiographic projections in 23 cases; in most of
them, the ﬁnal result of the procedure was ﬁlmed in a single
projection, usually the operator’s working view; and 3) 23
studies could not be processed with the 3D QCA software,
mostly due to digitization in a non-DICOM (Digital Imaging
and Communications in Medicine) format.
Baseline descriptives of LM BA. In the completely analyzable
cohort (n  266), distal and proximal BA had mean
pre-PCI end-diastolic values of 95.6°  23.6° and 105.9° 
21.7°, respectively. Distal and proximal BA values were
inversely correlated (r  0.75, p  0.001), followed a
normal distribution, and ranged from 44° to 165° and from
54° to 168°, respectively.
Effects of cardiac motion. End-systolic mean values of distal
and proximal BA were 87.1°  22.9° and 114.0°  19.6°,
respectively; there was a statistically signiﬁcant effect of
systolic motion on both parameters, a mean decrease of 8.5°
(p  0.001) for the distal BA, and a mean increase of 8.2°
(p  0.001) for the proximal BA. A similar effect was seen
with post-procedural values, at the same level of statistical
signiﬁcance.
Figure 1. 3D BA Analysis
Two 2-dimensional single-plane angiographic images displaying the left main coronary artery (LM) bifurcation, one ﬁlmed in a right anterior oblique caudal view
(A) and one in a left anterior oblique caudal view (B), are post-processed; the 3-dimensional (3D) reconstructed image (C) is created. The proximal angle is
deﬁned between the LM stem and the left circumﬂex (LCX); the distal angle is deﬁned between the left anterior descending (LAD) and LCX. After percutaneous coro-
nary intervention (D) the proximal bifurcation angle (BA) is enlarged, whereas the distal BA gets narrower (CardiOp-B, Paieon Medical, Ltd., Rosh Ha’ayin, Israel).
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Effects of PCI on angulation. The effects of PCI on BA are
summarized in Table 2. A PCI conferred a signiﬁcant mean
decrease in the distal BA (BA  4.5°, p  0.001) (Fig. 2),
whereas the proximal BA increased by a mean of 2.0° (p 
0.064). However, studying the Y-shaped LM bifurcations
(13.9%) separately, the opposite phenomenon was apparent;
distal BA increased after PCI by a mean of 10.3° (p 
0.001) and proximal BA decreased by 5.5° (p  0.056).
There was substantial individual variation for each angio-
graphic study. PCI had equivalent impact on the end-
systolic BA values.
Impact of BA on outcome. Outcome data to 12 months
stratiﬁed and compared across pre-PCI distal BA tertiles is
reported in Table 3. Freedom from MACCE was not
signiﬁcantly different whether diastolic or systolic values
were analyzed; respective tertiles were 82°, 82° to 106°,
and 107° and 77°, 77° to 96°, and 97°. Analysis with
the median values (96° and 86°, respectively) as cutoff had a
similar result.
Similar analysis of the subgroups where 1 stent or 2
stents were used in the LM bifurcation did not produce any
signiﬁcant differences between tertiles either (Fig. 3).
Discussion
The main ﬁndings of this study are: 1) 3D BA analysis
seems feasible, even in this demanding angiographic setting;
2) there is a large variation in the angulation parameters of
the LM; 3) cardiac motion modiﬁes the bifurcation angu-
lation; systolic motion results in a reduction of the distal and
an enlargement of the proximal BA; 4) PCI treatment
modiﬁes the distal BA; overall, angles get narrower after
PCI, whereas Y-shaped LM bifurcations increase their
distal BA after the procedure; and 5) MACCE rates
throughout 12 months after randomization did not differ
across pre-PCI distal BA values.
The European Bifurcation Club has consistently been
advocating the importance of BA measurements for the
prediction of procedural outcome (9,25). The unique nature
of the LM bifurcation requires the greatest possible accuracy in
measurements, provided by 3D QCA algorithms (16–18).
Feasibility and advantages of 3D analysis. Inadequate
cineangiography and difﬁcult anatomy were the main rea-
sons for less than optimal analysis in our study. Vessel
overlap and foreshortening are well-known pitfalls of 2D
analysis; resorting to operator expertise is not always the
answer for acquiring the optimal projections (26). In the last
10 years evidence has accumulated that 3D angiographic
reconstruction is accurate, sensitive, and reproducible
(17,18,20,27–30) with a high degree of correlation for BA
measurements in phantom studies (18). Reduced time
requirements for a single 3D reconstruction (60 s) with
real-time analysis facilitate the choice of optimal gantry
positions. Thus, we believe that, in a prospective study
where operators are obtaining cineangiograms with the view
to perform this kind of analysis, the number of non-
analyzable cases could be limited to 10%.
Baseline angulation parameters of the LM. Upon review of
relevant published reports, there is a single 2D-based
angiographic study by Chen et al. (12) reporting on the BA
in 37 LM patients submitted to crush stenting; distal BA
had a mean value of 76°  24° and came up as an
independent predictor of target lesion revascularization
(TLR).
Three recent multislice computer tomography studies
provide more than conventional angiographic data. Ka-
wasaki et al. (31) studied the angles of the LM bifurcation
in 209 patients and calculated a mean value of 72° for the
distal LM angle. Pﬂederer et al. (32) reported an average
value of 80°  27° for the angle between LAD and LCX,
and Rodriguez-Granillo et al. (33) reported a median distal
LM BA of 88.5° with an interquartile range of 68.8° to
Table 1. Patient Demographic Data and Clinical Characteristics
(n  266)
Age (yrs) 65.2 9.8
Male 73.7
BMI (kg/m2) 28.2 5.0
Diabetes mellitus 23.7
Insulin-requiring 6.0
Noninsulin-requiring 17.7
Hypertension 68.6*
Hyperlipidemia 80.5
Current smoker 20.3
Prior myocardial infarction 27.2
Unstable angina 29.7
Revascularization priority
Emergent 3.0
Urgent 7.1
Elective 89.9
Additive EuroSCORE 3.8 2.8
Total Parsonnet score 8.7 7.6
Values are mean SD or %. *Data available in 264 patients.
BMI  body mass index; equals weight in kilograms divided by the square of the height in
meters.
Table 2. Pre- Versus Post-PCI Angulation Parameters (n  266)
Pre-PCI Post-PCI p Value*
Diastolic proximal BA, ° 105.9 21.7 107.9 21.4 0.064
Systolic proximal BA, ° 114.0 19.6 114.5 18.6 0.621
SDV-proximal BA, ° 8.2 13.2 6.7 12.3 0.118
Diastolic distal BA, ° 95.6 23.6 91.1 22.0 0.001
Systolic distal BA, ° 87.1 22.9 83.0 20.8 0.001
SDV-distal BA, ° 8.5 12.5 8.1 12.7 0.670
*Paired t test, 2-sided, p signiﬁcant0.05.
BA  bifurcation angle; PCI  Percutaneous coronary intervention, SDV  systolic-diastolic
variation.
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101.4°. An important ﬁnding of this study was that the more
diseased individual vessels were, the wider the BA was.
Our study was based on 354 patients submitted to PCI of
the LM stem; notwithstanding the increased mean distal
BA values, the variation of our ﬁndings is comparable to
previous studies. As a matter of fact, Kawasaki measured the
angle complementary to the proximal BA, which is by
deﬁnition narrower than the angle between the 3D recon-
structed centerlines of the distal vessels, the one measured in
our study.
Systolic-diastolic variation of BA values. The enlargement of
the proximal BA and the reduction of the distal BA during
systolic motion of the heart is a novel ﬁnding unaccounted
for in the published data, possibly because deemed trivial or
obvious. However, we feel that, from a methodological
point of view, authors should deﬁne what BA values they
are reporting on, because of their signiﬁcant systolic-
diastolic variation.
Impact of PCI on the angulation. Louvard et al. (34) re-
ported that even the temporary insertion of an angioplasty
guidewire is sufﬁcient for the BA to be considerably mod-
iﬁed. This leads us to believe that the permanent implan-
tation of 1 or even 2 rigid metallic structures across the
bifurcation would modify the angulation.
Another debatable issue is the extent and the direction of
modiﬁcation of the angulation parameters. As evidenced by
our data, the distal BA is the primary variable modiﬁed. It
seems that, overall, angles are decreased, whereas the nar-
rowest pre-PCI angles are increased. Dvir et al. (35), with
CardiOp-B software, have recently reported on the impact
of PCI on the distal BA in 27 patients. Apart from
provisional stenting, where the angle was not modiﬁed,
every other technique or anatomy has resulted in a decrease
in distal BA. Di Mario et al. (36) has also reported on single
and double stent techniques and the change conferred, if
any, on the BA. This was a subgroup analysis of the TRUE
(TAXUS in real life usage evaluation) registry, comprising
1,069 patients and 191 bifurcations. Double stent tech-
niques, particularly Culotte and Crush, signiﬁcantly de-
creased the distal BA, whereas implantation of a single stent
induced a nonsigniﬁcant increase. In a similar report from
Kaplan et al. (37), distal BA was actually increased after
T stenting yet by a modest 2°; in regard to Culotte, previous
ﬁndings were reproduced.
Impact of BA on outcome. The impact of BA on immediate
procedural success or long-term outcome is discussed in
many studies. Dzavik et al. (10) identiﬁed high BA as an
Figure 2. BA Values Distribution
Histograms of end-diastolic distal bifurcation angle (BA) values before and after percutaneous coronary intervention (PCI) with superimposed normal curves; val-
ues are in degrees. Post-PCI mean values are signiﬁcantly decreased (p  0.001). Descriptive statistics (mean  SD, median, maximum, and minimum) are pro-
vided as well.
Table 3. Freedom From MACCE Across Pre-PCI Distal BA Tertiles
(n  266)
1st Tertile 2nd Tertile 3rd Tertile p Value*
Diastolic BA
30 days 95.4% 95.5% 94.4%
6 months 90.8% 89.9% 86.7%
12 months 82.8% 85.4% 81.1% 0.74
Systolic BA
30 days 95.4% 96.6% 93.4%
6 months 89.7% 89.8% 87.9%
12 months 80.5% 84.1% 84.6% 0.77
*Log-rank test between groups, p signiﬁcant0.05.
BA  bifurcation angle; MACCE  major adverse cardiac and cardiovascular events; PCI 
percutaneous coronary intervention.
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independent predictor of increased major adverse cardiac
events at 12 months after crush stenting of bifurcation
lesions; this was not the case after main vessel stenting only
(11). The study by Chen et al. (12) linked increased TLR
rates to higher distal BA values in an LM cohort, whereas
an association between high BA values and high restenosis
rates has also been veriﬁed by Adriaenssens et al. (13) in the
context of Culotte stenting, albeit excluding LM cases.
However, neither Di Mario et al. (36) nor Kaplan (37) has
found in their respective studies evidence that would sup-
port this hypothesis; Di Mario et al. (36), like Adriaenssens
et al. (13), excluded LM cases from his study.
Ormiston et al. (14) and Murasato (15) have already
proven in their bench studies that, in the context of crush
stenting, a steep proximal angle and hence a larger distal
angle are associated with less optimal expansion and appo-
sition of the SB stent, especially at the site of the ostium.
In contrast, theoretical considerations lead to the conclu-
sion that the outcome of either Crush or Culotte technique
would have been adversely inﬂuenced by a narrower distal
angle; this would be attributable to a more probable carina
shift limiting the diameter of the SB ostium in Crush (38)
and to an increased stent cell size necessary to span an
oblique ostium in Culotte (39). Consequently we are led to
speculate that added factors come into play to determine the
long-term outcome, such as ﬂuid biomechanics. High and
low shear stress areas are supposed to exist in close proximity
in steeply angulated bifurcations, thus promoting platelet
activation and stasis; Dzavik et al. (10) postulate that an
excess of metal in such an area would only aggravate these
phenomena, possibly leading to increased rates of thrombo-
sis and restenosis.
Our study did not corroborate the ﬁndings of several of
the studies referenced. Only when separately studying the
cases where 2 stents were implanted in the LM bifurca-
tion was there a trend toward lower event rates for the
patients with narrower diastolic pre-PCI distal BA values.
However, the strength of our study consists in the very fact
that the analysts were totally unaware of individual patient
data and clinical outcome; thus, this could be considered as
a double-blind approach. Moreover, this is the ﬁrst study
correlating 3D QCA-derived angulation data to long-term
MACCE; superior assessment of the anatomical changes
conferred by PCI will potentially unravel the interplay
between geometry and clinical outcome.
Study limitations. This study was performed as an explor-
atory analysis blinded to individual patient data, treatment,
and clinical outcome. Because analysis was independent
from the Case Report Form, no relevant subgroup analysis
could be performed. Consequently we also could not estab-
lish whether the systolic heart motion effect universally
outweighs the relevant PCI effect. Moreover, the limited
number of events precluded any detailed analysis of
MACCE components and increased the probability of a
Figure 3. Freedom From MACCE to 12 Months Across Diastolic Pre-PCI
Distal BA Values
Kaplan-Meier curves are shown for the entire analyzable cohort (n  266)
(A), the subgroup of patients with 1 stent in the left main (LM) bifurcation
(n  75) (B), and the subgroup of patients with 2 stents in the LM bifur-
cation (n  110) (C). No signiﬁcant difference is calculated in any of the
panels. Tertile values for diastolic distal bifurcation angle (BA) are reported.
The I bars indicate 1.5 SE. The p values were calculated with the log-rank
test. MACCE  major adverse cardiac and cardiovascular events.
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type II error. A post-hoc calculation revealed a diminished
power of either overall or subgroup analysis (not 30% at a
signiﬁcance level of 0.05).
Angulation parameters could not be determined in 25%
of patients in the study group; exclusion of one-half of these
studies was ascribed to difﬁcult anatomy and inadequate
cineangiography, a major confounder being a narrow distal
BA. This might have ultimately induced a bias for higher
mean distal BA values. However, this was a retrospective
post hoc analysis; had the angulation parameters been
calculated prospectively and online, a higher rate of com-
plete analysis could have been anticipated.
Conclusions
Three-dimensional BA analysis for the LM, before and
after PCI, is feasible; LM angulation parameters vary
considerably. Cardiac motion exerts a reciprocal effect on
proximal and distal BA, the former being increased and the
latter decreased during systole. A PCI modiﬁes the distal
BA; overall, angles are decreased, whereas the narrowest
pre-PCI angles are actually increased after the procedure.
Cumulative event rates throughout the ﬁrst 12 months after
randomization did not differ signiﬁcantly, when compared
across pre-PCI distal BA values. The potential long-term
predictive value of these parameters and their prospective
applicability during PCI merit further inquiry.
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Impact of 3-Dimensional Bifurcation Angle
on 5-Year Outcome of Patients After
Percutaneous Coronary Intervention for
Left Main Coronary Artery Disease
A Substudy of the SYNTAX Trial (Synergy Between Percutaneous
Coronary Intervention With Taxus and Cardiac Surgery)
Chrysaﬁos Girasis, MD,* Vasim Farooq, MBCHB,* Roberto Diletti, MD,*
Takashi Muramatsu, MD,* Christos V. Bourantas, MD, PHD,* Yoshinobu Onuma, MD,*
David R. Holmes, MD,y Ted E. Feldman, MD,z Marie-Angele Morel, BSC,x
Gerrit-Anne van Es, PHD,x Keith D. Dawkins, MD,k Marie-Claude Morice, MD,{
Patrick W. Serruys, MD, PHD*
Rotterdam, the Netherlands; Rochester, Minnesota; Evanston, Illinois; Natick, Massachusetts;
and Massy, FranceObjectives This study sought to investigate the impact of left main coronary artery (LMCA)
3-dimensional (3D) bifurcation angle (BA) parameters on 5-year clinical outcomes of patients
randomized to LMCA percutaneous coronary intervention (PCI) in the SYNTAX (Synergy Between
Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) trial.
Background BA can affect outcome after bifurcation PCI; 3D angiographic analysis provides reliable
BA measurements.
Methods The diastolic distal BA (between left anterior descending and left circumﬂex) and its systolic-
diastolic range were explored. A stratiﬁed post-hoc survival analysis was performed for 5-year major
adverse cardiac and cardiovascular events (MACCE) (all-cause death, cerebrovascular accident,
myocardial infarction, or repeat revascularization), a safety endpoint (all-cause death, cerebrovascular
accident, or myocardial infarction), and repeat revascularization. Analysis was performed in patients
where 3D BA was available pre- and post-PCI.
Results Of 266 patients eligible for analysis, 185 underwent bifurcation PCI (group B); 1 stent was
used in 75 patients (group B1), whereas 2 stents were used in 110 patients (group B2). Stratiﬁcation
across pre-PCI diastolic distal BA tertiles (<82, 82 to 106, 107) failed to show any difference in
MACCE rates either in the entire study population (p ¼ 0.99) or in group B patients (p ¼ 0.78). Group B
patients with post-PCI systolic-diastolic range <10 had signiﬁcantly higher MACCE rates (50.8% vs.
22.7%, p < 0.001); repeat revascularization and safety endpoint rates were also higher (37.4% vs.
15.5%, p ¼ 0.002, and 25.4% vs. 14.1%, p¼0.055, respectively). Post-PCI systolic-diastolic range <10
was an independent predictor of MACCE (hazard ratio: 2.65; 95% conﬁdence interval: 1.55 to 4.52;
p < 0.001) in group B patients.
Conclusions A restricted post-procedural systolic-diastolic distal BA range resulted in higher 5-year
adverse event rates after LMCA bifurcation PCI. Pre-PCI BA value did not affect the clinical
outcome. (J Am Coll Cardiol Intv 2013;6:1250–60) ª 2013 by the American College of Cardiology
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Percutaneous coronary intervention (PCI) for unprotected
left main coronary artery (LMCA) disease is emerging as
a reasonable treatment option alternative to coronary artery
bypass graft surgery, especially when concomitant coronary
artery disease is limited and comorbidities are present (1,2).
Data from major randomized trials (3–7) and many regis-
tries have led to the upgrade of PCI as a means of revas-
cularization for LMCA ostial and/or shaft stenosis to a class
IIa recommendation. However, bifurcation LMCA PCI was
assigned a class IIb recommendation; it was deemed to be ofSee page 1261
Abbreviations
and Acronyms
BA = bifurcation angle
CI = conﬁdence interval(s)
HR = hazard ratio(s)
LMCA = left main coronary
artery
MACCE = major adverse
cardiac and cardiovascular
events
MI = myocardial infarction
PCI = percutaneous coronary
intervention
QCA = quantitative coronary
angiography
SB = side branch
SDR = systolic-diastolic
range
2D = 2-dimensional
3D = 3-dimensionalconsiderably higher risk for adverse clinical outcomes than
surgery (1,2). Issues such as the choice of (drug-eluting)
stent, the number of stents used and individual techniques,
SYNTAX (Synergy Between Percutaneous Coronary
Intervention With Taxus and Cardiac Surgery) score, and
plaque distribution have all been addressed (8). However,
whereas the impact of bifurcation angle (BA) on immediate
post-procedural and especially the long-term outcome has
been studied in non-LMCA lesions (9–11), its relation to the
LMCA PCI is unclear. The studies reporting on this subject
were largely on the basis of BA measurements derived from
2-dimensional (2D) quantitative coronary angiography
(QCA) and therefore were prone to error; moreover, these
studies had a small sample size and/or limited outcome
data (12–14).
We have previously explored the 3-dimensional (3D)
QCA-based distribution of the LMCA BA variables (dia-
stolic and systolic values, pre- and post-PCI) in a report on
the basis of patients that were randomized to PCI in the
context of the SYNTAX trial; furthermore, we have
provided 12-month outcome data stratiﬁed across the distal
BA tertile values (15). At that time, the analysis did not
show enough evidence to support 3D BA as a potential
predictor of outcome; however, there was a weak trend
indicating higher adverse event rates in patients with wider
distal LMCA angles when 2 stents were implanted in the
LMCA bifurcation. Now having 5-year outcome data
available (16), we investigate once more the topic to attempt
to get conclusive evidence on the impact of 3D BA on very
long-term outcome after LMCA PCI and, if possible, to
gain insight into the possible mechanisms whereby this
effect is mediated.132Methods
Study population. This is a substudy of the SYNTAX trial
(4), which was a randomized, prospective, multicenter,
all-comers clinical trial with the overall goal of assessing
the optimum revascularization treatment for patients
with de novo 3-vessel disease or LMCA disease (either
isolated or in combination with 1-, 2-, or 3-vessel disease).
Patients (N ¼ 1,800) amenable to either treatment option
were randomized to PCI with polymer-based, paclitaxel-
eluting Taxus Express (Boston Scientiﬁc Corporation,
Natick, Massachusetts) stents or coronary artery bypass
graft surgery; they were also stratiﬁed according to the
presence or absence of LMCA disease. For the purpose of
this study, we reviewed the cineangiograms of the 354
patients who actually underwent PCI of the LMCA stem
(5). Patients with both distal
and nondistal LMCA lesions
were evaluated; the ones in
whom 3D angiographic recon-
struction could be performed to
derive the LMCA BA parame-
ters both pre- and post-proce-
dure constituted our original
study population (Fig. 1) (15).
This study was not pre-speciﬁed
in the SYNTAX trial protocol
and was not subsidized by the
ofﬁcial sponsor of the trial,
Boston Scientiﬁc Corporation.
Nevertheless, previous permis-
sion was sought and granted by
the steering committee to access
and analyze this dataset.
Treatment. Procedures were
performed according to local
practice and at the investigator’s
discretion. In the Taxus arm,
clopidogrel was mandated for at least 6 months after the
procedure, whereas patients were advised to maintain aspirin
therapy indeﬁnitely. Recommended procedural techniques
included complete coverage of lesions with stent overlapping
(where required) at both margins byw4 mm and use of ﬁnal
kissing balloons inﬂation after bifurcation stenting (5).
Endpoints and deﬁnitions. The primary endpoint of the
SYNTAX trial was a composite of major adverse cardiac and
Figure 1. Flow Diagram Indicating the Entire Study Population Synthesis
and Subgroups
Out of the entire randomized study population of 1800 patients, 354 patients
actually underwent PCI of the LMCA stem; however, 3D angiographic recon-
struction could be performed both pre- and post-PCI in only 266 patients.
Thereof, 185 patients underwent distal LMCA PCI, wherein 2 stents or more
were placed in 110 patients. LMCA ¼ left main coronary artery;
PCI ¼ percutaneous coronary intervention; pts ¼ patients; SYNTAX ¼ Synergy
Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery;
3D ¼ 3-dimensional.cardiovascular events (MACCE) (all-cause death, cere-
brovascular accident, myocardial infarction [MI], or repeat
revascularization) throughout the 12-month period following
treatment allocation. Deﬁnitions of clinical events have been
previously described in detail (4,17). All adverse events were
adjudicated by an independent clinical events committee;
stent thrombosis has been adjudicated according to the study
protocol. Patient follow-up has been conducted on an annual
basis until 5 years after treatment allocation.
Angiographic analysis. 3D reconstruction was performed
ofﬂine by 2 experienced operators (C.G. and Y.O.), who
were blinded to individual patient data and clinical outcome,
with a validated program for 3D QCA (CardiOp-B system,
version 2.1.0.151, Paieon Medical Ltd., Rosh Ha’ayin,
Israel). The distal BA was measured between the left ante-
rior descending and the left circumﬂex coronary arteries
designated as the distal main vessel and the side branch
(SB), respectively; 3D reconstructions were performed at
end diastole and end systole, both pre- and post-procedure.
In this study, the diastolic distal BA and its systolic-diastolic
range (SDR) were explored pre- and post-procedure. The
latter variable (SDR) was deﬁned as the absolute difference
between diastolic and systolic distal BA values. On occasion,
systolic values exceeded the diastolic ones; however, only
absolute (positive) terms were studied. To prospectivelygrade the complexity of coronary artery disease, the
Angiographic Core Laboratory (Cardialysis BV, Rotterdam,
the Netherlands) scored the angiograms according to the
SYNTAX score algorithm (18). LMCA bifurcation lesion
type was adjudicated according to Medina; [1,1,1], [1,0,1],
and [0.1,1] lesion types are summarily called true bifurcation
lesions. Because the staff of the angiographic core laboratory
was blinded to site information, adjudicated lesions for the
SYNTAX score derivation could not be matched between
core laboratory and site; we chose to report bifurcation type
per site to be concordant with the choice of stenting
technique.
Study design. Tertile and/or median values of the afore-
mentioned angulation variables were used to stratify clinical
outcomes. Pre-procedural values were explored over the
entire study population, that is patients with nondistal
(group A) and distal LMCA PCI (group B) (Fig. 1).
However, regarding the post-procedure values and the
change in LMCA bifurcation geometry conferred by PCI, it
was deemed more meaningful to study their association with
clinical outcomes only for patients in group B, whether they
had 1 stent (group B1) or 2 stents (group B2) placed across
the LMCA bifurcation.
Statistical analysis. Statistical analysis was performed using
SPSS for Windows (version 19.0, SPSS Inc., Chicago,
Illinois). Continuous variables are expressed as mean  SD
and compared between groups by the unpaired Student
t test; paired Student t test was employed for within-group
comparisons. Categorical variables are presented as counts
and/or percentages; comparisons were performed with the
chi-square test and the Fisher exact test as appropriate.
Cumulative 5-year event rates for MACCE, a safety
composite endpoint (all-cause death, cerebrovascular acci-
dent, or MI) and stent thrombosis were calculated according
to the Kaplan-Meier method. Event rates were compared
according to the Cox proportional hazards model. Inde-
pendent predictors of 5-year MACCE, repeat revasculari-
zation, and the safety endpoint were sought among variables
signiﬁcant beyond the level of p ¼ 0.10 in univariable
analysis. Potential predictors were checked for collinearity
before entering a Cox regression multivariable backward
stepwise model; variables with a variance inﬂation factor
>2.5 were disqualiﬁed. Crude and adjusted hazard ratios
(HRs) and corresponding 95% conﬁdence intervals (CIs)
are reported for qualifying variables. All statistical tests were
2-sided and a p value of <0.05 was considered statistically
signiﬁcant.
Results
Five-year clinical follow-up was attained for 259 (97.4%)
patients (median: 1,826 days, range: 4 to 2,082 days); 7
patients were lost to follow-up and were censored at days
389, 1,105, 1,442, 1,462, 1,462, 1,473, and 1,489,133
Table 1. Baseline Clinical Characteristics in Patients With LMCA PCI (n ¼ 266)
Nondistal LMCA
Group A, (n ¼ 81)
Distal LMCA
Group B, (n ¼ 185) p Value
Distal 1 Stent
Group B1, (n ¼ 75)
Distal 2 Stents
Group B2, (n ¼ 110) p Value
Age, yrs 64.9  9.4 65.3  10.0 0.76 64.2  10.3 66.1  9.7 0.21
Male 54 (66.7) 142 (76.8) 0.10 61 (81.3) 81 (73.6) 0.29
BMI, kg/m2 28.3  5.2 28.1  4.9 0.72 28.0  4.7 28.2  5.1 0.81
Diabetes mellitus 22 (27.2) 41 (22.2) 0.43 15 (20.0) 26 (23.6) 0.59
Hypertension 55/79 (69.6) 126 (68.1) 0.89 52 (69.3) 74 (67.3) 0.87
Hyperlipidemia 65 (80.2) 149 (80.5) 1.00 59 (78.7) 90 (81.8) 0.71
Current smoker 18 (22.2) 36 (19.5) 0.62 19 (25.3) 17 (15.5) 0.13
Prior myocardial infarction 25 (30.9) 47 (25.5) 0.37 20 (26.7) 27 (24.8) 0.86
Unstable angina 25 (30.9) 54 (29.2) 0.77 21 (28.0) 33 (30.0) 0.87
LVEF <30% 1 (1.2) 4 (2.2) 1.00 3 (4.0) 1 (0.9) 0.31
Prior TIA 5 (6.2) 9 (4.9) 0.77 3 (4.0) 6 (5.5) 0.74
Creatinine >200 mmol/l 0 (0.0) 5 (2.7) 0.33 2 (2.7) 3 (2.7) 1.00
Emergent revascularization priority 3 (3.7) 5 (2.7) 0.70 0 (0.0) 5 (4.5) 0.08
Additive EuroSCORE 3.7  2.3 3.8  2.9 0.79 3.6  3.1 4.0  2.8 0.39
SYNTAX score* 23.5  10.5 32.6  13.5 <0.001 30.6  12.4 34.0  14.1 0.10
Lesion number 2.6  1.6 3.0  1.8 0.23 3.1  1.7 2.9  1.8 0.76
Isolated LMCA 20 (24.7) 12 (6.5) <0.001 5 (6.7) 7 (6.3) 1.00
LMCA þ 1 vessel 27 (33.3) 22 (11.9) <0.001 13 (17.3) 9 (8.2) 0.07
LMCA þ 2 vessels 20 (24.7) 86 (46.5) 0.001 32 (42.7) 54 (49.1) 0.45
LMCA þ 3 vessels 14 (17.3) 65 (35.1) 0.003 25 (33.3) 40 (36.4) 0.75
Values are mean  SD or n (%). *Calculated by the core laboratory.
BMI ¼ body mass index; EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation; LMCA ¼ left main coronary artery; LVEF ¼ left ventricular ejection fraction; PCI ¼ percutaneous coronary
intervention; SYNTAX ¼ Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery; TIA ¼ transient ischemic attack.respectively. The baseline characteristics of the study pop-
ulation are shown in Table 1 stratiﬁed according to LMCA
lesion location and bifurcation stenting technique (1 or 2
stents). Compared with group A patients, in group B
patients, coronary artery disease was signiﬁcantly more
extensive as indicated by the increased SYNTAX score (32.6
 13.5 vs. 23.5  10.5, p < 0.001) and percentage of
patients with LMCA plus 2- or 3-vessel disease (81.6% vs.
42.0%, p < 0.001). Complete revascularization rates were
comparable between groups A and B (67.9% vs. 64.3%, p ¼
0.68); 3.0  1.9 stents with a total length of 51.0 39.0 mm
were used in the former, whereas 4.2 2.4 stents with a total
length of 77.7  47.9 mm were used in the latter (p < 0.001
for both).
Complex stenting techniques were applied to patients
with more complex bifurcation disease; 85 of 108 true
bifurcation lesions were treated with 2 stents (Table 2).
However, in 19 cases of a [1,1,1] bifurcation lesion, provi-
sional T stenting was performed; in 14 of these cases, the
procedure was ﬁnished with a kissing balloon inﬂation.
Overall, ﬁnal kissing balloon inﬂation was employed more
frequently after complex bifurcation stenting (p < 0.001).
BA variables. Angulation variables for patients with LMCA
bifurcation PCI are shown in Table 3. There is a signiﬁcant
post-procedural decrease in the diastolic distal BA (D¼
6.3, p < 0.001), whereas SDR is only slightly decreased
(D ¼ 0.5, p ¼ 0.50). On average, SDR is slightly134increased after single-stenting (D ¼ 0.7, p ¼ 0.45), whereas
moderately decreased by complex stenting (D ¼ -1.3,
p ¼ 0.17); however, direction and extent of change vary
signiﬁcantly among 2-stent techniques (p < 0.01) (Fig. 2).
Impact on outcome. Stratiﬁcation across pre-PCI diastolic
distal BA tertiles (<82, 82 to 106, 107) failed to show
any difference in MACCE rates either in the entire study
population (37.1%, 37.7%, and 35.6%, respectively,
p ¼ 0.99), or in group B patients (33.7%, 40.3%, and 35.6%,
respectively, p ¼ 0.78). Kaplan-Meier curves slightly
diverged for patients in group B2 (p ¼ 0.41), mainly due to
relatively increased safety endpoint rates for patients in the
middle tertile; this was not the case for group B1 (Fig. 3).
Repeat revascularization rates did not show any signiﬁcant
differences across tertiles (p ¼ 0.42 and 0.77 for groups B1
and B2, respectively) (Fig. 3); on the other hand, there was
a strong trend for increased MI rates for patients with BA
<82 in group B2 (17.5%, 16.8%, and 0.0% for low, mid-,
and high tertiles, respectively, p ¼ 0.06) that was not seen in
group B1 (5.3%, 4.2%, and 6.6%, respectively, p ¼ 0.91).
Stratiﬁcation across post-PCI diastolic distal BA tertile
values (<79, 79 to 98, 99) did not show any signiﬁcant
difference in MACCE rates in group B (37.1%, 31.0%, and
42.0%, respectively, p ¼ 0.29). There was a trend for
increased safety endpoint rates in patients in the third tertile
(13.5%, 17.7%, and 27.7% for low, mid-, and high tertiles,
respectively, p ¼ 0.12); however, this was not the case for
Table 2. Baseline Angiographic and Procedural Characteristics for
Patients With LMCA Bifurcation PCI (n ¼ 185)
Distal 1 Stent
Group B1,
(n ¼ 75)
Distal 2 Stents
Group B2,
(n ¼ 110) p Value
Bifurcation type per LMCA lesion <0.001
Medina 1,1,1 19 (25.3) 71 (64.5) <0.001
Medina 1,1,0 21 (28.0) 8 (7.3) <0.001
Medina 1,0,1 4 (5.4) 14 (12.7) 0.13
Medina 1,0,0 31 (41.3) 17 (15.5) <0.001
True bifurcation lesions 23 (30.7) 85 (77.3) <0.001
Nontrue bifurcation lesions 52 (69.3) 25 (22.7) <0.001
Bifurcation stenting technique N/A
Provisional T-stenting 75 (100.0) 0 (0.0)
Classic T-stenting,
main vessel ﬁrst
0 (0.0) 36 (32.7)
Classic T-stenting,
side branch ﬁrst
0 (0.0) 12 (10.9)
Modiﬁed T-stenting 0 (0.0) 6 (5.5)
Crush technique 0 (0.0) 18 (16.4)
Culotte technique 0 (0.0) 23 (20.9)
V stenting, kissing stents 0 (0.0) 13 (11.8)
Y stenting, touching stents 0 (0.0) 2 (1.8)
Final kissing balloon inﬂation 46 (61.3) 97 (88.2) <0.001
Complete revascularization 54 (72.0) 65 (59.1) 0.09
Total stents per patient 3.5  2.2 4.8  2.4 <0.001
Total stent length per
patient, mm
65.4  43.1 86.1  49.4 0.004
Values are n (%) or mean  SD.
N/A ¼ not applicable; other abbreviations as in Table 1.
Table 3. BA Variables for Patients With LMCA Bifurcation PCI
Distal 1 Stent
Group B1,
(n ¼ 75)
Distal 2 Stents
Group B2,
(n ¼ 110) p Value
Pre-PCI distal BA, diastolic  99.2  23.7 93.3  23.3 0.10
Post-PCI distal BA, diastolic  92.7  21.2 87.2  21.2 0.09
Pre-PCI SDR  11.0  7.1 11.1  8.8 0.92
Post-PCI SDR  11.7  7.8 9.8  7.6 0.12
Values are mean  SD.
BA ¼ bifurcation angle; SDR ¼ systolic-diastolic range (of distal BA); other abbreviations as in
Table 1.repeat revascularization rates (31.5%, 23.5%, and 23.8%,
respectively, p ¼ 0.55).
Systolic-diastolic BA range both pre- and post-procedure
had a median value of 10. There was no signiﬁcant
difference in MACCE rates for patients in group B with
pre-PCI SDR 10 (40.6% vs. 32.5%; HR: 1.25; 95% CI:
0.77 to 2.02; p ¼ 0.37). Conversely, patients with post-PCI
SDR <10 showed signiﬁcantly higher MACCE rates for
group B (50.8% vs. 22.7%; HR: 2.65; 95% CI: 1.58 to 4.44;
p < 0.001), group B1 (46.9% vs. 16.4%; HR: 3.47; 95% CI:
1.41 to 8.55; p ¼ 0.01) and group B2 (52.8% vs. 28.0%;
HR: 2.16; 95% CI: 1.15 to 4.07; p ¼ 0.02). The event rates
for all different endpoints for the entire group B are reported
in Table 4 stratiﬁed across the post-PCI SDR median value.
Moreover, in both subgroups, higher event rates were
recorded for patients with post-PCI SDR <10 regarding
repeat revascularization (p ¼ 0.07 and 0.02 for groups B1
and B2) and the safety endpoint (p ¼ 0.08 and 0.35 for
groups B1 and B2) (Fig. 4). Finally, group B patients with
even minimally increased SDR post-procedure (DSDR ¼
post-PCI SDR minus pre-PCI SDR) showed signiﬁcantly
lower MACCE rates (28.6% vs. 43.9%; HR: 0.60; 95% CI:
0.37 to 0.99, p ¼ 0.045), compared with patients with
DSDR 0.Stent thrombosis. Per protocol, stent thrombosis was adju-
dicated in 13 patients in the entire study population (4.9%).
Of those 13, 9 had LMCA bifurcation PCI (4.9%); thereof
8 belonged to group B2. Among these 9 patients, 5 events
occurred early (30 days), 1 event late (day 318), and 3
events very late (days 598, 835, and 1,594). If stratiﬁed
across diastolic distal BA, there was a trend for higher stent
thrombosis rates in the lowest angle tertiles (8.5%, 5.4%, and
1.6%, p ¼ 0.23, and 8.5%, 3.5%, and 3.3%, p ¼ 0.33, pre-
and post-PCI, respectively); however, difference was mainly
driven by early events (3 events each in the lowest angle
tertiles). There was also a trend for higher event rates for
patients with narrower post-PCI SDR (8.0% vs. 2.2%; HR:
3.75; 95% CI: 0.78 to 18.2, p ¼ 0.10) (Table 4), which
reﬂected a similar trend among group B2 patients with post-
PCI SDR <10 (12.2% vs. 2.0%; HR: 6.21; 95% CI: 0.77
to 50.0, p ¼ 0.09).
Multivariable analysis. In group B, next to a post-PCI SDR
of the distal BA <10, a number of variables were signiﬁ-
cantly associated with or showed a strong trend for (p < 0.10
in univariable analysis) higher MACCE rates (Table 5).
Total stent length was eliminated from analysis due to
collinearity with the total number of stents. The narrow
post-PCI SDR emerged as an independent predictor of
MACCE (HR: 2.65; 95% CI: 1.55 to 4.52, p < 0.001) next
to poor left ventricular ejection fraction (HR: 7.53; 95% CI:
2.63 to 21.6, p < 0.001) and the total number of stents
placed in a patient (HR: 1.13; 95% CI: 1.03 to 1.24,
p < 0.01). Following a similar analysis, a narrow post-PCI
SDR independently predicted increased rates for both repeat
revascularization (HR: 2.39; 95% CI: 1.26 to 4.52,
p < 0.01) next to the total number of stents (HR: 1.16; 95%
CI: 1.05 to 1.29, p < 0.01) and for the safety endpoint
(HR: 2.06; 95% CI: 1.03 to 4.12, p ¼ 0.04) next to previous
MI (HR: 2.93; 95% CI: 1.50 to 5.71, p < 0.01) and poor
left ventricular ejection fraction (HR: 4.78; 95% CI: 1.37 to
16.6, p ¼ 0.01).
Discussion
The following are the main ﬁndings of this study. 1) The
pre-procedural 3D QCA-derived diastolic distal BA of the135
Figure 2. Effect of Bifurcation Stenting on the SDR of the Distal BA
(A) Periprocedural change in systolic-diastolic range (SDR) according to the number of stents implanted. (B) Difference in SDR (DSDR ¼ post-PCI SDR – pre-PCI SDR)
according to bifurcation stenting technique. BA ¼ bifurcation angle; Mod-T ¼ modiﬁed T-stenting; PCI ¼ percutaneous coronary intervention; Prov-T ¼ provisional
T-stenting; V ¼ kissing stenting; Y ¼ touching stenting.LMCA bifurcation could not predict long-term clinical
outcomes after PCI for LMCA coronary artery disease.
Even when patients with LMCA bifurcation PCI were
examined separately, there was still no signiﬁcant impact of
this parameter on long-term clinical outcomes. 2) A narrow
(<10) post-PCI systolic-diastolic range of this angle was
shown to be signiﬁcantly associated with worse 5-year
clinical outcomes in patients undergoing LMCA bifurcation
PCI. Adjusted for various clinical, angiographic (including
extent of concomitant disease), and procedural variables, it
still proved an independent predictor of 5-year MACCE.
To our knowledge, this is the ﬁrst study ever to report on
such long-term clinical outcomes of LMCA PCI stratiﬁed136across BA parameters exclusively derived from 3D angio-
graphic bifurcation analysis. The relative merits of 3D
angiography have already been stressed (15); regarding the
BA derivation, 3D angiographic analysis is of apparent
importance as the bifurcation is a 3D structure, and there-
fore its maximal opening can be accurately appreciated only
in a 3D space (19). Moreover, on the basis of a phantom
validation study, 3D QCA has recently been shown to
provide more accurate and precise BA measurements than
2D software does (20).
Effect of SDR. The idea that a decreased post-PCI systolic-
diastolic range of movement of the LMCA (or any) bifur-
cation is associated with higher event rates may on ﬁrst
Figure 3. Impact of Pre-PCI Diastolic Distal BA on 5-Year MACCE, All-Cause Death, CVA, or MI (Safety Endpoint), and Repeat Revascularization
Kaplan-Meier curves shown for group B1 (A, C, E) and group B2 (B, D, F). CVA ¼ cerebrovascular accident; HR ¼ hazard ratio; LMCA ¼ left main coronary artery;
MACCE ¼ major adverse cardiac and cardiovascular events; MI ¼ myocardial infarction; other abbreviations as in Figures 1 and 2.inspection sound like a paradox. It would be assumed that in
the long term an increased range of torsion, ﬂexion, and
stretching of any metallic structure would lead to metal
fatigue and eventually strut fracture (21,22). The premise we
are making is the same, only seen in a different perspective.The diminished range of movement after the procedure,
even more pronounced after complex stenting (Fig. 2),
implies that the bifurcation has been “stiffened” by the stents
and forced into an unnatural conﬁguration. Therefore, the
myocardium and hence the epicardial coronary arteries strive137
Table 4. Five-Year Clinical Outcomes Stratiﬁed Across Post-PCI SDR in
Patients With LMCA Bifurcation PCI (Univariable Analysis)
SDR < 10
(n ¼ 92)
SDR  10
(n ¼ 93) <10 vs. 10
p
Value
MACCE 50.8 22.7 2.65 (1.58–4.44) <0.001
Death, CVA, or MI 25.4 14.1 1.95 (0.99–3.85) 0.055
Death 17.7 7.6 2.48 (1.02–6.02) 0.045
Repeat revascularization 37.4 15.5 2.70 (1.44–5.05) 0.002
MI 12.4 6.6 1.98 (0.73–5.35) 0.18
Stent thrombosis,
per protocol
8.0 2.2 3.75 (0.78–18.2) 0.10
Values are % or hazard ratio (95% conﬁdence interval).
CVA ¼ cerebrovascular accident; MACCE ¼ major adverse cardiac and cardiovascular events;
MI ¼ myocardial infarction; other abbreviations as in Tables 1 and 3.to revert to the previous geometry (23,24), thereby exerting
increased and repetitive strain on the metallic scaffolds. It
has been reported that the Taxus Express metallic platform
is not prone to strut fractures at least to the same extent as
the Cypher stent (Cypher, Cordis, Johnson and Johnson
Corporation, Miami, Florida) (22). This has been attributed
to the Taxus Express open-cell design, which is said to
enhance its conformability around bends (23) as well as to its
diminished radiopacity, which makes fractures more difﬁcult
to detect angiographically. Stent strut fractures have been
mostly explored in straight vessel segments; even there, high
vessel tortuosity and excessive vessel angulation during the
heart cycle were reported to be precipitating factors (24–26),
especially in the presence of long overlapping stents. Even
so, stent strut fractures seldom translate into stent throm-
bosis, MI, or sudden death (22), but rather in a hinge
motion associated with in-stent restenosis (26); however,
when seen in the context of the LMCA bifurcation,
otherwise occult restenotic lesions could very well lead to
catastrophic outcomes.
Effect of distal BA. Intuitively, the distal BA has been
associated with the risk of SB occlusion during stent
implantation in the main vessel (27); a shallow distal BA
makes a carina shift more probable, thereby resulting in
considerable residual stenosis (28). Moreover, for BA 70,
classic T stenting cannot fully scaffold the SB ostium
without stent struts protruding into the main vessel (29);
dedicated techniques, such as the crush and the culotte, that
fully cover the SB ostium have been developed to address
this issue. However, a shallow angle necessitates an increased
stent cell size to avoid jailing the SB ostium after the crush
or causing a napkin ring stenosis in the ostium of the distal
main vessel after a culotte. Theoretically, for BA w60,
a distal main vessel diameter of 3 mm and an SB diameter of
2.75 mm, a stent cell diameter of w3.3 mm would be
required (30), which could be achieved with the Taxus
Express metallic stent platform (31).
Moving to steeper angles, bench studies have shown that
for BA >80, full stent strut apposition cannot be achieved138with the crush (32,33) or the culotte techniques despite
sequential kissing balloon inﬂations (34); straightening of
the LMCA curvature could cause added distortion.
Thereby, gaps in support and drug application are left at the
SB ostium, which probably translate into higher adverse
event rates for highly angulated bifurcations (9–12). At
the same time, increasing BA have been associated with
decreasing lower wall shear stress values and increased
oscillatory ﬂow at the lateral walls opposite the carina
(35,36), which facilitate plaque proliferation and eventually
restenosis; contrary to sirolimus, paclitaxel cannot modify
the effect of low wall shear stress on neointima formation
(37). Expectedly, all these phenomena are exacerbated in the
presence of multiple stent strut layers, metallic neo-carinas,
and protruding and malapposed struts.
Implementation and clinical implications. A single 3D
angiographic reconstruction of a bifurcation requires 2
adequate images 30 apart with the least possible amount of
foreshortening and vessel overlap. For a given bifurcation,
there is usually 1 optimal view, whereas in any other direc-
tion certain features, usually the SB ostium, may be
obscured; retrospective collection of 2 adequate images can
be challenging. However, new software algorithms can
retrieve missing information even from 2 suboptimal images,
whereas the optimal view, if not among the images initially
acquired, can be suggested by a provisional 3D reconstruc-
tion on the basis of 2 suboptimal views (20). Moreover,
dedicated computation algorithms implemented in com-
mercially available 2D and 3D bifurcation QCA software
allow for accurate and reproducible BA calculation; time
requirements (<10 s for reconstruction of 2 images, <60 s
for 3 images) are not an issue.
The interventional cardiologist can do little to change the
geometrical conﬁguration of the LMCA bifurcation after
the stent implantation, as long as this is done according to
sound clinical practice facilitating free access to SB and good
stent strut apposition to the vessel wall. Our ﬁndings may
suggest a lesser degree of bifurcation stiffening with single
bifurcation stenting; however, no solid recommendation
could be issued on the basis of a single study. Nevertheless,
in those cases where a decreased post-procedural range of
movement can be manifested, there would probably be
a need for potent and prolonged platelet inhibition and
increased clinical surveillance.
Study limitations. This study was not pre-speciﬁed in the
SYNTAX trial protocol and therefore was probably under-
powered regarding the detection of a plausible effect of
pre-PCI angulation parameters on clinical outcomes. Our
analysis may have been further confounded by marked
heterogeneity in bifurcation techniques, the number of stents
used, the bifurcation type, the extent of ﬁnal kissing balloon
inﬂation, and other unforeseen and possibly unaccounted for
periprocedural phenomena. In addition, data on mainte-
nance of dual antiplatelet therapy were not available. On the
Figure 4. Impact of Post-PCI SDR of the Distal BA on 5-Year MACCE, All-Cause Death, CVA, or MI (Safety Endpoint), and Repeat Revascularization
Kaplan-Meier curves shown for group B1 (A, C, E) and group B2 (B, D, F). Abbreviations as Figures 1 to 3.other hand, per SYNTAX trial design, repeat revasculari-
zation events have not been adjudicated as to their anatomic
location (5); therefore, clinical events cannot be necessarily
ascribed to the LMCA lesion treatment. However, speciﬁ-
cally for SDR analysis, events have been adjusted in multi-
variable analysis for individual patient characteristics,
including additional vessel disease. Finally, Medinaclassiﬁcation according to visual assessment is less precise in
stratifying bifurcation lesion complexity; thus, detailed
subsegmental angiographic analysis would be warranted for
a better understanding of lesion complexity and possible
association with outcomes. As already mentioned, 3D QCA
analysis was not pre-speciﬁed in the SYNTAX trial
protocol; therefore, such detailed results are not available139
Table 5. Predictors of 5-Year MACCE in Patients With LMCA
Bifurcation PCI
Crude p Value Adjusted p Value
Prior myocardial infarction 1.99 (1.21–3.27) 0.007
Unstable angina 1.85 (1.13–3.03) 0.014
Diabetes mellitus 1.69 (1.00–2.85) 0.050
LVEF <30% 5.26 (1.90–14.6) 0.001 7.53 (2.63–21.6) <0.001
Additive EuroSCORE* 1.07 (1.001–1.15) 0.046
Total stents per patient* 1.17 (1.06–1.28) 0.001 1.13 (1.03–1.24) 0.009
Total stent length
per patient*
1.005 (1.00–1.01) 0.04
Post-PCI SDR <10 2.65 (1.58–4.44) <0.001 2.65 (1.55–4.52) <0.001
Values are hazard ratio (95% conﬁdence interval). *Per unit increase.
Abbreviations as in Tables 1, 3, and 4.from the current analysis. Angiographic analysis including
prospective collection of BA data in the ongoing EXCEL
(Evaluation of Xience Prime Everolimus Eluting Stent
System [EECSS] or Xience V EECSS or Xience Xpedition
EECSS of Xience Pro EECSS Versus Coronary Artery
Bypass Surgery for Effectiveness of Left Main Revasculari-
zation) trial on w3,100 patients undergoing LMCA PCI
could help us shed more light on this subject.Conclusions
This study assessed the impact of 3D distal BA parameters
on 5-year clinical outcomes after LMCA PCI on the basis of
the largest randomized trial to date. A restricted post-
procedural systolic-diastolic distal BA range translated into
signiﬁcantly higher adverse event rates 5 years after LMCA
bifurcation PCI; on the contrary, pre-procedural distal BA
did not affect the long-term clinical outcomes. It is possible
that this study provides us with new insights into the
biomechanics of stent failure in bifurcation lesions, the
LMCA bifurcation being the most important of all in
the human coronary tree.
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Abstract
Aims: Tryton side branch (SB) reverse culotte stenting has been employed for the treatment of left main 
(LM) stem bifurcations in patients at high risk for bypass surgery. The aim of this study was to assess acute 
angiographic results and six-month clinical outcome after implantation of the Tryton stent in the LM.
Methods and results: We studied 52 consecutive patients with LM disease treated in nine European centres. 
Angiographic and clinical data analysis was performed centrally. Fifty-one of 52 patients (age 68±11 yrs, 75% 
male, 42% unstable angina, SYNTAX score 20±8) were successfully treated with the Tryton stent. Medina class 
was 1,1,1 in 33 (63%), 1,0,1 in 7 (13%), 1,1,0 in 3 (6%), 0,1,1 in 8 (4%) and 0,0,1 in 1 (2%). The Tryton stent on 
a stepped balloon (diameter 3.5-2.5 mm) was used in 41/51 (80%) of cases. The mean main vessel stent diameter 
was 3.4±0.4 mm with an everolimus-eluting stent employed in 30/51 (59%) of cases. Final kissing balloon dilata-
tion was performed in 48/51 (94%). Acute gain was 1.52±0.86 mm in the LM and 0.92±0.47 mm in the SB. The 
angiographic success rate was 100%; the procedural success rate reached 94%. Periprocedural MI occurred in three 
patients. At six-month follow-up, the TLR rate was 12%, MI 10% and cardiac death 2%. The hierarchical MACE 
rate at six months was 22%. No cases of definite stent thrombosis occurred.
Conclusions: The use of the Tryton stent for treatment of LM bifurcation disease in combination with a con-
ventional drug-eluting stent is feasible and achieves an optimal angiographic result. Safety of the procedure 
and six-month outcome are acceptable in this high-risk lesion PCI. Further safety and efficacy studies with 
long-term outcome assessment of this strategy are warranted.
KEYWORDS
• 3-D quantitative 
coronary 
angiography
• dedicated 
bifurcation stents
• left main stem 
bifurcation
• procedural success
• six-month MACE
145
Introduction
Stenting of the left main (LM) stem is increasingly recognised as 
a valid revascularisation strategy in patients with significant dis-
ease involving this important segment of the coronary tree. 
Although coronary artery bypass surgery (CABG) is considered 
a superior treatment option for LM disease, some patient subgroups 
may still benefit from revascularisation by PCI. Randomised trials 
of LM PCI versus CABG have repeatedly revealed target vessel 
revascularisation (TVR) as the Achilles heel of the former1. How-
ever, recent studies have shown that patients with less diffuse coro-
nary disease in low SYNTAX score tertiles have comparable 
outcomes with PCI and CABG2. Having secured at least a similar 
safety profile, PCI of LM stenosis has been upgraded to a class IIa 
or IIb indication in the current European Society of Cardiology/
European Association for Cardio-Thoracic Surgery and American 
College of Cardiology/American Heart Association practice 
guidelines3,4.
Not all LM lesions have similar outcomes and, in fact, involve-
ment of the LM bifurcation is associated with suboptimal short-
term and long-term results when conventional stents are employed. 
Poor angiographic results are often obtained with the use of a pro-
visional stenting technique in cases where the side branch (SB) is 
significantly diseased. Refinement of interventional techniques and 
the introduction of dedicated devices may improve the outcome of 
LM PCI. The use of a dedicated bifurcation stent – the Tryton side 
branch stent in conjunction with a conventional stent in a “reverse 
culotte” technique – facilitates stenting and may potentially improve 
angiographic results and clinical outcome in patients who undergo 
LM bifurcation intervention. Indeed, use of this dedicated stent has 
been increasing in the “real world” even in “off-label” anatomic 
locations, including the LM bifurcation5.
The aim of the present study was to assess the acute angiographic 
outcome of LM bifurcation treatment with the Tryton stent (Tryton 
Medical, Inc., Durham, NC, USA) in conjunction with a conven-
tional stent. The acute and mid-term clinical outcome up to six 
months was also investigated.
Methods
The Tryton LM registry was established by retrospective inclusion 
of patients treated in nine European centres by very experienced 
operators. Procedural and clinical data of all consecutive patients in 
whom treatment of the LM with a Tryton stent was attempted were 
collected on a purposely designed electronic case report form 
(CRF), which was sent to the investigators. The investigators at 
each centre (see authors) were responsible for filling in the forms 
and vouch for the integrity of the data provided centrally for analy-
sis. Angiography films of the procedures and follow-up angiograms 
(when available) were collected centrally and analysed by three 
experienced interventional cardiologists (MM, CG, RJvG).
In this report, we present the data of the first 52 patients with LM 
bifurcation disease in whom the operators intended to use the 
Tryton stenting technique. The inclusion period spanned May 2008 
to October 2011.
Prespecified primary endpoints of the study included acute gain 
in the three segments of the bifurcation as measured by quantitative 
coronary angiography (QCA) as well as procedural and six-month 
clinical outcome in terms of major adverse cardiac events (MACE).
Patient population
Patients included were selected by the operators and, whenever fea-
sible, after case discussion by a heart team. In general, patients 
were either unfit for surgery, had previous bypass surgery, had iso-
lated LM with low SYNTAX scores or presented as an emergency. 
The size of the Tryton stent available at the time of patient enrol-
ment limited the range of vessel sizes that could be treated. The 
visually estimated reference diameter of the main vessel (MV) 
could be 2.5-5.0 mm and that of the SB in the range 2.5-2.75 mm. 
Also, the LM had to be ≥7 mm in length to allow an adequate land-
ing zone of the proximal part of the stent. However, the decision to 
treat the bifurcation and employ a Tryton stent remained at the dis-
cretion of the treating interventional cardiologist.
Device description and deployment sequence
The Tryton stent is a balloon-expandable cobalt chromium stent 
with strut thickness of 84 µm. The stent is available in one standard 
length of 19 mm and has three distinct zones: a distal SB zone, 
which is 6.5 mm long, a central transition zone 4.5 mm in length, 
and a proximal MV zone of 8 mm. The distal zone has a standard 
slotted tube workhorse stent design; the central transition zone con-
sists of three panels, while the proximal MV zone is composed of 
three fronds that terminate proximally in two circumferential bands 
(only one in the first-generation device). The stent is mounted either 
on a balloon with uniform diameter (straight type) or on a stepped 
balloon (tapered type). Stent sizes (proximal-distal) available during 
the study period were 2.5-2.5; 3.0-2.5; 3.5-2.5 and 3.5-3.0. The stent 
delivery system has four markers to delineate the proximal and distal 
ends of the stent as well as the proximal and distal parts of the transi-
tion zone. After optional wiring of both MV and SB for predilation, 
the Tryton stent is advanced over the wire into the SB and is posi-
tioned with the guidance of the two middle markers which should 
straddle the carina. Deployment of the stent is followed by retraction 
of the guidewire from the SB and repositioning it through the fronds 
of the transition zone into the distal MV. A standard stent is then 
advanced, positioned, and deployed in the MV, jailing the stented 
SB. Proximal optimisation technique can be employed at this time 
by inflating a balloon the size of the proximal MV with the distal 
marker at the ostium of the SB. This may facilitate wire recross into 
the SB for final kissing balloon (FKB) dilation. A case example is 
presented in Figure 1. Further details of the Tryton stent and deploy-
ment procedure have been described in detail elsewhere6.
Procedure
Patients were pretreated with aspirin and clopidogrel. Intravenous 
heparin was administered to maintain an activated clotting time of 
>250 seconds. Glycoprotein IIb/IIIa inhibitor use was left to the 
discretion of the treating interventional cardiologist. Delivery 
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 failures, need for additional overlapping stents to cover the whole 
lesion, additional balloon dilation and procedural angiographic and 
clinical complications were noted. Aspirin was prescribed indefi-
nitely while clopidogrel was prescribed for at least 12 months after 
the index procedure.
Clinical follow-up
In-hospital events were recorded in the patient’s clinical notes. 
Clinical follow-up was obtained by clinical visits or phone inter-
view during which data on hospital readmission and MACE were 
collected. Medical records, discharge summaries and any repeat 
angiography films of patients with suspected events were system-
atically reviewed and adjudicated by local cardiologists according 
to established criteria defined below.
Definitions
Device success was defined as successful deployment of the intended 
stent without system failure. Angiographic success was defined as 
<30% residual stenosis and TIMI 3 flow in both MV and SB after the 
procedure. Procedure success included angiographic success in the 
absence of in-hospital MACE, defined as a composite of cardiac 
death, myocardial infarction (MI) and ischaemia-driven TVR. MI 
was defined as clinical signs of acute ischaemia, associated with a 
CK-MB mass or troponin-T/troponin-I increase to ≥3 times the upper 
limit of normal and corresponding changes on a 12-lead electrocar-
diogram (ECG). TVR was defined as revascularisation of any part of 
the index coronary artery. Definite stent thrombosis was defined 
according to the Academic Research Consortium (ARC) definitions7.
Angiographic analysis
QUANTITATIVE CORONARY ANGIOGRAPHY
QCA was performed with the Cardiovascular Angiography Analysis 
System (CAAS; Pie Medical Imaging, Maastricht, The Netherlands) 
version 5.10, by experienced analysts blinded to the clinical data. All 
available studies were analysed with a dedicated 2-D bifurcation 
QCA algorithm, using matched projections, pre- and post-procedure, 
and end-diastolic frames. The vessel distal to the LM bifurcation 
where the distal Tryton stent was implanted was defined as the SB, 
whereas the vessel where the conventional stent was implanted was 
identified as the distal main vessel (DMV). A device-oriented analysis 
Figure 1. Implantation sequence of the Tryton stent in the left main stem bifurcation. This 78-year-old man was deemed high risk for surgery 
when he presented with unstable angina pectoris. The left main (LM) stem showed a Medina class 1,1,1 bifurcation lesion and further disease 
in segment 6 (A). The left anterior descending (LAD) and left circumflex (LCx) coronary arteries were wired and the latter was predilated with 
a 2.5 mm balloon (B). A 3.5-2.5×19 mm Tryton stent was positioned with the middle markers straddling the carina (C) and subsequently 
implanted by inflating the stepped balloon (D). The LCx wire was then retracted to the point of bifurcation and redirected into the LAD. After 
removal of the jailed first LAD wire, the LAD was predilated with a balloon (E) and a 3.5×18 mm XIENCE PRIME™ stent (Abbott Vascular, 
Redwood City, CA, USA) was placed along the LAD and across the LCx (F). After implantation of the stent, a second overlapping stent was 
used to treat the stenosis in segment 6 (G). The LCx was then rewired and final kissing balloon inflations were performed (H) with a good 
angiographic result (I).
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was performed, whereby the region of interest around the LM bifur-
cation was demarcated according to the stent borders as identified on 
the positioning/implantation cine runs. Specifically, the Tryton stent 
proximal and distal edges were defined as the proximal border of the 
proximal main vessel (PMV) and the distal SB border, respectively, 
whereas the distal DMV border was set at either the distal edge of the 
DES implanted through the Tryton stent or at the first major SB distal 
to the LM bifurcation in case of multiple overlapping stents. The 
minimal lumen diameter (MLD), reference vessel diameter (RVD) 
and percent diameter stenosis (DS) were quantified for the stented 
vessel segments and 5 mm peri-stent segments. Respective values for 
corresponding stent and segment were obtained from the six-segment 
bifurcation model (segments 1 and 2 for PMV, 3 and 4 for DMV, 5 
and 6 for SB)8; in addition, quantitative parameters for 3 mm ostial 
segments were derived from the 11-segment bifurcation model (seg-
ment 11 and 8 for DMV and SB, respectively) (Figure 2 and Fig-
ure 3). Reference vessel obstruction analysis was performed with 
either the automatic (interpolation) method or local reference method 
(single point for each vessel segment). The second method was 
mostly reserved for diffusely diseased vessel segments prior to treat-
ment9. Finally, proximal and distal bifurcation angle (BA) values 
were calculated.
In the cases where at least two angiographic images of the LM 
bifurcation separated by a viewing angle of ≥30° were available for 
both pre- and post-procedure, a 3-D reconstruction was also per-
formed with a dedicated bifurcation algorithm10. Specifically, 2-D 
analysis was performed first using the 2-D angiographic image 
showing the best (optimal) view of the LM bifurcation. After saving 
the 2-D analysis results (numerical values and graphs) the vessel 
contours of this optimal view were imported into the 3-D analysis 
algorithm together with the second 2-D image, which still required 
contouring following the procedure already described. In the 3-D 
reconstructed image, segmentation of the region of interest and 
reporting of angiographic quantitative parameters were analogous 
with the 2-D analysis; thereby results from 2-D and 3-D analyses 
were directly comparable.
The depth of implantation of the Tryton stent was measured by 
QCA using the two middle markers as illustrated in Figure 4. The 
angiography film showing the positioning of the stent prior to 
implantation was analysed for all but 11 cases in which this was not 
recorded. The distances between the proximal middle marker and 
the carina and the distal middle marker and the carina were meas-
ured. A difference of ≥1 mm between the two measurements was 
identified as inappropriate implantation.
SYNTAX SCORE
SYNTAX score was calculated by an experienced analyst as previously 
described using the programme on the website www.syntaxscore.com11.
STATISTICAL ANALYSIS
Continuous variables are expressed as mean±SD or as median (inter-
quartile ranges) whereas dichotomous data are summarised as counts 
Figure 2. Three-dimensional reconstruction pre- and post-procedure. A1-A2: A left and a right anterior oblique caudal view of a left main 
(0,1,1) bifurcation lesion are shown before stent placement; a Tryton stent will be placed from the proximal main vessel (P) into the side 
branch (S). Thin white lines demarcate the region of interest, whereas the red cross marks the common image point facilitating the 3-D 
reconstruction (A3); the most severe stenosis is located in the side branch ostium. B1-B3: Respective images post-procedure. Stenosis around 
the bifurcation is reduced, whereas minor obstruction is now located distal to the drug-eluting stent in the distal main vessel (M); PCI resulted 
in a slight increase in the 3-D distal bifurcation angle.
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and/or percentages. The paired t-test was employed for comparisons of 
quantitative parameters pre- and post-procedure and between 2-D and 
3-D estimates of the same parameters. Statistical analysis was per-
formed using SPSS software version 20 (SPSS, Chicago, IL, USA).
Results
Fifty-two LM bifurcation lesions were included in the TRYTON LM 
registry between May 2008 and October 2011. Table 1 shows the 
baseline characteristics of the study cohort. The mean age of patients 
was 68.3±10.8 years and 75% were male. Fifty-eight percent of 
patients presented for PCI with stable angina while 25% presented 
with a myocardial infarction and 8% were in cardiogenic shock.
Coronary lesion characteristics are summarised in Table 1. The 
average SYNTAX score was 20±8 and 19% of patients had a previ-
ous CABG. Five patients had two bifurcation lesions that needed 
revascularisation. Eighty-five percent of lesions were true bifurcation 
lesions (1,0,1 or 1,1,1 or 0,1,1) .
The mean reference diameters for the LM stem, DMB and SB 
were 4.00, 2.63 and 2.48 mm, respectively. The mean DS was 
39.5%, 36.2% and 41.8% for LM, DMB and SB, respectively. The 
mean angle between the LM and the SB was 139.4˚, while that 
between the DMB and the SB was 78.5˚.
All stents implanted during the procedure except for the Tryton 
stent were drug-eluting. Failure of delivery of the Tryton stent 
occurred in one patient despite repeated predilatation of a heavily cal-
cified LM and a very tight lesion of the left circumflex (LCx) coro-
nary artery. Eventually, a conventional drug-eluting stent (DES) was 
placed with a good angiographic result. For the rest of the cohort, a 
Tryton stent on a stepped balloon with a diameter of 3.5-2.5 mm was 
successfully deployed in 41/51 (80%) cases. In 11/51 (22%) cases, 
the distal zone of the Tryton stent was implanted in the left anterior 
descending (LAD) coronary artery. Six (55%) of these cases were pro-
tected by a left internal mammary artery. For the remaining five 
(45%), the LCx was larger in diameter than the LAD and the operator 
chose the latter as the “side branch”. The mean MV stent diameter 
Figure 3. Bifurcation segment models in the Cardiovascular Angiography Analysis System (CAAS). Segments 2, 3 and 5 in both models reflect 
the segments where the stents were placed in the proximal main vessel (P), distal main vessel (M) and side branch (S), respectively; segments 
1, 4 and 6 are corresponding 5 mm-long peri-stent segments. Segments 8 and 11 in the extended model (B) reflect 3 mm-long ostial segments 
for the side branch and distal main vessel, respectively.
Table 1. Baseline clinical and angiographic characteristics.
Baseline clinical characteristics n=52
Age, years 68.3±10.8
Male sex 75% (39)
Hypertension 60% (31) 
Diabetes 38% (20) 
Hypercholesterolaemia 58% (30) 
Current smoker 17% (9) 
Family history of coronary artery disease 30% (16) 
End stage renal failure 2% (1)
Previous percutaneous coronary intervention 35% (18) 
Previous coronary artery bypass surgery 19% (10) 
History of myocardial infarction 29% (15)
Clinical presentation
Stable angina 58% (30)
Unstable angina 17% (9)
ST-segment myocardial infarction 2% (1)
Non-ST-segment myocardial infarction 23% (12)
Cardiogenic shock 8% (4)
Angiographic characteristics
SYNTAX score 20±8
Left main stem bifurcation
MEDINA classification
1,1,1 63% (33)
1,1,0 6% (3)
1,0,1 13% (7)
1,0,0 0% (0)
0,1,1 8% (4)
0,0,1 2% (1)
0,1,0 0% (0)
Functional LIMA on LAD 19% (10)
LAD: left anterior descending coronary artery; LIMA: left internal 
mammary artery graft
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was 3.4±0.4 mm with an everolimus-eluting stent employed in 30/51 
(59%) of cases. FKB dilatation was performed in 48/51 (94%) bifur-
cation lesions. Table 2 summarises procedural parameters.
There were no device-related complications except for one deliv-
ery failure. Thus, the device success rate was 98%. Angiographic 
Table 2. Procedural characteristics.
Characteristics
Tryton implanted in LAD 22% (11/51) 
Tryton implanted in intermediate artery 2% (1/51)
Main vessel stent size
Diameter, mm 3.4±0.4
Length, mm 22.9±4.9
Main vessel stent type
Everolimus-eluting 59% (30/51)
Biolimus-eluting 14% (7/51)
Zotarolimus-eluting 8% (4/51)
Other DES 19% (10/51)
Additional stent in the side branch 15/49 (30%)
Additional stent in the main vessel 13/49 (27%)
Final kissing balloons 94% (48/51)
Device success 51/52 (98%)
Procedural success 49/52 (94%)
DES: drug-eluting stents; LAD: left anterior descending coronary artery
Figure 4. Depth of implantation assessement. The Tryton stent delivery system has four markers (depicted in orange boxes): the outer markers 
delineate the proximal and distal ends of the stent, while the two middle markers delineate the transition zone (A). The two middle markers (black 
arrows on angiographic images) should straddle the carina (white triangle) during implantation. Equal distances between the proximal middle 
marker (yellow arrow) and the distal middle marker (blue arrow) to a line perpendicular to the carina indicate appropriate implantation depth as 
exemplified in B and B.1. The implantation in C and C.1 is not deep enough (yellow>blue arrow), while that in D and D.1 is too deep (yellow<blue).
success was achieved in all patients (100%). One patient had a non-
flow-limiting dissection in the LAD following deployment of a MV 
conventional stent that was used in combination with the Tryton stent 
for treatment of a LAD/diagonal branch bifurcation lesion. The dis-
section at the proximal edge of the stent was covered by placement of 
an additional stent and the operator went on to treat the LM bifurca-
tion with a second Tryton stent, achieving a good result. The patient 
had no evidence of periprocedural infarction. A second patient also 
had two Tryton stents deployed to treat two bifurcation lesions during 
the same procedure with a good result. In total, three patients devel-
oped periprocedural MI without angiographic complications so that 
procedural success reached 94%.
QCA RESULTS
Two-dimensional analysis was performed in 46 cases. The other 
cases had to be excluded due to inadequate cineangiography either 
pre- or post-procedure (no clear view of the bifurcation, overlap-
ping vessel segments, presence of angiographic guidewires). 
Results for diameter-derived parameters for the overall 2-D analy-
sis are shown in Table 3A. Acute gain in the LM and in the SB was 
1.52±0.86 mm and 0.92±0.47 mm, respectively.
Three-dimensional analysis was feasible in 14 cases and results 
for diameter-derived parameters are shown in Table 3B. On aver-
age, two-dimensional BA values were larger as compared to the 
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3-D ones, both pre- and post-procedure (Table 4). However, the dif-
ference was significant for pre-PCI proximal BA values (145.1° vs. 
132.4°, p=0.03) only.
From the 46 angiography films analysed with 2-D QCA, the proximal 
BA changed by ≥5˚ in 65% (28/43) of cases, while the distal BA changed 
by more than ≥5˚ in 74% (32/43) of cases. For the distal BA, most cases 
with a change showed a narrowing of the angle and this occurred in 54% 
of the QCA cohort. On the other hand, the proximal BA most commonly 
widened (40% of cases) or remained the same (35%).
Depth of implantation of the Tryton stent was assessable in 77% 
(40/52) of cases. Depth was deemed appropriate in 38% (15/40). In 
43% (17/40) of those assessed, the implantation was not deep 
enough, while in 20% (8/40) implantation was too deep. These 
results are summarised in Table 5.
Table 3B. 2-D and 3-D QCA analysis of left main bifurcation pre- and post-procedure in 3-D analysable cases (n=14).
Pre-procedure in-stent
2-D 3-D
MLD RVD DS MLD RVD DS
PMV 2.61±1.08 4.05±0.73 36.41±20.72 2.82±0.99 3.83±0.67* 26.55±20.75**
DMV 1.55±0.49 2.48±0.30 37.19±18.88 1.61±0.63 2.54±0.38 37.39±18.25
SB 1.31±0.41 2.46±0.44 45.93±17.75 1.41±0.49 2.41±0.54 41.22±18.21
Tryton 1.38±0.48 3.13±0.70 55.77±12.70 1.45±0.56 2.84±0.85 48.17±15.46**
Ostial DMV 1.72±0.61 2.52±0.29 31.82±21.25 1.81±0.70 2.54±0.40 29.36±20.52
Ostial SB 1.44±0.55 2.45±0.43 40.77±22.94 1.54±0.62 2.40±0.53 35.96±23.33*
Post-procedure in-stent
2-D 3-D
MLD RVD DS MLD RVD DS
PMV 3.99±0.73 4.51±0.67 11.41±9.41 4.13±0.70 4.52±0.70 8.55±6.78
DMV 2.82±0.48 3.30±0.42 14.51±8.17 2.83±0.45 3.29±0.38 14.15±7.20
SB 2.38±0.39 2.86±0.50 16.70±6.86 2.42±0.35 2.78±0.46 12.55±4.82*
Tryton 2.83±0.87 3.53±1.15 19.38±6.03 2.60±0.55 3.04±0.71 13.95±4.51**
Ostial DMV 3.09±0.46 3.33±0.37 7.27±8.45 3.14±0.48 3.35±0.41 6.53±6.93
Ostial SB 2.49±0.46 2.87±0.50 13.12±8.29 2.56±0.47 2.82±0.50 9.06±7.30
2/3-D: two/three-dimensional; DMV: distal main vessel; DS: percent diameter stenosis; MLD: minimal lumen diameter; PMV: proximal main vessel; 
QCA: quantitative coronary angiography; RVD: reference vessel diameter; SB: side branch; *p≤0.05 compared to 2-D; ** p≤0.01 compared to 2-D
Table 3A. 2-D QCA analysis of left main bifurcation pre- and post-procedure (n=43).
Pre-procedure Post-procedure
In-stent In-stent
MLD (mm) RVD (mm) DS (%) MLD (mm) RVD (mm) DS (%) Acute gain p-value
PMV 2.42±0.98 4.00±0.77 39.5±20.2 3.94±0.75 4.50±0.82 11.9±9.9 1.52±0.86 <0.0001
DMV 1.67±0.51 2.63±0.43 36.2±17.6 2.75±0.41 3.26±0.43 15.5±8.9 1.07±0.58 <0.0001
SB 1.44±0.51 2.48±0.46 41.8±18.7 2.35±0.39 2.83±0.42 16.6±9.0 0.92±0.47 <0.0001
Tryton stent 1.62±0.78 3.34±0.90 51.7±17.5 2.78±0.86 3.51±1.14 20.1±8.7 1.16±0.97 <0.0001
Ostial DMV 1.91±0.64 2.68±0.43 28.6±19.3 3.06±0.53 3.33±0.42 8.3±9.1 0.87±0.56 <0.0001
Ostial SB 1.58±0.61 2.48±0.44 36.1±21.4 2.46±0.42 2.84±0.42 13.2±9.9 1.15±0.58 <0.0001
In-segment In-segment
MLD (mm) RVD (mm) DS (%) MLD (mm) RVD (mm) DS (%) Acute gain p-value
PMV 2.42±0.98 4.00±0.77 39.5±20.2 3.86±0.65 4.49±0.82 13.5±8.8 1.43±0.80 <0.0001
DMV 1.65±0.50 2.62±0.43 36.9±16.9 2.52±0.48 3.26±0.45 22.6±10.8 0.87±0.53 <0.0001
SB 1.41±0.51 2.48±0.46 42.8±18.4 2.15±0.44 2.81±0.42 23.6±11.1 0.74±0.52 <0.0001
Tryton stent 1.62±0.78 3.34±0.90 51.7±17.5 2.42±0.83 3.25±1.04 25.6±10.3 0.79±0.99 <0.0001
Ostial DMV N/A N/A N/A
Ostial SB N/A N/A N/A
2-D: two-dimensional; DMV: distal main vessel; DS: percent diameter stenosis; MLD: minimal lumen diameter; N/A: non-applicable; PMV: proximal 
main vessel; QCA: quantitative coronary angiography; RVD: reference vessel diameter; SB: side branch
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Table 6. Acute and 6-month clinical outcome.
Periprocedural adverse events 
Procedure-related MI 6% (3/50)
Target vessel revascularisation 0 (0/50)
ARC definite stent thrombosis 0 (0/50)
Cardiac death 0 (0/50)
MACE (hierarchical) 6% (3/50)
30-day adverse events
Myocardial infarction 6% (3/50)
Target vessel revascularisation 0% (0/50)
ARC definite stent thrombosis 0% (0/50)
All-cause death 4% (2/50)
Cardiac death 0% (0/50)
MACE (hierarchical) 6% (3/50)
6-month adverse events
Myocardial infarction 10% (5/50)
Target vessel revascularisation 12% (6/50)
Main vessel 12% (6/50)
Side branch 2% (1/50)
ARC definite stent thrombosis 0% (0/50)
All-cause death 6% (3/50)
Cardiac death 2% (1/50)
MACE (hierarchical) 22% (11/50)
Table 4. Bifurcation angles pre and post Tryton implantation.
Preprocedural Postprocedural
LM-SB DMB-SB LM-SB Angle change p-value DMB-SB Angle change p-value
2-D QCA (n=43) 139.4±34.7 78.5±32.7 142.8±29.2 3.4±18.8 0.24 75.2±27.1 –3.39±24.0 0.36
3-D QCA (n=14) 132.4±15.0 65.5±18.7 134.0±17.5 1.58±11.5 0.62 65.7±16.8 0.19±19.6 0.97
Table 5. Depth of implantation.
Tryton implantation parameters
Tryton successfully implanted 98% (51/52)
Implantation depth assessable 77% (40/51)
Proximal middle marker to carina distance, mm 3.11±1.85
Distal middle marker to carina distance, mm 1.35±1.87
Appropriate implantation 38% (15/40)
Implantation too deep 20% (8/40)
Implantation not deep enough 43% (17/40)
CLINICAL FOLLOW-UP
At a median of six months, one patient of the entire cohort treated 
with the Tryton stent was lost to follow-up. The events in the rest 
as well as the hierarchical MACE are reported in Table 6. One 
patient died of cardiovascular complications at 83 days after the 
index procedure. Two other patients died of non-cardiac causes, 
one from septic shock and the other from a gastrointestinal bleed. 
Apart from the three periprocedural MIs, two other patients suf-
fered a NSTEMI at 55 days and 92 days post procedure, respec-
tively. In the first patient, angiography revealed no obvious 
restenosis or culprit lesion, whereas in the second restenosis with 
a hazy lesion in the SB ostium was treated with balloon angio-
plasty. In total, six patients had TVR, all involving the SB, with 
one of them being referred for CABG because of concomitant MV 
and SB restenosis. All cases of TVR occurred in the side branch 
with QCA-derived reference diameter of <2.3 mm. The depth of 
implantation in cases of TVR was appropriate in two, too deep in 
two and not deep enough in two.
On further analysis of the baseline and follow-up angiography films 
of cases with restenosis, the following observations were made: all 
cases of restenosis involved the SB ostium. Evaluation of procedural 
steps revealed prolonged attempts at rewiring of the SB for FKB.
No cases of definite stent thrombosis were reported.
Discussion
Use of the Tryton side branch stent for treatment of LM bifurcation 
lesions was associated with a high rate of device and procedural 
success without complications in such a high-risk patient and lesion 
cohort. The angiographic result is excellent with optimal acute 
luminal gain in all three segments of the bifurcation including the 
distal MB and SB ostia as measured by 2-D and 3-D QCA. Although 
BA changes were observed to similar extents as previously 
described for two-stent techniques, they were not associated with 
adverse events at follow-up. At six months, TLR (12%) was due 
almost exclusively to SB ostium restenosis, an event that warrants 
in-depth evaluation.
Previous studies have shown that PCI of the LM has two distinct 
anatomical subcategories distinguished by their differential outcome 
in terms of restenosis. In fact, while treatment of disease limited to 
the shaft compares well with CABG results, that of the bifurcation is 
limited by excessive revascularisation rates. A LM substudy from the 
j-Cypher Registry found a three-year TVR rate of 3.6% for ostial 
lesions and significantly higher rates (17.1%) after bifurcation stent-
ing with early-generation sirolimus-eluting stents12. Two-stent strate-
gies including crush, culotte and T stenting provide better 
angiographic results at the expense of a more complex procedure 
with higher risk of complications and lack of superiority or even infe-
riority in terms of efficacy when compared to provisional T stenting. 
Reports of a 30.9% TVR rate at three years with two-stent techniques 
compared with a more acceptable 11.1% for provisional stenting are 
a matter of some concern12. An Italian survey also reported similar 
152
rates at two years with a similar difference between simple and more 
complex techniques (TLR-free survival 87% vs. 73%)13. Such trends 
are maintained up to five-year follow-up14. It is worth noting that the 
majority of two-stent techniques employed in these studies were 
crush and T stenting with under-representation of culotte stenting. 
The latter has the potential advantage of a better scaffolding of the 
distal vessel ostia and at the same time may minimise the number of 
unopposed struts at the bifurcation. In true bifurcation lesions with 
significant SB involvement, these features may be particularly advan-
tageous. The Tryton stent facilitates the reverse culotte technique 
and, as shown in previous reports, it simplifies the interventional 
technique leading to a low intraprocedural complication rate and 
excellent angiographic results. In our current registry, these theoreti-
cal advantages still resulted in a TLR rate of 12% at six months. 
Some important device-dependent and operator-dependent features 
have to be considered in order to understand how these may interact 
to affect clinical outcome.
DEPTH OF IMPLANTATION
The middle markers on the Tryton stent delivery system are essential 
to guide the desired depth of implantation of the device. Straddling 
the carina between the two markers allows correct positioning of the 
stent transition zone, resulting in good scaffolding of the SB ostium. 
This zone has a lower radial strength than the SB zone due to the 
design, which on the other hand allows for easier recross of wires, 
balloons and stents across it and along the MV. Therefore, a balance 
has to be sought, as implanting the device too deep will result in poor 
SB ostial scaffolding while too shallow an implantation will result in 
difficult MV rewiring. Most operators in our series preferred to keep 
the major part of the transition zone in the MV. This strategy probably 
provides better scaffolding of the SB ostium, while recrossing into 
the relatively large MV was not associated with any significant dif-
ficulty. Theoretically, this issue would be best explored with the use 
of intraprocedural intravascular ultrasound (IVUS) or optical coher-
ence tomography (OCT). However, it should be noted that inappro-
priate implantation depth was not predictive of restenosis up to six 
months post procedure.
STENT SIZING
Small branch vessels treated with the Tryton stent were more likely 
to have restenoses at follow-up. Indeed, five of the seven cases with 
restenosis at six months occurred in vessels less than 2 mm by QCA. 
Introduction of a drug-eluting version of the Tryton stent may poten-
tially overcome this problem in vessels ≤2.5 mm in diameter.
CHANGE IN BIFURCATION ANGLE AFTER TRYTON-
CONVENTIONAL STENT IMPLANTATION
Cardiac motion may change BA, namely widening the angle 
between the LM and the LCx, and simultaneously narrowing the 
angle between the LAD and the LCx by about 8˚15. PCI of the LM 
bifurcation also changes the angle in most instances, narrowing it 
by about 5˚. Our study showed similar changes with the use of 
a dedicated bifurcation stent.
In a recent 3-D QCA study, a change of ≥5° between either the 
PMB and SB or DMB and SB after stenting was considered signifi-
cant. Of the 102 bifurcations included in the study, 15 involved the 
LM. The angle between the DMB and SB changed significantly. Of 
note, the angle became wider with the use of complex as compared 
to simple bifurcation stenting techniques. However, this was not 
associated with adverse events. On the other hand, widening of the 
angle between the PMB and SB was associated with fewer events, 
while angle narrowing resulted in a higher rate of complications16. 
In our study, neither the angle at baseline nor a change in the angle 
after PCI was associated with adverse events, including restenosis. 
This, however, does not exclude a higher postulated risk of bifurca-
tion restenosis with very wide angles between the DMB and SB, as 
scaffolding at the point of bifurcation may be reduced. Such bifur-
cations are under-represented in our study cohort, reflecting appro-
priate selection of cases based on the anatomy by the treating 
interventional cardiologist. Therefore, the impact of bifurcation 
angle change on outcome in LM intervention in appropriately 
selected cases certainly remains limited.
OTHER PROCEDURAL CHARACTERISTICS THAT MAY HAVE 
AN IMPACT ON OUTCOME
Technical strategies to ensure long-term patency include lesion 
preparation with rotational atherectomy if lesions are significantly 
calcified, balloon predilatation17, use of cutting balloons when 
needed, implantation of stents at relatively high pressures, and post-
dilatation with non-compliant balloons. Use of IVUS imaging18 
may be of help in assessing the need for predilatation or atherec-
tomy, in appropriately sizing the vessel, and to evaluate the need for 
further post-dilatation after stenting in order to ensure good acute 
luminal gain. In patients undergoing bifurcation lesion PCI, FKB 
dilation has a positive effect on acute angiographic results, which 
seems to translate into better clinical outcome19. Indeed, the Nordic-
Baltic Bifurcation Study III showed that FKB dilation reduced 
angiographic SB restenosis at six months in bifurcation lesions 
other than distal LM, especially in patients with true bifurcations 
(7.9% vs. 15.4% [p=0.039] for all bifurcations and 7.6% vs. 20.0% 
[p=0.024] for true bifurcations)20. Prolonged attempts at rewiring 
the SB for FKB were noted on detailed analysis of the Tryton cases 
needing revascularisation at follow-up in the current registry. We 
can speculate that this may be the result of passage of the wire 
behind the struts of the SB ostial portion of the Tryton stent (pre-
sumably at the transition zone). If that is the case, kissing inflations 
would crush the transition zone against the ostium, resulting in 
reduced carina scaffolding despite the optimal acute angiographic 
result and restenosis. Another possible cause of SB restenosis could 
be the lack of an antiproliferative drug coating on the Tryton stent 
implanted in a site at high risk of restenosis, such as the LCx ostium.
QCA FOR BIFURCATION ANALYSIS
The mean values for diameter stenosis established by QCA analysis 
in the cohort are less than 50% in all three segments of the bifurcation. 
This implies that such measurements were not used in isolation to 
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determine whether the LM bifurcation should be treated or not. 
Discrepancy between eyeballing and QCA (overestimation of 
eyeballing), use of complimentary parameters such as lesion insta-
bility, pressure drop on engagement of the LM and other physiolog-
ical parameters may have instigated treatment. Angiographic 
derivation of the reference vessel diameter prior to intervention 
may underestimate the true lumen diameter, especially in diffusely 
diseased segments. In fact after stent implantation we observed an 
enlargement of the RVD. This occurs commonly with the LM since 
it is an end vessel and involvement starting from the ostium pre-
cludes measurement of the true RVD by angiography on the pre-
treatment film. Despite these plausible reasons for the low DS in 
treated LM bifurcations, we still cannot exclude overtreatment, i.e., 
intervention of apparently non-significant lesions with the interven-
tionalist being keen to treat if there is doubt about the significance 
as it is the LM.
LIMITATIONS
The present study has the intrinsic limitations of a registry. These 
cases are selected and therefore may not reflect use in all-comer LM 
lesions. In particular, the limited Tryton stent sizes available at the 
time of implantation may have affected the outcome. Therefore, it is 
more likely that the present results reflect stent performance in the 
range of vessel sizes treated in our cohort. There was no control group 
to compare the use of this dedicated bifurcation stent and stenting with 
other devices and techniques. Moreover, the number of patients 
enrolled in the registry is too limited to draw conclusions on definite 
and reproducible clinical outcome rates. Also, the majority of patients 
enrolled had no angiographic or other invasive imaging follow-up. 
QCA was not possible in 100% of the cohort for the reasons explained 
above. The use of intravascular imaging techniques (IVUS or OCT) 
was not available in the majority of cases and would have been useful 
for better evaluation of the cases of stent failure.
Conclusions
Use of the Tryton stent for treatment of LM bifurcation disease in 
combination with a conventional drug-eluting stent is feasible and 
results in optimal acute angiographic results. Safety of the proce-
dure and six-month clinical outcome are acceptable in this high-risk 
lesion PCI; further prospective safety and efficacy studies with 
intravascular imaging as well as long-term outcomes of this strategy 
are warranted.
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The SYNTAX Score Revisited: A Reassessment of the
SYNTAX Score Reproducibility
Scot Garg,1 MBChB, MRCP, Chrysaﬁos Girasis,1 MD, Giovanna Sarno,1 MD, PhD,
Dick Goedhart,2 PhD, Marie-Ange`le Morel,2 BSc, Hector M. Garcia-Garcia,2 MD, PhD,
Marco Bressers,2 MSc, Gerrit-Anne van Es,2 PhD, and Patrick W. Serruys,1* MD, PhD,
on behalf of the SYNTAX trial investigators
Objectives: To reassess the reproducibility of the SYNTAX score. Background: The
SYNTAX score appears to have an important role to play in the evaluation of patients
with complex coronary artery disease undergoing revascularisation. However, the cal-
culation of the SYNTAX score relies on the subjective assessment of lesions using cor-
onary angiography, and therefore is subject to intra-and inter-observer variability.
Methods: The SYNTAX score was calculated in 100 patients randomly selected from
the SYNTAX trial, on two occasions 8 weeks apart, by a team made up of three inter-
ventional cardiologists. The weighted kappa values were compared with values
obtained 1 year previously, when core lab analysts assessed the intra-observer repro-
ducibility amongst the same patient cohort. Results: The mean 6 standard deviation
difference in SYNTAX score was 2.1 6 7.6. The respective weighted kappa values for
the number of lesions, bifurcation lesions, ostial lesions, and total occlusions were
0.62, 0.36, 0.66, and 0.91 compared with 0.59, 0.41, 0.63, and 0.82 in the previous core
lab assessment. The weighted kappa for the intra-observer reproducibility of the SYN-
TAX score grouped into deciles was 0.54, and according to the terciles 22, >22–32,
>32 was 0.51 both indicating a moderate level of agreement beyond the level of
chance. In the previous assessment, the comparative kappa values were 0.45 and 0.53.
Conclusions: The SYNTAX score has moderate intra-observer reproducibility when
assessed by a team of three interventional cardiologists, which is consistent with a
prior evaluation performed by core lab analysts. The scoring of bifurcation lesions
remains the main source of inconsistency. VC 2009 Wiley-Liss, Inc.
Key words: SYNTAX score; intra-observer variability; SYNTAX trial
INTRODUCTION
Coronary artery bypass grafting (CABG) has histori-
cally been the preferred method of revascularisation in
patients with complex coronary artery disease (CAD);
however, recent evidence indicates that in speciﬁc
groups of patients, percutaneous coronary intervention
(PCI) can offer a safe and efﬁcacious alternative
treatment [1–4]. This expanding use of PCI [5] has
consequently increased the importance of developing a
systematic approach for risk stratifying these complex
patients. The ability to objectively decide, which
patients with complex CAD are suitable for PCI has
gained new ground recently following the introduction
of the SYNTAX score [6,7]. This lesion based scoring
system cannot only quantify coronary anatomy, but
studies also demonstrate that it has a role in the short
and long term risk stratiﬁcation of patients having per-
cutaneous revascularisation [1,4,8–10].
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The SYNTAX score is calculated using lesion
assessment based on coronary angiography, however,
this is subject to intra- and inter-observer variability
[11–13], which may ultimately affect the overall repro-
ducibility of the score. A poorly reproducible score
will limit its clinical application, and in particular will
make guideline recommendations based on speciﬁc
scores of limited value. The aim of this study was to
reassess the intra-observer SYNTAX score reproduci-
bility, and compare it to previously reported values,
which were obtained from an assessment by core lab
analysts (Cardialysis, Rotterdam, The Netherlands) of
the same patients 1 year earlier [7].
METHODS
Study Population
The study population comprised of 100 coronary
angiograms, which had been randomly selected from
patients who had been enrolled in the SYTNAX trial
[1]. These angiograms were exactly the same as those
which had been assessed in a previous intra-observer
reproducibility evaluation of the SYNTAX score,
which is described in full elsewhere [7].
SYNTAX Score Calculation
The SYNTAX score for each patient was calculated
prospectively by a team of three interventional cardiol-
ogists who scored all coronary lesions with a diameter
stenosis 50%, in vessels 1.5 mm, using the SYN-
TAX score algorithm, which is described in full else-
where [6,7] and is available on the SYNTAX score
website (www.syntaxscore.com) [14]. All three investi-
gators reviewed the coronary angiogram, and decided
by consensus: (i) the number of signiﬁcant lesions that
were present, (ii) which coronary segments were
involved, and (iii) the presence of any adverse lesion
characteristics. Once agreement had been reached one
investigator entered the data onto a dedicated software
package. The investigators were blinded to the clinical
baseline characteristics, procedural data, clinical out-
comes, and previously calculated SYNTAX score. Fur-
thermore, investigators continued to remain blinded to
the calculated SYNTAX score even after the all lesion
variables had been recorded.
Intra-Observer Reproducibility
To assess intra-observer reproducibility, the angio-
grams were reanalyzed by the same team of three
interventional cardiologists 8 weeks after the ﬁrst anal-
ysis. The investigators remained blinded to the results
of the ﬁrst analysis.
Statistics
The justiﬁcation for a sample size of 100 coronary
angiograms is provided elsewhere, [7] but in brief a
power calculation revealed that a group size of 100
coronary angiograms would be more than sufﬁcient to
achieve a reasonable and precise kappa-value.
The extent of intra-observer agreement beyond the
level of chance was measured as a percentage of the
total agreement using the kappa statistic. This is rou-
tinely used to assess the level of agreement between
two or more categorical observations in excess of a
chance agreement [15]. The kappa value was calcu-
lated using the standard formula: [observed agreement
 expected agreement]/[1  expected agreement]. The
qualitative classiﬁcation of the kappa value used to
interpret the degree of agreement beyond chance is
shown in Table I [16]. The standard kappa does not
take into account the degree of disagreement between
observers and all disagreement is treated equally as
total disagreement. Therefore, the Cicchetti-Allison
method was used to calculate the weighted kappa to
allow the relative differences between categorical vari-
ables to be appropriately quantiﬁed [17]. Those obser-
vations on the diagonal line in the table of round one
versus round two measurements (a corresponding score
in each round) were given a higher weight than obser-
vations further from the diagonal. In addition, the fur-
ther the observation was away from the diagonal, the
less weight it was given using a linear scale.
The weighted kappa statistic was calculated for as fol-
lows: (1) the total number lesions; (2) number of total
occlusions; (3) number of bifurcation lesions; (4) num-
ber of ostial lesions; (5) total SYNTAX score in deciles
(6) and SYNTAX score terciles (22, >22–32, >32).
All analyses were performed using SAS (Cary, NC)
version 8.02 by a dedicated statistician.
RESULTS
In total 92 (92%) angiograms were included in the
ﬁnal analysis. Eight of the angiograms were excluded
because they could not be viewed on two occasions as
a result of technical problems with the angiogram disk.
TABLE I. Quantitative Classiﬁcation of Kappa Values as a
Degree of Agreement Beyond the Level of Chance [16]
Kappa value Degree of agreement beyond chance
0 None
0.0 < Kappa  0.2 Slight
0.2 < Kappa  0.4 Fair
0.4 < Kappa  0.6 Moderate
0.6 < Kappa  0.8 Substantial
0.8 < Kappa  1.0 Almost perfect
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Reproducibility Assessment
The results recorded during the two rounds of the
study for the total number lesions; the number of total
occlusions; the number of bifurcation lesions; the num-
ber of ostial lesions; the total SYNTAX score in dec-
iles; and the SYNTAX score in terciles are shown in
Tables II–VII, together with the corresponding kappa
value for the degree of agreement between both meas-
urements beyond the level of chance. Table VIII shows
the comparison of kappa values between this assess-
ment of SYNTAX score reproducibility, and the previ-
ous assessment performed in the same population in
2008 [7].
SYNTAX Score
Figure 1 shows the SYNTAX score calculated for
each patient in both rounds of the study. The majority
of the values lie close to the line of concordance; how-
ever, ﬁve main outliers (highlighted) are present.
The overall mean SYNTAX score was 24.3 (range
4–54) and 26.4 (range 8–58) for rounds one and two,
respectively. The mean difference (measure of preci-
sion) was 2.1 with a standard deviation of 7.6 (measure
of accuracy). In the previous assessment in 2008, the
respective values for the mean score in round one,
mean score in round two, mean  standard deviation
of the difference were 31.3, 29.2, and 2.1  9.1,
respectively [7].
TABLE II. Total number of lesions recorded during both
rounds of the study
Shaded boxes represent concordant scores.
TABLE III. Number of Total Occlusions Recorded During Both
Rounds of the Study
Shaded boxes represent concordant scores.
TABLE IV. Number of Bifurcations Lesions Recorded During
Both Rounds of the Study
Shaded boxes represent concordant scores.
TABLE V. Number of Ostial Lesions Recorded During Both
Rounds of the Study
Shaded boxes represent concordant scores.
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DISCUSSION
The main ﬁnding from this study is that the SYN-
TAX score had moderate intra-observer reproducibility
when assessed by a team of three interventional cardi-
ologists, with the main source of inconsistency stem-
ming from the evaluation of bifurcation lesions. Fur-
thermore, these results are consistent with a previous
evaluation of the score’s reproducibility as performed
by core lab analysts.
The Rationale for Evaluating the SYNTAX Score
Reproducibility
The ability to select patients with complex CAD [tri-
ple vessel disease/left main stem disease (LMS)] who
are suitable for PCI has never been as important as in
the current environment where increasing numbers of
patients with multiple comorbidities are being investi-
gated, and treated for CAD [18]. These patients fre-
quently have complex CAD, and pose a challenging
clinical problem particularly as technological advances
have ensured that PCI can be used to treat the majority
of coronary lesions; however, this is not always the
most appropriate treatment. Furthermore, the ﬁnal deci-
sion regarding the method of revascularisation is also
no longer simply the outcome of a discussion between
physician and surgeon. Patients are becoming increas-
ingly involved in the decision making process, and,
therefore, an adequate method of risk stratiﬁcation is
important to enable them to make the most appropriate
decision for them, as an individual [19].
The recently developed SYNTAX score [6,7]
appears to have an important role to play in the evalua-
tion of these complex patients, thereby addressing
an unmet clinical need. Prospective data from the
SYNTAX trial and retrospective analysis of the
CUSTOMIZE registry has indicated that the SYNTAX
score can reliably identify those patients with complex
CAD most appropriately managed with CABG as
opposed to PCI [1,4]. Moreover, evidence from pro-
spective and retrospective analyses performed in over
4,000 patients so far suggests that the SYNTAX score
can also be used to predict short and long term clinical
outcomes in those undergoing PCI [1,8–10].
On the background of this increasingly complex de-
cision making process and the positive data from trials,
which have assessed the SYNTAX score’s perform-
ance, it is anticipated that the SYNTAX score will be
used increasingly in day-to-day clinical practice, and
may will eventually be incorporated into clinical prac-
tice guidelines. The likelihood of this happening, how-
ever, is highly dependent on the demonstration of an
adequately reproducible score. Importantly, this serves
to improve the conﬁdence that individual clinicians
have in using the score, and also increases the proba-
bility that clinicians will adhere to suggested recom-
mendations based on speciﬁc scores values.
TABLE VI. Total SYNTAX Score (in deciles) Calculated During
Both Rounds of the Study
Shaded boxes represent concordant scores.
TABLE VIII. Comparison of Weighted Kappa Values From 2008
and 2009 Reproducibility Assessment
Parameter
Kappa value
2008 study [7]
Kappa value
2009 study
Total number of lesions 0.59 0.62
Number of total occlusions 0.82 0.91
Number of bifurcation lesions 0.41 0.36
Number of ostial lesions 0.63 0.66
SYNTAX score (deciles) 0.45 0.54
SYNTAX score (terciles) 0.53 0.51
TABLE VII. SYNTAX Score According to Terciles Recorded
During Both Rounds of the Study
Shaded boxes represent concordant scores.
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SYNTAX Score Reproducibility
In this study, the overall reproducibility of the SYN-
TAX score was moderate, with a kappa value of 0.54.
To place this in the context of other subjective assess-
ments, the interpretation of T wave changes on an
exercise stress test; the assessment of regional wall
motion abnormalities on echocardiography; and the
previous intra-observer reproducibility of the SYNTAX
score have been shown to have kappa values of 0.25,
0.41, and 0.45, respectively [7,20,21].
One of the major factors inﬂuencing the SYNTAX
score’s reproducibility is the use of diagnostic coronary
angiography to assess lesion characteristics; however,
this currently represents the ‘‘gold-standard’’ investiga-
tion for patients with suspected CAD, and is unlikely
to change in the near future. It is well known that cor-
onary angiography is subject to intra- and inter-ob-
server variability [22] with assessment being inﬂuenced
by amongst other things the quality of the diagnostic
pictures, the angiographic views that are selected,
lesion eccentricity, operator experience and interpreta-
tion [11–13]. Moreover, previous studies have indi-
cated that the assessment of lesion severity based on
visual estimation is inferior when compared with quan-
titatively derived parameters. For example, Beauman
and Vogel [12] demonstrated that the visual estimation
of a 50% phantom stenosis by a group of observers
ranged between 30 and 95%.
Bifurcation lesions were the lesion type with the
lowest reproducibility, which is consistent with the pre-
vious study [7]. Of note discrepancies in the scoring of
bifurcation lesions, and in particular those involving
the distal LMS, were the main culprits in the ﬁve cases
with the greatest difference between round one and
round two scores (range: 19–26). This inconsistency
reiterates the difﬁculty in evaluating whether lesions
involving the distal LMS extend into the ostium of the
left anterior descending (LAD)/circumﬂex (Cx) coro-
nary artery. Vessel foreshortening and overlap make
visualization and accurate lesion assessment in this
region difﬁcult, particularly when using only coronary
angiography for assessment. In fact studies demonstrate
that LMS lesions are subject to the greatest degree of
intra- and inter-observer variability on coronary angi-
ography, when compared with lesions located else-
where in the coronary tree [23,24]. In practice a suspi-
cious lesion in this area warrants further evaluation
with intra-vascular ultrasound, coronary CT, and/or
functional assessment with fractional ﬂow reserve
[23,25,26]. In this study, lesion assessment was con-
ﬁned only to coronary angiography, however, the
reproducibility in the assessment of bifurcation lesions
Fig. 1. Five main outliers are observed which on retrospective analysis are mainly caused by
discrepancies in selecting the segments involved in bifurcation lesions, particular those
involving the distal left main stem.
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may well have improved if additional imaging had
been available as it is in clinical practice.
Importantly, the difference in SYNTAX score
between a lesion involving only the distal LMS, as
compared with a distal LMS lesion extending into the
ostium of the LAD/Cx is sufﬁciently large enough to
move a patient from a low tercile score where PCI is a
viable option, to the highest tercile where CABG is the
standard of care. This serves to reinforce the impor-
tance of appropriate evaluation of lesions, particularly
those suspected of involving the distal LMS.
Limitations
Although the kappa value is currently the accepted
standard measure of intra-observer reproducibility, it is
not without its limitations. By deﬁnition, it represents
agreement beyond the level of chance, however, the
actual level of chance agreement is variable and affected
by the prevalence of the disease being studied [27]. The
SYNTAX study was a multi-centre trial that enrolled
patients in many different countries, and as such there is
likely to be a genetic and geographic variation in the
prevalence of CAD seen amongst the trial population.
Nevertheless, this is not particularly relevant for the pur-
poses of this study as investigators were blinded to clini-
cal data. Conversely, an important factor which may
have directly affected the level of chance agreement
(and the resulting kappa) by acting as a surrogate for
prevalence was the differences noted amongst the study
population in both the quality of the diagnostic angio-
gram, and the angiographic views recorded. It follows
that the probability of chance agreement is likely to be
somewhat higher in those cases with a good quality
angiogram with ample views, when compared with
angiograms of poorer quality and limited views. There-
fore, in those situations where the prevalence is skewed,
for example as a result of an angiogram of excellent
quality, a low kappa value can result from genuine poor
agreement, or as a consequence of a high probability of
chance agreement [28]. Unfortunately, neither the diag-
nostic quality nor the number of views taken per angio-
gram were formally assessed in this study. The effect of
the angiograms’ quality on the prevalence of disease can
effectively be eliminated by using 100 blinded assessors
scoring the same angiogram. Overall the kappa values
obtained in this study should only be considered a guide,
and do not reﬂect the reproducibility of the SYNTAX
score in a different patient population with a different
prevalence of CAD.
Additional limitations include the experience of the
investigators in this study, who have each individually
assessed the SYNTAX score in over a thousand angio-
grams. A repeat assessment of the same angiograms
using investigators less familiar with the deﬁnitions,
and less experienced in using the SYNTAX score may
well provide different results.
CONCLUSIONS
This study has demonstrated moderate intra-observer
reproducibility of the SYNTAX score when assessed
by a team of three interventional cardiologists, which
is consistent with previous evaluations by core lab ana-
lysts. The scoring of bifurcation lesions remains a
source of inconsistency, which may be improved by
the use of additional imaging modalities together with
a review of its deﬁnition.
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Value of the SYNTAX Score for Risk
Assessment in the All-Comers Population of the
Randomized Multicenter LEADERS (Limus Eluted
from A Durable versus ERodable Stent coating) Trial
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Objectives We aimed to assess the predictive value of the SYNTAX score (SXscore) for major adverse cardiac events in the
all-comers population of the LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial.
Background The SXscore has been shown to be an effective predictor of clinical outcomes in patients with multivessel dis-
ease undergoing percutaneous coronary intervention.
Methods The SXscore was prospectively collected in 1,397 of the 1,707 patients enrolled in the LEADERS trial (patients
after surgical revascularization were excluded). Post hoc analysis was performed by stratifying clinical outcomes
at 1-year follow-up, according to 1 of 3 SXscore tertiles.
Results The 1,397 patients were divided into tertiles based on the SXscore in the following fashion: SXscore 8 (SXlow)
(n  464), SXscore 8 and 16 (SXmid) (n  472), and SXscore 16 (SXhigh) (n  461). At 1-year follow-up,
there was a signiﬁcantly lower number of patients with major cardiac event–free survival in the highest tertile of
SXscore (SXlow  92.2%, SXmid  91.1%, and SXhigh  84.6%; p  0.001). Death occurred in 1.5% of SXlow
patients, 2.1% of SXmid patients, and 5.6% of SXhigh patients (hazard ratio [HR]: 1.97, 95% conﬁdence interval
[CI]: 1.29 to 3.01; p  0.002). The myocardial infarction rate tended to be higher in the SXhigh group. Target
vessel revascularization was 11.3% in the SXhigh group compared with 6.3% and 7.8% in the SXlow and SXmid
groups, respectively (HR: 1.38, 95% CI: 1.1 to 1.75; p  0.006). Composite of cardiac death, myocardial infarc-
tion, and clinically indicated target vessel revascularization was 7.8%, 8.9%, and 15.4% in the SXlow, SXmid,
and SXhigh groups, respectively (HR: 1.47, 95% CI: 1.19 to 1.81; p  0.001).
Conclusions The SXscore, when applied to an all-comers patient population treated with drug-eluting stents, may allow pro-
spective risk stratiﬁcation of patients undergoing percutaneous coronary intervention. (LEADERS Trial Limus
Eluted From A Durable Versus ERodable Stent Coating; NCT00389220). (J Am Coll Cardiol 2010;56:272–7)
© 2010 by the American College of Cardiology Foundation
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The SYNTAX score (SXscore) is a comprehensive angio-
graphic scoring system that is derived entirely from the
coronary anatomy and lesion characteristics (1–3). It was
initially designed to quantify lesion complexity; however, it
is also able to predict major adverse cardiac events (MACE)
after percutaneous revascularization in patients with mul-
tivessel coronary artery disease (4–6) and/or left main
disease (7). More recent data indicate its ability to predict
periprocedural myocardial infarction (MI) in patients
undergoing elective percutaneous coronary intervention
(8). In this substudy of the LEADERS (Limus Eluted
from A Durable versus ERodable Stent coating) trial, in
which the SXscore was collected prospectively in 1,397
all-comer patients, we assessed its prognostic value for
MACE at 1-year follow-up.
Methods
Study population. LEADERS was a multicenter Euro-
pean noninferiority trial comparing the safety and efﬁcacy of
the BioMatrix Flex biolimus-eluting stent with a biodegrad-
able polymer (Biosensors, Morges, Switzerland) with the
Cypher Select sirolimus-eluting stent with a durable poly-
mer (Cordis, Bridgewater, New Jersey) in 1,707 all-comer
patients. Detailed study protocol can be found in the main
report (9). The study complied with the Declaration of
Helsinki and was approved by all institutional ethics com-
mittees. All patients provided written informed consent for
participation in the trial.
SXscore and angiographic analysis. From the baseline
diagnostic angiogram, each coronary lesion producing
50% diameter stenosis in vessels 1.5 mm was scored
separately and added together to provide the overall
SXscore, which was calculated prospectively using the
SXscore algorithm (described in full elsewhere) (1–3). All
angiographic variables pertinent to SXscore calculation were
computed by blinded core laboratory analysts (Cardialysis
B.V., Rotterdam, the Netherlands). The SXscore is not
currently validated in patients with acute MI or previous
percutaneous coronary intervention and coronary artery
bypass graft. Core laboratory analysts were blinded to all
clinical data, and therefore patients with occluded infarct–
related arteries were scored as occlusions of unknown
duration in a similar manner to any chronically occluded
artery. Those patients with in-stent restenosis lesions were
scored in the same manner as if the lesion was a de novo
lesion.
Study end points. Deﬁnitions of all end points are pro-
vided elsewhere (9). The primary end point of this substudy
was MACE, deﬁned as the composite of cardiac death, MI,
and clinically indicated target vessel revascularization
(TVR) within 9 months. Secondary end points were any
target lesion revascularization (both clinically and nonclini-
cally indicated), any TVR, cardiac death, death from any
cause, MI, stent thrombosis (deﬁned according to the
Academic Research Council
[10]), device success, and lesion
success.
The pre-speciﬁed principal
outcome of the angiographic
substudy was the in-stent per-
centage of diameter stenosis.
Secondary angiographic out-
comes were the in-segment per-
centage of diameter stenosis,
minimal lumen diameter, late lu-
men loss, and binary restenosis.
Statistical analysis. A stratiﬁed
post hoc analysis of clinical and
angiographic outcomes was per-
formed according to the tertiles
of the SXscore (4,5). Dedicated
software and visual coronary angiography served to deter-
mine the SXscore (1,2). All randomized patients without
previous surgical revascularization (1,397 of 1,707) were
included in the analysis. Angiographic outcomes were ana-
lyzed using SAS version 8 (SAS Institute, Cary, North
Carolina) Proc Mixed for continuous and Proc Genmod
for binominal outcomes, taking into account the within-
patient correlation structure of these data. The Cox
proportional hazards model was used to compare clinical
outcomes among the groups. All analyses were performed
using SAS version 8.02 by a dedicated statistician. All p
values and conﬁdence intervals (CIs) were 2-sided. Mul-
tivariate model included SXscore, diabetes, beta-blocker
use, stent type, and the presence of acute coronary
syndrome as covariates. Testing for (linear) trend was
done by using generalized linear models with SYNTAX
class as a covariable for continuous variables and the
Cochran-Armitage test for trend in categorical data.
Results
SXscore and baseline characteristics. The SXscore was
collected prospectively in 1,397 of the 1,707 patients
(81.8%) enrolled in the LEADERS trial. The score ranged
from 0 to 49, with a mean SD of 13.5 8.7 and a median
of 12 (interquartile range 7 to 19). In this post hoc analysis,
the SXscore tertiles were deﬁned as SXlow (SXscore 8)
(n  464), SXmid (SXscore 8 and 16) (n  472), and
SXhigh (SXscore 16) (n  461). Baseline clinical and
angiographic characteristics of the patients are listed in
Tables 1 and 2.
1-year outcomes. The SXscore signiﬁcantly predicted the
rate of MACE at 360 days (Table 3, Figs. 1 to 4). There was
a lower number of patients with MACE-free survival in the
highest tertile of the SXscore (SXlow 92.2%, SXmid 91.1%,
and SXhigh  84.6%; p  0.001). Death occurred in 1.5%
of patients with SXlow, 2.1% of patients with SXmid, and
5.6% of patients with SXhigh (hazard ratio [HR]: 1.97, 95%
CI: 1.29 to 3.01; p  0.002). The rate of MI tended to be
Abbreviations
and Acronyms
CI  conﬁdence interval
HR  hazard ratio
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
SXhigh  SYNTAX
score >16
SXlow  SYNTAX score <8
SXmid  SYNTAX score >8
and <16
SXscore  SYNTAX score
TVR  target vessel
revascularization
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higher in patients with SXhigh (MI HR: 1.2, 95% CI: 0.9
to 1.61; p  0.22). TVR was 11.3% in the SXhigh group
compared with 6.3% and 7.8% in the SXlow and SXmid
groups, respectively (HR: 1.38, 95% CI: 1.1 to 1.75; p 
0.006). Composite of cardiac death, MI, and clinically
indicated TVR was 7.8%, 8.9%, and 15.4% in the SXlow,
SXmid, and SXhigh groups, respectively (HR: 1.47, 95%
CI: 1.19 to 1.81; p  0.001).
Multivariate model. In a multivariate model, SXscore
remained a signiﬁcant predictor of MACE and mortality.
Patients in the SXhigh group had a 50% greater chance of
the composite of cardiac death, MI, and clinically indicated
TVR than patients in the SXmid group (p  0.001), which
was comparable to the 51% higher composite event rate
among diabetic patients (p  0.022). Use of the biolimus-
eluting stent tended to reduce the composite event rate by
26% (p  0.07).
Stent thrombosis rates. The rates of deﬁnite stent throm-
bosis were 0.9%, 2.1%, and 3.5% in the SXlow, SXmid, and
SXhigh groups, respectively.
Baseline Clinical CharacteristicsTable 1 Baseline Clinical Characteristics
Baseline Clinical Variables
SXlow
(n  464)
SXmid
(n  472)
SXhigh
(n  461)
p Value on Trend
(2-Sided)
Age 65 yrs 210 (45.3) 224 (47.5) 239 (51.8) 0.048
Male 346 (74.6) 344 (72.9) 340 (73.8) 0.79
Diabetes 93 (20.0) 117 (24.8) 111 (24.1) 0.15
Current smoking 134 (28.9) 121 (25.6) 126 (27.3) 0.61
Hypertension 353 (76.1) 353 (74.8) 324 (70.3) 0.048
Hypercholesterolemia 314 (67.7) 314 (66.5) 285 (61.8) 0.06
Family history of coronary artery disease 201 (43.3) 188 (39.8) 168 (36.4) 0.034
Renal insufﬁciency 17 (3.7) 21 (4.5%) 28 (6.1) 0.09
Previous MI 132 (28.5) 145 (30.7) 137 (29.7) 0.69
Previous PCI 179 (38.6) 165 (35.0) 147 (31.9) 0.036
PVD 26 (5.6) 36 (7.6) 31 (6.7) 0.51
Previous stroke 13 (2.8) 19 (4.0) 16 (3.5) 0.59
Clinical presentation
Stable 146 (31.5) 154 (32.6) 108 (23.4) 0.008
Unstable 127 (27.4) 89 (18.9) 88 (19.1) 0.002
STEMI 46 (9.9) 90 (19.1) 128 (27.8) 0.0001
Non-STEMI 90 (19.4) 90 (19.1) 97 (21.0) 0.54
Silent ischemia 55 (11.9) 49 (10.4) 40 (8.7) 0.12
Values shown are n (%).
MI  myocardial infarction; PCI  percutaneous coronary intervention; PVD  peripheral vascular disease; STEMI  ST-segment elevation
myocardial infarction; SXhigh  SYNTAX score 16; SXlow  SYNTAX score 8; SXmid  SYNTAX score 8 and 16.
Baseline Angiographic CharacteristicsTable 2 Baseline Angiographic Characteristics
Angiographic Variables SXlow SXmid SXhigh p Value
No. of diseased lesions per patient (based on SYNTAX application) 1.47 0.66 2.37 1.00 3.45 1.44 0.001
No. of treated lesions per patient (as deﬁned by the core laboratory) 1.2 0.46 1.47 0.7 1.69 0.86 0.001
Ratio of diseased to treated lesions 1.22 1.61 2.04 N/A
Coronary artery treated
LAD 162 (34.9) 242 (51.3) 296 (64.2) 0.001
LCX 140 (30.2) 144 (30.5) 164 (35.6) 0.079
RCA 216 (46.6) 209 (44.3) 174 (37.7) 0.007
2-vessel disease 49 (10.6) 102 (21.6) 138 (29.9) 0.001
3-vessel disease 3 (0.7) 13 (2.8) 23 (5.0) 0.001
Stent type
Biolimus-eluting 229 (49.3) 235 (49.8) 239 (51.8) 0.45
Sirolimus-eluting 235 (50.7) 237 (50.2) 222 (48.2) 0.45
No. of implanted stents 1.47 0.8 1.90 1.12 2.33 1.39 0.001
Total stent length/patient, mm 25.9 16.5 34.2 21.7 42.9 26.2 0.001
Chronic total occlusion 6 (1.3) 10 (2.1) 19 (4.1) 0.006
Moderate to severe calciﬁcation 23 (5.1) 96 (20.3) 184 (39.9) 0.001
Bifurcation lesion 57 (12.3) 161 (34.1) 184 (39.9) 0.001
Use of glycoprotein IIb/IIIa inhibitor 80 (17.2) 113 (23.9) 154 (33.4) 0.001
Values are mean  SD or n (%).
LAD  left anterior descending artery; LCX  left circumﬂex artery; N/A  not applicable; RCA  right coronary artery; other abbreviations as in Table 1.
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Discussion
Complexity of disease and lesion characteristics are well
recognized predictors of periprocedural complications (8)
and long-term mortality (11–13). The SXscore was devel-
oped to comprehensively assess lesion characteristics and is
based on the combination of classiﬁcations from the Amer-
ican Heart Association/American College of Cardiology,
modiﬁed BARI classiﬁcation, chronic total occlusion and
bifurcation scores, and Leaman classiﬁcation (1). It has
previously been applied in both the SYNTAX trial and
the ARTS II (Arterial Revascularization Therapies Study
II), both of which demonstrated the good predictive value
of the SXscore in patients with multivessel disease, with
the highest tertile patients having signiﬁcantly more
MACE during short-term (4,5) and long-term (6)
follow-up.
This study is the ﬁrst to report the utility of the SXscore
as a predictor of MACE, including cardiac death, in an
all-comers population including patients with acute coro-
nary syndromes. Overall, this patient population had much
lower SXscores than the SYNTAX trial population; how-
ever, despite this, the SXscore still appears to have good
discriminatory power for risk assessment.
Study limitations. The limitation of the SXscore is that it
does not incorporate clinical patient characteristics. Patients
who underwent previous coronary artery bypass graft sur-
gery have not been included because the SXscore algorithm
is only currently available for patients with de novo disease.
Modiﬁcations to the SXscore for risk stratiﬁcation in
patients after coronary artery bypass graft surgery are cur-
rently being developed. The SXscore of patients who
presented with acute MI or had previous percutaneous
Clinical Outcomes at 360 Days After Index PCI Based on Tertiles of SXscoreTable 3 Clinical Outcomes at 360 Days After Index PCI Based on Tertiles of SXscore
Type of Event Risk Factors Used
SXlow
(%)
SXmid
(%)
SXhigh
(%)
p Value
SYNTAX
HR,
SYNTAX
Lower Limit HR,
SYNTAX
Upper Limit HR,
SXscore
Death SYNTAX class, DM, STEMI 1.5 2.1 5.6 0.002 1.97 1.29 3.01
Stent thrombosis SYNTAX class, DM, STEMI 1.1 3 6.1 0.001 2.13 1.4 3.24
MI SYNTAX class, DM, STEMI, beta-blockers,
and treatment (BES vs. SES)
4.3 4.9 5.9 0.22 1.2 0.9 1.61
All TVR SYNTAX class, DM, STEMI, beta-blockers,
and treatment (BES vs. SES)
6.3 7.8 11.3 0.006 1.38 1.1 1.75
All TLR SYNTAX class, DM, STEMI, beta-blockers,
and treatment (BES vs. SES)
4.7 6.1 8.7 0.019 1.37 1.05 1.79
Composite of cardiac
death, MI, clinically
indicated TVR
SYNTAX class, DM, STEMI, beta-blockers,
and treatment (BES vs. SES)
7.8 8.9 15.4 0.001 1.47 1.19 1.81
BES biolimus-eluting stent(s); DM diabetes mellitus; HR hazard ratio; PCI percutaneous coronary intervention; SES sirolimus-eluting stent(s); TLR target lesion revascularization; TVR target
vessel revascularization; other abbreviations as in Table 1.
Figure 1 Kaplan-Meier Curves for MACE at 360 Days According to the SYNTAX Tertiles
Patients in the highest tertile of the SYNTAX score have an increased major adverse cardiac events (MACE) event rate (p  0.0002).
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coronary intervention were included in this analysis, despite
no previous validation in these patients. Scoring of the
infarct-related vessel as a chronic total occlusion may
confound the results and have complex effects on the
SXscore. There is the danger of overestimating the SXscore
if all ST-segment elevation MIs with an occluded infarct–
related vessel are taken as chronic total occlusions, particu-
larly because the lesion is likely to be easier to treat due to
the soft nature of plaque as opposed to an occlusion, which
has calciﬁed organized old thrombus and plaque (chronic
occlusion). Alternatively, there is the danger of underesti-
mating the SXscore because the underlying lesion complex-
ity will not be accounted for because the vessel beyond the
occlusion is not seen due to the occlusion. This is the subject
of an ongoing study. This study may have limitations
inherent to subgroup analysis (chance ﬁndings and under-
powering) (14–16).
Conclusions
This study demonstrates that the prognostic value of the
SXscore is valid for all patients with de novo coronary
artery disease undergoing percutaneous revascularization.
Figure 2 Kaplan-Meier Curves for Cardiac Death at 360 Days According to the SYNTAX Score Tertiles
Patients in the highest tertile of the SYNTAX score have a higher cardiac death rate (p  0.0001).
Figure 3 Kaplan-Meier Curves for All Myocardial Infarctions at 360 Days According to the SYNTAX Score Tertiles
There is no difference in the rate of overall myocardial infarctions across the tertiles of SYNTAX score (p  0.548 [NS]).
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Figure 4 Kaplan-Meier Curves for Target Lesion Revascularization at 360 Days According to the SYNTAX Score Tertiles
Patients in the highest tertile of the SYNTAX score have an increased risk of target lesion revascularization (p  0.036).
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Aims To investigate the ability of SYNTAX score and Clinical SYNTAX score (CSS) to predict very long-term outcomes in
an all-comers population receiving drug-eluting stents.
Methods
and results
The SYNTAX score was retrospectively calculated in 848 patients enrolled in the SIRolimus-eluting stent compared
with pacliTAXel-Eluting Stent for coronary revascularization (SIRTAX) trial. The CSS was calculated using age, and
baseline left ventricular ejection fraction and creatinine clearance. A stratified post hoc comparison was performed
for all-cause mortality, cardiac death, myocardial infarction (MI), ischaemia-driven target lesion revascularization
(TLR), definite stent thrombosis, and major adverse cardiac events (MACE) at 1- and 5-year follow-up. Tertiles for
SYNTAX score and CSS were defined as SSLOW ≤7, 7, SSMID ≤14, SSHIGH .14 and CSSLOW ≤8.0, 8.0
,CSSMID ≤17.0 and CSSHIGH .17.0, respectively. Major adverse cardiac events rates were significantly higher in
SSHIGH compared with SSLOW at 1- and 5-year follow-up, which was also seen at 5 years for all-cause mortality,
cardiac death, MI, and TLR. Stratifying outcomes across CSS tertiles confirmed and augmented these results. Within
CSSHIGH, 5-year MACE increased with use of paclitaxel- compared with sirolimus-eluting stents (34.7 vs. 21.3%,
P ¼ 0.008). SYNTAX score and CSS were independent predictors of 5-year MACE; CSS was an independent predictor
for 5-year mortality. Areas-under-the-curve for SYNTAX score and CSS for 5-year MACE were 0.61 (0.56–0.65) and
0.62 (0.57–0.67), for 5-year all-cause mortality 0.58 (0.51–0.65) and 0.66 (0.59–0.73) and for 5-year cardiac death 0.63
(0.54–0.72) and 0.72 (0.63–0.81), respectively.
Conclusion SYNTAX score and to a greater extent CSS were able to stratify risk for very long-term adverse clinical outcomes in an all-
comers population receiving drug-eluting stents. Predictive accuracy for 5-year all-cause mortality was improved using CSS.
Trial Registration Number: NCT00297661.
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Introduction
The SYNTAX score is a lesion-based angiographic scoring system
originally devised to grade the complexity of coronary artery
disease1 and thereby facilitate consensus in the study of a diagnos-
tic angiogram between surgeons and interventional cardiologists. In
the SYNTAX trial,2 it proved effective in predicting clinical out-
comes after elective percutaneous coronary intervention (PCI)
procedures in patients with three-vessel and/or left main coronary
artery disease.3 The score’s predictive ability for a number of clini-
cal outcomes has subsequently been assessed in patient cohorts
with a varying extent of coronary artery disease undergoing both
elective and emergent PCI procedures.4– 13 Several of these
studies have suggested that, being solely based on angiographic
variables, the SYNTAX score cannot account for the variability
related to clinical factors which are widely acknowledged to
impact on long-term outcomes, such as a patients’ age,14 left ven-
tricular ejection fraction,15 and renal function.16
A clinical score incorporating the aforementioned variables, the
ACEF score, has been retrospectively validated in patients under-
going elective coronary artery bypass grafting (CABG)
operations.17 Integration of this score, modified through the repla-
cement of serum creatinine with creatinine clearance, with the
SYNTAX score, in the Clinical SYNTAX score (CSS), has been
shown to improve the predictive ability for adverse clinical out-
comes after PCI.10,11,18 However, information regarding the very
long-term performance of either SYNTAX score or CSS in an all-
comers population is currently lacking.
The SIRolimus-eluting stent compared with pacliTAXel-Eluting
Stent for coronary revascularization (SIRTAX) trial19 was a pro-
spective, observer-blind, randomized controlled study comparing
the safety and efficacy of sirolimus-eluting stents (SES) and
paclitaxel-eluting stents (PES) in 1012 patients undergoing PCI
for either stable angina or an acute coronary syndrome. This
study design offers a convenient setting for describing the distri-
bution of the SYNTAX score and CSS in an all-comers population.
Furthermore, the availability of 5-year follow-up data permits a
more robust evaluation of both scores, in order to confirm their
potential to risk stratify clinical outcomes at very long-term after
the implantation of drug-eluting stents.
Methods
Patient population and coronary intervention
The design of the SIRTAX trial has been previously described.19
Patients were eligible to participate if they presented at least one
lesion with percentage diameter stenosis ≥50%, in a vessel with a
reference diameter between 2.25 and 4.00 mm that was suitable for
stent implantation. There were no limitations on the number of
lesions treated, number of vessels diseased or on the length of the
lesions. The study complied with the Declaration of Helsinki regarding
investigation in humans and was approved by the institutional ethics
committees at the participating centres. Written informed consent
was obtained from each patient before enrollment. There was no
industry involvement in the design, conduct or analysis of the study.
Patients were randomly assigned on a 1:1 basis to treatment with SES
(Cypherw; Cordis, Warren, NJ, USA) or PES (Taxusw, Boston Scientific,
Natick, MA, USA). No mixture of drug-eluting stents was allowed within
a given patient. All procedures were performed according to interven-
tional standards at the time. Before or at the time of the procedure,
patients received at least 100 mg of aspirin, a 300 mg loading dose of clo-
pidogrel, and unfractionated heparin (70–100 U/kg of body weight).
After the procedure, all patients were advised to maintain aspirin life-
long, and clopidogrel therapy was prescribed for 12 months irrespective
of stent type.
SIRTAX endpoints and definitions
All adverse events were adjudicated by an independent clinical events
committee throughout 5 years and have been reported separately.20
The pre-specified primary endpoint was a composite of major
adverse cardiac events (MACE) including death from cardiac causes,
myocardial infarction (MI), and ischaemia-driven target lesion revascu-
larization (TLR). The diagnosis of MI was based on the presence of new
Q waves of at least 0.4 s duration in ≥2 contiguous leads and an elev-
ated creatine kinase MB fraction. In the absence of pathologic Q waves,
the diagnosis of MI was based on an increase in the creatine kinase
level to more than twice the upper limit of the normal range with
an elevated level of creatine kinase MB or troponin I. Target lesion
revascularization was defined as an intervention (either surgical or per-
cutaneous) to treat a stenosis within the stent or within the 5-mm
borders adjacent to the stent. Revascularization was considered to
be driven by ischaemia, if percentage diameter stenosis was ≥50%
on the basis of quantitative coronary angiography in the presence of
ischaemic signs or symptoms, or ≥70% even in the absence of ischae-
mic signs or symptoms.
Stent thrombosis was diagnosed as an acute coronary syndrome
with angiographic documentation of either target vessel occlusion or
thrombus within or adjacent to the previously stented segment; apply-
ing Academic Research Consortium recommendations,21 definite stent
thrombosis was documented.
SYNTAX score and angiographic analysis
The SYNTAX score algorithm, which is described in full elsewhere and
is available on the SYNTAX score website (www.syntaxscore.com),
was employed to retrospectively score all coronary lesions deemed
to have a percentage diameter stenosis ≥50%, in vessels ≥1.5 mm.
All angiographic variables pertinent to SYNTAX score calculation
were computed by two experienced interventional cardiologists
(C.G., S.G.) on diagnostic angiograms obtained before the procedure.
In case of disagreement, the opinion of a third analyst (G.S.) was
obtained and the final decision was made by consensus. Analysts
were blinded to procedural data and clinical outcome. The final
score was calculated on a patient basis from the individual lesion
scores, which were saved in a dedicated database, and was not made
available to the analysts until after the completion of the study.
Patients with acute MIs were not included in the SYNTAX trial. In
the context of our study the culprit lesions were scored using the
angiographic views of the infarct-related arteries before any interven-
tion; in the absence of flow these were scored as total occlusions of
,3-months’ duration.9 Patients with prior CABG operation were
excluded from the analysis; a dedicated amendment for calculating
the score in the presence of grafts has not been made available yet.
Finally, in-stent restenosis lesions were scored as de novo ones.
Clinical SYNTAX score
The modified ACEF score was retrospectively calculated,18 based on
the patients’ left ventricular ejection fraction, age, and creatinine clear-
ance derived using the Cockcroft–Gault equation.22 Respective
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methodology has been amply described elsewhere. Values for variables
included in the modified ACEF score were recorded before the index
PCI. Clinical SYNTAX score was calculated multiplying the value of
SYNTAX score by the modified ACEF score.
Statistics
Statistical analysis was performed using SPSS 17.0 for Windows (SPSS,
Inc., Chicago, IL, USA). Patient characteristics and outcome measures
were stratified according to score tertiles among all patients with a cal-
culated CSS. Continuous variables are presented as mean+ 1 stan-
dard deviation (SD) or median values (25th to 75th percentile) as
appropriate; categorical variables are displayed as counts and/or per-
centages. Comparisons were performed with one-way analysis of var-
iance (ANOVA) for continuous variables following a normal
distribution and with the x2 test for categorical variables. The normal-
ity assumption was evaluated by the Kolmogorov–Smirnov test. Spear-
man’s rank correlation coefficient was used to measure the strength of
the association of SYNTAX score with CSS.
Cumulative event rates through all 5-years of follow-up were esti-
mated by means of the Kaplan–Meier method. Testing for trends in
event rates across score tertiles was done with the Cochran–Armitage
test in SAS software (SAS, version 9.2, Cary, NC, USA). All-cause mor-
tality, MACE, cardiac death, TLR, MI, and definite stent thrombosis
rates were compared across SYNTAX score and CSS tertiles accord-
ing to the Cox proportional-hazards model; the assumption of pro-
portional hazards was verified by visual inspection of the
log-minus-log curves. Independent predictors of 5-year MACE, all-
cause mortality, and cardiac death were sought among variables
significant beyond the level of P ¼ 0.10 in univariable analysis. Potential
predictors were checked for collinearity before entering a multivari-
able backward stepwise model; variables with a variance inflation
factor .2.5 were disqualified. Crude and adjusted hazard ratios and
corresponding 95% confidence intervals are reported for qualifying
variables.
SYNTAX score, CSS, and multivariable models were also evaluated
in terms of calibration and discrimination for 5-year MACE, cardiac,
and all-cause mortality. Calibration was evaluated with the Hosmer–
Lemeshow (H–L) goodness-of-fit test, wherein a lower x2 statistic
and a higher corresponding P-value implied a better match between
the estimated probabilities and the actual events. Discrimination was
explored with the areas under the receiver-operating characteristics
(ROC) curves; an area of 1.0 would indicate perfect discrimination,
whereas an area of 0.5 indicates the total absence of discriminatory
power. Areas-under-the-curves (AUCs) for SYNTAX score, CSS, and
multivariable models were compared with the DeLong method23
using MedCalc for Windows, version 11.6.0.0 (MedCalc Software,
Mariakerke, Belgium). Finally, in order to formally assess, whether
CSS improved the risk stratification over the SYNTAX score, a net
reclassification improvement (NRI) analysis was performed.24
To complete our analysis, a stratified comparison of clinical out-
comes between SES and PES was also performed across SYNTAX
score and CSS tertiles using Cox regression analysis. To determine
whether there was an interaction between treatment arm and
scores’ tertiles, likelihood ratio tests were used.
All statistical tests were two-sided and a P-value , 0.05 was
considered statistically significant.
Results
Analysis was performed for 848 patients (1792 lesions). Scores
were not evaluable in 91 cases due to prior CABG; another 57
angiograms were either not available or not fully evaluable in the
acquired views. Finally in 16 cases, data on creatinine clearance
could not be retrieved, consequently CSS could not be calculated;
clinical outcomes of these 164 patients excluded from the analysis
are shown in Supplementary material online, Table S1.
The SYNTAX score ranged from 1 to 42, with a mean+ SD of
11.7+ 7.3, and a median of 10 (6.0–16.0). The CSS ranged from
0.7 to 272.2, with a mean + SD of 17.4+ 20.5, and a median of
11.6 (6.4–21.2); expectedly, there was a strong correlation
between the two scores (r ¼ 0.87, P, 0.001). Both scores were
non-parametric and their distribution was skewed to the right
(Figure 1). Tertiles for SYNTAX score and CSS were defined as
SSLOW ≤7, 7, SSMID ≤14, SSHIGH .14 and CSSLOW ≤8.0,
8.0, CSSMID ≤17.0 and CSSHIGH .17.0, respectively.
Figure 1 Scores’ distribution in the SIRTAX trial population. Histograms of SYNTAX score (left side) and Clinical SYNTAX score (right side)
with superimposed normal curves; in both cases the distribution is skewed to the right. Histogram for Clinical SYNTAX score is truncated at
the 98th percentile value. Mean+ SD values and median values plus inter-quartile range (IQR) are reported.
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Baseline characteristics and risk factors stratified across
SYNTAX score tertiles are reported in Table 1 and data pertinent
to the procedure and the score calculation are reported in Table 2.
Stratified clinical outcomes
One-year outcomes across SYNTAX score tertiles are reported in
Supplementary material online, Table S2; 5-year outcomes across
SYNTAX score tertiles are shown in Figure 2. Five-year MACE
rates were significantly higher in SSHIGH compared with SSLOW
[24.2 vs. 12.5%, HR: 2.10 (1.40–3.16), P, 0.01], which was also
the case for 5-year all-cause mortality, cardiac death, MI,
and TLR rates; for all these endpoints there was a significant
trend (P ≤ 0.03) for higher event rates with increasing SYNTAX
score tertiles.
Stratifying outcomes across CSS tertiles (Table 3 and see Sup-
plementary material online, Table S3) led to similar results for
the comparisons between high and low score tertiles. However,
in contrast to the SYNTAX score analysis, event rates for MACE
and TLR were significantly higher in CSSHIGH compared with
both CSSMID and CSSLOW at 1- and 5-year follow-up; this held
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Table 1 Baseline clinical characteristics and risk factors
Characteristic SS ≤7 (n 5 293) 7< SS ≤14 (n 5 287) SS >14 (n 5 268) P-value
Age (years + SD) 60.7 + 10.6 61.4 + 11.2 63.7 + 11.3 0.004
Male gender, n (%) 218 (74.4) 219 (76.3) 211 (78.7) 0.48
Body mass index +SD 27.4 + 4.2 27.4 + 4.0 27.0 + 3.8 0.41
Diabetes mellitus, n (%) 45 (15.4) 50 (17.4) 66 (24.6) 0.04
Hypertension, n (%) 171 (58.4) 175 (61.0) 160 (59.7) 0.85
Hyperlipidaemia, n (%) 176 (60.1) 159 (55.4) 146 (54.5) 0.66
Current smoking, n (%) 124 (42.3) 100 (34.8) 93 (34.7) 0.41
Previous MI, n (%) 73 (24.9) 78 (27.2) 73 (27.2) 0.56
Previous PCI, n (%) 51 (17.4) 51 (17.8) 48 (17.9) 0.94
Peripheral vascular disease, n (%) 19 (6.5) 17 (5.9) 13 (4.9) 0.84
Stable angina pectoris, n (%) 163 (55.6) 115 (40.1) 108 (40.3) ,0.001
Acute coronary syndromes, n (%) 130 (44.4) 172 (59.9) 160 (59.7) ,0.001
Unstable angina, n (%) 14 (4.8) 23 (8.0) 12 (4.5)
Non ST-segment elevation MI, n (%) 74 (25.3) 61 (21.3) 63 (23.5)
ST-segment elevation MI, n (%) 42 (14.3) 88 (30.7) 85 (31.7)
Multi-vessel coronary artery disease, n (%) 96 (32.8) 107 (58.2) 209 (78.0) ,0.001
Left ventricular ejection fraction (% +SD) 60.2 + 9.4 56.8 + 11.4 53.3 + 12.6 ,0.001
Serum creatinine (mg/dL +SD) 0.93 + 0.33 0.95 + 0.54 1.02 + 0.83 0.14
Creatinine clearance (mL/min/1.73 m2 +SD) 98.6 + 34.9 99.5 + 35.8 91.6 + 34.8 0.02
MI, myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation; SS, SYNTAX score.
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Table 2 Procedural characteristics and lesions adjudicated in SYNTAX score
Characteristics per patient SS ≤7 (n5 293) 7 <SS ≤14 (n5 287) SS >14 (n 5 268) P-value
Mean number of lesions +SD 1.4 + 0.6 2.1 + 0.9 2.9 + 1.2 ,0.001
Bifurcation-trifurcation lesions +SD 0.1 + 0.3 0.6 + 0.6 0.9 + 0.8 ,0.001
Total occlusions +SD 0.1 + 0.3 0.3 + 0.5 0.6 + 0.6 ,0.001
Lesions treated +SD 1.2 + 0.5 1.4 + 0.6 1.5 + 0.6 ,0.001
One lesion treated, n (%) 237 (80.9) 180 (62.7) 150 (56.0) ,0.001
Two lesions treated, n (%) 49 (16.7) 91 (31.7) 99 (36.9)
Three lesions treated, n (%) 7 (2.4) 16 (5.6) 19 (7.1)
Mean number of stents +SD 1.1 + 0.3 1.2 + 0.4 1.2 + 0.6 ,0.001
Total stent length +SD 20.5 + 11.4 26.9 + 14.8 30.0 + 16.8 ,0.001
SES usage, n (%) 139 (47.4) 150 (52.3) 137 (51.1) 0.48
PES usage, n (%) 154 (52.6) 137 (47.7) 131 (48.9) 0.48
PES, paclitaxel-eluting stents; SD, standard deviation; SES, sirolimus-eluting stents; SS, SYNTAX score.
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Figure 2 Clinical outcomes at 5-year follow-up stratified across SYNTAX score tertiles. Kaplan–Meier curves are presented for major
adverse cardiac events, ischaemia-driven target lesion revascularization, myocardial infarction, all-cause mortality (death), cardiac death and defi-
nite stent thrombosis. Tertiles for SYNTAX score were defined as SSLOW ≤7, 7 ,SSMID ≤14, SSHIGH .14. Pairwise comparison results are
presented as hazard ratios plus 95% confidence intervals and respective P-values.
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also for all-cause mortality, cardiac death, and MI at 5 years. Defi-
nite stent thrombosis rates were directionally but not significantly
higher in CSSHIGH compared with both CSSMID and CSSLOW at
1-and 5-year follow-up.
SYNTAX Score vs. Clinical
SYNTAX score
The ROC curves for MACE, all-cause mortality, and cardiac death
at 5-year follow-up are shown in Figure 3. The AUC for CSS was
significantly larger compared with the one for SYNTAX
score regarding cardiac death [0.72 (0.63–0.81) vs. 0.63 (0.54–
0.72), P ¼ 0.002] and all-cause mortality [0.66 (0.59–0.73) vs.
0.58 (0.51–0.65), P, 0.001]. The AUC for MACE was decreased
for both scores, being not significantly larger for CSS [0.62 (0.57–
0.67) vs. 0.61 (0.56–0.65), P ¼ 0.24].
In terms of calibration, CSS was more robust compared with
SYNTAX score for all-cause mortality (x2 ¼ 6.148, P ¼ 0.63 vs.
x2 ¼ 7.674, P ¼ 0.36) and slightly less robust for cardiac death
(x2 ¼ 9.695, P ¼ 0.29 vs. x2 ¼ 7.377, P ¼ 0.39). Similar to discrimi-
nation, calibration for MACE was worse for SYNTAX score and
CSS when compared with that for mortality (x2 ¼ 9.968, P ¼
0.19 and x2 ¼ 15.619, P ¼ 0.05).
When reclassifying patients with all-cause mortality from SS into
CSS tertiles, 14/72 (19.5%) patients with events were moved to
higher risk categories (upward) and 3/72 (4.2%) to lower risk cat-
egories (downward), thus resulting in a net gain of 15.3% (Table 4).
In patients without events, 95 were moved downward and 99
upward, on aggregate a net loss of 0.5%; consequently the NRI
was 14.7% (z ¼ 2.46, P ¼ 0.014). Following the same
procedure, NRI for cardiac mortality was more pronounced
19.1% (z ¼ 2.36, P ¼ 0.018); on the other hand, NRI for patients
with MACE was negligible (0.6%, P ¼ 0.88) (see Supplementary
material online, Tables S4 and S5).
Multivariable analysis
Independent predictors for MACE, all-cause mortality and cardiac
death at 5-year follow-up are reported in Tables 5 and 6. Because
of the strong correlation between SYNTAX score and CSS, each
score was entered separately in the multivariable analysis together
with other variables significant in univariable analysis. There were
no collinearity issues among potential predictors, even when CSS
was tested together with left ventricular ejection fraction, age,
and creatinine clearance (variance inflation factor ,1.76 for all
parameters). Nevertheless, the latter three variables being com-
ponents of ACEF and hence of CSS, were left out of models includ-
ing CSS, in order to minimize collinearity.
Both scores were independent predictors of MACE (in separate
models) next to the number of treated lesions. Addition of dia-
betes did not significantly impact discrimination for either the
CSS (P ¼ 0.68) or the SYNTAX score model (P ¼ 0.88); cali-
bration improved for the former but got worse for the latter.
Regarding all-cause mortality, CSS was an independent predictor
next to diabetes. Addition of diabetes to CSS resulted in a
model with larger AUC (P ¼ 0.36) but worse calibration compared
with stand-alone CSS. Similar to all-cause mortality, CSS was an
independent predictor for cardiac death next to diabetes. Addition
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of diabetes to CSS resulted in a model with slightly larger AUC
(P ¼ 0.52) and better calibration compared with stand-alone CSS.
Stratified analysis of drug-eluting stents
performance
Overall adverse clinical event rates for each treatment arm are
reported in Table 7 for the 848 patients included in this substudy.
Stratified comparisons of PES vs. SES across CSS tertiles for clinical
outcome measures at 1- and 5-year follow-up are shown in
Figures 4 and 5, respectively. Among patients in the higher CSS
tertile, there was an increase in MACE rates with PES compared
with SES at 1-year follow-up [23.9 vs. 8.6%, HR: 3.02 (1.56–
5.83), P ¼ 0.001], which was mainly driven by increased
TLR rates in the PES arm [18.1 vs. 6.5%, HR: 2.91 (1.36–6.25),
P ¼ 0.004]. Higher MACE rates for the PES arm persisted at 5
years [34.7 vs. 21.3% for SES, HR: 1.85 (1.17–2.93), P ¼ 0.008],
whereas differences in TLR rates were no longer significant [22.0
vs. 14.0%, HR: 1.70 (0.96–3.02), P ¼ 0.07]. The interaction term
between treatment arm and CSS tertiles for 5-year MACE had a
P ¼ 0.050, suggesting a genuine effect, whereas for 1-year MACE,
P ¼ 0.10. Interaction term P-values for all-cause mortality, MI and
TLR were 0.76, 0.26, 0.29 at 1-year and 0.43, 0.18, 0.39 at 5-year
follow-up, respectively.
Stratifying outcome across SYNTAX score tertiles led to similar
results regarding the performance of PES vs. SES (see Supplemen-
tary material online, Figures S1 and S2). However, the interaction
term between treatment arm and SYNTAX score tertiles for all
endpoints at 1- and 5-year follow-up had a P-value consistently
.0.05; thus conclusions drawn from these results should be inter-
preted with caution.
Discussion
The main findings of this study indicate that the SYNTAX score,
and to a greater extent the CSS, have an important role to play
in the risk stratification of very long-term clinical outcomes in an
all-comers population receiving drug-eluting stents. Both scores
were identified as independent predictors of 5-year MACE, never-
theless having modest discriminatory power and calibration for this
endpoint. Clinical SYNTAX score was also an independent predic-
tor of 5-year all-cause mortality and cardiac death; its superior dis-
criminatory power and calibration compared with SYNTAX score
resulted in a significant improvement in risk stratification. An
additional potential role of the CSS in the assessment of stent per-
formance was also identified.
Although the current study employed comparable inclusion cri-
teria to the two most recent all-comers studies, the mean
SYNTAX score of 11.7 was lower than the 13.5 and 14.6 seen
in the LEADERS and RESOLUTE studies, respectively7,11; similarly
CSS tertile values in our study were lower compared with the
Figure 3 Receiver operating characteristic (ROC) curves for SYNTAX score and Clinical SYNTAX score. Left: 5-year major adverse cardiac
events. Middle: 5-year all-cause mortality (death). Right: 5-year cardiac death. AUC, area-under-the-curve, CI, confidence interval, CSS, Clinical
SYNTAX score.
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Table 4 Five-year all-cause mortality reclassification
into CSS tertiles
CSS tertiles
CSSLOW CSSMID CSSHIGH Total
Patients with events
SS tertiles SSLOW 14 1 3 18
SSMID 2 11 10 23
SSHIGH 0 1 30 31
Total 16 13 43 72
Patients without events
SS tertiles SSLOW 227 40 8 275
SSMID 39 174 51 264
SSHIGH 0 56 181 237
Total 266 270 240 776
SS, Clinical SYNTAX score; SS, SYNTAX score.
Score tertiles as defined in text.
Patients indicated in bold were moved to higher risk (above the diagonal) and
lower risk (below the diagonal) categories respectively, when reclassified.
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RESOLUTE (0–11.2, .11.2–24.7, .24.7). This observation is not
surprising considering the differing time periods when patients
were enrolled in the three studies (SIRTAX 2003–2004,
LEADERS 2006–2007, RESOLUTE 2008), and the increasing
number of co-morbidities now seen in patients presenting for
revascularization. On the other hand, the ARTS II trial enrolled
patients during a similar time to the SIRTAX study; however,
inclusion criteria required patients to have at least two-vessel cor-
onary artery disease.25 The prevalence of multi-vessel disease in
SIRTAX was close to 60%,19 and therefore the lower mean and
tertile cut-off values, seen for the SYNTAX score and CSS in
the current study are entirely expected.
As mean SYNTAX score values decrease in patient cohorts with
less complex disease compared with the seminal SYNTAX trial,
one would hypothesize that differences in clinical outcomes
between individuals would go increasingly undetected by a score
solely based on angiographic parameters; clinical variables may
therefore compensate for this possible decrease in sensitivity of
the SYNTAX score. This hypothesis has been explored in
diverse patient populations by integrating clinical information
together with angiographic parameters into hybrid risk scores,
such as the CSS,11,18 the Global risk classification (GRC)10,26 and
the New Risk Stratification (NERS).27 In our study, we chose
CSS as the most parsimonious of these hybrid scores to assess
the incremental value of clinical data in risk stratification over
stand-alone SYNTAX score; thereby we tried to limit statistical
over-fitting and multiple collinearity between potential
predictors.28
The discriminatory power for MACE was similar for SYNTAX
score and CSS in our study; C-statistics were comparable with
the findings for 5-year MACE in the ARTS II (AUC: 0.57 and
0.62)18 and for 1-year MACE in the RESOLUTE (AUC: 0.59 and
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Table 5 Independent predictors of adverse events at 5-year follow-up (models including SYNTAX score)
Variables HR (95% CI)a P-value AUC (95% CI)c H–L x2 (P-value)c
MACE
SYNTAX scoreb 1.03 (1.01–1.05) 0.003 0.63 (0.58–0.68) 7.78 (0.46)
Number of lesions treated 1.54 (1.21–1.96) ,0.001
All-cause mortality
Ageb 1.06 (1.04–1.09) ,0.001 0.71 (0.65–0.78) 10.967 (0.20)
Diabetes mellitus 2.14 (1.32–3.46) 0.002
Cardiac death
Ageb 1.07 (1.03–1.11) ,0.001 0.75 (0.67–0.83) 5.425 (0.71)
Diabetes mellitus 2.01 (1.05–3.85) 0.04
LVEFb 0.97 (0.94–0.99) 0.006
AUC, area under the curve; CI, confidence interval; H–L, Hosmer–Lemeshow; HR, hazard ratio; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac events.
aAfter adjustment for confounding factors.
bPer unit increase.
cFor the entire model.
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Table 6 Independent predictors of adverse events at 5-year follow-up (models including CSS)
Variables HR (95% CI)a P-value AUC (95% CI)c H–L x2 (P-value)c
MACE
CSSb 1.009 (1.005–1.013) ,0.001 0.65 (0.60–0.69) 10.214 (0.25)
Number of lesions treated 1.58 (1.24–2.01) ,0.001
All-cause mortality
CSSb 1.011 (1.006–1.015) ,0.001 0.68 (0.61–0.75) 7.576 (0.48)
Diabetes mellitus 2.21 (1.34–3.66) 0.002
Cardiac death
CSSb 1.012 (1.006–1.018) ,0.001 0.74 (0.65–0.82) 5.614 (0.69)
Diabetes mellitus 2.23 (1.13–4.39) 0.02
AUC, area under the curve; CI, confidence interval; CSS, Clinical SYNTAX score; H–L, Hosmer–Lemeshow; HR, hazard ratio; MACE, major adverse cardiac events.
aAfter adjustment for confounding factors.
bPer unit increase.
cFor the entire model.
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0.62)11 and better compared with the CUSTOMIZE registry left
main PCI population (AUC for 2-year MACE 0.52 and 0.50 for
SYNTAX score and CSS, respectively).10 Nevertheless, risk strati-
fication was not very well balanced between score tertiles; specifi-
cally, CSS showed diminished ability to discriminate between
patients at low and intermediate risk, reflecting findings of earlier
studies.10,18 SYNTAX score was recently shown to have higher dis-
criminatory power for repeat revascularization11; since MACE
rates were mainly driven by TLR rates in our study, the lack in
reclassification improvement with CSS can be explained.
On the other hand, for harder endpoints, such as the all-cause
and cardiac mortality, significantly better discrimination and equi-
valent or better calibration compared with SYNTAX score
translated into more refined risk stratification with the CSS.
Interestingly, whereas C-statistics for both scores regarding mor-
tality were comparable with respective measures in the ARTS II
and CUSTOMIZE populations, calibration measures were
improved in our study. This refinement in stratification resulted
in CSS being an independent predictor for mortality, contrary
to SYNTAX score, as also demonstrated in similar studies.11,13
Very long-term mortality is expected to be dependent on well-
known predictors of outcome after PCI, such as age and diabetes
mellitus; age is included in the CSS, while diabetes mellitus is
known to impact on renal function. Similarly, the EuroSCORE,29,30
which has also been shown to be effective in risk stratifying
patients, either as a stand-alone score or integrated in
GRC,10,26 does not include assessment of diabetic status, but
renal function. Diabetes was an independent predictor for all-
cause and cardiac mortality next to CSS in our study; nevertheless
a model incorporating CSS and diabetes did not significantly
improve discrimination or calibration for these outcomes. We
may assume that to a certain extent the effect of diabetes has
translated into higher angiographic complexity and diminished
creatinine clearance.
An added finding of our study is the differential performance of
PES and SES for patients in the highest SYNTAX score and CSS
tertiles. In the original SIRTAX trial publication,19 there was a sig-
nificant increase in the primary endpoint at 9-month follow-up in
patients allocated to PES compared with SES; this difference in
MACE was mainly driven by the increased TLR rates in the PES
treatment arm and was attributed to increased angiographic or
procedural complexity. In successive reports from the same
group, similarly significant differences in 2-year MACE have been
reported between PES and SES, when implanted in vessels with
a reference size ,2.75 mm,31 or when studied separately in dia-
betic patients.32 In both analyses, differences in MACE were
driven by significantly decreased TLR rates with SES. Not unex-
pectedly, in our study, significantly increased MACE rates with
PES were observed within the subgroup of patients with increased
angiographic complexity. It has already been suggested in the
LEADERS33 and the RESOLUTE11 trials, that SYNTAX score
could identify a subgroup of patients, where there is a difference
in clinical outcomes between devices. Nevertheless, in our study
respective hazard ratios were inflated, when MACE was stratified
across the CSS tertiles; more importantly, the respective inter-
action term between treatment arm and CSS tertiles reached stat-
istical significance for 5-year MACE, indicating a potential role of
CSS-based stratification in device selection. However, it should
be recognized that this was a subgroup analysis, not pre-specified
in the original study, thus the superiority seen with SES could be
the result of a type I error.
Limitations
The current study is limited by its post hoc nature. As the cardiol-
ogists adjudicating the diagnostic angiograms were blinded to pro-
cedural data, and taking into account the modest reproducibility of
SYNTAX score even among experienced cardiologists,34 a discre-
pancy in results cannot be ruled out, would the scores have been
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Table 7 Clinical outcomes at 1- and 5-year follow-up by treatment arm (univariable analysis)
PES, n 5 422, % SES, n5 426, % HR (95% CI) PES vs. SES P-value
1-year outcome
Death 2.1 1.4 1.53 (0.54–4.29) 0.42
Cardiac death 1.4 0.9 1.52 (0.43–5.40) 0.51
Myocardial infarction 4.1 2.8 1.44 (0.69–3.02) 0.33
TLR (ID) 10.8 5.7 1.95 (1.19–3.20) 0.008
MACE 13.6 7.5 1.86 (1.20–2.86) 0.005
Stent thrombosis (definite) 1.7 1.9 0.88 (0.32–2.44) 0.81
5-year outcome
Death 8.4 8.8 0.97 (0.61–1.54) 0.89
Cardiac death 5.1 4.6 1.13 (0.61–2.10) 0.70
Myocardial infarction 7.3 5.8 1.28 (0.75–2.20) 0.36
TLR (ID) 14.8 12.3 1.26 (0.87–1.82) 0.23
MACE 20.7 17.7 1.22 (0.90–1.67) 0.20
Stent thrombosis (definite) 4.2 4.1 1.02 (0.52–2.00) 0.96
CI, confidence interval; HR, hazard ratio; ID, ischaemia driven; MACE, major adverse cardiac events; PES, paclitaxel-eluting stents; SES, sirolimus-eluting stents; TLR, target lesion
revascularization.
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Figure 4 Stratified comparison between treatment arms for clinical outcomes at 1-year follow-up. Events are stratified across Clinical
SYNTAX score tertiles defined as CSSLOW ≤8.0, 8.0 ,CSSMID ≤17.0, CSSHIGH .17.0. Clinical outcomes’ abbreviations as defined in text.
PES, paclitaxel-eluting stents, SES, sirolimus-eluting stents, N/A, non-applicable.
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Figure 5 Stratified comparison between treatment arms for clinical outcomes at 5-year follow-up. Events are stratified across Clinical
SYNTAX score tertiles defined as CSSLOW, 8.0, 8.0 , CSSMID ≤ 17.0, CSSHIGH . 17.0. Clinical outcomes’ abbreviations as defined in
text. PES, paclitaxel-eluting stents, SES, sirolimus-eluting stents.
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collected prospectively. However, in the case of the SIRTAX trial,
this is purely hypothetical, as the SYNTAX score algorithm had not
been developed at the time of patient enrolment.
Well-known limitations of the SYNTAX score should also be
acknowledged. Patients with prior CABG had to be excluded
from the study; moreover, scoring acute coronary occlusions as
total occlusions may have resulted in an inflation of the individual
scores overestimating the complexity of recanalization. However,
it has been recently shown that SYNTAX score values derived
after the instrumentation of the infarct-related artery and there-
fore probably lower compared with the values derived with the
standard method, could have resulted in an erroneous risk stratifi-
cation; it should not be overlooked that the absence of flow itself
holds an adverse impact on long-term outcome.9 Moreover, irre-
spective of the method used, SYNTAX score for acute MI patients
was proven to improve the discriminatory power of models solely
based on clinical variables, such as the TIMI risk score.35 Lastly, in
our study, multivariable analysis adjusted for clinical presentation,
rendering SYNTAX score and CSS as independent predictors of
MACE and CSS as independent predictor of mortality.
Conclusions
The SYNTAX score and to a greater extent the CSS were able to
stratify risk for very long-term adverse clinical outcomes in an
all-comers population receiving drug-eluting stents. Predictive
accuracy for 5-year mortality was improved using the CSS.
Within the highest score tertiles 5-year MACE increased with
use of paclitaxel- compared with sirolimus-eluting stents. This
study is yet another step to map the performance of SYNTAX
score and CSS in the entire range of coronary artery disease
seen in daily clinical practice.
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online.
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Abstract
Aims: The SYNTAX Score (SXscore) has established itself as an important prognostic tool in patients under-
going percutaneous coronary intervention (PCI). A limitation of the SXscore is the inability to differentiate 
outcomes in patients who have undergone prior coronary artery bypass graft (CABG) surgery. The CABG 
SXscore was devised to address this limitation.
Methods and results: In the SYNTAX-LE MANS substudy 115 patients with unprotected left main coronary 
artery disease (isolated or associated with one, two or three-vessel disease) treated with CABG were prospectively 
assigned to undergo a 15-month coronary angiogram. An independent core laboratory analysed the baseline SXscore 
prior to CABG. The 15-month CABG SXscore was calculated by a panel of three interventional cardiologists. The 
CABG SXscore was calculated by determining the standard SXscore in the “native” coronary vessels (“native 
SXscore”) and deducting points based on the importance of the diseased coronary artery segment (Leaman score) 
that have a functioning bypass graft anastomosed distally. Points relating to intrinsic coronary disease, such as bifur-
cation disease or calcification, remain unaltered. The mean 15-month CABG SXscore was significantly lower 
compared to the mean baseline SXscore (baseline SXscore 31.6, SD 13.1; 15-month CABG SXscore 21.2, SD 11.1; 
p<0.001). Reproducibility analyses  (kappa [k] statistics) indicated a substantial agreement between CABG SXscore 
measurements (k=0.70; 95% CI [0.50-0.90], p<0.001), with the points deducted to calculate the CABG SXscore the 
most reproducible measurement (k=0.74; 95% CI [0.53-0.95], p<0.001). Despite the limited power of the study, 
four-year outcome data (Kaplan-Meier curves) demonstrated a trend towards reduced all-cause death (9.1% vs. 1.8%, 
p=0.084) and death/CVA/MI (16.4% vs. 7.0%, p=0.126) in the low compared to the high CABG SXscore group.
Conclusions: In this pilot study the calculation of the CABG SXscore appeared feasible, reproducible and 
may have a long-term prognostic role in patients with complex coronary disease undergoing surgical revas-
cularisation. Validation of this new scoring methodology is required.
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•  CABG SYNTAX 
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Introduction
The SYNTAX Score (SXscore) (http://www.syntaxscore.com)1-5 has 
established itself as an important prognostic tool in risk stratifying 
patients being considered for revascularisation, and has been vali-
dated in patients undergoing percutaneous coronary intervention 
(PCI) at one-year follow-up6-11. In addition, the SXscore has been 
applied to contemporary drug-eluting stent trials enrolling “all-com-
ers” type populations, and has been shown to be an independent 
predictor of one-year mortality and major adverse cardiac events 
(MACE)12-14.
As a consequence, the SXscore is now advocated in both the 
European and the US revascularisation guidelines in aiding the risk 
stratification of patients with complex coronary artery disease to the 
most appropriate revascularisation modality15-17. Furthermore, the US 
FDA (Food and Drug Administration) recommends the application of 
the SXscore in selecting low-intermediate SXscore patients with 
unprotected left main coronary artery disease in the ongoing EXCEL 
Trial (ClinicalTrials.gov Identifier: NCT01205776), and low SXscore 
patients suitable for transcatheter aortic valve implantation in the 
SURTAVI Trial (ClinicalTrials.gov Identifier: NCT01586910). 
However, a limitation of the SXscore is the inability to apply it usefully 
to patients who have previously undergone CABG.
Based on the principles first defined by Leaman et al (Leaman 
score)18, the SXscore takes into account both the coronary anatomy 
and also the importance of the diseased coronary artery segment 
supplying the myocardium – termed “vessel-segment weighting”. 
Although the baseline SXscore, calculated prior to surgical revas-
cularisation, has been shown not to have any effect on the short to 
long-term prognosis after CABG3,4,7,19,20, it was hypothesised that a 
suitably developed CABG SXscore that takes into account native 
coronary disease anatomy, including features such as calcification, 
bifurcation disease and the effects of surgical revascularisation on 
the vessel-segment weighting, may have potential clinical and 
research applications. The purpose of this pilot study is to examine 
the feasibility of the newly developed CABG SXscore in the 
SYNTAX-LE MANS angiographic substudy21.
Methods
The overall study design of the all-comers SYNTAX Trial3,5,22 and 
the SYNTAX-LE MANS substudy21 have previously been 
described. In brief, SYNTAX-LE MANS was a predefined sub-
study of patients from the randomised SYNTAX Trial who pro-
vided a separate written, informed consent for the substudy entry21. 
Eligible patients were those with left main disease (isolated or asso-
ciated with one, two or three-vessel disease) who did not have renal 
dysfunction (defined as creatinine >2.0 mg/dL [150 μmol/L]) or 
hypersensitivity to contrast agents that could not be adequately pre-
medicated. Per protocol, the time window for the 15-month angio-
gram was set between 14 and 16 months post-allocation. Patients 
enrolled in the study who had a clinically driven angiogram from 9 
to 13 months (inclusive) after treatment allocation were permitted 
to use the earlier coronary angiogram to fulfil the 15-month angio-
graphic requirement.
CABG SYNTAX SCORE ANALYSIS
Baseline and 15-month coronary angiograms were analysed side by 
side by a panel of three interventional cardiologists to calculate the 
15-month CABG SXscore. All reviewers were blinded to the clini-
cal outcomes of the patient analyses and to the baseline SXscore, 
undertaken prior to CABG by an independent core laboratory (Car-
dialysis BV, Rotterdam, The Netherlands) as part of the original 
SYNTAX Trial3.
The CABG SXscore calculation was repeated on 30 randomly 
selected cases at a three-month interval with the reviewers blinded 
to the original baseline and CABG SXscores. Intraobserver repro-
ducibility analyses were undertaken.
CABG SYNTAX SCORE
The CABG SXscore is essentially the SXscore of the “native” coro-
nary vessels (“native SXscore”), with points deducted based on the 
vessel-segment weighting of the bypassed coronary vessel as previ-
ously proposed by Leaman et al18.
SYNTAX SCORE
In brief, the SXscore1-4 was developed by combining the impor-
tance of a diseased coronary artery segment by the vessel-segment 
weighting (Leaman score)18, adverse characteristics of such a lesion 
for revascularisation (ACC/AHA lesion classification)23,24 and the 
Medina classification system for bifurcation lesions25. Each vessel 
segment, 1.5 mm in diameter or greater (Figure 1, labelled 1 to 16), 
with a ≥50% diameter stenosis by visual estimation, is awarded 
a multiplication factor related to coronary lesion location and sever-
ity (Figure 2). Further characterisation of the coronary lesions leads 
to the addition of more points, which includes features of total 
occlusions (duration, length, blunt stump, presence of bridging col-
laterals or side branch), presence of bifurcation (based on the 
Medina classification) or trifurcation disease (number of diseased 
branches involved), side branch angulation, aorto-ostial lesion, 
severe tortuosity, lesion length >20 mm, heavy calcification, throm-
bus and diffuse or small vessel disease. An online SXscore algo-
rithm1 automatically summates each of these features to calculate 
the final total SXscore.
LEAMAN SCORE
The Leaman score is based on the severity of luminal diameter nar-
rowing, and is weighted according to the usual blood flow to the left 
ventricle (LV) in each vessel or vessel segment based on whether 
the coronary system is right or left dominant18.
In a right dominant system the right coronary artery (RCA) sup-
plies approximately 16% and the left coronary artery (LCA) 
approximately 84% of the blood flow to the LV. This 84% is nor-
mally directed 66% to the left anterior descending (LAD) and 33% 
to the left circumflex (LCx) vessels. Thus the LAD and LCx respec-
tively carry approximately 3.5 times and 1.5 times as much blood as 
the RCA. In a left dominant system the LV receives all of its blood 
supply from the LCA; consequently, the RCA is not weighted and 
its value is assigned to the LCA, thereby leading to a heavier vessel-
segment weighting of the LAD and LCx compared to a right domi-
nant system18,26-28. These principles ultimately formed the basis of 
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the segment-weighting factors that were incorporated into the 
SXscore (Table 1)1-4.
CALCULATION OF THE CABG SYNTAX SCORE
In order to allow consistency and reproducibility in the application 
of the CABG SXscore, five rules were adhered to in calculating the 
CABG SXscore.
1.  The SXscore of the native coronary vessels (native SXscore) was 
analysed using the standard methodology (http://www.syntax-
score.com)1, utilising the bypass graft angiogram as necessary to 
allow visualisation of the entire vessel.
2.  All the bypass grafts were analysed to establish the vessel-seg-
ment weighting of the “protection” conferred by the bypass grafts 
(Figure 1, Table 1).
3.  Based on the presence of obstructive or non-obstructive bypass 
disease by visual assessment, segment-weighting points were 
deducted from the native SXscore:
a.  Patent bypass graft to a significant coronary lesion: segment-
weighting points for the coronary lesion were deducted, pro-
vided there was no intervening significant coronary disease 
(Figure 3).
Figure 1. The effect of right and left arterial dominance on the segment numbering – refer to Table 1 for the segment-weighting for the 
respective arterial segments. Anatomical description of the segment numbers has previously been described2 and is included in the 
supplementary appendix. 
Figure 2. Segment-weighting multiplication factors utilised in the SYNTAX Score – used to calculate the points required to deduct from the 
“native SXscore” to calculate the CABG SYNTAX Score.
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b.  Occluded bypass graft: native SXscore remained unaltered 
(Figure 3).
c.  Bypass graft with obstructive (50-99%) disease (Figure 4):
 i.  obstructive native coronary lesion (50-99%): no segment-
weighting points deducted;
ii.  occluded native coronary lesion (100%, TIMI 0 flow): x3 
segment-weighting points deducted.
With an obstructive native coronary lesion (50-99%), it is 
assumed that a significantly diseased graft (50-99%) would confer 
no additional benefit to the blood supply to the affected coronary 
vessel; consequently, there would be no net gain or loss in the seg-
ment-weighting points to the native SXscore. Conversely, if the 
coronary vessel was occluded, then a diseased graft (50-99%) 
would provide “ischaemic protection” to the territory supplied by 
the occluded lesion. Consequently, the segment-weighting factor 
Figure 3. Example of the calculation of the CABG SXscore in a 
patient with distal left main trifurcation disease and an occluded mid 
RCA. The native SXscore was 23 (upper images). A patent LIMA to 
the LAD with no intervening obstructive coronary disease (lower left 
image) led to the deduction of 3.5×2 points (x2 segment-weighting 
due to ischaemic LAD) from the native SXscore. An occluded SVG to 
the intermediate led to no points being deducted (inset lower left 
image). A patent SVG to the distal RCA led to 1×5 points (x5 
segment-weighting due to occluded mid RCA) deducted from the 
native SXscore. Final CABG SXscore was therefore 23-7-5=11 points.
LIMA: left internal mammary artery; SVG: saphenous vein graft; 
RCA: right coronary artery. Black arrows indicate obstructive native 
coronary disease; white arrows indicate patent anastomosis sites of 
grafts to vessels
Table 1. Coronary vessel segment-weighting based on the 
principles first established by Leaman et al18 and incorporated 
into the SYNTAX Score2. Refer to Figure 1 for location of segment 
numbers on the coronary tree based on arterial dominance.
Segment number
Right 
dominance
Left 
dominance
1  (RCA proximal) 1 0
2  (RCA mid) 1 0
3  (RCA distal) 1 0
4  (Posterior descending artery) 1 n/a
16  (Posterolateral branch from RCA) 0.5 n/a
16a  (Posterolateral branch from RCA) 0.5 n/a
16b (Posterolateral branch from RCA) 0.5 n/a
16c (Posterolateral branch from RCA) 0.5 n/a
5 (Left main) 5 6
6 (LAD proximal) 3.5 3.5
7 (LAD mild) 2.5 2.5
8 (LAD apical) 1 1
9 (First diagonal) 1 1
9a (First diagonal) 1 1
10 (Second diagonal) 0.5 0.5
10a (Second diagonal) 0.5 0.5
11 (Proximal circumflex artery) 1.5 2.5
12 (Intermediate/anterolateral artery) 1 1
12a (Obtuse marginal) 1 1
12b (Obtuse marginal) 1 1
13 (Distal circumflex artery) 0.5 1.5
14 (Left posterolateral) 0.5 1
14a (Left posterolateral) 0.5 1
14b (Left posterolateral) 0.5 1
15 (Posterior descending artery) n/a 1
RCA: right coronary artery; LAD: left anterior descending artery; n/a: not 
applicable
would be reduced from x5 (occluded vessel) to x2 (non-occluded 
vessel with a significant lesion [50-99%]), i.e., a deduction of x3 
segment-weighting factor from the native SXscore.
4.  Any further native coronary disease clearly identified through the 
angiograms of the bypass grafts were added to the native 
SXscore. Lesions ≥3 reference vessel diameters were viewed as 
two separate lesions and within this distance as one lesion.
5.  If an obstructive coronary lesion interferes with the blood flow to the 
vessel being protected by the bypass graft, then the points deducted 
were for the segment weighting of the lesion only (Figure 5).
Points related to the lesion characteristics of the “native” coronary 
disease, such as calcification, bifurcation disease, total occlusion, 
etc., would remain unaltered as these reflect the native coronary anat-
omy. Further detail on the SXscore/Leaman score and applications of 
the CABG SXscore are provided in the Supplementary Appendix.
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Figure 4. Principle of “ischaemic protection” in the CABG SXscore. 
Upper image: occluded mid RCA (segment 2 - black arrows) with 
bridging collaterals: native SXscore for the RCA is 8. Lower image: 
SVG anastomosed to distal RCA (white arrow). If the SVG was free of 
obstructive disease then the CABG SXscore would be 8 minus 
(1×5)=3 points. If the SVG was diseased with an obstructive lesion as 
illustrated (lower image, black arrow) the distal RCA would be under 
“ischaemic protection”. Consequently x2 weighting factor for the 
RCA should remain – therefore x3 weighting needs to be deducted 
leading to a CABG SXscore of 8 minus (1×3) points=5 points. If the 
SVG was occluded then the CABG SXscore would remain unaltered 
at 8 points. RCA: right coronary artery; SVG: saphenous vein graft
STATISTICAL ANALYSIS
Continuous variables are expressed as means±SD. Comparisons of 
means and four-year outcomes (Kaplan-Meier curves) were performed 
with the paired t-test and log-rank test respectively. Intraobserver 
variability (tertile partitioning) was determined with kappa statistics 
(<0 none, 0-0.20 slight, 0.21-0.40 fair, 0.41-0.60 moderate, 0.61-0.80 
substantial, 0.81-1.00 almost perfect) on the native SXscore, deducted 
points and CABG SXscore4. A two-sided p-value <0.05 was consid-
ered significant for all tests. Analyses were conducted with SAS Sys-
tem Software Version 8.0+ (SAS Institute, Cary, NC, USA) and 
SPSS 17.0 (SPSS Inc., Chicago, IL, USA).
Results
In total, 271 patients were enrolled in the SYNTAX-LE MANS 
study, 115 of whom were enrolled in the CABG arm. Available 
15-month coronary angiograms were suitable for analysis in 113 of 
115 (97.4%) CABG patients. No patients died in the CABG arm 
from baseline to undergoing the 15-month coronary angiogram. 
One patient had no angiographic films available and a further 
patient did not have native coronary vessels filmed. Baseline char-
acteristics for the SYNTAX-LE MANS substudy have been pub-
lished previously21.
COMPARISONS OF THE BASELINE SYNTAX SCORE AND 
15-MONTH CABG SYNTAX SCORE
Comparisons of the baseline SXscores and 15-month CABG 
SXscores demonstrated a significant decline in the mean value of 
the 15-month CABG SXscores (Figure 6). Both the baseline 
SXscore and the 15-month CABG SXscore appeared to be broadly 
normally distributed with the mean 15-month CABG SXscore sig-
nificantly moved to the left (Figure 7). The mean 15-month CABG 
SXscore was significantly lower compared to the mean baseline 
SXscore (baseline SXscore 31.6, SD 13.1; 15-month CABG 
SXscore 21.2, SD 11.1; p<0.001) (Figure 7).
Comparisons of the baseline SXscore and 15-month native 
SXscore did not demonstrate any significant statistical differences 
(baseline SXscore 31.6, SD 13.1; 15-month native SXscore 31.1, 
SD 12.2; p=0.50). The mean number of points deducted from the 
15-month native SXscore to derive the CABG SXscore was 9.9 
(SD 5.3) (Figure 8).
REPRODUCIBILITY ANALYSES
The intraobserver variability for the 15-month native SXscore 
(k=0.70; 95% CI: 0.50-0.91, p<0.001), points deducted from the 
native SXscore to derive the 15-month CABG SXscore (k=0.74; 
95% CI: 0.53-0.95, p<0.001) and the final 15-month CABG 
SXscore (k=0.70; 95% CI: 0.50-0.90, p<0.001) were all substantial. 
The number of points deducted to derive the 15-month CABG 
SXscore was the most reproducible measurement.
CLINICAL OUTCOMES
Due to limited power the present outcome analyses should be inter-
preted as exploratory and hypothesis-generating. The CABG 
SXscores were separated into two groups, divided by the median of 
the normally distributed 15-month CABG SXscores into low (0-21) 
(n=58) and high-risk groups (≥22) (n=55).
Four-year clinical outcome data demonstrated a trend towards an 
increased mortality in the high CABG SXscore group compared to 
the low CABG SXscore group (low CABG SXscore: 1.8%, high 
CABG SXscore: 9.1%, p=0.084) (Figure 9). Furthermore, an 
increase in the composite of all-cause death/cerebrovascular acci-
dent (CVA)/ myocardial infarction (MI) at four years was also evi-
dent in the high CABG SXscore group compared to the low CABG 
SXscore group (low CABG SXscore: 7.0%, high CABG SXscore: 
16.4%, p=0.126).
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Figure 6. Reduction in the CABG SYNTAX Score at scheduled 
coronary angiography at 15 months, compared to the baseline 
SYNTAX Score (n=113).
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Figure 7. Distribution of the baseline SYNTAX Scores and the 
15-month CABG SYNTAX Scores (n=113). Note the significant 
decrease in the mean CABG SYNTAX Score compared to the mean 
baseline SYNTAX Score (p<0.001). SD: standard deviation.
Figure 5. Example of the calculation of the CABG SXscore in a patient with mid left main and two-vessel coronary disease. Native SXscore was 21. 
A patent LIMA anastomosed to the mid LAD, with upstream native mid LAD disease, and led to the segment-weighting (2.5×2 points) of the mid 
LAD (segment 7) being deducted from the native SXscore (left image). The LCx was protected by two OM SVGs leading to a deduction of 1.5×2 
points from the native SXscore (middle image). The occluded PLV was protected by an SVG leading to the deduction of 0.5×5 points from the native 
SXscore (right image). Final CABG SXscore was therefore 21-5-3-2.5=10.5 points. LAD: left anterior descending artery; LCx: left circumflex; OM: 
obtuse marginal; RCA: right coronary artery; PLV: posterior left ventricular branch of the RCA; LIMA: left internal mammary artery; SVG 
saphenous vein graft. Black arrows indicate obstructive native coronary disease; white arrows indicate patent anastomosis sites of grafts to vessels.
Notably, the Kaplan-Meier curves for all clinical outcomes in the 
low and high CABG SXscores did not start to separate until after 
one year of follow-up, with continued separation of the curves up 
to four years of follow-up. A peak in the incidence of all-cause 
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revascularisation was observed at approximately 15 months sec-
ondary to the scheduled study coronary angiogram triggering repeat 
revascularisation (Figure 9).
Discussion
The main findings of this pilot study are: 1) that the application of 
the newly developed CABG SXscore appears feasible; 2) that the 
15-month CABG SXscore demonstrated a significant decrease in 
value compared to the baseline SXscore (prior to CABG), second-
ary to a deduction in points attributed to the segment-weighting of 
the revascularised coronary vessels; 3) that the CABG SXscore 
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Mean deducted points 9.9 (S.D. 5.3)
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Figure 8. Distribution of the deducted points from the native SXscore 
to calculate the CABG SXscore (n=113). SD: standard deviation.
appears to be a reproducible technique when performed by a panel 
of interventional cardiologists experienced in the reporting of the 
SXscore; 4) that the deduction of the segment-weighting related 
points due to the presence of bypass grafts was the most reproduc-
ible technique; and 5) that the CABG SXscore may have a long-
term prognostic role. Further validation of this newly developed 
score is required.
The findings from this present study are consistent with the 
methodology adopted by Leaman et al when applying the Leaman 
score to patients pre and post CABG18, namely that the segment-
weighting for the treated vessel would be deducted if it had a func-
tioning bypass graft anastomosed distal to the treated lesion. In 
comparison to the baseline SXscore, a clear and significant reduc-
tion in the 15-month CABG SXscore was evident. The main differ-
ence between the CABG SXscore and the Leaman score was that 
the points relating to lesion characteristics in the CABG SXscore 
remained.
One of the unavoidable limitations of the present study was that 
the coronary angiograms were taken 15 months post CABG and the 
results compared to the baseline SXscore taken prior to surgery. The 
mean baseline SXscore and the 15-month native SXscore did how-
ever not differ significantly (baseline SXscore 31.6, SD 13.1; 
15-month native SXscore 31.1, SD 12.2; p=0.50), making the poten-
tial effects of native coronary disease progression at 15 months likely 
to be of lesser significance.
Conversely, as reported in the SYNTAX-LE MANS substudy, 
over a quarter of the CABG patients (27.2%) had a significantly 
diseased (≥50% to <100%) or obstructed (100%) bypass graft at 
15 months21. These findings may have led to the underestimation of 
the 15-month CABG SXscore compared to if the CABG SXscore 
had been performed post CABG surgery. Although it has previously 
been reported that early bypass graft occlusion rates may be associated 
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Figure 9. Clinical outcomes separated by the median of the CABG SYNTAX Score into low (0-21) (n=58) and high (≥22) (n=55) score groups. 
A non-significant trend towards higher mortality (left image) and all-cause death/CVA/MI (middle image) were evident in the high CABG 
SYNTAX Score group at four years. The peak in repeat all-cause revascularisation between years one and two (right image) were secondary to 
patients undergoing scheduled coronary angiography, the findings of which triggered repeat revascularisation. CVA: cerebrovascular 
accident; MI: myocardial infarction
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with adverse clinical events29-31, the reported loss of the bypass 
grafts in SYNTAX-LE MANS were not significantly associated 
with early MACCE21.
It may be speculated that a proportion of these bypass grafts 
may potentially have been unnecessary. Early bypass graft 
patency rates for functionally significant native coronary lesions 
have been shown to be significantly higher compared to those for 
bypass grafts with functionally insignificant native coronary 
lesions32-34. Furthermore, angiographically defined percentage 
diameter stenoses or the minimum lumen diameter of native coro-
nary vessels29,35 and grafts that have competitive filling with the 
treated native vessel36,37 have been shown to be predictors of 
insufficient flow and/or early graft failure. Consequently, despite 
the limitations, the 15-month CABG SXscore may potentially be 
representative of patients who have been surgically revascularised 
at baseline.
ASSOCIATION OF THE CABG SYNTAX SCORE WITH CLINICAL 
OUTCOMES
The SXscore taken prior to surgery has consistently been shown not 
to have any significant effect on the short to long-term prognosis 
after CABG2-4,7,19,20. It has previously been suggested that this obser-
vation may be related to the fact that bypass grafts are anastomosed 
distal to the proximal disease regardless of the complexity of the 
native coronary disease, providing there are suitable graftable tar-
gets4,38. With the CABG SXscore this concept is potentially chal-
lenged, with the observation of a non-significant trend towards 
a higher longer-term mortality and death/MI/CVA in the high (com-
pared to the low) CABG SXscore group. MACCE was not exam-
ined as the 15-month scheduled coronary angiogram triggered 
repeat revascularisation (Figure 9).
PREVIOUS STUDIES
Alderman et al39 previously demonstrated in The Bypass Angio-
plasty Revascularisation Investigation (BARI) trial – consisting 
of patients treated with percutaneous or surgical revascularisation 
who underwent entry and five-year coronary angiographic fol-
low-up – that native coronary disease progression (and not the 
extent of initial revascularisation) was the predominant determi-
nant of the recurrence of angina and jeopardised myocardium at 
five years. Notably within the BARI Trial two thirds of the 
increase in myocardial jeopardy at five years was in previously 
untreated coronary vessels.
Although other studies have suggested that incomplete surgical 
revascularisation may be associated with short and long-term 
adverse outcomes40,41, further predominantly more contemporary 
studies have suggested that “reasonable” incomplete surgical revas-
cularisation does not have an adverse effect on long-term clinical 
outcomes42-45. Furthermore, the long-term survival of patients 
treated with surgical revascularisation in the CASS (Coronary 
Artery Surgery Study)46 and Rotterdam47 registries has been shown 
to be associated with more extensive preoperative coronary disease, 
which in turn was linked to the higher prevalence and severity of 
other clinical risk factors.
In addition, the Duke graft index48 – an anatomical-based scoring 
system for patients who had previously undergone CABG – was 
demonstrated to be significantly more associated with long-term 
prognosis compared to the native coronary anatomy prior to CABG. 
Remarkably, the Duke graft index had a design concept that in prin-
ciple was similar to the CABG SXscore, namely associating anatom-
ical coronary disease (Duke Graft index: based on the number of 
diseased coronary territories; CABG SXscore: a more sophisticated 
assessment of the coronary anatomy as previously described) with 
the level of protection to the diseased territories conferred by bypass 
grafts in both scores.
IMPLICATIONS OF THE CABG SYNTAX SCORE FOR CLINICAL 
PRACTICE
The CABG SXscore may thus be regarded as both a marker of ana-
tomical coronary disease complexity, and of the degree of revascu-
larisation secondary to the deduction of segment-weighting points 
related to the bypass grafts. Furthermore, it may be speculated that 
the CABG SXscore consisting of anatomical characteristics of the 
coronary vessel – such as bifurcation disease, calcification, total 
occlusions, etc. – may reflect the clinical risk profile of the patient 
and the likelihood of native coronary (and possibly non-coronary as 
detailed below) atherosclerotic disease progression which, impor-
tantly, may actually target the bypass grafts.
It has previously been suggested that the SXscore is a marker of 
patients with a more adverse clinical risk profile who have evi-
dence of systemic atherosclerotic disease, and are thus at greater 
longer-term cardiovascular and cerebrovascular risk19,20,49. This 
hypothesis is supported by the significant and direct relationship 
of the 10-year predicted Framingham risk scores with the preva-
lence and magnitude of coronary artery calcium scores50. In addi-
tion, the ankle-brachial index51-54 and common carotid 
intima-media thickness55-58, both markers of extra-cardiac disease, 
have been correlated with the severity of coronary artery disease 
and even clinical events.
Notably, the clinical outcomes in the present study did not start to 
separate until after one year, and continued to separate at up to four 
years (Figure 9). It may be further hypothesised that the curves 
would continue to separate in the longer term where the clinical 
manifestations of continued native atherosclerotic coronary disease 
progression, and importantly bypass graft disease progression par-
ticularly with SVG, would become more apparent. Consistent with 
these hypotheses are the findings that SVGs have been shown to be 
protective in the first seven years, and that thereafter mortality 
increases significantly in parallel to the gradual loss of SVG 
patency47,59. 
POTENTIAL CLINICAL AND RESEARCH APPLICATIONS OF 
THE CABG SYNTAX SCORE
Potential clinical applications of the CABG SXscore include long-
term risk stratification of patients who have previously undergone 
CABG to aid in the identification of a group at high risk for future 
clinical events and repeat revascularisation. Even without the use of 
a CABG SXscore, it may be further postulated that higher SXscore 
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patients may benefit more from undergoing revascularisation with 
more durable grafts that have a proven long-term patency (e.g., 
LIMA and RIMA) compared to SVG60,61.
Although aggressive risk factor control would undoubtedly improve 
the prognosis of all these patients, perhaps future study may target 
patients with a higher SXscore/CABG SXscore who may potentially 
benefit from more aggressive risk factor control with established and 
emerging drugs that cause atherosclerotic disease regression.
Other potential applications of the CABG SXscore in a research 
setting include the allowance of the incorporation of CABG patients 
into contemporary stent trials measuring the SXscore, where such 
patients are at present excluded.
STUDY LIMITATIONS
As previously discussed, apart from the time frame at which the 
CABG SXscore was taken, the main limitation of this study is that 
there was limited power to examine long-term clinical outcomes. 
Despite this limitation, a non-significant trend towards more 
adverse clinical outcomes in the higher CABG SXscore group was 
seen, which is further supported by the concept of the Duke graft 
index, as previously discussed48.
One other limitation is that the CABG SXscore does not account 
for the type of graft anastomosed and the characteristics of the graft 
disease (if present), except if there is obstructive graft disease or not. 
This is perhaps more notable with the LIMA bypass graft given its 
proven higher long-term patency rates compared to other types of 
bypass graft60,61. The hypothesis central to the CABG SXscore does, 
however, relate to the native SXscore and its apparent association 
with clinical comorbidity, with the additional “protection” conferred 
by the bypass grafts. Furthermore, reducing the CABG SXscore by 
an arbitrary number of points based on the type and numerous ana-
tomical complexities of the bypass graft would substantially increase 
the complexity of the analyses, making this impractical.
FUTURE DIRECTIONS
Potentially, the integration of the CABG SXscore into an online 
algorithm, as is currently available with the SXscore1, may serve to 
simplify the calculation of the CABG SXscore. The functional 
SYNTAX Score – a fractional flow reserve (FFR) guided SYNTAX 
scoring methodology – has recently been demonstrated to improve 
the diagnostic accuracy of the SXscore62. Furthermore, the feasibil-
ity of undertaking non-invasive anatomical and fractional flow 
measurements has since been proven, utilising computational 
fluid dynamics applied to coronary computed tomography (CT) 
angiography63. The application of this emerging technology to the 
CABG SXscore may improve the diagnostic accuracy and repro-
ducibility of the CABG SXscore. In addition, the non-invasive 
combined coronary CT and FFR technology may potentially allow 
for the automatic adjustment of the vessel-segment weighting for 
coronary vessels based on actual measured blood flow, in order to 
calculate a more “physiological” functional CABG SXscore.
Conclusion
The calculation of the CABG SXscore is feasible, reproducible and 
may have a long-term prognostic role in the assessment of risk in 
patients undergoing coronary artery bypass grafting. Confirmation 
and validation of the findings from this pilot study are required in 
larger studies.
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Chapter 17      
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We recently reported the coronary artery bypass graft (CABG) 
SYNTAX Score, an objective measure of anatomical complexity and 
revascularisation post coronary artery bypass graft (CABG) surgery1. 
At four-year follow-up, a non-significant trend towards more adverse 
clinical outcomes, including all-cause death, was reported in the 
higher CABG SYNTAX group (≥22)1. The final five-year outcomes 
of the SYNTAX trial have recently been reported2,3. We report the 
five-year outcomes of the CABG SYNTAX Score from the CABG 
arm of the SYNTAX-LE MANS left main angiographic substudy.
At five years, significantly greater all-cause death was seen in the 
high CABG SYNTAX Score group (≥22) compared to the low CABG 
SYNTAX Score group (<22) (14.5% vs. 9.1%, log rank p-value=0.012) 
(Figure 1). Similarly, significantly greater five-year all-cause death/
cerebrovascular accident (CVA)/myocardial infarction (MI) (log rank 
p-value=0.025) and MACCE (major adverse cardiac and cerebrovas-
cular events) (log rank p-value=0.050) were reported.
Incomplete revascularisation (ICR) has recently been hypothe-
sised and shown to be a surrogate marker of a greater burden and 
complexity of coronary disease, other vascular disease, and clinical 
comorbidity, in both CABG and PCI (percutaneous coronary inter-
vention) treated patients4,5. Specifically, in the all-comers CABG 
and PCI arms of the SYNTAX trial, adverse long-term (four-year) 
clinical outcomes  – including mortality, all-cause revascularisation, 
and MACCE – were shown to occur more frequently in patients 
who were incompletely revascularised.
The CABG SYNTAX Score and its PCI equivalent, the residual 
SYNTAX Score6, both provide objective measures of the complexity 
of the residual disease and level of revascularisation. These scores 
may aid in determining a level of “reasonable revascularisation” after 
undergoing surgical or percutaneous-based revascularisation7, and 
may have a long-term prognostic role in identifying high-risk patients 
undergoing CABG or PCI. Validation studies are awaited.
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Figure 1. Outcomes (Kaplan-Meier curves) separated by the median of the CABG SYNTAX Score into low (0-21) (n=58) and high (≥22) 
(n=55) score groups. At 5 years, significantly greater all-cause mortality (left image), significantly greater all-cause death/CVA/MI (middle 
image) and MACCE (right image) were evident in the high CABG SYNTAX Score group compared to the low CABG SYNTAX Score group. 
Note the peak in MACCE at approximately 18 months secondary to patients undergoing scheduled coronary angiography, the findings of 
which triggered repeat revascularisation. Log rank p-values are shown.
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  Summary and conclusions      
 
 
 
 
 
 
 
 
 Bifurcation QCA: development and validation Since its inception in 1958, invasive coronary angiography has been considered essential in the diagnostic evaluation of coronary artery disease and the guidance of percutaneous coronary intervention (PCI). Quantitative coronary angiography (QCA) has already been proven an objective and reproducible way to quantify the extent of coronary stenoses located in single-vessel segments. However, in the analysis of bifurcation lesions, the validity of single-vessel QCA has been brought into dispute, as it fails to predict the functional significance of ostial side-branch (SB) stenosis. Dedicated bifurcation software algorithms have been developed in order to make up for the shortcomings of single-vessel QCA. However definitions of angiographic measures, such as the reference vessel diameter (RVD), are at variance, thus resulting in different measures for the percent diameter stenosis (DS). Therefore, the European Bifurcation Club has advocated the reconciliation of diverse methodologies and the creation of a standard QCA approach for the evaluation of bifurcation lesions. However, before embarking on the validation of these algorithms we had to come up with a suitable gold standard. After a thorough review of the relevant literature, we designed and precision manufactured six plexiglas phantoms (Chapter 2), each phantom mimicking a coronary vessel with three successive bifurcations lesions with variable anatomy and Medina class.  Using the aforementioned bifurcation phantoms, we first validated two models for bifurcation two-dimensional (2-D) QCA analysis (Chapter 3) each of them reporting minimal lumen diameter (MLD), RVD and DS over a varying number of segments. The former, a simplified 6-segment model, reflects the proximal main vessel (PMV), the distal main vessel (DMV) and the SB allowing a quick overview of results during a procedure. The latter, a more detailed 11-segment model, provides additional sets of results for ostial DMV and SB positions and the bifurcation region itself aiming at accurate localization of MLD, RVD and DS pre-, post-PCI and at follow-up angiography. Both models provided highly repeatable results in terms of diameter derived parameters and in excellent agreement with each other and with the true phantom dimensions. However, this study had two limitations; firstly, accuracy and precision was somewhat diminished for small phantom MLD values (≤0.70 mm) and secondly, only local reference (user-defined) obstruction analysis was employed.   
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 An advanced lumen detection algorithm integrated into the following version of the same software improved MLD quantification for true MLD <0.7 mm and thereby resulted in highly accurate and precise diameter measurements over the entire range of diameter values anticipated in clinical practice (Chapter 4). Furthermore, an optimized algorithm for automatic reference (interpolated) obstruction analysis, resulted in significantly higher reproducibility for RVD and DS values compared with local reference analysis. Naturally these effects are pronounced in real coronary cases. Operators may choose different landmarks dependent on individual perception of what constitutes a true bifurcation. Thus analyzed segments may become exceedingly long and tapered, which is the case where automatic reference analysis is preferred. Local reference analysis can still be beneficial in ectatic or diffusely diseased vessels, where interpolation could be severely mistaken, based on either too large or too small diameter values, respectively.  Next to diameter-derived measurements, 2-D bifurcation angle (BA) was calculated with a dedicated algorithm following the definitions adopted by the European Bifurcation Club; angle calculations were model independent and highly reproducible.  Bearing in mind that the phantom BA values were determined in a 3-D space, the 2-D BA calculated values showed remarkable accuracy and precision not varying significantly between software versions. The widest opening of a given bifurcation and the best view of the SB ostium usually coexist in one single good 2-D image, the antero-posterior view in the phantoms’ design. Declining accuracy and precision for 2-D BA calculations in rotated views reflect this phenomenon (Chapter 3 and 4). In order to overcome potential limitations associated with 2-D QCA of bifurcation lesions, we developed a novel and dedicated 3-D bifurcation QCA software (Chapter 5). We described the methodology, whereby combining two 2-D image data sets, the new software is able to correct for the geometric distortion of the angiography gantry, perform a spatially accurate 3-D reconstruction and true quantitative 3-D bifurcation analysis determining lesion characteristics including BA values. The novelty but also the accuracy of the reconstruction and the derived measurements heavily relies upon the definition of the central bifurcation area, described as the polygon of confluence.  Since 3-D reconstruction combines two 2-D projections, the issue of overlapping vessels in tortuous bifurcation lesions may still be a problem; a reconstruction utilizing more than two projections may yield optimal 3-D images, at the expense of increasing 
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 complexity of analytical software. Following this reasoning, we revised our 3-D reconstruction methodology in order to allow reconstructions of more than two 2-D projections (Chapter 6). Furthermore, we adopted the methodology described for 2-D bifurcation automatic reference obstruction analysis applying it to the 3-D reconstructed model. Concepts introduced in Chapter 4 are projected to the current 3-D methodology, resulting in a comprehensive 3-D bifurcation QCA analysis. Measurements for MLD, RVD, DS and BA derived from the QCA 3-D bifurcation software were validated against our precision manufactured phantom bifurcations (Chapter 6) showing high accuracy, precision and reproducibility. 
In vitro validation has the obvious limitation of being based on static objects, acquired under ideal angiographic conditions. In our phantom bifurcations, lesions were circular-shaped in cross-sectional view for design simplicity and due to manufacturing constraints. On the contrary, more than 50% of coronary lesions are asymmetric, where 2-D analysis is known to be inaccurate. Furthermore, as opposed to straight phantom vessel segments, coronary vessels usually have curved trajectories, which augment the effect of foreshortening in 2-D projection images. Therefore, we have to assume that the incremental value of 3-D bifurcation QCA as compared to 2-D analysis may have been underestimated. Visual assessment has been the intuitive way to interpret the coronary angiogram; nevertheless, “eyeballing” has been proven to be rather inaccurate and highly variable. This effect is even more pronounced in bifurcation lesions compared with single-vessel segments. The intuitive way, in which even experienced operators interpret stenosis severity at or close to the ostia of distal bifurcation branches, is by referring to the PMV segment, thus resulting in overestimated DS values. Conversely, lesions in the PMV may be underestimated. Indeed, these phenomena were replicated when conducting our survey among experts in the field of bifurcation PCI (Chapter 7); visual estimates of DS in phantom bifurcation lesions were highly variable compared to current bifurcation QCA standards. The recorded large variability of visual estimates in equivocal stenoses and the low inter-observer agreement in derived Medina classification may justify the inclusion of online bifurcation QCA in the decision making process.   
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 Bifurcation QCA in clinical studies  Following the development and validation of dedicated bifurcation QCA software, the application in real-life clinical settings was the next step. We reported long-term outcome data on the V stenting technique in de novo bifurcation lesions using drug-eluting stents in patients from the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and the T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) registries (Chapter 8). We concluded that in this real-world cohort, late clinical events stand in accord with studies on competitive techniques. Early outcome was less encouraging, probably due to the baseline risks, but on closer scrutiny could appear circumstantial and endpoint-dependent. Angiographic parameters, both diameter-derived ones as well as BA values, were determined with dedicated bifurcation QCA algorithms according to a multiple segment model in all patients where films could be retrieved, thereby confirming feasibility of analysis in this relatively small study. Furthermore, we investigated the long-term clinical outcomes and independent predictors of major cardiac events in unprotected left main coronary artery disease patients treated by PCI with drug-eluting stents in patients from the RESEARCH and T-SEARCH registries (Chapter 9). We reported a late increase in adverse events up to 4 years, which warrants careful follow-up of the patients receiving drug-eluting stents in the left main stem. Among other variables BA was evaluated as a possible parameter for risk stratification. Although 3-D QCA was available, it was feasible in only half the patients due to the unavailability of 2 separate angiographic views of more than 30° apart; in the remaining patients 2-D QCA was performed. Pre-PCI distal BA, that is the angle between the left anterior descending and left circumflex arteries following the European Bifurcation Club definition, was determined both in the diastolic and systolic phase. Systolic BA values exhibited a weak statistical association with the 4-year patient-oriented composite endpoint in the univariate analysis, wherein patients with higher pre-PCI BA values showed a trend for worse outcome. However, BA did not remain as a significant predictor of adverse clinical outcomes in the multivariate analysis; this could be attributed to heterogeneous QCA analysis and a relatively small number of patients. Motivated by these mixed signals, a promise for predictive ability of the BA parameters in an underpowered study with relatively low rates of 3-D analysis, we decided to further investigate the 3-D BA parameters of the left main coronary artery, the effect of 
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 PCI on this angulation, and the impact of 3-D BA on 1-year clinical outcomes in a larger cohort, namely the patients randomized to left main PCI within the SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery)  trial 
(Chapter 10). Complete 3-D BA analysis, before and after PCI, was feasible in 75% of cases; one could expect that prospective collection of appropriate cineangiograms with the view to perform this kind of analysis could further limit the number of non-analyzable cases to <10%. This study was the largest one to-date to describe the 3-D left main angulation; BA parameters were shown to vary considerably. Furthermore, we showed that cardiac motion exerts a reciprocal effect on proximal and distal BA, the former being increased and the latter decreased during systole. In addition, PCI primarily modifies the distal BA; overall, angles were decreased, whereas the narrowest pre-PCI angles were actually increased after the procedure. However, our analysis did not show enough evidence to support 3-D BA as a potential predictor of outcome; there was a weak trend indicating higher adverse event rates in patients with wider distal left main angles when 2 stents were implanted in the left main bifurcation.  As soon as the 5-year clinical outcomes of the SYNTAX trial were made available, the impact of 3-D BA parameters was further investigated (Chapter 11). Similar to our 1-year findings, stratification across pre-PCI diastolic distal BA tertiles failed to show any difference in adverse event rates either in the entire study population or in the patients who had actually undergone bifurcation PCI. On the other hand, bifurcation PCI patients with a restricted post-PCI systolic-diastolic distal BA range, meaning a diminished “freedom of movement” of the left main bifurcation, showed significantly higher adverse event rates. Even when adjusted for various clinical, angiographic and procedural variables, it still proved an independent predictor of 5-year adverse clinical events. It is possible that this study provides us with new insights into the biomechanics of stent failure in bifurcation lesions, the left main bifurcation being the most important of all in the human coronary tree. Finally, we reported the acute procedural and 6-month clinical outcomes after left main PCI with a dedicated bifurcation stent in patients included in the TRYTON left main multicentre registry (Chapter 12). The use of the dedicated bifurcation stent studied for treatment of left main bifurcation lesions was associated with a high rate of device and procedural success without complications in such a high-risk patient and lesion cohort. 
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 Angiographic analysis was performed per protocol with the dedicated 2-D bifurcation QCA algorithm presented and validated in Chapter 4 of this thesis following a standardized operator procedure. Diameter-derived measures from both 11- and 6-segment models were of apparent use when adjudicating the post-procedural angiographic results; effect of PCI on BA parameters was also studied. Interestingly, the mean DS values established by QCA analysis in this cohort were lower than 50% in PMV, DMV and SB. This implies that angiographic measurements were not the sole criterion used to determine whether the left main bifurcation should be treated or not. Equally to our surprise, 3-D QCA analysis was feasible in only ~30% of the cases. Notwithstanding the per protocol angiographic analysis, the high level of expertise among operators involved and the challenging anatomy, one would have to conclude that proper prospective acquisition of angiograms both pre- and post-procedure, as well as incremental value of 3-D QCA are lessons that still need to be learned.   
The SYNTAX score and other derivative scores  The SYNTAX score is an important tool to grade angiographic complexity; it has been integrated in both the European and U.S. revascularization guidelines for the risk stratification of patients with complex coronary artery disease, facilitating the choice of the most appropriate revascularization modality. In the randomized SYNTAX trial, it proved effective in predicting clinical outcomes after elective PCI procedures in patients with three-vessel and/or left main coronary artery disease. We assessed the SYNTAX score‘s predictive ability for a number of clinical outcomes in “all-comers” populations with a varying extent of coronary artery disease undergoing both elective and emergent PCI procedures. Initially, we reviewed the reproducibility of the SYNTAX score (Chapter 13). Despite its important role in risk stratification, the calculation of the SYNTAX score relies on the visual assessment of coronary lesions, and therefore is subject to intra-and inter-observer variability. In our study, the SYNTAX score was calculated on two occasions 8 weeks apart in 100 patients randomly selected from the SYNTAX trial by a team made up of three interventional cardiologists. Our analysis demonstrated that the SYNTAX score has moderate intra-observer reproducibility, which is consistent with a prior evaluation performed by core lab analysts. The scoring of bifurcation lesions remains the main 
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 source of inconsistency, which may be improved by the use of additional imaging modalities together with a review of its definition. Furthermore, we assessed the predictive value of the SYNTAX score for major adverse cardiac events both in the already described cohort of unprotected left main PCI patients from the RESEARCH and T-SEARCH registries as well as in the all-comers population of the LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) trial. In the former study, SYNTAX score emerged as an independent predictor for both all-cause mortality and the patient-oriented composite endpoint up to 4 years, wherein patients in the high score tertile demonstrated significantly higher event rates (Chapter 9). Similarly, in LEADERS a significantly higher number of patients showed major adverse events in the highest tertile of SYNTAX score at 1-year follow-up. However, it is important to mention that overall this patient population had much lower SYNTAX scores than the SYNTAX trial population and/or the left main registries; nevertheless, the SYNTAX score still appeared to have good discriminatory power for risk assessment. Thereby, we demonstrated that the prognostic value of the SYNTAX score is valid for all patients with de novo coronary artery disease undergoing percutaneous revascularization (Chapter 14). In Chapter 15 we investigated the ability of SYNTAX score and Clinical SYNTAX score to predict very long-term outcomes in an all-comers population enrolled in the SIRolimus-eluting stent compared with pacliTAXel-Eluting Stent for coronary revascularization (SIRTAX) trial. In this trial SYNTAX score mean and tertile values were even lower than the respective ones in the LEADERS reflecting the earlier time periods of enrolment and the lower prevalence of comorbidities in SIRTAX. Therefore, clinical variables would be expected to compensate for this possible decrease in sensitivity of the SYNTAX score. Our results showed that both SYNTAX score and Clinical SYNTAX score were independent predictors of 5-year major adverse cardiac events. In addition, Clinical SYNTAX score was an independent predictor for 5-year mortality; its superior discriminatory power and calibration compared with SYNTAX score resulted in a significant improvement in risk stratification for respective mortality endpoints. An additional potential role of the Clinical SYNTAX score regarding the risk stratification in stent selection was also identified, wherein significantly increased adverse event rates 
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 with paclitaxel-eluting stents were observed within the subgroup of patients with the highest Clinical SYNTAX score.  A limitation of the SYNTAX score is the inability to differentiate outcomes in patients who have undergone coronary artery bypass graft (CABG) surgery. We discussed the rationale, development and feasibility of the newly developed CABG SYNTAX score 
(Chapter 16), and we concluded that the calculation of this score appeared feasible, reproducible and may have a long-term prognostic role in patients with complex coronary disease undergoing surgical revascularization. Furthermore, we reported the 5-year outcomes from the CABG arm of the SYNTAX-LE MANS left main angiographic substudy stratified across the mean CABG SYNTAX score (Chapter 17). According to our analysis significantly greater rates of 5-year all-cause mortality and other adverse composite endpoints were evident in the high CABG SYNTAX score group compared to the low score group. The CABG SYNTAX score and its PCI equivalent, the residual SYNTAX score, both provide objective measures of the complexity of the residual disease and level of revascularization. These scores may aid in determining a level of “reasonable revascularization”, and may have a long-term prognostic role in identifying high-risk patients undergoing CABG or PCI.               
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     Samenvatting en conclusies                   
 Kwantitatieve coronair angiografie van bifurcaties: de 
ontwikkeling en validatie Sinds de start van invasieve coronair angiografie in 1958 is het gebruik hiervan niet meer weg te denken uit de dagelijkse praktijk van het katheterisatie laboratorium en wordt deze afbeeldings techniek beschouwd als een essentieel onderdeel in de diagnostische evaluatie van coronaire hartziekte en de begeleiding van percutaan coronaire interventie (PCI). Kwantitatieve coronaire angiografie (QCA) kan gebruikt worden om de omvang van de stenosis graad in coronair segmenten te bepalen, en de objectiviteit en reproduceerbaarheid van deze methode zijn al aangetoond. Echter, het gebruik van QCA in een segment die een bifurcatie bevat staat ter discussie, omdat met de huidige methode niet afdoende de significante stenoses gedetecteerd worden. Met software, die speciaal ontwikkeld is om de stenosis graad in een bifurcatie segment te bepalen, zijn een aantal beperkingen van de huidige QCA opgelost. Echter het bepalen van een referentie diameter (RVD) in het gebied rond een bifurcatie is niet vanzelfsprekend, en kan bij het kwantificeren van de stenose graad als nog tot grote variaties in diameter stenose (DS) leiden. Daarom pleit de Europese Bifurcatie Club voor een standaard methodologie voor het bepalen van de stenose graad in een bifurcatie segment.  Voor het valideren van de nieuwe bifurcatie-QCA software is een relevante gouden standaard vereist. Omdat zo’n gouden standaard niet beschikbaar was hebben we na een grondig review van de relevante literatuur, 6 plexiglas bifurcatie fantomen ontwikkelt met behulp van precisie technologie (Hoofdstuk 2). Elk fantoom bevat drie opeenvolgde bifurcaties met variërende anatomie, stenose graad en Medina klasse.  Met behulp van de fantomen konden we 2 type 2-D bifurcatie-QCA software (6-segmenten model, 11- segmenten model) valideren en de minimale lumen diameter (MLD), de RVD en de DS bepalen (Hoofdstuk 3). Met het 6-segmenten model worden data gerapporteerd van zowel het proximale hoofd vat (PMV), het distale hoofd vat (DMV) en de zijtak (SB) en hiermee kan eenvoudig een overzicht verkregen worden van de bifurcatie dimensies tijdens een procedure. Het 11-segmenten model geeft gedetailleerdere informatie over de bifurcatie en vooral over de dimensies van het ostial gedeelte van de distale branches en de zijtak posities. Dit model is vooral geschikt om de 
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 locatie van de MLD, RVD en DS voor en na een bifurcatie behandeling en bij follow-up te vergelijken. Beide software methodes waren goed reproduceerbaar wat betreft de verkregen diameter gebaseerde parameters en in goede overeenstemming met elkaar en met de dimensies van het fantoom. Echter, deze studie toonde ook aan dat deze methodes a) niet goed presteren voor lumen diameters <0.7mm en b) dat alleen de zgn. lokalereferentie diameter analyse (‘user-gedefinieerd’) wordt bepaald.  Een geavanceerd lumendetectiealgoritme geïntegreerd in de volgende versie van de dezelfde software, verbeterde de MLD-kwantificering voor MLD <0.7mm en resulteerde daardoor in zeer nauwkeurige diameter metingen over het gehele diameter bereik die in de klinische praktijk kan worden verwacht (Hoofdstuk 4). Verder resulteerde een geoptimaliseerd algoritme voor automatische referentie (geïnterpoleerde) bepaling in aanzienlijk hogere reproduceerbaarheid voor RVD- en DS-waarden in vergelijking met lokale referentieanalyses. Vanzelfsprekend is de verbetering het meest uitgesproken in daadwerkelijke klinische coronaire vaataandoeningen.Technici kunnen op basis van oriëntatiepunten en individuele perceptie bepalen wat een echte bifurcatie is. Aldus kunnen geanalyseerde segmenten buitengewoon lang worden en taps toelopend, in die gevallen heeft automatische referentie-analyse de voorkeur. Het lokaal bepalen van de referentie diameter kan nog steeds nuttig zijn in ectatische of diffuus zieke vaten, waar interpolatie tot te grote of te kleine diameters kan leiden.  Naast de parameters, die zijn afgeleid van de lokale metingen, worden ook de 2-D bifurcatiehoeken berekend met een toegewijd algoritme welke werkt volgens de definities van de Europese Bifurcatie Club. Onze resultaten toonden aan dat de berekende hoeken onafhankelijk waren van het gebruikte model en zeer reproduceerbaar. Ondanks dat de fantoom bifurcatie hoeken in 3-D zijn gedefinieerd, bleken de hoeken die met de 2-D software waren bepaald, opmerkelijk nauwkeurig en precies en was er niet veel variatie in uitkomst tussen de softwareversies. De grootste hoek van een bifurcatie en de beste afbeeldingsprojectie van het ostium van de zijtak bestaan meestal naast elkaar in een enkele goede 2-D afbeelding, d.w.z. de antero-posterieure richting voor het fantoom. De nauwkeurigheid en precisie namen dan ook af als de fantoom bifurcatie werd afgebeeld vanuit een andere, geroteerde, hoek 
(Hoofdstuk 3 en 4). 
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 Om mogelijke beperkingen in verband met de 2-D QCA kwantificatie van de bifurcatie te minimaliseren, hebben we een nieuwe 3-D bifurcatie QCA-software ontwikkeld 
(Hoofdstuk 5). We beschreven de methodologie, waarbij twee 2-D angiografie beelden werden gecombineerd tot een 3-D reconstructieve van de bifurcatie. Deze nieuwe software kan corrigeren voor de geometrische vervorming van de 2-D angiogrammen en een kwantitatieve analyse uitvoeren van de 3-D gereconstrueerde bifurcatie. De nauwkeurigheid van de 3-D reconstructie en de afgeleide metingen zijn sterk afhankelijk van de definitie van het centrale splitsingsgebied, beschreven als de ‘polygoon of confluence’ (POC).  Omdat de 3-D reconstructie is gebaseerd op twee 2-D projecties, kunnen overlappende, kronkelige zijtakken een probleem vormen bij het correct reconstrueren van het bifurcatie gebied; een 3-D reconstructie die gebaseerd is op meer dan twee 2-D projecties kan een beter resultaat opleveren. Dit betekent wel dat de analyse software hiermee veel complexer wordt. Naar aanleiding van deze redenering hebben we onze 3-D software herzien en het gebruik van meer dan twee 2-D projecties mogelijk gemaakt 
(Hoofdstuk 6). Verder hebben we de methodologie die is beschreven voor de 2-D bifurcatie automatische referentieobstructie-analyse toegepast op de 3-D gereconstrueerde bifurcaties. Concepten geïntroduceerd in Hoofdstuk 4 worden geprojecteerd op de huidige 3-D methodologie, resulterend in een uitgebreide 3-D bifurcatie-QCA-analyse. Metingen voor MLD, RVD, DS en Bifurcatie-hoek (BA) afgeleid van de QCA 3-D bifurcatiesoftware werden gevalideerd tegen onze met precisie gefabriceerde fantomen (Hoofdstuk 6) en toonden een hoge nauwkeurigheid, precisie en reproduceerbaarheid.  In vitro validatie heeft de voor de hand liggende beperking dat deze is gebaseerd op statische objecten en dat de beelden zijn verkregen onder ideale angiografische omstandigheden. De vernauwingen in onze fantomen waren concentrisch als gevolg van productie beperkingen. Echter, meer dan 50% van coronaire plaques zijn asymmetrisch, en juist deze asymmetrie geeft vaak aanleiding tot onnauwkeurigheden. Bovendien zijn de bifurcaties in het fantoom gelegen in een plat vlak. Echter, de bifurcaties in humane coronair vaten hebben meestal gebogen trajecten uit het 2-D vlak en vormen daarmee ware 3-D geometrieën. Als deze ware 3-D geometrieën worden afgebeeld met 2-D projecties worden ze soms verkort weergegeven. Daarom moeten we aannemen dat de 
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 incrementele waarde van 3-D bifurcatie QCA in vergelijking met 2-D analyse is onderschat met het gebruik van het huidige fantoom.   Visuele beoordeling was de intuïtieve manier om het coronaire angiogram te interpreteren; desalniettemin is het bewezen dat "Eye balling" nogal onnauwkeurige en zeer variabele uitkomsten geeft. Deze onnauwkeurigheden vinden we vaker bij vernauwingen in bifurcaties, dan bij vernauwing in een gewoon segment. De intuïtieve manier waarop zelfs ervaren operatoren de stenose ernst in het distale hoofd vat en de zijtak interpreteren is gebaseerd op de diameter van het proximale hoofd vat en resulteert daarmee vaak in een overschatting van DS-waarden. Omgekeerd kunnen vernauwingen in de PMV worden onderschat. Inderdaad, deze observaties werden bevestigd tijdens het uitvoeren van ons onderzoek onder experts op het gebied van bifurcatie behandeling (Hoofdstuk 7); visuele schattingen van DS in de fantoom bifurcaties waren zeer variabel in vergelijking met de huidige bifurcatie QCA-normen. De geregistreerde grote variabiliteit van visuele schattingen in twijfelachtige stenosen en de lage inter-observer overeenkomst in de Medina classificatie kan de rechtvaardiging vormen voor de opname van online bifurcatie-QCA in het besluitvormingsproces.  
Kwantitatieve coronair angiografie van bifurcaties in 
klinische onderzoeken Na de ontwikkeling en validatie van specifieke bifurcatie-QCA-software was de toepassing in de klinische praktijk in real-time de volgende stap. We rapporteerden lange-termijn uitkomstgegevens van de V-stentingtechniek in de-novo bifurcaties behandeld met medicijn afgevende stents (DES) bij patiënten van de RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) en de T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) studies (Hoofdstuk 8). We concludeerden dat in deze real-world cohorten, late klinische gebeurtenissen overeenkomen met studies over competitieve technieken. De eerste uitkomsten waren minder bemoedigend, waarschijnlijk vanwege de risicofactoren op baseline, maar bij nadere beschouwing leken deze anekdotisch en eindpuntafhankelijk. Angiografische parameters, zowel diameter-afgeleide als BA-waarden, werden bepaald met toegewijde bifurcatie QCA-algoritmen volgens het meerdere-segmenten model in alle patiënten 
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 waarvan cinefilms konden worden teruggevonden. Hierdoor werd de uitvoerbaarheid van analyse in dit relatief kleine onderzoek bevestigd. Verder hebben we de lange-termijn klinische uitkomsten en onafhankelijke voorspellers van belangrijke cardiale gebeurtenissen onderzocht bij patiënten met aandoening van de linkerhoofdkransslagader behandeld met DES in de RESEARCH- en T-SEARCH studies 
(Hoofdstuk 9). We rapporteerden een toename van late bijwerkingen tot 4 jaar, welke een zorgvuldige follow-up vereiste van deze patiënten behandelt met DES in de linker hoofdstam. Naast andere variabelen werd de BA beoordeeld als een mogelijke parameter voor risicostratificatie. Hoewel 3-D QCA beschikbaar was, was het bij slechts de helft van de patiënten uitvoerbaar vanwege het niet beschikbaar zijn van 2 afzonderlijke angiografische projecties met meer dan 30° verschil; bij de overige patiënten werd 2-D QCA uitgevoerd. Pre-PCI distale BA, d.w.z. de hoek (volgens de definitie van de European Bifurcation Club) tussen linker anterieure dalende bloedvat (LAD) en linker circumflex (LCX), werd zowel in de diastolische als de systolische fase bepaald. Systolische BA-waarden vertoonden een zwakke statistische associatie met patiënt-georiënteerde samengestelde eindpunten (PoCE) in de univariate analyse op 4-jaar follow-up, waarbij patiënten met hogere pre-PCI BA-waarden een trend toonden voor slechtere uitkomsten. BA bleek echter niet een significante voorspeller van ongunstige klinische resultaten in de multivariate analyse; dit kan worden toegeschreven aan de heterogene QCA-analyse en een relatief klein aantal patiënten. Gestimuleerd door deze gemengde signalen en de belofte van het voorspellend vermogen van de BA-parameters in deze underpowered studie met relatief weinig 3-D analyses, hebben we besloten om de 3-D BA-parameters van de linkerhoofdkransslagader verder te onderzoeken, het effect van PCI op deze BA, en de impact van 3-D BA op de 1-jaars klinische uitkomsten in een groter cohort, namelijk de patiënten gerandomiseerd naar hoofdstam PCI binnen de SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial (Hoofdstuk 
10). Complete 3-D BA-analyse, voor en na PCI was haalbaar in 75% van de gevallen; men zou kunnen verwachten dat prospectieve verzameling van geschikte cine-angiogrammen het aantal niet-analyseerbare gevallen verder zou kunnen terugdringen tot <10%. Deze studie was de grootste tot nu toe om de 3-D hoofdstam BA te beschrijven; BA-parameters bleken aanzienlijk te variëren. Verder toonden we aan dat 
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 hartbeweging een onderling effect uitoefent op proximale en distale BA, waarbij de eerste werd verhoogd en de laatste afnam tijdens de systole. Bovendien modificeert een PCI ingreep vooral de distale BA; in het algemeen waren de hoeken afgenomen terwijl de smalste pre-PCI-hoeken na de procedure juist waren toegenomen. Onze analyse toonde echter niet genoeg bewijs om 3-D BA te ondersteunen als een potentiële voorspeller van de klinische uitkomst; er was een trend die wijst op hogere bijwerkingen bij patiënten met een wijdere BA wanneer 2 stents waren geïmplanteerd in de linker hoofdstam bifurcatie. Zodra de 5-jaars klinische resultaten van de SYNTAX-trial beschikbaar waren, werd de impact van 3-D BA-parameters verder onderzocht (Hoofdstuk 11). Net als bij onze 1-jarige bevindingen, leek de stratificatie van pre-PCI diastolische distale BA-tertielen geen enkel verschil te vertonen in de mate van bijwerkingen in de gehele studiepopulatie versus patiënten die bifurcatie-PCI hadden ondergaan. Aan de andere kant toonden bifurcatie-patiënten met een beperkt post-PCI systolisch-diastolisch distaal BA-bereik (d.w.z. een verminderde "bewegingsvrijheid" van de linker hoofdvertakking), significant hogere ongunstige bijwerkingen. Zelfs na correctie voor verschillende klinische, angiografische en procedurele variabelen bewees het nog steeds een onafhankelijke voorspeller te zijn van nadelige klinische gebeurtenissen op 5-jaar. Het is mogelijk dat deze studie ons nieuwe inzichten verschaft in de biomechanica van het falen van de stent in bifurcatieletsels, waarbij de linker hoofdstam bifurcatie de belangrijkste kransslagader is. Ten slotte, rapporteerden we de acute procedurele en klinische resultaten 6 maanden na PCI van de hoofdstam met een speciale bifurcatie-stent in de multicenter TRYTON studie 
(Hoofdstuk 12). Het gebruik van deze specifieke bifurcatiestent die werd bestudeerd voor de behandeling van hoofdstam bifurcatie laesies was geassocieerd met een hoog percentage stent-device en procedure succes zonder complicaties in deze hoog risico laesies/patiënten. Angiografische analyse werd uitgevoerd met het speciale 2-D bifurcatie QCA-algoritme gepresenteerd en gevalideerd in Hoofdstuk 4 van dit proefschrift volgens een gestandaardiseerde procedure. Diameter-afgeleide metingen van zowel 11- als 6-segmentmodellen waren doelmatig bij het beoordelen van de post-procedurele angiografische resultaten; effect van PCI op BA-parameters werd ook bestudeerd. Interessant is dat de gemiddelde DS-waarden vastgesteld met behulp van 
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 QCA-analyse in dit cohort minder dan 50% waren in PMV, DMV en SB. Dit impliceert dat angiografische metingen niet het enige criterium was dat werd gebruikt om te bepalen of de hoofdstam bifurcatie al dan niet behandeld moest worden. Ook waren we verbaasd dat 3-D QCA-analyse slechts in ~30% van de gevallen mogelijk was. Ondanks de angiografische per-protocol analyse, het hoge niveau van deskundigheid van de betrokken operators en de uitdagende anatomie, moeten we concluderen dat een goede prospectieve acquisitie van angiogrammen zowel vóór als na de procedure en de incrementele waarde van 3-D QCA lessen zijn die nog geleerd moeten worden.  
De SYNTAX-score en andere afgeleide scores De SYNTAX-score is een belangrijk hulpmiddel om de angiografische complexiteit te beoordelen; het is geïntegreerd in zowel de Europese als Amerikaanse revascularisatie-richtlijnen voor de risicostratificatie van patiënten met complexe coronaire hartziekte zodat de keuze van de meest geschikte revascularisatiemodaliteit wordt vergemakkelijkt. In de gerandomiseerde SYNTAX-studie bleek het effectief bij het voorspellen van klinische uitkomsten na electieve PCI bij patiënten met drie-vat en/of linker hoofdstamlijden. We hebben de voorspellende waarde van de SYNTAX-score beoordeeld voor een aantal klinische uitkomsten in "all-comers" populaties met een verschillende mate van coronaire hartziekte in zowel electieve als urgente PCI-procedures. In eerste instantie hebben we de reproduceerbaarheid van de SYNTAX-score beoordeeld 
(Hoofdstuk 13). Ondanks de belangrijke rol in risicostratificatie, is de berekening van de SYNTAX-score afhankelijk van visuele beoordeling van coronaire laesies en is daarom onderhevig aan intra- en inter-observer variabiliteit. In onze studie werd de SYNTAX-score twee maal berekend met een interval van 8 weken in 100 patiënten willekeurig geselecteerd uit de SYNTAX-studie door een team bestaande uit drie interventionele cardiologen. Onze analyse toonde aan dat de SYNTAX-score een gematigde intra-observer reproduceerbaarheid heeft, wat consistent is met een eerdere evaluatie uitgevoerd door corelaboratory analisten. Het scoren van bifurcatie-laesies blijft de belangrijkste bron van inconsistentie, die kan worden verbeterd door het gebruik van aanvullende beeldvormingmodaliteiten samen met een herziening van de definitie. 
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 Verder hebben we de voorspellende waarde van de SYNTAX-score voor belangrijke cardiale gebeurtenissen beoordeeld, zowel in het al beschreven cohort van de hoofdstam PCI-patiënten uit de RESEARCH- en T-SEARCH-registers als ook in de populatie van de ‘all-comers’ LEADERS (Limus Eluted from A Durable versus ERodable Stent coating) studie. In de vorige studie kwam de SYNTAX-score naar voren als een onafhankelijke voorspeller voor zowel mortaliteit als ook voor patiëntgeoriënteerde samengestelde eindpunten (PoCE) tot 4 jaar, waarbij patiënten in het tertiel met hoge SYNTAX-score significant hogere incidentiepercentages vertoonden (Hoofdstuk 9). In de LEADERS studie zagen we een significant hoger aantal patiënten met ernstige bijwerkingen in het hoogste tertiel van de SYNTAX-score na 1 jaar follow-up. Het is echter belangrijk om te vermelden dat deze patiëntenpopulatie over het algemeen een veel lagere SYNTAX-score had dan de SYNTAX-studie populatie en/of de PCI hoofdstam populatie; desalniettemin leek de SYNTAX-score nog steeds een goede discriminerende waarde te hebben voor risicobeoordeling. Daarbij hebben we aangetoond dat de SYNTAX-score een prognostische waarde heeft voor alle patiënten die een PCI ondergaan voor de-novo coronaire hartziekte (Hoofdstuk 14). In Hoofdstuk 15 hebben we de potentie van de SYNTAX-score en de Clinical SYNTAX-score onderzocht op het voorspellen van de resultaten op zeer lange termijn in een ‘all-comers’ populatie van de SIRTAX studie (SIRolimus-eluting stent compared with pacliTAXel-Eluting Stent for coronary revascularization). In deze studie waren de gemiddelde SYNTAX-score en de tertielwaarden zelfs lager dan die in de LEADERS studie, dit reflecteert een vroegere tijdsperiode van inclusie en de lagere prevalentie van comorbiditeiten in de SIRTAX. Daarom werd verwacht dat de klinische variabelen deze mogelijke afname in sensitiviteit van de SYNTAX-score compenseren. Onze resultaten lieten zien dat zowel de SYNTAX-score als de Clinical SYNTAX-score onafhankelijke voorspellers waren van 5-jaars cardiale gebeurtenissen. Bovendien was de Clinical SYNTAX-score een onafhankelijke voorspeller voor mortaliteit gedurende 5 jaar; het superieure onderscheidend vermogen en kalibratie in vergelijking met de SYNTAX-score resulteerde in een significante verbetering van de risicostratificatie voor de respectievelijke mortaliteit eindpunten. Een extra potentiële rol van de Clinical SYNTAX-score met betrekking tot de risicostratificatie en stentselectie werd ook geïdentificeerd, waarbij significant verhoogde ongunstige bijwerkingen met de paclitaxel-eluerende 
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 stents werden waargenomen binnen de subgroep van patiënten met de hoogste Clinical SYNTAX-score. Een beperking van de SYNTAX-score is het onvermogen om uitkomsten te differentiëren bij patiënten die een coronaire bypass operatie (CABG) hebben ondergaan. We bespraken de rationale, ontwikkeling en haalbaarheid van de nieuw ontwikkelde CABG SYNTAX-score (Hoofdstuk 16) en we concludeerden dat de berekening van deze score haalbaar en reproduceerbaar leek en mogelijk een lange termijn-prognostische rol speelt bij patiënten met complexe coronaire aandoeningen die chirurgisch worden behandeld. Verder rapporteerden we de 5-jaarsresultaten van de CABG-arm van de SYNTAX-LE-MANS(hoofdstam)substudie, gestratificeerd voor gemiddelde CABG SYNTAX-score (Hoofdstuk 17). Volgens onze analyse waren significant hogere percentages van 5-jaars mortaliteit en andere ongunstige eindpunten zichtbaar in de hoge CABG SYNTAX-score groep in vergelijking met de groep met de laagste score. De CABG SYNTAX-score en PCI-equivalent (de residuele SYNTAX-score), bieden beide objectieve metingen van de complexiteit van de residuele coronaire ziekte en mate van revascularisatie. Deze scores kunnen helpen bij het bepalen van het niveau van "redelijke revascularisatie" en kunnen mogelijk op lange termijneen prognostische rol spelen bij het identificeren van hoog risicopatiënten die CABG of PCI ondergaan.   
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Thoraxcenter 
Senior staff 
Professor Pim de Feyter: A perfect gentleman in and outside of the Cathlab; a cardiologist 
and a researcher of huge caliber. Unfortunately I did not have the opportunity to do many 
cases with him, since I was still in my early steps in my clinical assignment, when he 
stepped out of the CathLab. However, in any given opportunity, especially during the 
EuroPCR and the EuroIntervention editorial meetings, I could only respect his huge 
academic background, appreciating his openness to new ideas, whereas at the same time 
he would make kind but poignant suggestions, where he felt there was room for 
improvement. Last but not least, I will forever be grateful to him for acknowledging and 
embracing Elina’s research potential and mentoring her towards her PhD.  
The late Professor Wim van der Giessen was an imposing figure, not only for his skill and 
vast knowledge on the field of Interventional Cardiology, but also for his overall education 
and approach to medicine, music, philosophy and life. Always maintaining his cool, he was 
keen to let me work our cases in the CathLab as a first operator, always prepared to help, 
but equally patient to let me finish a given case, no matter how difficult, and give me the 
credit afterwards. Naturally this required respecting his overall philosophy towards 
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patients and, not before long, adopting his mentality reflected in lines such as “why do 
you want to do this? Are you gonna make the patient better?”, “no” you had to reply, “so, 
don’t do it”; or the famous moto “take the money and run” as soon as you were done 
tackling an elderly patient’s culprit lesion. I was really sad and shocked to hear the news 
about his untimely demise; his presence and guidance would have been invaluable, and 
he will sorely be missed. 
Peter de Jaegere: When I arrived at Thoraxcenter and for the next few years, Peter was 
almost entirely dedicated to the TAVI program, a field then almost impenetrable to a 
rookie from an operator’s perspective, hence we did not work so frequently in the 
Cathlab; nevertheless, similar to Wim, he was always welcoming young fellows taking on 
responsibilities under his supervision. 
Robert-Jan van Geuns: A motivated and clearly talented interventional cardiologist, 
probably one of the seniors with whom I have worked most frequently in the Cathlab. 
Working on that many cases together, it was not always possible to avoid occasional 
friction between a rising star such as him and an often impatient, “pushy” Greek fellow 
such as myself. Fortunately, we managed to come to terms acknowledging our mutual 
dedication to the task, do challenging procedures together, especially on the field of 
bifurcation PCI, and even collaborate on some manuscripts, to the extent that his place in 
my thesis’ plenary committee is entirely expectable. 
Evelyn Regar and Eric Duckers: Devoted scientists, each of them on her/his own field, 
striving for perfection regarding acquisition and adherence to the protocol. I will always 
remember Evelyn being the most adamant of all when it came to speaking 100% Dutch in 
the Cathlab, or Eric always maintaining his cool, always speaking in a (very) low voice “in 
order to have everybody paying attention”, and with a genuine interest in anyone’s 
current and future research projects.  
Martin van der Ent: I remember Martin as a fast and effective operator, especially in 
emergencies (always going to “twintig” when direct stenting culprit lesions in MIs), always 
fond of difficult procedures, especially CTOs. I guess it served him well to leave for Zuider 
Ziekenhuis, in order to enjoy more allocated time for this kind of procedures. 
Arie de Vries and Attila Dirkali: Both of them being on the on-call rooster in Thoraxcenter 
in the time where the PCI service had not started yet in Dordrecht, I enjoyed their good 
company and co-working spirit, especially in my early steps as a first operator. As a matter 
of fact, Arie was my senior in the vast majority of my early on-calls; his patience and 
willingness to help me gain confidence in my first primary PCIs is naturally very much 
appreciated. 
My compatriot George Sianos definitely put in a good word for me during my first series 
of interviews, which I am grateful for. However, we just overlapped for a mere 12 days, 
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before he left for Greece; this is how I missed out on the challenge of working with 
George in the Cathlab! 
Last but not least, Professor Felix Zijlstra: I definitely enjoyed working with him in the 
Cathlab, taking the opportunity of doing case after case as a first operator under his very 
discrete supervision. Unfortunately, due to inconvenient timing, I missed the opportunity 
of extending my stay in Thoraxcenter, despite his initially more than welcoming approach 
to the matter.  
 
Clinical Fellows 
Carl Schultz, Joanna W… (let’s not pretend I could ever spell or pronounce her last name 
correctly) and Nicholas van Mieghem shared for a shorter or longer time the 
interventional fellows room with me. If a single word comes to mind for all three of them, 
this would be “dedicated”. Carl was sure to rent an apartment just opposite the 
Thoraxcenter; he could not afford to waste time, neither as a fellow nor as a young senior. 
Joanna sure made good use of her US background and her American upbringing always 
looking out for practical solutions. I have to admit that to the best of my knowledge she 
was probably the one with the highest percentage of enrolled patients; despite her at first 
moderate Dutch, she would strive and to a large part also succeed to find a perfect match 
between a given study protocol, be it for SECRITT or any of the stent and/or imaging trials, 
and her patients of the day. And Nicholas, what can you mention first about Nicholas, eh? 
His competitive nature I guess, as reflected in his screensaver capture of him swimming 
butterfly-style, in his quick American ways going back to his NY days, his purely aggressive 
approach in the Cathlab, and finally our inside “15 minute” joke; this was allegedly the 
setup and acquisition time needed for a near infrared spectroscopy scan of a culprit MI 
lesion, at least in the beginning, evidently an eternity for Nicholas, before he could be 
allowed to attack the lesion. Considering all this, their respective accomplishments and 
professional success, be it in Australia for Carl, Amsterdam for Joanna, or the 
Thoraxcenter for Nicholas, are entirely deserved. 
Anne-Louise Gaster and Steve Ramcharitar belonged to the prior generation of clinical 
fellows, hence I did not have the opportunity to work with them. However, I had time 
enough to appreciate Anne-Louise’s kind heart and warm hospitality in her house on the 
outskirts of Rotterdam, and we even made it together with Elina and Anne-Louise’s 
boyfriend to the blooming Keukenhof gardens, which was one of our most enjoyable 
excursions in the Netherlands. On the other hand, Steve’s published research overlapped 
to a certain extent with my bifurcation related projects; I therefore partially followed his 
work and could appreciate his enthusiasm and his zeal to succeed. Michael Magro, on the 
opposite hand, was a clinical fellow from Malta who was equally interested in bifurcation 
PCI but was also involved in an array of research topics. Michael was one of the kindest, 
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most humble and self-sacrificing fellows I have ever come across; in the end, these 
qualities helped him succeed in a place of fierce competition. Naturally, I would also like 
to mention my compatriot Apostolos Tzikas, whom I also shared the fellows’ room with. 
Apostolos focused on the TAVI procedures and succeeded to conclude a concise thesis in 
a relatively short time thanks to the mentorship of Peter de Jaegere, as he was eager to 
embark on some clinical work as well, following the Structural Heart program in Montreal.   
Finally, I would like to thank all the Dutch fellows we shared the room with (and there 
have been so many of them), for being friendly, cooperative, and eager to show me the 
ropes around the lab, the ward, the clinics, and, at least in the start, occasionally check my 
Dutch, either in my angio/PCI reports or when asking patients for consent.  
 
Cathlab staff 
I would naturally like to acknowledge the work and professionalism of the entire Cathlab 
staff, with whom I had to work long and hard, quite often in the wee hours, but also 
enjoyed their company between procedures. Marjo de Ronde definitely stands out as the 
head nurse anyone would like to have in any Cathlab; steadfast, decisive, protective of her 
staff, but ever so friendly and pleasant to anybody willing to work hard. Tieneke, 
Marianne, Elsa, Linda, Mercedes, Houda, Rixt, Dick, Bas, Nico, John de Heide, you were all 
willing to help out, at first assisting with simple but important aspects of the job, such as 
the table set-up, and later on during the procedures as my back-up.  
On the other hand, my utter respect goes out to all Cathlab technicians Anne-Marie, 
Karen, Angelique, John de Vries, Elco, Sander, Rob, Patrick and Paul, small geniuses to a 
certain degree, who knew their way around virtually every piece of equipment, helping 
out with the acquisition, the interpretation and the measurements during cases. A special 
thank you from my side should go out to John, Elco and Sander, for offering their help 
with the retrieval and copy of literally hundreds of angio CDs for my first QCA studies. And 
then it is Jürgen Ligthart; as a matter of fact, Jürgen never needed a last name or further 
introduction. To every fellow having ever worked a single day in that Cathlab he was 
always a smiling face welcoming you to the Thoraxcenter at the same time being a tireless 
teacher and a brilliant scientist, who had indulged in all imaging and acquisition 
technologies, especially in IVUS, to a level even today unparalleled by a large part of 
seasoned interventional cardiologists. 
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Cardialysis 
Research Fellows 
There have been so many fellows in Cardialysis throughout this time-period, I am afraid I 
am going to overlook somebody; if so, certainly not intentionally, but probably due to the 
fact that I spent half the working week in Thoraxcenter. 
Hector: Obviously, I could not start with anybody else but my first and only Mexican friend 
so far. From my point of view, Hector does not belong to this group, since he had already 
arrived in Rotterdam three and a half years before myself; the word coordinator rather 
comes to mind. Already mastering IVUS with a global view of every other intravascular 
imaging technology, he was next to Prof the one trying to match every new-comer with an 
evolving project, obviously also depending on one’s preferences. More than that, he 
would be the one trying to reconcile differences between fellows consistently trying to 
bring everybody together during our lunch breaks or dinners. I am quite sure that to a 
certain extent this controlled, reconciling behavior had to do with the fact that he enjoyed 
the company of his lovely wife and family. This was the major factor that would keep him 
going through a seemingly endless effort to get a European license in order to practice 
medicine, especially Interventional Cardiology, on Dutch soil. I was surprised to hear that 
he had left for Washington, US, since he had become such an integral part of Cardialysis, 
however I trust that he followed an opportunity he could not refuse. 
Nieves was also already there upon my arrival, on her way to become the OCT expert she 
is. Beyond her diligence on the seemingly endless analysis of OCT runs, she was such a 
sweet and pleasant individual, that everybody was happy seeing her not only finish her 
PhD, but much more importantly, finding her companion in life in Koen. Taka Okamura 
definitely filled her shoes regarding OCT related projects, naturally also becoming an 
expert on the field, to be succeeded by the other Taka (Muramatsu), an equally devoted, 
slightly more extrovert young Japanese fellow. 
Naturally, when one talks of fellows with a taste for OCT, one definitely has to mention 
Lorenz Räber and Maria Radu, and their scientific “child”, the OCT Atlas. Lorenz came in 
from Bern at the suggestion of Professor Stephan Windecker to run a relatively short, but 
immensely productive fellowship. However, I am proud to say that even before coming to 
Rotterdam, we had already paved the way for his Cardialysis days with our joint project on 
the SIRTAX study. It was clear from the start that he was very committed, and I am quite 
sure that a great career in Interventional Cardiology is in the making. Maria on the other 
hand had different things on her plate to begin with, thus we did not interact to the same 
degree; however, she was very sociable and pleasant, eager to bring people together 
organizing dinners especially at Christmas time.  
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Scot Garg: A brilliant mind, a charismatic writer who could absorb information in record 
time and then dissect a given topic in more ways than one could imagine; at the same 
time a very down to earth and easy to work with guy. Mentioning Scot, I instantly think 
about Giovanna Sarno as well, since the three of us had a very fruitful collaboration in 
relatively short time, co-authoring a number of manuscripts. Giovanna being a very bright 
and talented Italian girl and having already defended her PhD was nevertheless constantly 
on the lookout for bigger and better opportunities; having moved for a number of years 
now to Sweden, I hope she finally found what she was looking for.  
Salvatore Brugaletta and Roberto Diletti arrived in Rotterdam at pretty much the same 
time; I can still recall seeing them for the first time at the thesis defense of Scot and 
Apostolos. Both of them enjoyed a great deal of success, Roberto taking on a clinical 
assignment and in the end becoming a senior at Thoraxcenter, and Salvatore defending 
his thesis and then moving back to his beloved Barcelona to carry on with clinical work. 
Nonetheless, it was never all work for them, as we used to enjoy every now and then a 
dinner together with Elina and her best Italian friend Alexia. Speaking of Barcelona, Josep 
Gomez-Lara comes to mind; a really extrovert Catalan fellow, with a tangible passion for 
his home city, soccer and naturally Barcelona FC! Juan-Luis on the other hand was an 
elegant, talented fellow from Spain, with a huge array of interests. He has developed a 
taste for OCT related research, which must have served him well in his ongoing endeavors 
around Europe for the last years; I sincerely hope he finds the perfect working 
environment without having to compromise too much. 
Vasim Farooq: A very enthusiastic fellow from the UK, all too eager to convince other 
fellows of his point of view, including myself. I do feel I still have to apologize to other 
fellows on his behalf as well for occasionally creating too much noise throughout 
Cardialysis during our common projects on the CABG SYNTAX score; it was not that we 
were arguing, we were just adjudicating the angiograms very vividly! And a last thing in 
order to restore the historical truth; Vas, according to his thesis acknowledgements, is still 
in possession of a certain recording of myself allegedly admitting I was wrong. My dear 
Vas, you can be even prouder; that statement actually read “Yes Vas, you are right!!”  
Christos (Chris) Bourantas: A talented Greek fellow, a prolific author, so concentrated on 
his projects that he would occasionally face certain difficulties (!) with trains, buses, and 
automobiles, especially when abroad; the stories are endless thanks to his very vivid 
descriptions! Elina and I were privileged to attend his wedding with his wife Thekla, but 
also happy to meet with their growing family whenever the opportunity was given. 
  
Technicians, personnel, industry and more… 
I had a very fruitful cooperation with all the technicians involved in QCA analysis, 
especially Wietze, learning a lot from each other. Being to a rather small part involved in 
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IVUS and OCT related projects I naturally had to resort for help to relevant technicians as 
well. I am afraid I am at a loss for names, however Ravindra definitely stands out, thanks 
to his vivid personality but also because he was the one most eager to accompany us 
during lunch time. I would like to thank Koen and Glenda for their technical assistance, our 
statisticians, Gerrit-Anne van Es, Ana Guimaraes, and naturally Bianca Backx and Monique 
Schuijer, from the time of my involvement with Tryton IDE and ABSORB, not only for their 
professionalism but also because they were so much fun to be with! 
Paul Cummins was the managing editor of EuroIntervention during my time in Rotterdam; 
more than that, he was the one to consult with during my first days in Rotterdam 
regarding simple logistics, accommodation, or the nearest bar/restaurant for any given 
occasion. He was also the one giving me hints regarding the first papers I would review for 
the journal. Sylvie was his tireless assistant always trying to help fellows either with their 
own manuscripts or with their review assignments. 
It would really be unforgivable, if I did not bring up the people from industry, with whom I 
worked very close together. From Pie Medical in particular, I would like to thank Folkert 
Tijdens, an ever smiling gentleman and resourceful engineer, Jean-Paul Aben, the brains 
behind the development of their software and an invaluable co-author in my validation 
papers, René Guillaume and Boudewijn Verstraelen for trusting me with the validation of 
their products at the same time fully respecting my validation plan and above all my 
scientific integrity and independence. I would also like to acknowledge Professor Hans 
Reiber and Gerhard Koning for their co-operation in my validation of Medis bifurcation 
QCA software in a spirit of professionalism and collaboration, and the people from Paieon, 
the company which provided us with the 3-D QCA software I used during my SYNTAX 
bifurcation angle studies, a tiring, often frustrating, but in the end quite rewarding 
project. 
Hanny Boutkan: On a first, simple level, Hanny has been Prof’s secretary since late 2010; 
naturally even dissecting this simple fact, one has to be reminded whose secretary she 
really is. On a personal level, Hanny is by far one of the kindest persons I have ever come 
across; more than that utterly professional, proactive and hard working. In particular, I 
must give her the credits for constantly but gently pushing me towards my thesis defense 
continuously sending out reminders for regulations and deadlines, even when my 
enthusiasm had dissipated. Finally, when the goal was in plain sight, she facilitated the 
process to the best of her abilities following up on seemingly endless correspondence, 
many times in out-of-office hours. And what’s priceless; every e-mail invariably started 
with her heartfelt salutations in Greek!  
Marie-angèle: In a nutshell, the heart and soul of the entire organization; in more detail, a 
tireless administrator, the hardest working analyst, a welcoming face to every fellow 
coming to Cardialysis and when needed a buffer zone between him/her and Prof. 
Especially regarding my QCA projects Marie-angèle was the person to show me the 
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workstations and the software, help me liaise with Cardialysis personnel and industry, 
and, what’s more important, provide the assurance that she would always be around 
somewhere in the building, mostly in her office on the second floor, to lend a helping 
hand if necessary. And all of this integrated with a charming, cheerful and ever so 
enjoyable personality, with a warm laughing voice equally loud with my own; the ruckus 
the two of us could create just having an occasional drink was unprecedented to the point 
that Prof could track us from a distance even in a crowded airport such as JFK “just 
following the noise”! Hence, almost from day one, there was never a shred of doubt in my 
mind that she would be one of my paranymphs! 
 
Professor 
One cannot be appreciative enough either of Prof’s achievements on the field of 
Interventional Cardiology or, not less importantly, of his decisive contribution to the 
career of any fellow who had the privilege of serving under him, as a research or as a 
clinical fellow; in my case it was both, hence twice the honor and the responsibility. The 
thought occurred at first to try and cite the numbers of published peer-reviewed 
manuscripts, theses, fellows, awards etc; I almost immediately discarded it. Any attempt 
to write up-to-date numbers would be futile; I would have to run to the publisher every 
other day and correct the numbers, such a prolific writer and overwhelming personality 
that Prof is.  
Even during my cardiology fellowship I had the opportunity of attending a number of 
lectures he had given in Greek congresses; it was the early DES era and his appearance 
was larger than life. However, my first ever face to face meeting was March 22, 2007 for 
my scheduled interview. It had been set rather late in the afternoon, and he had just 
finished with a number of challenging TAVI cases. Still in his scrubs Prof was going through 
a large pile of printed material on his desk searching for my CV; when he found it and read 
my first name, Greek first names being notoriously difficult to pronounce, I can remember 
him lifting his head asking kindly but yet decisively “and what should we call you?” I felt it 
was time to be practical and replied “I suppose we could cut it down to Chris”, hence I 
was stuck with that ever since. 
The start of my fellowship was initially unimpressive. However, several weeks into this 
awkward “marinating” phase, my office phone rang on a Monday morning; it was Anja, 
Prof’s former secretary, telling me on his behalf that I would have to take care of an 
outstanding bifurcation QCA analysis for the V-stenting registry, a project started by a 
former fellow. When I called her back after an initial surprise to ask for details, she just 
replied “he wants it by Friday”. With that the famous Patrick Serruys universal fellow 
routine started consisting in but not limited to early morning and/or late night phone calls 
praising other fellows’ work and asking about the progress of your own projects, early 
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Sunday morning visits to his attic, endless meetings, you name it. Only later would you 
realize how this routine consistently brought the best out of you, speaking volumes for 
Prof’s unsurpassed people management skill. Having worked with a vast array of 
ambitious young people from all over the globe he had the wisdom of adapting his ways 
to one’s personality, if he saw promise. In my case and during my early days at least, 
diplomacy was admittedly not among my strong points; Prof was wise to let this slide and 
valued my straight talking, even if at times it was a little bit bolder than expected. Later 
on, when he had become sure I had found my way, he was generous in accolades of my 
work actively helping with grant submissions, scholarships and professional solicitation.  
Regarding my clinical training, when seeing CG/PWS written on the Cathlab schedule 
board next to the cases of the next day, I just knew I would have to be prepared for 
everything! One can easily imagine that when you have Prof almost literally breathing 
down your neck, scrutinizing your way with the wires equally with your line of thinking 
and intellectual justification of your actions, no matter your level of self-confidence, you 
would simply have to deliver, almost invariably having a much faster heart rate than the 
patient. Naturally after that kind of exposure there would be hardly ever any clinical 
setting that would stress me more, which I soon realized that I would have to be eternally 
grateful for to Prof.   
Treasuring all of this experience I realized that defending my thesis even at this later time 
would certainly be worthwhile, this way also acknowledging Prof’s contribution to my 
career. After all, one of the highlights of my Rotterdam times has been the opportunity to 
attend the Patrick Serruys symposium in May 2012 honoring Prof’s legacy and see him 
enjoy the deserved admiration, friendship and love surrounded by his co-workers, friends 
and family; this is certainly a large but distinguished company everybody would like to be 
a member of.  
 
Friends and family 
I would like to start by mentioning our dear Greek friends Natasa, Roula and Dimitris, 
whom Elina and myself were fortunate to meet with early on during our Rotterdam days; 
enjoying their company regularly during weekends we kind of kept our home country a 
little bit closer, even when away. All of them have been for a long time now accomplished 
professionals deeply rooted in the Netherlands, and it is always a privilege and a 
motivation to meet with them every time we return to Rotterdam. 
My dear parents have always been there for me and my brother, consistently and almost 
selflessly trying to provide us with the best possible education. It was no surprise that 
when the opportunity arose for me for a fellowship in Rotterdam, they facilitated my early 
steps without any hesitation, even with a sense of consolation since Rotterdam would be 
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at least on this side of the Atlantic as opposed to a US alternative. Regrettably they could 
not make it to Rotterdam even for a short visit, however I think they would have loved it; 
by some strange coincidence my father had already spent some 2 ½ years in the greater 
Belgium, Netherlands and Luxemburg area almost forty years before!  
Last but not least, Elina, my soul-mate, best friend and companion in life and since 2013 
my wife. Our relationship has been intricately connected with Rotterdam; it was not even 
three months after we had started dating, that I had come to Rotterdam for my 
interviews. Elina was back then finishing with her medical diploma; the perspective of me 
departing for Rotterdam alone gave her ample motivation to graduate just in time to 
accompany me on this great adventure. I understand that it must have been frustrating 
for her during the first months having no concrete plans, or when later on she repeatedly 
came so close to starting a PhD in the Netherlands, but yet could not nail it. It turned out 
to be for the best, since thanks to Pim de Feyter she was integrated in MSCT related 
projects with a shared appointment in Cardiology and Radiology Departments in Erasmus 
MC which led to her thesis, but more importantly to a time well and productively spent. 
During these early times it was probably her love for me but also for travel and adventure 
that kept her going, which was after all the thing that originally brought us together. I 
cannot stress enough the level of her contribution to any success I might have had in my 
fellowship, either by her sheer presence and emotional support, but to a certain part even 
due to her phenomenal computer skills, Elina being to the date an avid provider of 
whatever computer application I would need to facilitate my writing and my 
presentations. Finally, I would probably not have come around to defending my thesis, if it 
were not for Elina insisting otherwise in her own uniquely quiet but ever so consistent and 
powerful ways. After all, this would only be the most fitting closure of the first but ever so 
challenging and worthwhile chapter of many more to come in our common life!  
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